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CHARACTERIZATION OF BACTERIAL METABOLITES 
INVOLVED IN HOST PATHOGEN RESISTANCE 
Kavita J. Rangan, Ph.D. 
The Rockefeller University 2015 
The intestinal microbiome can mediate host resistance to enteric pathogens by 
modulating host immunity or by directly inhibiting pathogen growth and virulence. 
Although the abundance and diversity of bacterial metabolites in the intestine is 
appreciated, the majority of intestinal bacteria and bacterial products have not been 
characterized in the context of microbiota-mediated pathogen resistance. In this thesis, 
we describe two projects aimed at developing new methodologies to study how intestinal 
bacteria, and the metabolites they generate, inhibit bacterial pathogenesis. 
In Chapters 2 and 3, we use a chemical reporter strategy to analyze fatty acid 
protein modifications in bacteria. Dietary and bacterially-produced fatty acids can 
modulate the virulence of various pathogens, such as Salmonella typhimurium, possibly 
through covalent protein modification. We demonstrate that alkynyl-functionalized fatty 
acids can be metabolized and covalently attached to known fatty-acylated proteins in E. 
coli. Proteomic analysis of modified proteins revealed an unconventional fatty-acid 
modification on the metabolic enzyme YjgF, highlighting the utility of this method for 
the discovery of novel sites of fatty-acylation. Using these reporters, we also explored the 
effects of fatty acids on S. typhimurium virulence. Our results in S. typhimurium 
underscored the extensive fatty acid metabolism of this pathogen as compared to E. coli, 
and revealed a potential fatty acid modification on the virulence factor HilA. In addition, 
we demonstrated that alkynyl-functionalized short chain fatty acids, like natural fatty 
acids, can inhibit the secretion of Salmonella virulence factors in vitro. Overall, our 
results suggest that alkynyl-functionalized fatty acids may be useful for analyzing 
Salmonella metabolism and virulence. 
In Chapter 4, we describe a C. elegans model system that we used to investigate 
the effects of Enterococcus faecium on bacterial pathogenesis. Probiotic strains of E. 
faecium can inhibit the virulence of several intestinal pathogens, including Salmonella 
typhimurium, but it is unknown if E. faecium directly targets pathogens or modulates host 
immunity. Through a combination of genetic, biochemical, and proteomic approaches, 
we identified a secreted peptidoglycan hydrolase (SagA) from E. faecium that confers 
protection against Salmonella pathogenesis. Our results indicate that SagA does not 
directly inhibit pathogen growth, but instead remodels peptidoglycan in vivo to enhance 
host resistance to pathogenesis. We define specific peptidoglycan fragments that are 
sufficient for mediating host protection, and show that this protection requires the host 
gene tol-1. Notably, introduction of SagA into a non-protective intestinal bacteria, E. 
faecalis, is sufficient to mediate host protection in C. elegans as well as germ-free mice, 
suggesting that SagA acts through evolutionarily conserved host pathways. We 
hypothesize that SagA-generated peptidoglycan fragments may strengthen intestinal 
barrier integrity through local innate immune activation to confine pathogens to the 
intestinal lumen. Our results suggest that commensal bacteria can restrict intestinal 
pathogens by directly modifying microbial-associated molecular patterns in the intestine. 
Overall, the projects described in this thesis underscore the role of bacterial 
metabolites, such as fatty acids and peptidoglycan fragments, in restricting intestinal 
pathogens.
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CHAPTER 1. Mechanisms of pathogen restriction by the intestinal microbiome 
Composed of over 1013 cells from some 300 different species, the human 
intestinal microbiome regulates host nutrition and metabolism, immune system 
maturation and homeostasis1, and resistance to enteric pathogens2-4. Despite individual 
heterogeneity in microbial composition, trends in community structure can be correlated 
with host health and disease5. Microbial dysbiosis is associated with various diseases, 
including: allergy6, diabetes7, obesity8, and inflammatory bowel disease9. The importance 
of the microbiome in pathogen restriction is broadly demonstrated in germ-free and 
antibiotic-treated animals, which exhibit chronic colitis and an increased susceptibility to 
bacterial pathobionts and pathogens10-12.  
Over the last decade, various mechanisms of pathogen restriction by the intestinal 
microbiome have been elucidated. These fall generally into two categories, namely: (1.) 
The modulation of host immunity to restrict pathogens and (2.) The direct inhibition of 
pathogen growth and virulence (Figure 1.1). In this Chapter, we will discuss these modes 
of commensal-mediated pathogen restriction, with a focus on the molecular and genetic 
bacterial factors involved. 
Mechanisms of pathogen restriction through host immunomodulation. 
Recognition of microbial-associated molecular patterns (MAMPs) by both 
intestinal epithelial cells and lymphoid cells is required for proper immune system 
development and response to bacterial pathogens13. MAMPs are conserved microbial 
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factors, such as bacterial cell-surface components, that elicit innate immune responses 
upon recognition by pattern recognition receptors. Toll-like receptors, Nod-like receptors, 
and C-type lectin receptors all respond to MAMPs derived from commensal bacteria and 
pathogens alike. 
Figure 1.1. An overview of microbiota-mediated pathogen restriction mechanisms. 
A schematic of different mechanisms by which intestinal bacteria can inhibit bacterial 
pathogens. On the left-hand side, mechanisms of direct pathogen inhibition are 
illustrated.  These include: competition over nutrients such as iron and specific 
monosaccharides; the production of metabolites including short-chain fatty acids 
(SCFAs)14-16, fucose17, and secondary (2°) bile acids18 that can inhibit pathogen growth 
and virulence pathways; as well as the production of antimicrobials such as 
bacteriocins19,20. On the right-hand side, indirect mechanisms of pathogen inhibiton, 
through host immune modulation, are depicted. These include: MAMP-induced 
enhancement of epithelial barrier function, involving the secretion of antimicrobial 
proteins (AMPs), mucins, and secretory IgA (sIgA)21,22; induction of pro-inflammatory 
TH17 cell differentiation23; as well as the induction of anti-inflammatory TReg cell 
proliferation24-26.  
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The activation of these pattern recognition receptors leads to a variety of 
downstream immune responses. Toll-like receptor (TLR) signaling in response to a 
diversity of microbial factors leads to NF-κB activation and the production of pro-
inflammatory cytokines, antimicrobial proteins, and TH1-type immunity27. NOD1 and 
NOD2 are peptidoglycan recognition receptors that activate NF-κB and MAPK pathways 
to promote autophagosome formation, TH2-type immunity, as well as the production of 
pro-inflammatory cytokines and antimicrobial proteins28. Other Nod-like receptors 
(NLRs) sense a variety of bacterial factors and are involved primarily in inflammasome 
formation29. C-type lectin receptors (CLRs) are largely involved in fungal immunity, 
however mucus sensing by Dectin-1 is important for immune homeostasis30. In addition, 
CLRs recognize mycobacterial surface sugars, leading to the production of pro-
inflammatory cytokines and TH17 development. The basal immune responses elicited by 
these receptors in response to intestinal bacteria helps maintain immune system 
homeostasis31.  
Bacterial surface components including lipo-polysaccharide, lipo-teichoic acid, 
peptidoglycan, capsular polysaccharides, flagellin, and surface proteins can all be 
recognized by pattern recognition receptors to modulate intestinal immunity32. For 
example, lipo-teichoic acids from commensal Lactobacillus are recognized by TLR-2, 
and stimulate pro-inflammatory immune responses33,34. In contrast, NOD2 recognition of 
Lactobacillus peptidoglycan stimulates an anti-inflammatory response that alleviates 
chemically-induced colitis35. TLR-5 recognition of bacterial flagellin by dendritic cells 
leads to production of the antimicrobial peptide RegIIIγ, which limits colonization of 
vancomycin-resistant Enterococcus36,37. Surface layer protein A (SlpA) produced by 
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Lactobacillus acidophilus is recognized by the C-type lectin receptor DC-SIGN on 
dendritic cells, although it is not known how this affects host response to pathogens38. 
Hyper-activation of pattern recognition receptors may be prevented by controlling 
the localization and abundance of receptors, as well as by specific negative regulators of 
the downstream pathways. Variability in the specific bacterial cell-surface components 
that are recognized may also tailor host immune responses to pathogenic or commensal 
bacteria. 
One important downstream response of microbial pattern recognition is the 
modulation of epithelial barrier function21. Secreted mucins, antimicrobial proteins, and 
secretory IgA (sIgA), all serve to exclude bacteria from a sterile zone maintained close to 
the surface of intestinal epithelial cells22. Recognition of intestinal bacterial MAMPs 
helps to maintain this barrier. For example, administration of lipo-polysaccharide and 
peptidoglycan can restore the mucous barrier in germ-free mice, and protect against 
chemically-induced colitis39. Intestinal bacteria can specifically enhance the production of 
various components necessary for maintaining barrier function. For example, in vitro, 
Lactobacillus can enhance epithelial cell secretion of the mucin Muc340. In mice, 
commensal bacteria taken up by dendritic cells induce IgA production to enhance barrier 
function41. 
An important aspect of epithelial barrier function is the production of 
antimicrobial peptides42. Toll-like receptor recognition of commensal bacteria by Paneth 
cells leads to the production of antimicrobial proteins, including the C-type lectins 
RegIIIβ and RegIIIγ43,44. This, in turn, restricts penetration through the mucosa by both 
pathogenic and commensal bacteria44,45. Specific bacteria and bacterial components can 
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induce the production of RegIIIγ and other antimicrobial proteins. For example, mono-
colonization of mice with just Bacteroides thetaiotaomicron can increase the expression 
of RegIIIγ43. As mentioned earlier, TLR-5 recognition of flagellin can also enhance 
RegIIIγ production36,37. Recognition of flagellin from the commensal E. coli strain Nissle 
1917 also induces the production of another antimicrobial protein, β-defensin-2, by 
epithelial cells in vitro46,47. NOD2 recognition of peptidoglycan leads to the secretion of 
another type of antimicrobial protein, α-defensin, and is required for the inhibition of 
Listeria monocytogenes infection in mice48. 
The regulation of tight junctions and epithelial cell turnover by intestinal bacteria 
also serves to enhance epithelial barrier integrity. In vitro, Lactobacillus plantarum can 
enhance the expression of epithelial cell tight junction proteins49,50, and reduce damage to 
the epithelia caused by enterohemorrhagic E. coli (EHEC) infection51. In mice, indole 
produced by intestinal bacteria can also enhance the expression of tight junction proteins, 
and protect against chemically-induced colitis52,53. Lactobacillus rhamnosus secretes two 
putative peptidoglycan hydrolases, p75 and p40, that activate Akt to inhibit apoptosis and 
enhance epithelial cell proliferation54,55. In mice, acetate production by Bifidobacterium 
longum also prevents epithelial cell apoptosis as well as Shiga toxin translocation to 
inhibit EHEC pathogenesis56,57. 
Intestinal bacteria can also promote the development and differentiation of innate 
lymphoid cells, IgA-producing cells, and T cells. TH17 cells and TReg cells are important T 
cell subsets that mediate pro-inflammatory and anti-inflammatory responses in the 
intestine respectively. Specific intestinal bacteria can skew the ratio of these two cell 
types, which can differentially affect bacterial pathogenesis. For example, adhesion of 
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segmented filamentous bacteria (SFB) to intestinal epithelial cells induces the 
differentiation of TH17 cells, which leads to the production of pro-inflammatory 
cytokines, antimicrobial peptides, and secretion of IgA. These responses cumulatively 
inhibit C. rodentium infection23. Specific microbial products present in the lumen, such as 
ATP, can also drive the differentiation of TH17 cells58. Intestinal bacteria can also induce 
the proliferation of anti-inflammatory TReg cells. For example, dendritic cell presentation 
of the Bacteroides fragilis capsular polysaccharide, polysaccharide A, promotes the 
development of anti-inflammatory TReg cells, which protect against both chemically- and 
bacterially-induced colitis24-26. Bifidobacterium infantis can also increase TReg cell 
numbers to inhibit Salmonella typhimurium-mediated inflammation although the 
microbial factors involved are unknown59. 
Mechanisms of direct pathogen inhibition by intestinal bacteria. 
Besides modulating host immunity, intestinal bacteria can restrict enteric 
pathogens through metabolic competition, direct killing, or the inhibition of pathogen 
virulence mechanisms. The effects of metabolic competition on pathogen colonization 
can be observed in the case of Citrobacter rodentium infection of mice60. C. rodentium 
transiently colonizes the intestines of wild-type mice, but persistently colonizes the 
intestines of germ-free mice. This differential colonization is due to metabolic 
competition over monosaccharides. Mono-colonization of mice with intestinal bacteria 
that fully rely on monosaccharide metabolism, limits C. rodentium use of this essential 
nutrient, and hence limits colonization. In a similar fashion, the combined sugar 
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metabolism of commensal E. coli strains HS and Nissle 1917 has been suggested to 
inhibit EHEC colonization in mice61. 
Iron is an essential, but limiting nutrient in the intestine. For this reason, many 
intestinal bacteria produce iron-chelating siderophores to increase iron uptake. Host-
secreted antimicrobial proteins, such as lipocalin-2, restrict bacterial growth by binding 
and inactivating diverse bacterial siderophores. However, bacterial pathogens, including 
Salmonella enterica, evade lipocalin-2-mediated growth inhibition by producing 
modified siderophores that cannot be bound by lipocalin-2 62,63. In this context, E. coli 
Nissle 1917, which expresses four iron uptake systems resistant to lipocalin-2, competes 
against Salmonella for iron to limit Salmonella colonization and subsequent 
inflammation64. 
In addition to limiting pathogen growth through metabolic competition, some 
intestinal bacteria can specifically kill pathogens by producing bacteriocidal compounds. 
Metagenomics analysis of the intestine has revealed an abundance of natural products, 
including antibiotics, encoded by intestinal bacteria65. The role of antibiotics generated in 
vivo, however, is unclear. A well-characterized class of bacterially-encoded 
antimicrobials are bacteriocins. Bacteriocins are diverse lytic peptides that are generally 
of narrow-spectrum activity against related bacterial species66. Lactobacillus species 
encode a variety of bacteriocins19,20, and some, such as plantaricin, which is produced by 
Lactobacillus plantarum, are expressed in the intestine67. In the context of intestinal 
infection, the bacteriocin Abp118 produced by Lactobacillus salivarus has been shown to 
inhibit Listeria monocytogenes infection in mice68. Another bacteriocin, thurucin CD, 
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which is produced by Bacillus thuringensis, limits Clostridium difficile proliferation in an 
in vitro human distal colon model while largely maintaining the intestinal microbiota69,70.  
Intestinal bacteria can also directly affect pathogen virulence mechanisms. 
Pathogens regulate the expression of virulence genes by sensing various environmental 
factors, some of which can be modified by intestinal bacteria. For example, expression of 
the Shigella flexneri Type-3 secretion system involved in host cell invasion is regulated 
by oxygen availability. S. flexneri senses a local increase in oxygen availability close to 
the intestinal epithelial surface, and in response, increases virulence gene expression71. 
Intestinal bacteria that adhere to the mucosa, such as Lactobacillus rhamnosus72 could 
potentially inhibit Shigella invasion by consuming local oxygen. 
The concentration of different metabolites can also affect pathogen virulence. For 
example, the expression of fucosidases by Bacteroides thetaiotaomicron cleaves fucose 
from host mucins. EHEC senses fucose levels through the FusKR two-component 
system, and in response decreases the expression of virulence genes required for the 
formation of attaching and effacing lesions (AE lesions)17. Bacterial fermentation in the 
intestine results in the secretion of diverse short-chain fatty acids. Short-chain fatty acids 
can directly modulate the virulence of various pathogens, possibly through covalent 
protein modification. For example, Salmonella enterica decreases the expression of a 
Type-3 secretion system required for host cell invasion in response to the short-chain 
fatty acids butyrate and propionate14-16. In mice, acetate production by Bifidobacterium 
breve inhibits the production of Shiga toxin by EHEC 73. Secreted factors from B. 
thetaiotaomicron can also inhibit EHEC Shiga toxin expression, although the 
mechanisms underlying this inhibition are unknown74. The products of bacterial 
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metabolism can also inhibit pathogen growth directly. For example, Clostridium scindens 
generates secondary bile acids that inhibit C. difficile growth in mice18. In some cases, 
microbiota-generated metabolites can enhance pathogen virulence. For example, 
succinate produced by B. thetaiotaomicron, can be consumed by C. difficile to enhance 
intestinal colonization75. In the case of Citrobacter rodentium, succinate specifically 
enhances Type-3 secretion system expression, and hence virulence76.  
Pathogen sensing of inter-species quorum sensing molecules, such as N-acyl 
homoserine lactones (AHLs), has been proposed as a possible mechanism by which 
intestinal bacteria could modulate virulence. Both EHEC and Salmonella encode the 
transcription factor required for AHL recognition, SdiA, but lack the machinery to 
synthesize AHLs77,78. In the case of EHEC, AHLs repress the expression of virulence 
genes involved in the formation of AE lesions, but enhance the expression of acid-
resistance genes79. Consistent with this, SdiA is required for EHEC colonization of the 
cow rumen, but has no affect on intestinal colonization. Curiously, AHLs are largely not 
found in the intestine80,81, making the relevance of AHL-mediated quorum sensing in the 
intestine unclear. Intestinal bacteria may respond to other quorum sensing pathways, 
however, as intestinal delivery of auto-inducer-2 can alter microbiome reconstitution 
after antibiotic treatment82. 
Strategies of pathogen-mediated competition. 
Just as the microbiome employs numerous strategies to restrict pathogens, 
bacterial pathogens have evolved a variety of strategies to compete with the microbiome. 
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Many of the characterized strategies revolve around generating a distinct niche and/or 
gaining access to unique nutrients. In a simple sense, adhesion to the surface of intestinal 
epithelial cells by enteropathogenic E. coli and C. rodentium, or invasion into host cells 
by Salmonella could be viewed as a means to evade competing intestinal bacteria. The 
utilization of unique nutrients is another way to avoid competition with the microbiota. 
For example, pathogenic strains of E. coli consume a unique subset of mucus-derived 
sugars as compared to commensal strains of E. coli83.  
Pathogen-induced inflammation is a mechanism to disrupt the microbiome84 and 
release unique metabolites, giving pathogens a growth advantage. For example, 
Salmonella-induced intestinal inflammation leads to the generation of tetrathionate. 
Tetrathionate respiration by Salmonella confers a growth advantage over other intestinal 
bacteria that rely on fermentation85. In the inflamed intestine, ethanolamine utilization by 
both Salmonella86 and pathogenic E. coli87 can also enhance colonization88. Inflammation 
can also lead to the outgrowth of non-pathogenic members of the microbiota. For 
instance, nitrate released in the inflamed intestine is used in anaerobic respiration by 
commensal E. coli strains89. The effect of such shifts in microbiota composition on 
bacterial pathogenesis is unclear. 
Pathogens can also directly kill intestinal bacteria. For example, Salmonella 
enterica produces the bacteriocin Colicin Ib, which can kill E. coli in the inflamed 
intestine90. Vibrio cholera uses a Type-6 secretion system to deliver antimicrobial 
effectors to intestinal bacteria, such as E. coli91. Self-immunity to this secretion system is 
required for intestinal colonization, which suggests that V. cholera employs Type-6 
secretion in vivo92.  
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Introduction to the work presented in this thesis. 
The examples outlined in this Chapter highlight the dynamic nature of bacterial 
interactions in the intestine. Different model systems can emphasize the various 
contributions of host, commensal, and pathogen within this niche. Clarifying specific 
commensal determinants of pathogen restriction requires integrating in vitro and in vivo 
approaches. 
In the following chapters, we describe two projects aimed at developing new 
methodologies to study how intestinal bacteria restrict bacterial pathogenesis. In Chapters 
2 and 3, we use a chemical reporter strategy to analyze long-chain and short-chain fatty 
acid protein modifications in bacteria. In Chapter 2, we assess the utility of these 
reporters in E. coli for the visualization and identification of fatty-acid modified proteins. 
In Chapter 3, we apply this method to explore the effects of long-chain and short-chain 
fatty acids on Salmonella pathogenesis in vitro. In Chapter 4, we describe a C. elegans 
model system that we use to investigate the effects of Enterococcus faecium on 
Salmonella pathogenesis. 
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CHAPTER 2. Visualization and large-scale profiling of protein fatty-acylation in 
bacteria using bio-orthogonal chemical reporters. 
INTRODUCTION. 
Fatty acids are important metabolites that modulate the activity of microbes and 
host cells in vivo. Intestinal bacteria are exposed to millimolar concentrations of short-
chain fatty acids93, which are generated from microbial fermentation. In contrast, free 
long-chain fatty acids derived from ingested fats are present at micromolar 
concentrations94. For intracellular bacterial pathogens, fatty acids can be a key nutrient 
source. For example, M. tuberculosis relies heavily on host fatty acids as a carbon source, 
and mutants of fatty acid metabolism are attenuated in mice95. Other pathogens, such as 
Salmonella, are generalists, exploiting a wide variety of host carbon sources96,97. The shift 
from an extracellular to intracellular lifestyle is cued by changes in a variety of factors, 
including pH, antimicrobial peptides, and the concentration of various cations and 
nutrients98,99. The modulation of bacterial physiology and virulence in response to fatty 
acids, however, is not well understood. Besides altering metabolic flux, exposure to fatty-
acids can regulate cell function through the post-translational modification of proteins. 
Long-chain fatty acylation of proteins can modulate protein localization, folding, 
as well as interactions with other proteins. In bacteria, the canonical form of protein 
lipidation is sequence-specified and results in N-terminal tri-acylation (Figure 2.1a) 100,101. 
In E. coli K-12, such bacterial lipoproteins are predicted to constitute approximately 2% 
of the proteome. These lipoproteins are a functionally diverse subset of membrane-
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associated proteins that are involved in various cellular processes including membrane 
maintenance, transport, and signal transduction. Many lipoproteins have also been 
implicated in the virulence and immune evasion mechanisms of bacterial pathogens, and 
have been found to enhance antigenicity, adhesion, and antibiotic resistance in a variety 
of pathogens102. In addition, lipoproteins can stimulate host innate immunity through 
recognition by TLR-1, TLR-2, and TLR-6. Despite their clinical relevance and role in 
numerous essential membrane processes, the majority of bacterial lipoproteins remain 
uncharacterized. This is due, in part, to a lack of robust and convenient tools for the 
detection and large-scale analysis of lipoproteins in bacteria. 
Figure 2.1. Long-chain fatty acid protein modifications in E. coli. 
a. Schematic of a bacterial lipoprotein modification in E. coli. An N-terminal cysteine is
modified with a thioether-linked diacyl glyceryl moiety and an amide-linked palmitate. 
n=15-18. b. Schematic of E. coli hemolysin A (HlyA) fatty-acylation. Two internal lysine 
residues (K564 and K690) are fatty-acylated by HlyC through an amide linkage. n=14. 
For both (a.) and (b.), the blue bar represents protein. 
The most well-characterized form of protein lipidation in bacteria is the 
generation of N-terminally tri-acylated lipoproteins. Although the precise modification 
can vary across species, the general pathway is largely conserved. This enzymatic 
pathway has been best-characterized in E. coli, which exhibits a 15-18 carbon chain-
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length preference101 (Figure 2.1a). Post-translational protein lipidation is directed by an 
N-terminal signal sequence comprising a lipobox motif with an invariant cysteine (Cys) 
residue. This lipobox motif is well-conserved, enabling the prediction of lipoproteins 
from primary amino-acid sequence across bacterial genomes. Lipobox-containing 
proteins are translocated through the inner membrane, where the enzyme Lgt installs a 
diacylglyceryl moiety, derived from membrane phospholipids, onto the lipobox Cys 
residue through a thioether linkage. The signal sequence of this prolipoprotein is cleaved 
by Lsp, and the newly generated N-terminus is fatty-acylated by Lnt. Mature lipoproteins 
are then selectively sorted to the inner or outer membrane by secondary recognition 
elements. 
Although this pathway is the predominant form of protein lipidation in E. coli, 
maturation of the toxin hemolysin (HlyA) and related RTX family exotoxins occurs 
through a unique protein fatty-acylation pathway (Figure 2.1b) 103. Hemolysin is fatty-
acylated via an amide linkage on two internal lysine residues by the dedicated acyl-
transferase, HlyC. HlyC is cotranscribed with HlyA, and requires acyl-ACP as a donor, 
exhibiting chain-length preference through enhanced affinity for myristoyl-ACP. The 
prevalence of other non-canonical mechanisms of lipidation is not known and requires 
further investigation. 
At the start of this study, existing methods available for the identification and 
analysis of long-chain fatty acid protein modifications in bacteria were limited to 
radioactive labeling and bioinformatic approaches. Labeling with radioactive fatty acids 
has low sensitivity and is not amenable to large-scale proteomic studies. Bioinformatic 
predictions are limited to lipoproteins containing a recognizable N-terminal lipobox 
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signal motif. As aforementioned, this motif directs the canonical form of protein 
lipidation in Gram-negative bacteria, but the prevalence of non-canonical mechanisms of 
lipidation is not known, making proteomic analysis essential for exploring the diversity 
of lipid-modified proteins in bacteria. The large-scale analysis of short-chain fatty acid 
protein modifications has been focused primarily on lysine acetylation104,105. Proteomic 
profiling of lysine acetylation has been achieved through acetyl-lysine antibody pull-
down followed by mass spectrometry. However, protein modifications on alternative 
residues or with alternative short-chain fatty acids have not yet been systematically 
assessed. 
Bio-orthogonal chemical reporter strategies have been used to characterize and 
discover fatty-acylated proteins in several eukaryotic systems106. Briefly, a bio-orthogonal 
chemical reporter refers to any functionalized reporter that can be covalently reacted to a 
secondary detection tag through a non-cellular reaction. In particular, the Hang laboratory 
has developed alkyne-functionalized fatty acid reporters that can be specifically reacted 
to azide-modified detection tags through Cu(I)-catalyzed cycloaddition (Figure 2.2a-c). 
Once fed to cells, alkynyl-fatty acids are metabolized and installed onto endogenous 
protein targets. Modified proteins can then be either visualized using a fluorescent 
detection tag (Figure 2.2a), or isolated with a biotin secondary tag (Figure 2.2b). At the 
time of this study, these reporters had not been used to explore the diversity of 
endogenously expressed bacterial fatty-acylated proteins. Given that the enzymatic 
machinery required for fatty acid processing and protein modification is different 
between eukaryotes and bacteria, the utility of alkynyl-fatty acid reporters in bacteria 
needed to be assessed. 
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Our goal in this study was to determine if alkynyl-fatty acid reporters could be 
used to visualize and identify fatty-acid modified proteins in bacteria. We first focused on 
characterizing long-chain fatty acid chemical reporters in E. coli. Because bacterial 
lipoproteins are a well-characterized class of fatty-acid modified proteins, we could 
validate these reporters using known and predicted lipoproteins. 
RESULTS. 
To assess the incorporation of long-chain fatty acid chemical reporters onto 
proteins in E. coli, we metabolically labeled E. coli K12 with alkynyl-fatty acid (alk-FA) 
reporters of varying chain lengths (alk-12, alk-14, and alk-16). Bacterial cell lysates were 
then reacted with the fluorophore azido-rhodamine (Figure 2.2a) via Cu(I)-catalyzed 
azide-alkyne cycloaddition (CuAAC) (Figure 2.2c). Alk-FA-modified proteins were 
visualized by in-gel fluorescence, revealing selective and chain-length dependent labeling 
of proteins (Figure 2.3a). Since alk-14 qualitatively labeled E. coli proteins most 
efficiently, we focused on further characterizing this fatty acid reporter. Alk-14 was 
rapidly incorporated into proteins (Figure 2.3c) and labeling was robust at low 
micromolar dosing (Figure 2.3b). For all subsequent experiments, we labeled cells with 
20 µM alk-14. At this dose, alk-14 had no effect on E. coli growth rate (Figure 2.3d). 
To determine if alk-14 is incorporated into known lipoproteins, we generated a C-
terminally His6-tagged construct of the lipoprotein NlpE107. This construct was driven by 
an IPTG-inducible promoter, and expressed in E. coli BL21(DE3). In-gel fluorescence 
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visualization of purified NlpE-His6 showed specific labeling of NlpE-His6 by alk-14 
(Figure 2.3e). 
Figure 2.2. Bio-orthogonal labeling strategy for the analysis of fatty-acid modified 
proteins. 
a. Structure of azido-rhodamine. Rhodamine (highlighted in red) allows imaging by in-
gel fluorescence. b. Structure of azido-azo-biotin. Biotin (highlighted in red) allows 
protein pull-down with streptavidin beads (see Figure 3a) for subsequent protein 
identification. The azo-benzene moiety allows specific protein elution from streptavidin 
beads using sodium dithionite. c. Strategy for the covalent modification and analysis of 
fatty acid modified proteins. Bacteria are metabolically labeled with alkyne-
functionalized fatty acids (alk-12, alk-14, alk-16, alk-2, alk-3, or alk-4). Cells are lysed, 
and modified proteins are reacted with azido-functionalized detection tags (a.) and (b.) by 
Cu(I)-catalyzed azide-alkyne cycloaddition (CuAAC) for subsequent imaging or pull-
down studies. 
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Figure 2.3. Characterization of alk-14 labeling in E. coli. 
a. Profile of E. coli proteins labeled with alkyne-fatty acids (alk-FA) of varying chain
length separated by SDS-PAGE. Modified proteins were imaged by rhodamine 
fluorescence. Alk-FA were used at 20 µM. (-) indicates DMSO control treatment. 
Coomassie blue (CB) indicates protein loading. b. Labeling of E. coli proteins with 
varying doses of alk-14. From left to right, E. coli were labeled with 0, 5, 10, 20, 50 and 
100 µM of alk-14. c. Time dependence of alk-14 labeling of E. coli. E. coli were labeled 
for 0-60 minutes with 20µM alk-14. Note: pelleting and washing of cells before lysis 
took ~10 minutes, during which time, alk-14 incorporation occurs. d. Growth curves of 
E. coli treated with 20µM alk-14 (blue line) or DMSO control (black line). Data averaged 
from three experiments. Error bars (not visible) represent ± standard deviation. e. alk-14 
labeling of E. coli expressing the His6-tagged lipoprotein NlpE under an IPTG-inducible 
promoter. Total cell lysate and elution after His6 purification are shown. 
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Figure 2.4. Enrichment and identification of fatty acid modified proteins 
a. Strategy for the pull-down and identification of acyl-modified proteins. Bacteria are
metabolically labeled with alkyne-fatty acids. Cells are lysed, and proteins are reacted 
with azido-azo-biotin by Cu(I)-catalyzed azide-alkyne cycloaddition (CuAAC). Biotin-
modified proteins are enriched upon binding to streptavidin beads. Proteins are 
specifically eluted off of streptavidin beads with sodium dithionite, and separated by 
SDS-PAGE. Proteins are then subjected to in-gel trypsin digestion for proteomics 
analysis. b. Alk-14-labeled proteins retrieved from E. coli using the azido-azo-biotin 
affinity tag. E. coli expressed IPTG-inducible NlpE-His6 as a control for lipoprotein pull-
down. Cells were metabolically labeled under inducing and non-inducing conditions with 
20 µM alk-14 and labeled lysates were reacted with azido-rhodamine for in-gel 
visualization (left). The remaining lysate was reacted with azido-azo-biotin, and labeled 
proteins were captured on streptavidin beads. Captured proteins were eluted with Na2S2O4 
and total eluant was visualized by Coomassie blue (CB) (right). The red star indicates an 
eluted band corresponding to the predicted molecular weight of NlpE. c. alk-2 and alk-14 
labeled proteins retrieved from E. coli using the azido-azo-biotin affinity tag. Cells were 
metabolically labeled with 5 mM alk-2 or 20 µM alk-14. 20 µg of labeled lysates were 
reacted with az-Rho for in-gel visualization (left). The remaining lysate was reacted with 
azido-azo-biotin, and labeled proteins were captured on streptavidin beads. Captured 
proteins were eluted with Na2S2O4 and total eluant was visualized by CB (right).  
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Figure 2.4. Enrichment and identification of fatty acid modified proteins 
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Having established by fluorescence visualization that alk-14 labels a diversity of 
proteins, and is incorporated into a known lipoprotein, we sought to use alk-14 for the 
large-scale enrichment and identification of fatty acid modified proteins. To do this, we 
reacted alk-14-labeled E. coli cell lysates with a cleavable azido-azo-biotin affinity tag108 
(Figure 2.2b and 2.4a). This secondary tag allows for the enrichment of biotinylated 
proteins with streptavidin beads. Enriched modified proteins are then selectively eluted 
with sodium dithionite (Na2S2O4), and recovered proteins are separated by SDS-PAGE 
for gel-based proteomics.  
Figure 2.5. Summary of alk-14 modified proteins identified in E. coli. 
a. High confidence proteins identified by LC-MS/MS from experiments described in
Figure 3b and c. The y-axis represents the sum of peptide-spectral counts from the three 
proteomics runs. The x-axis represents arbitrary protein number. Predicted lipoproteins 
are highlighted in red. Proteins validated as alk-14-modified in this study are indicated. 
Induction of NlpE-His6 in Experiment 2 is reflected in the high number of spectral counts 
for this protein. b. alk-14 labeling of C-terminally His6-tagged lipoproteins SlyB and 
YggG. His6-tagged GroL was used as a negative control. Proteins were expressed from an 
IPTG-inducible promoter. Total cell lysates and elutions from the His6-purifications are 
shown. Anti-His6 Western blot (WB) indicates protein loading.  
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As a positive control for lipoprotein recovery, we labeled E. coli expressing NlpE-
His6 under both inducing and non-inducing conditions. Coomassie blue visualization of 
the Na2S2O4-eluted proteins showed that NlpE-His6 was strongly recovered in the IPTG-
induced sample as compared to the non-induced sample (Figure 2.4b). In a separate 
experiment, we labeled E. coli with either alk-14 or an alkynyl-acetic acid analog, alk-
2109, to determine if protein labeling and pull-down was generic to any alkyne-
functionalized reporter (Figure 2.4c). As compared to alk-14, alk-2 did not efficiently 
label bacterial proteins by fluorescence profiling, and few proteins were recovered after 
Na2S2O4-elution (Figure 2.4c). 
Proteomics analysis of the three alk-14 labeled samples yielded 45 high 
confidence alk-14 labeled candidate proteins, of which 69% were known or predicted 
lipoproteins, based on prediction by LipoP110 (Figure 2.5a, Appendix 1). An additional 51 
candidates were identified with medium confidence, of which only 12% were predicted 
lipoproteins (Appendix 2). As expected, NlpE was substantially enriched in the IPTG-
induced samples. In addition to recovering predicted lipoprotein candidates, we also 
selectively recovered acyl-carrier protein (AcpP) from alk-14 labeled samples, suggesting 
that alk-14 is accepted into the fatty acid synthesis pathway. Of the 150 proteins 
identified from the alk-2 labeled sample, only 3% were predicted lipoproteins, indicating 
that lipoprotein labeling is specific to alk-14 and not due to general labeling of proteins 
by alkynyl-functionalized substrates (Appendix 3). Although our lab has shown that alk-2 
can be installed into sites of histone lysine acetylation in mammalian cells109, only 23% of 
the alk-2 proteins we identified in E. coli were previously reported to be lysine 
acetylated. This suggests that alk-2 is not be a robust acetic-acid analogue in E. coli, and 
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may reflect differences in substrate specificity of the acetylation machinery between 
eukaryotes and prokaryotes. 
We next validated alk-14 labeling on additional proteins selectively recovered 
from alk-14 labeled E. coli. We confirmed alk-14 labeling of SlyB, a known lipoprotein, 
and YggG, a predicted but unverified lipoprotein, by fluorescence detection of C-
terminally His6-tagged constructs after affinity purification (Figure 2.5b). Non-specific 
labeling due to over-expression is unlikely since no labeling was observed with the over-
expressed non-lipidated protein, GroL-His6 (Figure 2.5b). 
One of the proteins identified in our alk-14 samples not predicted to be a 
lipoprotein was YjgF, a highly conserved protein found in all domains of life involved in 
branched chain amino acid synthesis111. To verify alk-14 labeling of YjgF, we generated 
an N-terminally His6-tagged YjgF construct (His6-YjgF). Attachment of an N-terminal 
His6-tag helps rule out the possibility that YjgF bears an unrecognized N-terminal signal 
peptide, since the N-terminus is cleaved after lipoprotein modification. We were able to 
robustly detect and purify His6-YjgF by His6 affinity, indicating retention of the N-
terminal His6-tag. Alk-14 modification was verified by in-gel fluorescence detection of 
purified His6-YjgF (Figure 2.6a). YjgF contains one internal cysteine (Cys) residue at 
position 107, as a potential site of alk-14 modification that is conserved in many bacterial 
homologs of YjgF. To determine if Cys107 is the site of alk-14 modification, we 
generated a Cys107 to Serine mutant (His6-YjgF-C107S). We observed no alk-14 
labeling of His6-YjgF-C107S by in-gel fluorescence detection, suggesting that YjgF is 
indeed fatty acid modified at this residue (Figure 2.6a). 
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Figure 2.6. Characterization of YjgF fatty acid modification. 
a. alk-14 labeling of His6-tagged YjgF on Cysteine107. Mutation of Cysteine107 to
Serine abrogates alk-14 labeling. Both wild-type YjgF and YjgF C107S were expressed 
from an IPTG-inducible promoter. Total cell lysates and elutions from the His6-
purifications are shown. Anti-His6 Western blot (WB) indicates protein loading. b. Dose-
dependent competition of alk-14 labeling on His6-purified His6-YjgF by palmitate, but 
not sodium acetate. Palmitate was used at increasing concentrations of 20 µM, 200 µM, 
and 400 µM. Sodium acetate was used at increasing concentrations of 200 µM, 2 mM, 
and 4 mM. Coomassie blue (CB) shows protein loading. c. His6-YjgF is not labeled by 
short-chain fatty acid reporters alk-2, alk-3, or alk-4, nor by a non-hydrolyzable alk-16 
analogue (nh). alk-2, alk-3, and alk-4 were used at 5 mM, nh and alk-14 were used at 20 
µM. d. Cellular fractionation of alk-14 labeled E. coli expressing SlyB-His6, e. GroL-
His6, f. His6-YjgF, or His6-YjgF C107S. Cells were lysed by osmotic shock, and lysates 
were separated into cytoplasmic (C) or membrane (M) fractions. Samples were reacted 
with azido-rhodamine, and His6-tagged proteins were purified on Ni-NTA beads. Eluant 
was separated by SDS-PAGE, and gels were analyzed by in-gel fluorescence. Anti-His6 
Western blot (WB) or Coomassie blue (CB) staining indicate protein loading. SlyB-His6 
and GroL-His6 serve as controls for cellular fractionation and alk-14 labeling. Three 
independent replicates of cellular fractionation of His6-YjgF and His6-YjgF C107S are 
shown.  
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To determine whether the alk-14 labeling we observe on YjgF is reflective of 
long-chain fatty acid modification, we performed competition experiments of alk-14 
labeling with palmitic acid or sodium acetate. Alk-14 labeling on His6-YjgF was 
effectively competed away with increasing amounts of palmitic acid, but not with sodium 
acetate (Figure 2.6b), suggesting that YjgF is covalently modified with a long-chain fatty 
acid metabolite. Consistent with this, His6-YjgF was not labeled by short-chain fatty acid 
analogues alk-2, alk-3, or alk-4109 (Figure 2.6c).  
Figure 2.7. E. coli growth and protein labeling with a non-hydrolyzable alkynyl-
fatty acid analogue. 
a. Structure of alk-16nh. b. Growth curve of E. coli labeled with DMSO (control), alk-16,
or alk-16nh (nh). c. Fluorescence profile of E. coli proteins modified by alk-16 or alk-
16nh. By fluorescence, alk-16 and alk-16nh label similar protein profiles to a similar 
extent. (-) indicates DMSO control.  
To evaluate whether any processing of alk-14 is necessary for covalent 
attachment to YjgF, we assessed labeling of His6-YjgF with the non-hydrolyzable long-
chain fatty acid analogue alk-16nh112 (Figure 2.7a). Alk-16nh has an oxygen replacing the 
a
kDa
75
25
37
alk-FA:       -   16   nh
az
id
o-
rh
od
am
in
e
C
B
b
O
D
60
0
Hour
DMSO
alk-16
nh
0 2 4 6 8
0.0
0.5
1.0
1.5
2.0
c
O
OH
O
( )
11
26	  
β-carbon, thereby theoretically preventing both degradation and elongation of fatty acid 
chain length. However, alk-16nh should still be incorporated into both membrane 
phospholipids113 and proteins, since it can still be CoA-modified. Alk-16nh did not affect 
E. coli growth and labeled a similar protein profile as alk-16 (Figure 2.7b-c), which is 
consistent with our results that the majority of proteins labeled with long-chain fatty acid 
reporters in E. coli are bona fide lipoproteins. However, in-gel fluorescence visualization 
of alk-16nh labeling showed no labeling of purified His6-YjgF (Figure 2.6c), suggesting 
that some chain-length processing of alk-14 is necessary before modification of YjgF. 
To determine if fatty-acid modification alters YjgF membrane association, we 
fractionated alk-14 labeled E. coli expressing either His6-YjgF of His6-YjgF-C107S into 
cytoplasmic and membrane fractions. Using SlyB and GroL as membrane-associated, and 
cytoplasmic controls respectively (Figure 2.6d-e), we were confident that our 
fractionation method robustly separated these protein populations. We found that His6-
YjgF and His6-YjgF-C107S fractionated similarly to both the cytoplasmic and membrane 
compartments (Figure 2.6f). Likewise, alk-14-modified YjgF was found in both the 
cytoplasmic and membrane-bound fractions, although it was consistently more enriched 
in the membrane-associated fraction (Figure 2.6f). This suggests that fatty acid 
modification of Cys107 does not influence the localization of YjgF to membranes. 
Although several structural studies have been conducted on YjgF family 
proteins114-117, the biochemical activity of YjgF has only recently been elucidated. YjgF 
deaminates reactive enamine/imine intermediates formed in pyridoxal 5’ phosphate-
dependent reactions important to branched-chain amino acid biosynthesis118,119. YjgF 
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Figure 2.8. Profiling of fatty-acid modified proteins across bacterial species. 
a. Fluorescence profiling of alk-FA-modified proteins in various bacteria. E. coli, B.
subtilis, S. typhimurium, P. aeruginosa, and M. smegmatis were labeled with 20 µM of 
alk-12, alk-14, or alk-16 for 30 minutes in LB media. Cell lysates were reacted with 
azido-rhodamine, then separated by SDS-PAGE and visualized by in-gel fluorescence. 
Coomassie blue (CB) staining indicates protein loading. b. Fluorescence profiling of 
short-chain fatty-acid-modified proteins in E. coli. alk-2, alk-3, and alk-4 were used at 5 
mM, while alk-12, alk-14, and alk-16 were used at 20 µM.  
converts imines to alpha-keto-acids, releasing ammonia, which may decrease the levels 
of toxic metabolites in the cell. Important to this enzymatic function is the coordination 
of water in the active site of YjgF to attack the imine118. Binding of alpha-keto butyrate117 
and the coordination of water by YjgF family proteins have been confirmed by structural 
studies115. Cys107 is involved in the hydrogen bonding necessary for the coordination of 
water. Therefore, the modification of Cys107 with a fatty acid metabolite would likely 
alter or abolish enzymatic function of YjgF. This may be a mechanism to regulate YjgF 
activity, and suggests an interesting coupling of amino acid and fatty acid metabolism 
that warrants future investigation. 
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Having established that alk-14 is a useful tool in E. coli for the visualization and 
large-scale identification of lipoproteins, we sought to generally evaluate the utility of 
long-chain fatty acid reporters across various bacterial species. We labeled Gram-
negative bacteria (Salmonella enterica and Pseuodomonas aeruginosa), Gram-positive 
bacteria (Bacillus subtilis), and mycobacteria (Mycobacteria smegmatis) with alk-12, alk-
14, and alk-16 (Figure 2.8a). By in-gel fluorescence visualization, we saw robust labeling 
and distinct fluorescence profiles amongst the bacteria evaluated (Figure 2.8a). This 
suggests that long-chain alkynyl-fatty acid reporters may be useful in different bacterial 
species to study fatty acid protein modifications. 
Our analysis of alk-2 labeling in E. coli suggested that this reporter is not robustly 
incorporated as an acetic acid analogue onto proteins. To evaluate protein labeling by 
other short-chain fatty acid reporters, we compared protein profiles of E. coli labeled with 
alk-2, alk-3, and alk-4 by fluorescence visualization (Figure 2.8b). Alk-3 and alk-4 
labeled similar protein profiles, distinct from alk-2 (Figure 2.8b), suggesting that these 
reporters are incorporated onto different proteins than alk-2. Future proteomics analyses 
on alk-3 and alk-4 modified proteins may lend insight into the effects of short-chain fatty 
acids on bacterial physiology. 
SUMMARY. 
In this Chapter, we have demonstrated that the long-chain fatty acid reporter alk-
14 can be used to visualize and identify lipoproteins in E. coli. The discovery of lipobox-
independent fatty-acid modification on YjgF highlights the strength of this methodology 
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for identifying novel lipid-modified proteins. Future investigation into the effects of this 
modification on YjgF enzyme activity is of interest. Our survey of alk-FA labeling in 
other bacterial species suggests that this method may be a general strategy for evaluating 
bacterial lipoproteins. 
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MATERIALS AND METHODS. 
Strains. 
E. coli K12 strain EC100, E. coli DH5α, E. coli BL21 (DE3), Salmonella enterica 
serovar typhimurium strain IR715, Pseudomonas aeruginosa strain PAO1, and Bacillus 
subtilis 168 were grown in LB media (BD Difco) at 37 °C. Mycobacterium smegmatis 
strain mc2155 was grown in LB was supplemented with 0.05% Tween-80. When 
necessary, ampicillin was used at 100 µg/ml. 
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Chemicals. 
All chemicals were obtained either from Sigma-Aldrich, MP Biomedicals, Alfa Aesar, 
TCI, Fluka, or Acros and were used as received unless otherwise noted. Azido- and 
alkynyl-fatty acids, azido-rhodamine and azido-diazo-biotin were previously 
synthesized108,109,112,120. 
Fluorescence labeling and visualization of alkynyl-fatty acid modified proteins. 
Metabolic labeling of bacteria with alkynyl-fatty acids: 
For metabolic labeling, bacterial cultures of OD600 = 1.7-2.0 (absorbance was 
determined by SpectraMax M2) were labeled with 20 µM alk-12, alk-14, alk-16, or alk-
16nh (from a 50 mM stock in DMSO) or 5 mM alk-2, alk-3, or alk-4 (from a 200 mM 
stock of alk-FA Na+ salt in water). As a negative control, the same volume of DMSO or 
water was added in lieu of alkynyl-fatty acid. Cells were incubated at 37 °C for time 
indicated and pelleted at 5000 g for 5 minutes. Cells were washed with PBS (2x), and 
then lysed as described below or flash frozen and stored at -80 °C for future lysis. 
Preparation of cell lysates: 
Cell pellets were lysed in 0.1% SDS buffer (50 mM triethanolamine (TEA), 150 
mM NaCl, 0.1% SDS, 1X EDTA-free protease inhibitor cocktail (Roche), 5 mM PMSF 
from a 250 mM stock in EtOH, 0.1 µl benzonase (Sigma)) by sonicating pellet for 10 
seconds, then incubating on ice for 10 minutes. 5 µl of 10 mg/ml lysozyme (in ddH2O) 
(Sigma) was added to each sample. Samples were incubated on ice for 30 minutes. Then, 
12% SDS buffer (in 50 mM TEA, 150 mM NaCl) was added to bring final SDS 
31	  
concentration to 4%. Cells were sonicated in 5 second intervals until the lysates were 
clear. Cell lysates were centrifuged at 1000 g for 5 min to remove cell debris and 
supernatant was collected. Protein concentration was determined by BCA assay (Pierce). 
Typical protein concentration obtained was between 3-5 mg/ml. 
CuAAC reaction: 
50 µg of cell lysate was brought up to 45 µl volume in 4% SDS buffer (50 mM 
TEA, 150 mM NaCl, 4% SDS). 5 µl of click chemistry reagents were added to the lysate 
as a master mix: azido-rhodamine: 0.1 mM, from a 10 mM stock solution in DMSO; 
tris(2-carboxyethyl)phosphine hydrochloride (TCEP): 1 mM, from a 50 mM freshly 
prepared stock solution in ddH2O; tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine 
(TBTA): 0.1 mM, from a 2 mM stock in 4:1 tert-butanol:DMSO; and CuSO4-5H2O: 1 
mM, from a 50 mM freshly prepared stock in ddH2O. 
Samples were incubated at room temperature for 1 hour. After incubation, 
proteins were precipitated by chloroform/methanol precipitation as follows: 4X MeOH, 
1.5X chloroform, and 3X ddH2O by volume were added to CuAAC reaction and 
vortexed. Samples were centrifuged at 20,000 g for 1 minute and the aqueous layer was 
removed. Samples were washed two times with 4X methanol, mixing gently by 
inversion, centrifuging at 20,000 g for 1 minute, then decanting off the supernatant each 
time. Protein pellets were air-dried, then resuspended by sonication in 35 µl buffer and 15 
µl 4X SDS sample buffer (250 mM 0.5M Tris-Cl pH 6.8, 8% SDS, 40% glycerol, 0.4% 
bromo-phenol blue, 20% 2-mercaptoethanol), and heated at 95 °C for 5 minutes. 20 µg of 
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protein corresponding to 20 µl was loaded per lane for separation by SDS-PAGE (Bio-
Rad Criterion Tris-HCl 4%-20% gel). 
Visualization by in-gel fluorescence: 
Proteins separated by SDS-PAGE were visualized by in-gel scanning using an Amersham 
Biosciences Typhoon 9400 variable mode imager (excitation 532 nm, 580 nm filter, 30 
nm band-pass). 
Growth curves. 
Comparing growth with alk-14 vs. DMSO: E. coli was grown overnight at 37 °C, in 2 ml 
of LB media. This culture was diluted 1:1000 in fresh LB media containing either 20 µM 
alk-14 (as a 50 mM stock in DMSO) or an equal volume of DMSO. 1 ml aliquots of the 
culture were removed at given time points, and OD600 was measured. Each condition (alk-
14 and DMSO) was done in triplicate.  
Comparing growth with alk-16 vs. alk-16nh: E. coli was grown overnight at 37 °C, in 2 
ml of LB media. This culture was diluted 1:1000 in fresh LB media containing either 20 
µM alk-16 or alk-16nh (as a 50 mM stock in DMSO). 1 ml aliquots of the culture were 
removed at given time points, and OD600 was measured. 
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Plasmids used in this study. 
Table 2.1. Cloning primers used in this study. The given genes were PCR amplified 
out of the E. coli genome using these primer sets. 
Gene name Primer sequences 
nlpE FW: aaaggatccaatggtgaaaaaagcgatag 
RV: tttgaattcttctgccccaaactactgcaa 
slyB FW: aaaggatccatgattaaacgcgtattgg 
RV: tttctcgaggcgcggagaaacggtcacc 
yggG FW: aaaggatccaatgaaaattcgcgcctta 
RV: tttgaattcttcttaatcccatccgcgc 
groL FW: aaagaattcaatggcagctaaagacgtaa 
RV: tttaagcttcatcatgccgcccatgc 
yjgF FW: aaaggatccaagcaaaactatcgcgacg 
RV: tttctgcagttagcgacgaacagcgatc 
The nlpE PCR product was cut with BamH1 and EcoR1; slyB was cut with Xho1 
and BamH1; yggG was cut with BamH1 and EcoR1; and groEL was cut with EcoR1 and 
HinD3. PCR products were ligated to the pET21a vector cut with corresponding 
restriction enzymes, yielding C-terminal His6-tagged proteins. The yjgF PCR product 
was cut with BamH1 and Pst1 and was ligated to the pETDUET-1 vector cut with 
BamH1 and Pst1, yielding an N-terminal His6-tagged protein. All ligations were 
transformed into EC100 chemically competent cells for sequencing of plasmid DNA. 
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Sequence-verified constructs were then transformed into BL21(DE3) chemically 
competent cells for expression. 
His6-YjgFC107S was constructed from His6-yjgF in the pET-DUET-1 vector 
using the Stratagene site directed mutagenesis kit (Agilent) as per the manufacturer's 
protocol with the following mutagenesis primer set: 
FW: cccggcacgttcttctgttgaagttgcccg 
RV: cgggcaacttcaacagaagaacgtgccggg 
Analysis of His6-tagged proteins. 
For labeling and over-expression of proteins, BL21 (DE3) cultures were 
inoculated 1:100 with overnight cultures, and grown for 2 hours or until culture OD600 ~ 
0.4. Cultures were induced with 1 mM IPTG and labeled with 20 µM of alk-14 or alk-
16nh, or 5 mM of alk-2, alk-3, or alk-4 for 4 hr. Non-induced and non-labeled controls 
were included for each experiment. Cells were pelleted at 5000 g for 5 minutes and 
washed 2X with PBS. Cells were lysed and reacted with azido-rhodamine via CuAAC as 
described above. His6-tagged proteins were purified from cell lysates on a small-scale 
using Ni-NTA agarose beads (Qiagen) as per the manufacturer's protocol. Total lysates 
and eluants were analyzed either by Commassie blue staining or by Western blot using 
anti-His6 HRP conjugated polyclonal antibody (Bethyl Laboratories) at a 1:10,000 
dilution. 
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Palmitic acid and sodium acetate competition of YjgF labeling. 
LB media supplemented with varying amounts of palmitic acid (from a 100mM stock in 
DMSO) or sodium acetate (from a 1M stock in water) was inoculated at a 1:100 dilution 
of an overnight culture of E. coli carrying His6-yjgF. This culture was grown shaking at 
37 °C to OD600 = 0.4. 1mM IPTG was added to induce expression of His6-yjgF, and cells 
were grown for 15 minutes. Then, 20µM alk-14 was added and cells were labeled for 3 h 
45 m. Cells were lysed and reacted with azido-rhodamine via CuACC as described 
above. His6-YjgF was purified from cell lysates as described above. Total lysates and 
eluants were analyzed by in-gel rhodamine fluorescence and Coomassie blue staining. 
Subcellular fractionation. 
IPTG induced, alk-14 labeled E. coli expressing GroL-His6, SlyB-His6, His6-YjgF, or 
His6-YjgF C107S were pelleted at 5000 g for 10 m. Cells were washed once in 30mM 
Tris buffer pH 8.1 then re-suspended in 20% sucrose (w/v) in 30mM Tris (pH 8.1). 100 
µg lysozyme was added and samples were incubated on ice for 30 minutes. Distilled 
water with 1X EDTA-free protease inhibitor cocktail (Roche), 5 mM PMSF (from a 250 
mM stock in EtOH), and 0.1 µl benzonase (Sigma) was added and samples were 
sonicated in 5 second bursts 5 times. Samples were then centrifuged at 5000 g for 10 m to 
remove unlysed cells. Supernatant was then centrifuged at 20,800g for 1.5 hour. 
Supernatant was collected as the cytoplasmic fraction. The pellet was washed twice in 
water, centrifuging 1.5 hours at 20,800g after each wash, then lysed in 4% SDS buffer. 
This was considered the membrane fraction. Protein concentration was determined by 
BCA assay (Pierce). Samples were then reacted with azido-rhodamine via CuACC, then 
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separated by SDS-PAGE. Gels were scanned for in-gel fluorescence, then stained with 
Coomassie blue. A parallel gel was run to perform a Western Blot using polyclonal anti-
His6 HRP conjugated antibody at a 1:10,000 dilution. 
Azido-biotin labeling and enrichment of alk-14 modified proteins for MS ID. 
Metabolic Labeling: 
E. coli Experiments 1 and 2: An overnight culture of E. coli carrying pET21a-NlpE-His6 
was diluted 1:1000 in fresh LB and grown until OD600 = 0.4. Cells were induced with 1 
mM IPTG, 20 µM alk-14 was added to the culture, and cultures were grown for 4 hours. 
Non-induced samples were also prepared. DMSO controls for alk-14 labeling were also 
prepared for both induced and non-induced cultures. 
E. coli Experiment 3: LB was inoculated 1:1000 from an overnight culture of E. coli and 
cells were grown in LB media to OD600 = 1.8. 20 µM alk-14 (from a 50 mM stock in 
DMSO) or 5 mM alk-2 (from 200 mM stock of alk-2 Na+ salt in water) were added to the 
media and cells were labeled for 30 min. A DMSO control for alk-FA labeling was also 
prepared. 
CuAAC reaction: 
Cell lysates (10 – 20 mg) were brought up to a volume of 8.9 ml with a final SDS 
concentration of 2%. To this, 200 µl of 5 mM azido-diazo-biotin; 200 µl of 50 mM 
TCEP; 500 µl of 2 mM TBTA; and 200 µl of 50 mM CuSO4 were added, and samples 
were incubated for 1.5 hours at room temperature. After incubation, proteins were 
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precipitated by chloroform/methanol precipitation as described: 4x MeOH, 1.5X 
chloroform, and 3X ddH2O were added to reaction, and samples were vortexed 
vigorously. Samples were centrifuged at 5200 g for 30 minutes, and the aqueous layer 
was removed. Samples were washed two times with 4X methanol, by vortexing 
vigorously, centrifuging at 5200 g for 30 minutes, then decanting off the supernatant each 
time. Protein pellets were air-dried, then resuspended in 1 ml 4% SDS buffer and 20 µl 
0.5 M EDTA pH 8. Protein concentration was estimated by BCA assay. 
Streptavidin bead capture: 
CuAAC reacted proteins (5-15 mg) were added to PBS-washed high-capacity 
streptavidin agarose beads (Thermo scientific) (beads in a 50% Brij buffer slurry, 100 µl 
per 5 mg protein). Beads were incubated with cell lysates for 1 hour at room temperature 
with rocking. Beads were then washed 2X with 10 ml of 0.1% SDS in PBS, 3X with 10 
ml PBS, 2X with 50 mM ABC, then incubated for 30 minutes with freshly made 8 M 
urea solution (500 µL 8 M urea, 25 µl 200 mM TCEP, 25 µl 400 mM iodoacetamide). 
Beads were washed 2X with 50 mM ABC, then transferred to a dolphin tube with 1 ml 
ABC. Proteins were eluted off beads in two steps with a total of 400 µl freshly prepared 
elution buffer (0.5% SDS, 25 mM Na2S2O4 in 50 mM ABC) by rocking for 1 hour at 
room temperature, then for 30 minutes. Eluant was concentrated using a Microcon YM-
10 centrifugal filter (Millipore) as per manufacturers protocol. Microcon filters were 
rinsed twice with 50 µl 1% SDS/75 mM BME to collect all sample, and samples were 
dried by vacuum at room temperature. Samples were resuspended in 25 µl LDS buffer 
(1X LDS (Invitrogen), 5% BME), boiled for 5 minutes at 95 ºC, spun at 1000 g for 1 
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minute, then separated by SDS-PAGE. Gels were stained with Coomassie blue and 
destained overnight (40% methanol, 10% acetic acid, 50% water) 
Sample preparation for MS ID: 
Each gel lane was cut into 8 slices. Slices were minced, and pieces were washed once in 
50 mM ABC, twice in 1:1 50 mM ABC to acetonitrile (ACN), and once in ACN. Slices 
were dried by speed-vac. 2 µg of trypsin in 50 mM ABC was added to each gel slice, and 
slices were incubated overnight at 37 ºC. Proteins released from the gel were collected, 
and gel slices were washed in 1:1 50 mM ABC:ACN + 0.1% TFA twice, collecting the 
supernatant each time. The pooled supernatant was dried by speed-vac then resuspended 
in 25 µl 0.1% TFA in water for analysis by LC-MS/MS, performed at the Rockefeller 
University Proteomics Facility. 
Analysis of MS data: 
Peptides were identified using SEQUEST version 28 (revision 13) and X!Tandem 
searched against either the EcoProt E. coli complete proteome with 10 ppm precursor 
mass and 1 Da fragment mass tolerance. Cysteines were considered constantly modified 
by carboxyamidomethylation. Allowable variable modifications in Sequest included 
oxidation on methionine and tryptophan, deamidation of asparagine and glutamine. 
Allowable variable modifications in X!Tandem were the same with the addition of amino 
acid cyclization with an N-terminal glutamine or iodoacetamide-capped cysteine (-NH3), 
or glutamic acid (-OH) resulting in N-terminal pyrrolidone carboxylic acids. Sequest and 
X!Tandem data was then imported into Scaffold for Peptide Prophet filtering. Peptides 
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with ≥95% likelihood of correct assignment were accepted. Proteins matched with 2 or 
more tryptic peptides were accepted; for those proteins, non-tryptic peptides were also 
accepted. From these data compiled by Scaffold, high and medium confidence thresholds 
were assigned by spectral counts, High confidence was assigned as >10 spectral counts 
and >10 fold enrichment above unlabeled control, and medium confidence was assigned 
as >5 spectra counts and >5 fold enrichment above the unlabeled control. 
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CHAPTER 3. Analysis of fatty acid protein modifications in Salmonella enterica. 
INTRODUCTION. 
Salmonella enterica is the causative agent of gastroenteritis and typhoid fever 
worldwide98,121. During infection, Salmonella migrates from the lumen of the intestine to
inside host cells. Broadly, two pathogenicity islands, termed SPI-1 and SPI-2, mediate the 
invasion into host cells and subsequent adaptation to the intracellular environment. SPI-1 
and SPI-2 each encode Type-3 secretion systems to inject bacterial effector proteins into 
host cells. The injection of SPI-1 effector proteins causes transient actin remodeling to 
induce Salmonella internalization, as well as transient inflammation. Passive mechanisms 
of invasion, such as disruption of tight junctions or phagocytosis by dendritic cells122,123, 
do not cause as much inflammation. SPI-2 effectors proteins are involved in intracellular
survival mechanisms including the formation of a Salmonella-containing vacuole (SCV). 
A variety of environmental cues regulate the gene expression changes necessary 
to facilitate the transition from extracellular to intracellular niche99,124. Many two-
component systems are involved in sensing changes in pH, oxidative stress, and the 
concentration of different metabolites to regulate gene expression. Among these, the 
PhoP/Q two-component system is activated upon acidic pH and Mg2+ starvation, and is 
required for intracellular survival125. PhoP is thought to regulate, directly or indirectly, the 
expression of ~5% of the genome, particularly genes involved in virulence processes 
including: outer membrane modification to evade immune detection126, antimicrobial 
peptide resistance, and expression of the SPI-2 Type-3 secretion system127. 
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Concomitantly, PhoP/Q represses genes involved in invasion of host cells128,129, as this 
process is presumably no longer required. PhoP/Q also regulates the expression of 
lipoproteins including SlyB, an outer membrane lipoprotein that negatively regulates 
PhoP/Q130.  
Both long-chain and short-chain fatty acids can modulate Salmonella virulence. 
For example, unsaturated, but not saturated, long-chain fatty acids directly repress PhoQ 
activity131. Short-chain fatty acids secreted by intestinal bacteria regulate Salmonella SPI-
1 gene expression in a chain-length dependent manner. Specifically, acetate enhances 
invasion through activation of SPI-1 gene expression16, while propionate and butyrate14 
are inhibitory. The mechanisms underlying this differential regulation by short-chain 
fatty acids are not well characterized, although post-translational modification of the SPI-
1 transcriptional regulator HilD with a propionate-derived metabolite has been 
suggested15. 
In bacteria, the diversity and function of short-chain fatty acid protein 
modifications has only recently been explored104,105. In particular, multiple recent 
proteomics studies have highlighted the extent of lysine acetylation132-135. This widespread 
reversible modification regulates key cellular processes including transcription, 
translation, protein folding, and central metabolism. Lysine acetylation of protein active 
sites or interaction surfaces can modulate protein function. For example, in E. coli, 
acetylation of the response regulator RcsB inhibits its ability to bind target DNA, 
preventing transcription136. In Salmonella enterica, the widespread acetylation of 
metabolic enzymes regulates the flow of central carbon metabolism134. Besides protein 
acetylation, the modification of proteins with other short-chain fatty acids also occurs. 
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For example, lysine propionylation on the propionyl-CoA synthetase PrpE inhibits its 
function137. Other short-chain fatty acid-derived metabolites, such as malonate138 and 
succinate139-141, can also modify proteins. However, the prevalence and diverse functions 
of these modifications are not known. 
The enzymatic machinery involved in short-chain fatty acid protein modifications 
is best characterized for acetylation. Lysine acetylation can be either enzyme-mediated or 
non-enzymatic. In enzyme-mediated lysine acetylation, the protein acetyltransferase YfiQ 
(Pat) transfers an acetyl group from acetyl-CoA onto protein targets. In non-enzymatic 
lysine acetylation, acetyl phosphate, generated by acetate kinase (Ack), transfers its 
acetyl group onto lysine135,142. Acetylation via either mechanism is subject to enzyme-
mediated de-acetylation by the de-acetylase CobB143. Another form of enzyme-mediated 
acetylation is N-terminal acetylation. This seemingly rare constitutive modification 
occurs only on a handful of ribosomal proteins and requires specific N-terminal 
acetyltransferases. The enzymes involved in other short-chain fatty acid modifications are 
not known. However, Pat and CobB appear to be relatively promiscuous, as both protein 
propionylation137 and succinylation139 can be mediated by these enzymes.  
Having demonstrated the utility of alkynyl-long-chain fatty acid reporters for the 
analysis of lipoproteins in E. coli, we explored protein fatty-acylation in Salmonella 
enterica serovar typhimurium (S. typhimurium) in response to different virulence-
stimulating in vitro culture conditions. In addition, we evaluated the utility of alkynyl-
short-chain fatty acid reporters to study the inhibitory effects of short-chain fatty acids on 
Salmonella pathogenicity. 
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RESULTS. 
To investigate virulence-associated changes in lipoprotein expression, we labeled 
S. typhimurium with alk-14 in LB, MgM, and MgM+ media. We chose these media as a 
simple way to mimic virulence states representative of SPI-1 and SPI-2 activation. In LB, 
S. typhimurium basally expresses SPI-1 genes, and secretes SPI-1 effectors into the 
culture supernatant (Figure 3.1a). MgM is a low pH (5.0), low Mg2+ (10 µM) minimal 
media designed to mimic the intracellular environment144. In this media, the PhoP/Q two-
component system is activated, and the SPI-1 locus is suppressed (Figure 3.1a). To 
isolate PhoP/Q Mg2+ specific responses, we also labeled Salmonella in a modified MgM 
media we call MgM+. This media is modified to be neutral pH (7.2) and high Mg2+ (10 
mM). In this media, although SPI-1 effector secretion was inhibited, we did detect 
expression of the effector SopE2 by Western blot in cell lysates (Figure 3.1a), suggesting 
that transcription of the SPI-1 locus was not inhibited. To verify activation of PhoP/Q in 
MgM media specifically, we performed one proteomics experiment using S. typhimurium 
expressing FLAG-tagged MgtB145, which is a PhoP-activated Mg2+ transporter146. By 
Western blot, we detected MgtB-FLAG expression only in Salmonella grown in MgM 
media (Figure 3.1b). Alk-14-labeled S. typhimurium cell lysates were reacted with azido-
rhodamine for in-gel fluorescence profiling and with azido-azo-biotin for affinity 
enrichment and gel-based proteomics (Figure 3.1b). 
Proteomics analysis of the three alk-14 labeled LB samples yielded 250 high 
confidence candidate proteins, ~5.5 times as many as identified from E. coli (Appendix 
4). Curiously, only 10% of these high confidence proteins were predicted to be 
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lipoproteins (Figure 3.1c). This is in contrast to the E. coli dataset, where ~70% of the 
high confidence proteins labeled by alk-14 were predicted lipoproteins (Figure 3.1c). 
Instead, 49% of the high confidence proteins we recovered from S. typhimurium were 
metabolic enzymes, in contrast to the 13% identified from our E. coli dataset (Figure 
3.1c). These included enzymes involved in both fatty acid catabolism and biosynthesis, 
suggesting the metabolism of alk-14 and the subsequent incorporation of an alk-14-
derived metabolite into further metabolic pathways (Figure 3.2).  The metabolism of alk-
14 into shorter-chain acyl-CoA derivatives was suggested by labeling of the acetyl-coA 
synthetase, Acs, as well as numerous enzymes in the TCA cycle, glyoxlate shunt, 
pyruvate dehydrogenase, and gluconeogenesis/glycolysis pathways (Figure 3.2). 
Covalent modification of the enzymes in these pathways with an alkyne-acetyl analogue 
is likely, given that lysine acetylation has been previously reported on several of these 
enzymes as a means to regulate carbon flux134. Indeed, ~15% of the proteins we identified 
are known to be acetylated. The abundant labeling of these enzymes could also represent 
covalent intermediates of enzyme activity.  The extensive metabolism of alk-14 by 
Salmonella but not E. coli, may be due to the highly diverse and redundant metabolic 
activity unique to Salmonella, which is thought to represent an adaptation to 
pathogenicity96,97. 
Despite the metabolic processing of alk-14, we recovered the protein YjgF from 
our alk-14 labeled LB samples, suggesting that fatty acid modification of YjgF is 
conserved (Appendix 4). YjgF shares 94% sequence identity between E. coli and S. 
typhimurium, and the site of modification, Cys107, is conserved. To validate alk-14 
labeling of S. typhimurium YjgF, we generated a C-terminally His6-tagged construct of 
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Salmonella YjgF (YjgF-His6), and expressed it in E. coli BL21 (DE3) for labeling and 
purification. By in-gel fluorescence visualization, we saw alk-14 labeling of purified 
YjgF-His6 (Figure 3.1d), confirming that S. typhimurium YjgF is fatty acid modified. 
Proteomics analysis of our MgM and MgM+ datasets revealed a breakdown of 
alk-14 into numerous metabolic pathways, similar to that seen in the LB dataset 
(Appendices 5 and 6). From the MgM+ samples, we identified the SPI-1 effector proteins 
SipA, SipB, and SopB (Appendix 5), which is consistent with the expression of SopE2 
we observed in MgM+ cell lysates. In contrast, we did not identify any SPI-1 effector 
proteins from the MgM dataset (Appendix 6). Activation of PhoP/Q in MgM media was 
evidenced by the identification of PhoP itself, as well as PhoP-activated proteins PhoN, 
MgtB, OmpX, and SlyB147 (Appendix 6). Interestingly, we recovered the SPI-1 
transcriptional regulator HilA from our MgM dataset (Appendix 6). PhoP/Q represses 
expression of the SPI-1 locus through the inhibition of HilA128. The direct modification of 
HilA with a fatty acid derived metabolite could be a mechanism of inhibition. Activation 
of HilA requires the integration of several inputs upstream of the transcriptional 
regulators HilE, HilC, HilD, and RtsA124. The activity of HilD, which positively regulates 
HilA, has been shown to be inhibited by propionate, but not acetate15. Post-translational 
modification of HilD with either propionate or acetate134 may mediate this regulation. The 
covalent modification of both HilD and HilA with fatty acid derived metabolites could 
serve to fine-tune the regulation of SPI-1 expression by short-chain fatty acids. 
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Figure 3.1. Summary of alk-14 modified proteins identified in S. typhimurium. 
a. Profile of proteins secreted by S. typhimurium in different media visualized by
Coomassie blue staining (CB). Effector proteins are secreted in LB and BHI media, but 
not MgM+, MgM, or N-minimal (Nmin) media. Anti-HA Western blot (WB) of SopE2-
CPG2-HA from cell lysates of the same cultures. SopE2 is a SPI-1 effector protein 
required for host cell invasion. SopE2 is not expressed in MgM or N+ media. Ponceau 
staining (Pon) shows loading control. b. Representative gels of alk-14-labeled proteins 
retrieved from S. typhimurium using the azido-azo-biotin affinity tag. S. typhimurium 
were grown in LB, MgM+ or MgM media. Cells were metabolically labeled with 20 µM 
alk-14 and labeled lysates were reacted with azido-rhodamine for in-gel visualization 
(left). The remaining lysate was reacted with azido-azo-biotin, and labeled proteins were 
captured on streptavidin beads. Captured proteins were eluted with Na2S2O4 and total 
eluant was visualized by Coomassie blue (CB) (right). Anti-FLAG WB shows expression 
of MgtB-FLAG in MgM media, but not MgM+ or LB media. For a list of proteins 
identified, see Appendices 4-6. c. Pie charts of high-confidence candidate proteins 
recovered from alk-14 labeling in LB for E. coli as compared to S. typhimurium. 
Proportion of predicted lipoproteins (aqua), metabolic enzymes (purple) or other proteins 
(grey) is as indicated. d. Alk-14 labeling of S. typhimurium YjgF-His6. YjgF was cloned 
from S. typhimurium and expressed with a C-terminal His6-tag in E. coli BL21(DE3) 
under an IPTG-inducible promoter. Total cell lysates and elutions from the His6-
purifications are shown. Coomassie blue (CB) indicates protein loading. 
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Figure 3.1. Summary of alk-14 modified proteins identified in S. typhimurium. 
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Figure 3.2. Metabolism of alk-14 by S. typhimurium 
Schematic showing alk-14-labeled enzymes involved in central metabolism identified in 
the S. typhimurium LB proteomics dataset. All enzymes in the fatty acid degradation, 
fatty acid biosynthesis, TCA cycle, glyoxylate shunt, and glycolysis/gluconeogenesis 
pathways are shown. Enzymes recovered with high confidence in alk-14 samples are 
highlighted in red. alk-14 theoretically feeds into the fatty acid degradation pathway as 
indicated.  
To take a more direct approach to assess the protein modifications possibly 
underlying the regulation of the SPI-1 locus by short-chain fatty acids, we first assessed 
whether alk-3 and alk-4 could mimic the inhibitory effects of short-chain fatty acids on 
SPI-1 effector secretion. We analyzed SPI-1 effector secretion in vitro in the presence of 
alk-3 or alk-4109 (Figure 3.3a and b). By Coomassie blue staining, we observed a dose-
dependent reduction in secretion for both alk-3 and alk-4, which is consistent with the 
inhibitory effects on SPI-1 secretion by propionate and butyrate respectively (Figure 
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3.3b). To measure secretion rate, we used a Salmonella reporter strain previously 
developed by the Hang laboratory that expresses SopE2-CPG2-HA under its endogenous 
promoter148. Secreted CPG2 cleaves a dye presented in the media, resulting in a color 
change that allows quantification of secretion rate. Measuring SopE2-CPG2-HA 
secretion confirmed dose-dependent inhibition of secretion by alk-3 and alk-4 (Figure 
3.3c). Fluorescence visualization of alk-3 and alk-4 modified proteins in the culture 
supernatant revealed modification of several effector proteins (Figure 3.3b). In alk-3 and 
alk-4 labeled cell lysates, we observed an abundance of modified proteins (Figure 3.3a). 
Future proteomics analysis of these labeled proteins may give insight into the inhibitory 
effect of short-chain fatty acid reporters. Although alk-2-labeling in E. coli suggests that 
it does not function as an acetic acid analogue, it will be interesting to re-evaluate alk-2 
labeling in Salmonella, and determine if it can enhance SPI-1 secretion. 
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Figure 3.3. Protein labeling and inhibition of SPI-1 effector secretion by short-chain 
fatty acids. 
a. Fluorescence profiling of alk-4ONa and alk-3ONa-modified proteins in S. typhimurium
cell lysates. Cells were metabolically labeled with an increasing dose of either alk-4ONa 
or alk-3ONa in LB media (an increasing dose of 3 mM, 5 mM, 10 mM, and 20 mM was 
used for each reporter). 5 mM and 20 mM NaCl were used as a control for salt addition. 
(-) indicates water control. Coomassie blue (CB) indicates protein loading. b. 
Fluorescence profile (top) and Coomassie blue staining (bottom) of SPI-1 protein 
secretion in culture. Increasing dose of alk-4ONa and alk-3ONa inhibits the secretion of 
SPI-1 effector proteins, while an increasing dose of NaCl has no effect on secretion. c-e. 
SopE2-CPG2-HA secretion assays from culture supernatants of cells exposed to 
increasing doses of c. NaCl, d. alk-4ONa, and e. alk-3ONa. SopE2-CPG2-HA secretion 
decreases in a dose dependent manner with alk4ONa and alk-3ONa, but not with NaCl.  
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Figure 3.3. Protein labeling and inhibition of SPI-1 effector secretion by short-chain 
fatty acids. 
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SUMMARY. 
Our studies in Salmonella have emphasized the metabolic differences between E. 
coli and Salmonella that make lipoprotein characterization in Salmonella using alk-14 
difficult. The study of alk-14 metabolism by Salmonella could be a viewed as a 
cautionary tale for using this reporter in the analysis of bacterial lipoproteins. 
Alternatively, alkyne-functionalized fatty acid reporters could be used in pulse-chase 
experiments to study lipid metabolism, turnover, or enzyme specificity, as it affects 
protein modification. Such experiments would be complementary to metabolic studies 
that use 13C-isotope labeling. Future studies requiring a lipoprotein-specific reporter in 
Salmonella could evaluate the utility of alk-16nh112, which theoretically cannot engage 
fatty acid metabolic pathways. 
Our alk-14 proteomics analysis in Salmonella nonetheless suggests an intriguing 
fatty-acid modification on HilA that warrants future investigation. Future work 
characterizing the effects of short-chain fatty acid protein modifications on virulence 
using the reporters alk-3 and alk-4 seems to be a promising avenue, as these reporters 
function similarly to propionate and butyrate in inhibiting SPI-1 mediated effector 
secretion. In fact, recent work by Jerry Zhang from the Hang laboratory has confirmed 
that alk-14, alk-3, and alk-4 all label HilA, although the precise modification(s) and how 
they affect protein function remain to be determined. 
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MATERIALS AND METHODS. 
Strains. 
E coli DH5α, E. coli BL21-RIL(DE3), and Salmonella enterica serovar typhimurium 
strain IR715 were grown in LB (BD Difco). S. typhimurium strain MgtB-FLAG was a 
gift from Eduardo Groisman145.  
Plasmids used in this study.  
The S. typhimurium strain carrying SopE2-CPG2-HA was generated by Jacob Yount148. 
SopE2-CPG2-HA is encoded on the pWSK29 vector, which carries ampicillin resistance. 
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pET21a-YjgFStm-His6: YjgF was PCR amplified out of the S. typhimurium genome 
using the following primer set: 
FW: AAAGGATCCAATGAGCAAAACTATTGCGACGG 
RV: TTTGAATTCTTGCGACGAACAGCGATCGCTTCA 
The PCR product was cut with BamH1 and EcoR1 and ligated to cut pET21a vector. 
pET21a-YjgFStm-His6 was transformed into E. coli DH5α for sequencing, and the 
sequence-verified construct was transformed into E. coli BL21-RIL(DE3) for expression. 
Metabolic labeling and click chemistry methods for alkynyl-fatty acid labeled protein 
visualization and proteomics are essentially the same as outlined in Chapter 1 Materials 
and Methods, with the following modifications: 
Salmonella typhimurium Experiments 1, 2, and 3: Overnight cultures of S. typhimurium 
were diluted 1:1000 into fresh LB and grown up to OD600 = 1.4. For labeling in LB, 
culture was pelleted, washed @X in LB, resuspended in fresh LB with 20 µM alk-14 (or 
DMSO as negative control) and labeled for 4 hours. For labeling in MgM or MgM+ 
media, cultures were pelleted then washed 2X in MgM media144 (100 mM Tris-HCl, 5 
mM KCl, 7.5 mM (NH4)2SO4, 1 mM KH2PO4, 0.5 mM K2SO4, 38 mM glycerol, 10 µM 
MgCl2, 0.1% casamino acids, pH 5) or MgM+ media (100 mM Tris-HCl, 5 mM KCl, 7.5 
mM (NH4)2SO4, 1 mM KH2PO4, 0.5 mM KH2PO4, 38 mM glycerol, 10 mM MgCl2, 0.1% 
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casamino acids, pH 7), resuspended in either MgM or MgM+ with 20 µM alk-14 (or 
DMSO as negative control) and labeled for 4 hours. 
After LC-MS/MS, peptides were searched against the S. typhimurium 14028 complete 
proteome found on Uniprot. 
SPI-1 protein secretion assays. 
SPI-1 secretion in different media: 2 ml of LB, BHI, MgM, MgM+, or N-minimal 
media149 (0.1 mM Tris-HCl, 5mM KCl, 7.5 mM (NH4)2SO4, 0.5 mM K2SO4, 1 mM 
KH2PO4, 0.2% glucose, 38 mM glycerol, 10 µM MgCl2, 0.1% casamino acids, pH 7.4) 
was inoculated 1:30 with an overnight culture of S. typhimurium expressing SopE2-
CPG2-HA. Cultures were grown for 4 hours, shaking at 37 °C, the pelleted at 7000 g for 
5 minutes. 1 ml of culture supernatant was precipitated with trichloro acetic acid (TCA) 
at a final concentration of 10% overnight at 4 °C. Precipitated proteins were pelleted at 
20,800 g for 30 minutes, rinsed 2 times in acetone, then air-dried. Proteins were then 
separated by SDS-PAGE and visualized by Coomassie blue staining. A parallel gel was 
run for anti-HA (Clonetech) Western blot and Ponceau staining. 
SPI-1 secretion in the presence of alk-3, alk-4, or NaCl: For each condition, 2 mL of LB 
was inoculated 1:30 with an overnight culture of S. typhimurium. Varying concentrations 
of alk-3, alk-4 or NaCl was added to media. Cultures were processed as described above. 
Proteins were separated by SDS-PAGE and visualized by rhodamine fluorescence and 
Coomassie blue staining. 
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SopE2-CPG2-HA assay. 
 The SopE2-CPG2-HA secretion assay was performed as described by Yount et al148. 
Varying doses of alk-3, alk-4 or NaCl were added to each secretion reaction. 
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CHAPTER 4. Characterization of a bacterial secreted peptidoglycan hydrolase that 
enhances host resistance to Salmonella. 
INTRODUCTION. 
As discussed in Chapter 1, the intestinal microbiome mediates host resistance to 
enteric pathogens through a variety of direct and indirect protection mechanisms. Recent 
concerns over the spread of antibiotic resistance, as well as enhanced pathogen virulence 
after antibiotic-induced dysbiosis150,151, have made the development of probiotic therapies 
an attractive alternative to antibiotics. Indeed, the clinical potential of microbiota-based 
therapies against infectious disease is now being explored. Available treatments are still 
limited, however, with fecal transplantation for Clostridium difficile infection being the 
only FDA-approved therapy152,153. Transitioning to more targeted therapeutics requires a 
better understanding of the specific protection mechanisms of individual bacterial 
species. 
The characterization of beneficial bacterial species has been facilitated by germ-
free and gnotobiotic animal models. Although these models reduce the complexity of the 
microbiota, they do not reduce the complexity of the host immune system, which has co-
evolved with, and is regulated by, the intestinal microbiome. We reasoned that a more 
simplified animal model could be useful as an initial screening platform to identify new 
commensal factors relevant to inhibiting bacterial pathogenesis. These candidate 
commensal factors could then be tested for activity in more complex mammalian models. 
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We chose to develop C. elegans as a model host for the mechanistic exploration 
of commensal-pathogen interactions in the intestine. C. elegans has been used 
extensively as a model organism for studying evolutionarily conserved aspects of innate 
immunity and microbial pathogenesis154,155. C. elegans lacks an adaptive immune 
response, as well as innate immune cells. Instead, the C. elegans innate immune system 
comprises both constitutive and induced signaling pathways, many with homology to 
mammalian innate immune components. In response to intestinal infection, C. elegans 
mounts pathogen-specific immune responses156,157, which can lead to behavioral 
changes158 as well as the expression of antimicrobial and stress response effectors. The 
mechanisms of pathogen recognition, however, have not been characterized. The C. 
elegans genome lacks a diversity of putative TLRs or NLRs; however, it encodes over 
250 C-type lectin domain containing proteins159, which may function as pattern 
recognition receptors. 
Despite differences in host immunity, several human pathogens, including 
Salmonella enterica160,161, are pathogenic to C. elegans. After being ingested, Salmonella 
establishes a persistent luminal infection in C. elegans, ultimately resulting in death. In 
non-typhoid human infections, the majority of Salmonella persist extracellularly in the 
intestine98. Transient inflammation associated with invasion is thought to give the luminal 
population a competitive advantage over other intestinal bacteria162. In C. elegans, the 
requirement of Salmonella virulence factors involved in host cell invasion and 
intracellular replication is unclear163. Internalization of Salmonella by the intestinal 
epithelia has been reported, but bacteria were found mostly contained within 
autophagosomes and are subsequently degraded164. It is possible, then, that Salmonella 
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virulence determinants during infection of C. elegans instead reflect conserved 
adaptations to extracellular intestinal life required in non-systemic diarrheal disease. 
Broadly speaking, the C. elegans intestinal milieu is thought to have a similar 
physiology to the mammalian small intestine165. The intestinal epithelium is composed of 
polarized cells with apical microvilli. Cells are connected by apical junctions, which are 
homologous to mammalian tight junctions166. Coating the microvilli is a peritrophic 
matrix/glycocalyx167 containing unstructured proteoglycans168,169 that is functionally 
similar to the mammalian intestinal mucosa, acting as a barrier and filter. The basolateral 
basement membrane is composed of extracellular matrix proteins, including homologues 
of laminin and type IV collagen170. The intestinal lumen has a pH ranging from ~6 to ~4 
from pharynx to tail171, and comprises lysozymes, digestive enzymes, and antimicrobial 
peptides secreted by the intestinal epithelia. 
In the laboratory, C. elegans do not have an endogenous intestinal microbiota, and 
instead feed on a monoculture of E. coli OP50172. However, many species of bacteria are 
able to colonize the worm intestine. In the wild, C. elegans harbor live bacteria and yeasts 
in their intestine173, although the extent and composition of a stable C. elegans intestinal 
microflora is unknown. Interestingly, aerobically grown Enterococcus faecium can 
colonize the C. elegans intestine without causing apparent disease174. For this reason, we 
chose to focus on E. faecium as a model “commensal” in our studies. 
Enterococci are facultatively anaerobic, lactic acid bacteria, formerly classified as 
Group D Streptococci175. Enterococci are part of the intestinal microbiome of diverse 
animal species176,177 including: mammals, reptiles, birds, lamprey178, snails179, and flies. 
For this reason, Enterococci are regarded as primordial founding members of the 
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intestinal microbiome. In humans, E. faecium and E. faecalis constitute the predominant 
species of colonizing Enterococci. Although found throughout the small and large 
intestine, E. faecium and E. faecalis numbers are concentrated in the jejunum, ileum, and 
caecum180. 
In animals including chickens, pigs, dogs, and mice, probiotic strains of E. 
faecium have been shown to inhibit the pathogenesis of various enteric pathogens, 
including Salmonella enterica181,182. A variety of mechanisms have been proposed, 
including: secretion of antimicrobial bacteriocins183, modulation of host immunity184, and 
prevention of pathogen adhesion185; but the relevant in vivo protection mechanisms have 
remained unclear. Nevertheless, E. faecium is included in veterinary probiotic 
formulations against diarrheal disease. In humans, the utility of E. faecium as a 
therapeutic is limited due to its potential to acquire pathogenicity after antibiotic 
treatment in nosocomial infections186,187. Decoupling the beneficial effects of E. faecium 
from the risks associated with using E. faecium as a probiotic could greatly increase its 
therapeutic potential. 
In this study, we aimed to develop C. elegans as a model system to characterize E. 
faecium-mediated restriction of Salmonella pathogenesis. We hoped that in the absence 
of an endogenous microbiota and host adaptive immune system, we would be able to 
distill commensal-pathogen interactions relevant to more complex mammalian models. 
Thus, our C. elegans model system would provide a bridge between in vitro studies and 
mouse models, to discover and characterize the conserved bacterial factors underlying E. 
faecium probiotic function. 
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RESULTS. 
For our experiments, we used Salmonella enterica serovar typhimurium strain 
IR715 (S. typhimurium) as a model pathogen. This strain is a naladixic acid resistant 
variant of strain 14028, and both strains are comparably pathogenic to C. elegans (Figure 
4.1a). To investigate whether E. faecium can inhibit Salmonella pathogenesis in C. 
elegans, we developed a pulsed treatment-infection assay (Figure 4.1c). The standard C. 
elegans Salmonella infection model is one of continuous re-infection188, but Salmonella is 
known to persistently colonize the worm intestine160, and can shorten lifespan even after 
just 1 hour of infection (Figure 4.1b). We reasoned that a pulsed infection time would 
maximize our chances of recapitulating dynamic commensal-pathogen interactions in the 
worm intestine, and perhaps highlight more subtle protection mechanisms that constant 
re-infection could obscure. After surveying a few different treatment and infection time 
windows, we decided on a 1 day treatment - 1 day infection regimen (Figure 4.1c). In our 
assay, worms were treated with different bacteria on agar plates for 1 day, then infected 
with S. typhimurium on agar plates for another day (Figure 4.1c). Worms were then 
transferred onto E. coli OP50 agar plates for the remainder of the assay, and survival was 
scored. Control worms were fed E. coli OP50 for all stages of the assay. 
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Figure 4.1. A pulsed treatment infection assay for analyzing E. faecium-mediated 
inhibition of Salmonella pathogenesis. 
a. Survival curve of Salmonella pathogenesis in a continuous infection assay. Worms
were fed E. coli OP50, S. typhimurium strain IR715 or S. typhimurium strain 14028. b. 
Survival curve after 1 hour pulsed Salmonella infection. Worms were fed E. coli OP50 or 
S. typhimurium on BHI agar plates for 1 hour before transfer to E. coli OP50-NGM plates 
for the remainder of the assay. c. Schematic of pulsed treatment-infection assay. See text 
for details. d. Pulsed treatment-infection assay with a 1 day treatment and 1 day infection. 
Legend indicates treatment-infection. Abbreviations: E. coli OP50 (OP); S. typhimurium 
(Stm); E. faecium (Efm). For a, b, and d, data points represent mean ± standard deviation 
for 3 plates of 30 worms each. 
In this assay, C. elegans survival was increased in worms fed E. faecium prior to 
infection with S. typhimurium as compared to worms fed E. coli OP50 (Figure 4.1d). 
63	  
Because E. faecium grows poorly on standard nematode growth medium, we performed 
the treatment and infection steps on BHI agar, which is commonly used to assess the 
effects of Enterococcus on C. elegans survival. However, continuous feeding on E. coli 
OP50 grown on BHI agar has been reported to be pathogenic to worms174. E. faecium 
treatment prior to 1 day of feeding on E. coli OP50 grown on BHI prolonged survival, 
indicating an inhibition of intrinsic E. coli OP50 pathogenesis (Figure 4.2b). However, 
we did not observe a decrease in survival when worms were fed E. coli OP50 prior to 
Salmonella infection as compared to non-pathogenic Bacillus subtilis 168 (Figure 4.2c). 
This suggests that in a pulsed treatment format, E. coli OP50 only marginally contributes 
to pathogenesis in our assay. 
Figure 4.2. Contribution of E. coli OP50 pathogenesis. 
a. Pulsed treatment-infection assay comparing 1 day E. coli OP50 treatment, 1 day
Salmonella infection (OP-Stm) to a 2 day Salmonella infection (Stm-Stm). b. Pulsed 
treatment-infection assay showing E. faecium treatment inhibits E. coli OP50 
pathogenesis. c. Pulsed treatment-infection assay showing that B. subtlis treatment does 
not inhibit Salmonella pathogenesis. Abbreviations: E. coli OP50 (OP); S. typhimurium 
(Stm); E. faecium (Efm), B. subtilis (Bs). For a-c, data points represent mean ± standard 
deviation for 3 plates of 30 worms each. 
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E. faecium is a genetically divergent species, with an abundance of mobile genetic 
elements and below 95% average nucleotide identity across some strains189,190. 
Nevertheless, we found that multiple strains of E. faecium were able to inhibit Salmonella 
pathogenesis, including a pig fecal isolate (NCTC 7171), two commensal human fecal 
isolates (Com12 and Com15), and a pathogenic human blood isolate (DO) (Figure 4.3a 
and b). These results suggest that despite genetic variation across the E. faecium strains 
tested, the mechanism of E. faecium protection is conserved. In our study, we chose to 
further characterize E. faecium strain Com15. 
Figure 4.3. Inhibition of Salmonella pathogenesis by various E. faecium strains. 
a. Pulsed treatment-infection assay comparing treatment with E. faecium strains Com15,
Com12, and NCTC 7171. b. Pulsed treatment-infection assay comparing treatment with 
E. faecium strains NCTC 7171 and DO. Abbreviations: E. coli OP50 (OP); S. 
typhimurium (Stm). For a and b, data points show mean ± standard deviation for 3 plates 
of 30 worms each. 
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Figure 4.4. Characterization and imaging of GFP- and mcherry-Salmonella infected 
C. elegans. 
a. Continuous infection assay comparing wild type Salmonella to GFP-Salmonella (Stm,
GFP) pathogenesis. b. Pulsed treatment-infection assay comparing wild type Salmonella 
to GFP-Salmonella pathogenesis. c. Fluorescence imaging of C. elegans infected with 
GFP-Salmonella (GFPStm) at day 6 in a continuous infection assay. The dotted lines 
indicate the outline of the worm body. Scale bar = 100 µm. d. Fluorescence imaging of 
C. elegans infected with GFP-Salmonella at day 3 in a pulsed infection assay. The images 
have been adjusted to show GFP auto-fluorescence of the gut. The lumen of the intestine 
is dark (top image). GFP-Salmonella appear to be ingested (bottom image) but do not 
subsequently colonize. The arrow indicates GFP-Salmonella in the isthmus of the 
pharynx. The dotted lines indicate the outline of the worm body. Scale bar = 50 µm. e. 
Continuous infection assay comparing wild type Salmonella (Stm, wt) to mcherry-
Salmonella (Stm, mch) pathogenesis. f. Pulsed treatment-infection assay comparing wild 
type Salmonella to mcherry-Salmonella pathogenesis. g. Fluorescence images of C. 
elegans infected with mcherry-Salmonella (mcherryStm) at day 3 post-infection. The 
dotted lines indicate the outline of the worm body. Scale bar = 100 µm. Abbreviations: E. 
coli OP50 (OP); S. typhimurium (Stm); E. faecium (Efm). For a, b, d, and f, data points 
show mean ± standard deviation for 3 plates of 30 worms each. 
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Figure 4.4. Characterization and imaging of GFP- and mcherry-Salmonella infected 
C. elegans. 
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To investigate the mechanism of E. faecium-mediated protection, we first 
analyzed the effect of E. faecium treatment on S. typhimurium colonization. Previous 
studies analyzing Salmonella colonization of worms have used Salmonella expressing 
GFP, although to our knowledge the relative pathogenicity of such strains has not been 
assessed. In mammalian cell culture models of Salmonella pathogenesis, certain strains of 
GFP-Salmonella exhibit attenuated virulence191. We found that GFP-S. typhimurium was 
pathogenic in a continuous infection model (Figure 4.4a), but non-pathogenic in the 
pulsed infection model (Figure 4.4b). This attenuation of pathogenicity seemed to be 
dependent on colonization, as GFP fluorescence imaging 3 days post-infection revealed 
little to no intestinal colonization (Figure 4.4c and d). For this reason, we instead used 
mcherry-S. typhimurium, which we found to be pathogenic in both a continuous and 
pulsed infection setting (Figure 4.4e and f). Fluorescence imaging of mCherry-S. 
typhimurium 3 days post-infection showed comparable Salmonella colonization of worms 
with or without E. faecium-treatment (Figure 4.4g). 
Salmonella colony forming units (CFUs) recovered from lysed worms throughout 
the infection assay revealed robust initial Salmonella colonization of worms regardless of 
prior E. faecium treatment (Figure 4.5a). Interestingly, in E. faecium-treated worms, we 
observed a ~2 log decrease in Salmonella colonization 1 day post-infection. By 3 days 
post-infection, however, Salmonella titer was similar in OP50- and E. faecium-treated 
Salmonella-infected worms. The transient decrease in Salmonella CFUs may reflect 
niche competition between Salmonella and E. faecium, or an induced antimicrobial host 
response. To determine if this transient decrease in Salmonella colonization represented 
direct niche competition early in our assay, we monitored E. faecium CFUs throughout 
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the infection assay as well (Figure 4.5b). E. faecium initially colonized worms to ~105 
CFUs/worm. After infection, however, E. faecium numbers decreased to ~10-102 per 
worm for the remainder of the assay. The decrease in Salmonella numbers 1 day post-
infection did not coincide with an outgrowth of E. faecium, suggesting that this decrease 
is not due to simple niche competition. 
Figure 4.5. E. faecium transiently affects Salmonella colonization. 
a. Salmonella CFUs measured in C. elegans throughout the pulsed treatment-infection
assay. b. Enterococcus CFUs measured in C. elegans throughout the pulsed treatment-
infection assay. For a and b, the background shading represents stages of the pulsed 
treatment-infection assay. Green indicated treatment, red indicates infection, and grey 
indicates E. coli OP50 feeding. The data points represent average CFUs from 5 worms ± 
standard deviation from two independent experiments. The dotted line indicates detection 
limit. Abbreviations: E. coli OP50 (OP); S. typhimurium (Stm); E. faecium (Efm). 
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Figure 4.6. Electron microscopy of Salmonella-infected C. elegans. 
a. Electron microscopy of transverse sections of C. elegans (top), and magnification of
intestinal region (bottom) at day 4 post-infection in the pulsed treatment-infection assay. 
Conditions are as indicated on top. The blue coloring indicates the intestinal microvilli; 
the red coloring indicates the intestinal lumen. Arrows in the top middle panel indicate 
bacteria that have breached the epithelial barrier and escaped the lumen (top arrow) as 
well as loss of overall worm turgidity (bottom arrow). Scale bar (top row) = 5 µm. Scale 
bar (bottom row) = 200 nm. b. Images of worms from day 1 post-infection in the pulsed 
treatment-infection assay. Conditions are as indicated in (a.) Scale bar = 1mm. 
Abbreviations: E. coli OP50 (OP); S. typhimurium (Stm); E. faecium (Efm). 
70	  
Electron microscopy of worm transverse sections 4 days post-infection revealed 
substantial degradation of the intestinal microvilli in OP50-treated Salmonella-infected 
worms compared to uninfected or E. faecium-treated worms (Figure 4.6a). In OP50-
treated Salmonella-infected worms, we observed extensive tissue damage and bacteria 
transgressing the lumen (Figure 4.6a, middle panel). We do not believe this represents 
Type-3 secretion-mediated invasion, but rather bacterial outgrowth resulting from 
destruction of the intestinal barrier. In contrast, despite bearing a comparable bacterial 
load, E. faecium-treated worms appear to have contained the infection to the intestinal 
lumen and show no apparent tissue damage (Figure 4.6a, right panel), possibly indicating 
an enhancement in epithelial barrier function21. Consistent with these images, we 
observed that E. faecium-treated worms appeared less fragile and more motile than 
OP50-treated worms after infection (Figure 4.6b). Taken together, these results 
demonstrate that E. faecium does not prevent Salmonella colonization, and suggest that 
E. faecium is not acting through niche competition or a bactericidal mechanism. 
To determine if E. faecium could inhibit pathogenesis when delivered after 
Salmonella infection, we inverted the order of our treatment-infection assay, and assessed 
E. faecium-mediated protection. When administered after infection, E. faecium was 
unable to inhibit pathogenesis (Figure 4.7a). We measured both S. typhimurium and E. 
faecium CFUs throughout the assay, to determine if differences in colonization efficiency 
could account for the difference we observed in survival (Figure 4.7b and c). Order of 
treatment and infection did not largely affect Salmonella colonization (Figure 4.7b). 
Regardless of treatment-infection order, we also observed a similar transient decrease in 
Salmonella CFUs (Figure 4.7b), suggesting that this decrease in Salmonella titer is not 
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key to the mechanism underlying E. faecium-mediated protection.  In addition, infection 
with Salmonella did not inhibit subsequent E. faecium colonization (Figure 4.7c), 
indicating that E. faecium colonization alone is not sufficient for protection. This suggests 
that some sort of host priming may be necessary for E. faecium-mediated protection. 
Figure 4.7. E. faecium cannot inhibit Salmonella pathogenesis when delivered after 
infection. 
a. Pulsed treatment-infection assay showing that E. faecium administered after
Salmonella infection cannot inhibit pathogenesis. b. Salmonella CFUs measured in C. 
elegans throughout the assay shown in (a.) c. Enterococcus CFUs measured in C. elegans 
throughout the assay shown in a. For a, data points represent mean ± standard deviation 
for 3 plates of 30 worms each. For b and c, data points represent average CFUs from 5 
worms ± standard deviation of three technical replicates. The dotted line indicates 
detection limit. Abbreviations: E. coli OP50 (OP); S. typhimurium (Stm); E. faecium 
(Efm). 
72	  
Figure 4.8. E. faecium-mediated protection is long-lasting. 
a. Schematic of the pulsed treatment-infection assay with a 1 to 3 day delay introduced.
See text for details. b. Pulsed treatment-infection assay with a 1 day delay. c. Pulsed 
treatment-infection assay with 3 day delay. d. Schematic of a treatment- continuous 
infection assay. See text for details. e. Survival curve showing that E. faecium can inhibit 
pathogenesis in a continuous infection assay. For b, c, and e, data points represent mean ± 
standard deviation for 3 plates of 30 worms. Abbreviations: E. coli OP50 (OP); S. 
typhimurium (Stm); E. faecium (Efm). 
To assess the duration of protection afforded by E. faecium pre-treatment, we 
introduced a time delay between the treatment and infection steps of our assay (Figure 
4.8a). After 1 day treatment, we transferred worms to E. coli OP50 plates for 1 or 3 days, 
before infection with Salmonella. We found that E. faecium was able to inhibit 
pathogenesis after a 1 or 3 day delay to infection (Figure 4.8b and c). Longer time delays 
were difficult to assess due to age-related mortality. We also evaluated E. faecium-
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mediated protection against continuous Salmonella infection. In our continuous infection 
assay, worms were treated with either OP50 or E. faecium for 1 day, then transferred to 
Salmonella infection plates for the remainder of the assay (Figure 4.8d). In this 
continuous infection model, E. faecium still inhibited Salmonella pathogenesis (Figure 
4.8e). Taken together, these data suggest that E. faecium employs a long-lasting 
protection mechanism that requires a priming phase, suggestive of an induced immune 
response. 
We next explored whether specific factors produced by E. faecium were sufficient 
for protection against S. typhimurium pathogenesis. To do this, we developed a modified 
liquid treatment-infection assay (Figure 4.9a). In this assay, worms were bathed in 
different treatment wells for 2 hours, then transferred to Salmonella infection plates. 
After 1 day of infection, worms were transferred to E. coli OP50 plates for the remainder 
of the assay, and survival was scored. Using this assay, we found that E. faecium culture 
supernatant was as efficient as live E. faecium cultures in inhibiting Salmonella 
pathogenesis (Figure 4.9b), indicating that E. faecium colonization is not necessary for 
protection. Activity of the supernatant was sensitive to proteinase-K treatment (Figure 
4.9c), trichloroacetic acid precipitation (Figure 4.9d), and 10-kDa size exclusion (Figure 
4.9e), leading us to analyze the protein composition of E. faecium culture supernatant by 
mass spectrometry (Figure 4.10a). Proteomic analysis of E. faecium culture supernatant 
revealed 55 high-confidence secreted proteins and an enrichment of peptidoglycan 
remodeling factors (Figure 4.10b and Appendix 7). We focused on secreted antigen A 
(SagA), the most abundant protein identified from the supernatant (Figure 4.10b). 
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Figure 4.9. An E. faecium secreted protein can inhibit Salmonella pathogenesis. 
a. Schematic of liquid treatment-pulsed infection assay. See text for details. b. E. faecium
culture supernatant (Efm,sup) inhibits Salmonella-induced death as well as live E. 
faecium culture (Efm,live). OP50 culture supernatant (OP,sup) is not protective. c. 
Proteinase-K-treated E. faecium culture supernatant (Efm,sup,protK) loses activity 
compared to untreated E. faecium culture supernatant (Efm,sup). Untreated media (BHI) 
and proteinase-K-treated media (BHI,protK) are inactive. d. Trichloroacetic acid (TCA) 
precipitated E. faecium culture supernatant (Efm,sup,TCA) loses activity. Untreated 
media (BHI) and TCA precipitated media (BHI,TCA) are inactive. e. 10-kDa MWCO 
column filtered E. faecium culture supernatant (Efm,sup,FT) is inactive. Untreated media 
(BHI) and 10-kDa MWCO column filtered media (BHI,FT) are inactive. For b-e, data 
points represent mean ± standard deviation for 3 plates of 30 worms each. Abbreviations: 
E. coli OP50 (OP); S. typhimurium (Stm); E. faecium (Efm). 
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Figure 4.10. SagA is an abundantly secreted protein. 
a. Coomassie stained SDS-PAGE of E. faecium Com15 culture supernatant (Efm sup)
subsequently digested for mass spectrometry analysis. The dotted lines indicate gel slices 
made for trypsin digestion. b. Summary of proteins identified by mass spectrometry from 
E. faecium culture supernatant. Proteins shown were identified with at least 2 unique 
peptides and 10 peptide spectrum matches (PSMs). Proteins involved in peptidoglycan 
remodeling are highlighted in red. For the complete list of proteins identified, see 
Appendix 7. c. Schematic of SagA domain organization. The Type-1 signal peptide 
sequence is yellow, the predicted coiled-coil (CC) domain is orange, and the NlpC/p60 
type hydrolase domain is blue. Amino acid number is as indicated. d. Stain-free imaging 
of culture supernatants from various E. faecium strains (1:Com15, 2:Com12, 3:NCTC 
7171, and 4:DO) and E. faecalis strains (5:OG1RF, 6:V583) separated by SDS-PAGE. 
Arrow indicates a protein band corresponding to typical SagA migration.  
SagA encodes a putative secreted peptidoglycan hydrolase that contains a Type-1 
signal peptide, an uncharacterized N-terminal coiled-coil domain, a linker region with 
Ser/Thr-rich repeats, and a C-terminal NlpC/p60-type hydrolase domain (Figure 4.10c). 
While no hydrolase activity has been reported, SagA has been shown to bind extracellular 
matrix proteins in vitro192. The NlpC-p60-type hydrolase domain is a cysteine 
endopeptidase domain common amongst bacteria193. The regulation of this enzymatic 
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activity, however, is not well understood, and may be specified by other domains. 
Typically, NlpC-p60-type enzymes are involved in peptidoglycan remodeling during 
growth and division. The protein sequence of SagA is highly conserved within E. 
faecium, and it is regarded as an essential gene192. Although the function of SagA is 
unknown, SagA has high structural similarity to the CHAP-domain containing protein 
PcsB from S. pneumoniae (91% coverage, 34% sequence identity), which is required for 
normal cell septation194.  
Figure 4.11. SagA is expressed by E. faecium in the C. elegans intestine. 
Fluorescence images of C. elegans treated for 1 day with E. faecium or E. faecium 
expressing psagA:mcherry. The dotted lines indicate the outline of the worm body. Scale 
bar = 200 µm. 
To determine if SagA secretion was relevant to our treatment-infection assays 
with live E. faecium, we assessed whether sagA was expressed by E. faecium during 
colonization of C. elegans. To do this, we generated an E. faecium strain expressing 
mCherry under the sagA promoter (psagA:mcherry). Fluorescence imaging of worms 
treated for 1 day with psagA:mcherry suggested that SagA is indeed expressed during E. 
faecium colonization (Figure 4.11). To test SagA activity in worms directly, we 
expressed C-terminally His6-tagged SagA from both E. coli BL21-RIL(DE3) and E. 
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faecium Com15 (Figure 4.12a). Cleavage of bacterial Type-1 signal peptides occurs upon 
secretion and can be required for proper protein activity195. For this reason, we purified 
SagA-His6 from the culture supernatants of both E. coli and E. faecium rather than from 
cell lysates. Remarkably, treatment of worms with SagA-His6 purified from either source 
was sufficient to inhibit Salmonella pathogenesis (Figure 4.12b).  
Figure 4.12. Purified SagA is sufficient to inhibit Salmonella pathogenesis. 
a. Coomassie stained SDS-PAGE of culture supernatants and His6 purifications of SagA-
His6 from E. faecium Com15 (Efm) and E. coli BL21-RIL(DE3) (Ec). b. SagA-His6 
purified from either E. coli BL21-RIL(DE3) (SagA, Ec) or E. faecium Com15 (SagA, 
Efm) is sufficient to inhibit Salmonella pathogenesis. Data points represent mean ± 
standard deviation for 3 plates of 30 worms each. Abbreviations: E. coli OP50 (OP); S. 
typhimurium (Stm); E. faecium (Efm). 
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We noticed that SagA-His6 purified from E. faecium appeared as a smear of bands 
around 75 kDa, higher than the predicted molecular weight of 54 kDa (Figure 4.12a). 
This banding appearance is characteristic of glycosylation, which has been shown to 
regulate the activity of other peptidoglycan hydrolases196. Although SagA from E. 
faecium strain DO (which bears 91% identity to SagA from E. faecium Com15) was 
previously reported as not glycosylated192, the abundance of serine and threonine residues 
present in the linker region of SagA are indicative of O-glycosylation. We used the 
periodic-acid-Schiff stain method to visualize the glycosylated proteins in E. faecium 
culture supernatant separated by SDS-PAGE (Figure 4.13a). Using this method, we 
detected a stained protein with a gel migration typical to SagA, and confirmed SagA 
identity by mass spectrometry of the excised gel band (Appendix 8). Interestingly, 
although SagA-His6 purified from E. coli migrates higher than predicted, it appears as a 
crisp band, suggesting that it is not glycosylated (Figure 4.12a). We compared 
glycosylation of SagA-His6 purified from E. faecium and E coli, and confirmed that 
SagA-His6 purified from E. coli is indeed not glycosylated (Figure 4.13b). The unusual 
migration of SagA-His6 purified from E. coli may be due to the stretch of charged and 
polar residues within the linker region, or to additional protein modifications. 
Nevertheless, the fact that SagA purified from either E. coli or E. faecium can inhibit 
Salmonella pathogenesis suggests that glycosylation is not necessary for SagA activity. 
79	  
Figure 4.13. SagA is a glycosylated protein. 
a. Coomassie blue staining and glycoprotein-staining of E. faecium Com15 culture
supernatant (Efm sup). The blue arrow indicates a protein band corresponding to typical 
SagA migration. Both of the indicated stained bands were excised for mass spectrometry 
analysis presented in Appendix 8. b. SDS-PAGE of culture supernatants and SagA-His6 
purifications from E. faecium Com15 (Efm) and E. coli BL21-RIL(DE3) (Ec). Samples 
were visualized by Coomassie blue staining, glycoprotein-staining, and anti-His6 Western 
blot (WB) as indicated. SagA is glycosylated in E. faecium but not E. coli. 
In vitro, SagA can bind the extracellular matrix proteins fibrinogen, fibronectin, 
collagen type-I, collagen type-IV, and laminin192, which are found in the intestinal 
basement membrane. C. elegans has homologues of both laminin and type-IV collagen170. 
We wondered if SagA could bind to the worm, possibly forming some sort of barrier to 
inhibit Salmonella pathogenesis. We measured binding of SagA-His6 to worms by 
Western blot, and were unable to detect any SagA-His6 in worms after pulsed Salmonella 
infection (Figure 4.14). This suggests that SagA is only transiently associated with the 
worm, making the idea of a physical barrier to infection unlikely. 
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Figure 4.14. SagA does not robustly adhere to C. elegans. 
Anti-His6 Western blot (WB) for SagA-His6 in infected worms at indicated days post 
Salmonella (Stm) infection. Anti-actin WB was used as a sample loading control. “SagA” 
lane shows typical His6 blotting.  
To determine if the NlpC/p60-type hydrolase domain of SagA is required for 
protection of C. elegans, we generated a deletion mutant of the entire C-terminal 
NlpC/p60-type hydrolase domain (∆Cterm) as well as an active site mutant of SagA 
(Figure 4.15a and b). To generate the active site mutant, we mutated the putative enzyme 
catalytic residues (Cys443, His494, and His506) to alanine. Both of these mutant proteins 
were expressed, secreted, and purified from E. coli BL21-RIL(DE3) (Figure 4.15c). We 
tested these mutant proteins for activity in C. elegans, and found that while wild type 
SagA inhibited Salmonella pathogenesis as well as E. faecium culture supernatants, the 
active site mutant and ∆Cterm were not protective (Figure 4.15d), indicating that the 
NlpC/p60-type hydrolase domain is required for SagA activity. 
Given that the hydrolase domain of SagA is required for its protective activity, we 
wondered if SagA could directly affect Salmonella growth or virulence. Fluorescence 
imaging of mCherry-S. typhimurium (Figure 4.16a and b) and Salmonella CFU 
measurements (Figure 4.16c) from untreated, SagA-treated, and active site mutant-treated 
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infected worms were comparable, indicating that SagA, like E. faecium treatment, does 
not affect Salmonella colonization of C. elegans. Additionally, exogenous addition of 
SagA had no effect on Salmonella growth rate in culture (Figure 4.16d). These results 
suggest that SagA does not act through a bactericidal mechanism. 
Figure 4.15. Enzymatic activity of SagA is required for inhibition of Salmonella 
pathogenesis.  
a. Schematic showing the point mutations made to generate the active site mutant of
SagA-His6. b. Schematic showing the truncation made to generate the C-terminal domain 
deletion of SagA-His6 (∆Cterm). c. Coomassie stained SDS-PAGE of culture 
supernatants and His6 purifications of SagA-His6, the active site mutant (AS), and 
∆Cterm from E. coli BL21-RIL(DE3). d. Survival curve showing that bovine serum 
albumin (BSA), the active site mutant (AS), and ∆Cterm do not inhibit Salmonella 
pathogenesis, while SagA and E. faecium culture supernatants (Efmsup) do. Data points 
represent mean ± standard deviation for 3 plates of 30 worms each. 
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Figure 4.16. SagA treatment does not inhibit Salmonella colonization of C. elegans 
or growth in culture. 
a. Survival curve showing that wildtype S. typhimurium (Stm, wt) and mcherry-S.
typhimurium (Stm, mch) are equally pathogenic in a liquid treatment-pulsed infection 
assay. Data points represent mean ± standard deviation for 3 plates of 30 worms each. b. 
Fluorescence imaging of C. elegans infected with mcherry-S. typhimurium (mchStm) at 
day 5 post-infection. The dotted lines indicate the outline of the worm body. Scale bar = 
200 µm. c. Salmonella CFUs measured in C. elegans throughout the liquid treatment 
pulsed infection assay. Data points represent average CFUS from 10-20 worms ± 
standard deviation of three technical replicates. The dotted line indicates detection limit. 
d. Growth curves of S. typhimurium in LB media + 10 µg/ml SagA or BSA.
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Figure 4.17. Salmonella Type-3 secretion systems are dispensible for C. elegans 
pathogenesis. 
a. Wildtype S. typhimurium (Stm, wt) and a ∆invA mutant are equally pathogenic to C.
elegans in a continuous infection assay. InvA is a component of the SPI-1 needle 
complex required for effector secretion (see (e.)). b. Wildtype S. typhimurium and a 
∆invA/∆spiB double mutant are equally pathogenic to C. elegans in a continuous 
infection assay. SpiB is a component of the SPI-2 needle complex required for effector 
secretion. c. Wildtype S. typhimurium and a ∆invA mutant are equally pathogenic to C. 
elegans in a pulsed infection assay. d. Wildtype S. typhimurium and a ∆spiB mutant are 
equally pathogenic to C. elegans in a pulsed infection assay. e. SagA has no affect on 
SPI-1 secretion in culture. Salmonella cultures were grown in LB + 10 µg/ml BSA, 
SagA, or the active site mutant (AS). PBS indicates control treatment. For a-d, data points 
represent mean ± standard deviation for 3 plates of 30 worms each. 
In mammals, Salmonella pathogenesis relies primarily on two Type-3 secretion 
systems for host cell invasion and subsequent intracellular replication121. In C. elegans, 
the role of Type-3 secretion in pathogenesis is unclear. Deletion mutants of several 
Salmonella Type-3 secretion factors have been reported to exhibit attenuated 
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virulence161,163,197,198. However, Salmonella does not appear to actively invade C. elegans 
intestinal cells, and instead remains extracellular. In both continuous and pulsed infection 
assays, we found no attenuation of Salmonella pathogenesis with SPI-1 or SPI-2 Type-3 
secretion mutants (Figure 4.17a-d). This suggests that the virulence pathways involved in 
invasion and intracellular survival may not be required for pathogenesis in C. elegans, 
making them unlikely targets of SagA activity. In culture, addition of SagA had no effect 
on the secretion of S. typhimurium type III protein effectors (Figure 4.17e), suggesting 
that SagA does not target SPI-1 Type-3 secretion to inhibit pathogenesis. 
As described earlier, E. faecium can inhibit the mild pathogenesis of E. coli OP50 
(Figure 4.2b). We also found that E. faecium-treated worms were more resistant to 
pathogenesis caused by the Gram-positive intestinal pathogen Enterococcus faecalis 
strain V583174 (Figure 4.18). This suggests that the mechanism of C. elegans protection 
can be generalized to other pathogens, making a Salmonella-specific mechanism 
unlikely. 
Figure 4.18. E. faecium can inhibit E. faecalis pathogenesis.  
Survival curve showing that E. faecium can protect worms from E. faecalis V583 
pathogenesis. Abbreviations: E. coli OP50 (OP); S. typhimurium (Stm); E. faecium 
(Efm); E. faecalis (Efl). Data points represent mean ± standard deviation for 3 plates of 
30 worms each. 
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Figure 4.19. SagA expression and secretion by E. coli causes cell lysis. 
a. Growth curves of E. coli BL21-RIL(DE3) in LB media + 10 µg/ml SagA or BSA. b.
Growth curves of E. coli BL21-RIL(DE3) expressing SagA-His6 or the active site mutant 
(AS) under an IPTG-inducible promoter. Dotted line indicates time of IPTG induction. c. 
OD600 of E. coli BL21-RIL(DE3) expressing SagA-His6, the active site mutant (AS), or 
SagA-SS under an IPTG-inducible promoter. Measurements were taken 1 hour post-
induction and normalized to the OD600 of a mock-induced non-expressing BL21-
RIL(DE3) culture. Bars represent mean ± s.e.m. from three independent experiments. 
Significance was calculated by unpaired t test. For **, p < 0.01. d. Anti-His6 Western 
blots of cell lysate or culture supernatant (Sup.) from E. coli BL21-RIL(DE3) expressing 
SagA-His6, the active site mutant (AS), or Sag-SS after IPTG induction. SagA-SS is 
mostly retained in the cell lysates, while SagA and the active site mutant are secreted. 
As with Salmonella, the addition of exogenous SagA had no effect on the growth 
rate of E. coli in culture (Figure 4.19a). However, we did notice that induction of SagA 
expression in E. coli led to a decrease in culture optical density (OD) (Figure 4.19b), 
indicating cell lysis. In contrast, expression of the active-site mutant of SagA or a signal 
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sequence mutant of SagA (SagA-SS) did not decrease culture OD (Figure 4.19b-d). This 
is consistent with our observations that leaky low-level constitutive expression of SagA, 
but not the active site mutant, in E. coli from the low-copy number plasmid, pAM401, 
strongly impaired E. coli growth on agar and in culture (data not shown). One 
explanation for the secretion-dependent toxicity of SagA expression in E. coli is that 
SagA is a functional hydrolase that can cleave E. coli peptidoglycan when properly 
targeted to the periplasm during secretion. 
We generated additional mutant protein constructs to assess the function of the N-
terminal domain and the linker region of SagA (Figure 4.20a-c). Interestingly, we were 
unable to express deletion mutants of the N-terminal domain, either with or without the 
signal sequence, in E. coli. Given that SagA expression causes cell death, this may 
suggest a regulatory function for this domain. We also generated a deletion mutant of the 
linker region (∆Linker) (Figure 4.20c). The linker region of SagA is made up of an 
unusual series of serine, threonine, and glutamate-rich repeats, which might be involved 
in localizing SagA to specific sites in the intestine. We compared cell lysis resulting from 
∆Linker induction as compared to wild-type SagA. ∆Linker induction did not lead to cell 
lysis, indicating reduced hydrolytic activity (Figure 4.20d). This suggests that the linker 
region is required for hydrolase function, and may reflect improper protein folding or 
substrate targeting. We assessed the ability of ∆Linker to inhibit Salmonella pathogenesis 
in C. elegans, and found that this mutant was not protective (Figure 4.20e). These results 
reinforce the correlation between SagA hydrolase activity and inhibition of Salmonella 
pathogenesis in C. elegans. 
87	  
Figure 4.20. Characterization of the ∆Linker SagA mutant. 
a and b. Schematics showing an two different N-terminal truncations made in SagA-His6 
that resulted in no protein expression in E. coli BL21-RIL(DE3). c. Schematic showing a 
truncation in the linker region of SagA to generate ∆Linker. d. Growth curves of E. coli 
BL21-RIL(DE3) expressing SagA-His6 or ∆Linker under an IPTG-inducible promoter. 
Dotted line indicates time of IPTG induction. e. Survival curve showing that treatment 
with ∆Linker does not inhibit Salmonella pathogenesis. Data points represent mean ± 
standard deviation for 3 plates of 30 worms each. 
Given that SagA does not attenuate Salmonella growth, we hypothesized that 
SagA may hydrolyze peptidoglycan fragments in trans to activate host immunity. 
Consistent with this hypothesis, we found that the flow-thru from 5 kDa-MWCO column-
filtered culture supernatants of E. coli expressing SagA, but not the active site mutant, 
protected C. elegans from Salmonella pathogenesis (Figure 4.21a). We confirmed 
removal of SagA from the column flow-thru by Western blot (Figure 4.21b), suggesting 
that lower molecular weight products of SagA activity are sufficient for C. elegans 
protection. To test if SagA-generated E. coli peptidoglycan fragments can protect worms 
from Salmonella pathogenesis, we digested purified E. coli peptidoglycan with lysozyme 
and either SagA or the active site mutant, then filtered the digests through a 5 kDa-
MWCO column to exclude protein. C. elegans treated with the SagA peptidoglycan 
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Figure 4.21. SagA-treated peptidoglycan can inhibit Salmonella pathogenesis. 
a. Survival curve showing that 5-kDa MWCO-column filtered E. coli culture
supernatants expressing SagA-His6 (Ec, sagA,FT) but not the active site mutant 
(Ec,AS,FT) can inhibit Salmonella pathogenesis. b. Coomassie blue staining and anti-
His6 WB of E. coli culture supernatants expressing SagA-His6 or the active site mutant 
(AS). Supernatant was filtered through a 5-kDa MWCO column. Full unfiltered 
supernatant (Full), column concentrate (C), and column flow-through (FT) are as 
indicated. c. Survival curve showing that purified E. coli peptidoglycan treated with 
SagA then filtered through a 5-kDa MWCO-column (PG, SagA) can inhibit Salmonella 
pathogenesis. Peptidoglycan treated with the active site mutant (PG, AS) is not 
protective. d. Survival curve showing that water treated with either SagA (H20, SagA), or 
the active site mutant (H20, AS) then filtered through a 5-kDa MWCO-column, cannot 
inhibit Salmonella pathogenesis. For a, c, and d, data points represent mean ± standard 
deviation for 3 plates of 30 worms each. 
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digests survived similarly to SagA-treated worms, whereas active site mutant digests 
failed to attenuate Salmonella pathogenesis (Figure 4.21c). To control for column 
removal of SagA, we performed mock digests of water with SagA or the active site 
mutant, and confirmed that the filtered mock digests were non-protective (Figure 4.21d). 
These results suggest that SagA-generated peptidoglycan fragments, and not SagA itself, 
are responsible for protecting C. elegans from Salmonella pathogenesis. This hypothesis 
is consistent with the role of bacterial cell-wall components, including peptidoglycan, as 
activators of innate immunity in other animals28,199. 
In E. faecium, SagA is essential192, suggesting that it likely has a cell intrinsic 
function in peptidoglycan remodeling. SagA expression in E. coli, however, causes cell 
lysis, suggesting that either the specificity or regulation of SagA enzymatic activity is 
altered. We previously showed that filtration of E. faecium culture supernatant through a 
10kDa-size exclusion column abolishes activity (Figure 4.9e). This may be due to 
differences in the specific peptidoglycan fragments generated or to differences in the 
abundance of peptidoglycan shed into the supernatant. Different bacterial species 
recycle peptidoglycan during growth to varying extents200,201. For example, E. coli is 
thought to shed ~8% of its peptidoglycan during exponential growth202, while B. subtilis 
sheds ~50%203. To our knowledge, the extent of peptidoglycan recycling in E. faecium 
has not been quantified, but this process could account for the differential activity of E. 
faecium and E. coli filtered culture supernatants. Another more attractive explanation 
comes from the differences in peptidoglycan structure between E. faecium and E. coli 
(Figure 4.22a and b). Peptidoglycan varies across species largely in the peptides linking 
the sugars together. As a putative D,L-endopeptidase, SagA is predicted to cleave 
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between D-iGln and L-Lys, which is in an area that differs between E. faecium and E. 
coli, and would result in different cleavage products. However, since E. coli 
peptidoglycan is an unnatural substrate for SagA activity, we do not know where SagA 
may optimally cleave in this structure, or what cleavage products may result. 
Figure 4.22. The structure of peptidoglycan. 
a. Structure of E. coli (and Salmonella) peptidoglycan. D-isoglutamate (D-iGlu) can also
be substituted by D-glutamate (D-Glu). b. Structure of E. faecium peptidoglycan. D-Asx 
indicates that both D-aspartate (Asp) and D-asparagine (Asn) at found at that position. D-
iGlx indicates that both D-isoglutamate (D-iGlu) and D-isoglutamine (D-iGln) are found 
that position. 
To determine what peptidoglycan fragment(s) are generated from SagA 
enzymatic activity, we used the UV-active compound 8-amino-naphthalene 1,3,6-
trisulfonic acid (ANTS) to label and track peptidoglycan fragments204,205. ANTS 
covalently reacts with sugars through reductive amination, allowing for native gel 
separation and visualization of sugar-containing small molecules, such as peptidoglycan 
fragments (Figure 4.23a). With this method, we analyzed filtered culture supernatants of 
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E. coli cultures expressing either SagA-His6 or the active site mutant (Figure 4.23b). We 
detected a SagA-specific UV-active band that migrated similarly to the ANTS-labeled 
synthetic peptidoglycan fragments MurNAc-L-Ala and GlcNac (Figure 4.23c). 
Interestingly, did not migrate similarly to MurNAc-L-Ala-D-Glu (MDP), which is the 
predicted monosaccharide cleavage product of SagA activity. We did not detect this 
fragment in filtered E. faecium culture supernatant (Figure 4.23c), suggesting that SagA 
activity results in different or more abundant peptidoglycan cleavage products in E. coli 
as compared to E. faecium. 
Because E. coli culture supernatant contains additional cell wall components 
beyond peptidoglycan, we wanted to analyze SagA digests of purified peptidoglycan by 
the same method. In vitro digestion of purified E. coli peptidoglycan with lysozyme and 
either SagA or the active site mutant yielded a similar cleavage fragment (Figure 4.23d), 
suggesting that this fragment is indeed peptidoglycan derived. We suppose the identity of 
this fragment is most likely MurNAc-L-Ala rather than GlcNAc, given that SagA is 
predicted to be an endopeptidase. However, it is possible this fragment represents a 
different peptidoglycan fragment altogether. HPLC separation and mass spectrometry to 
determine the identity of this fragment is in progress. 
We next assessed the activity of MurNAc-L-Ala, GlcNAc, and several other 
synthetic peptidoglycan fragments in protecting C. elegans from Salmonella 
pathogenesis. Treatment of C. elegans with 50 µM of MurNAc-L-Ala-D-Glu (MDP), 
MurNAc-L-Ala-D-Glu-mDAP (MTP(mDAP)), MurNAc-L-Aala-D-Gln-L-Lys 
(MTP(Lys)), MurNAc-L-Aala-D-Gln-L-Lys-D-Asn (MTP-D-Asn), Tri-Lys, Tri-DAP, 
iD-Glu-mDAP, or GlcNAc did not inhibit Salmonella pathogenesis (Figure 4.24a-d). 
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Figure 4.23. SagA hydrolase activity visualized by ANTS labeling. 
a. Schematic of ANTS labeling reaction. See text for details. b. Culture supernatants
(sup.) of E. coli expressing either SagA-His6 or the active site mutant (AS). Supernatants 
were filtered through 10-kDa MWCO columns, dried, ANTS labeled, then separated by 
native PAGE. Gel was visualized by UV. Expression of SagA releases a unique ANTS-
labeled fragment into the supernatant. Lysozyme treatment of the supernatant does not 
alter ANTS-labeling profile (+ Lys). c. Unique fragment found in the SagA-expressing E. 
coli supernatant co-migrates with GlcNAc and MurNAc-Ala. This fragment is not 
detected in E. faecium (Efm), E. faecalis (Efl), or E. faecalis-sagA (EflsagA) culture 
supernatants. d. ANTS-labeled enzymatic digest of purified E. coli peptidoglycan (PG) 
with lysozyme and SagA yields a similar fragment (indicated with an asterix) as that 
found in SagA-expressing E. coli supernatant. ANTS-labeled cell lysates of E. coli 
expressing either SagA or the active site mutant (AS) are similar. 
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Figure 4.24. Small synthetic peptidoglycan fragments can inhibit Salmonella 
pathogenesis in C. elegans.  
Survival curves showing that a. MTP(mDAP), MTP-D-Asn, b. MTP(Lys), c. MDP, 
GlcNAc, and d. TriDAP, TriLys, and iGlu-mDAP do not inhibit Salmonella 
pathogenesis, while e. MurNAc and MurNAc-Ala do. For a-e, data points represent mean 
± standard deviation for 3 plates of 30 worms. Abbreviations: E. coli OP50 (OP); S. 
typhimurium (Stm). 
However, treatment with either MurNAc or MurNAc-L-Ala inhibited Salmonella 
pathogenesis (Figure 4.24e). Correlating our in vitro ANTS-labeled peptidoglycan digest 
data to our C. elegans activity assays, we hypothesize that SagA hydrolysis of 
peptidoglycan generates MurNAc-L-Ala, which can activate innate immunity in C. 
elegans. 
To determine if E. faecium acts through major C. elegans immune pathways to 
inhibit Salmonella pathogenesis, we surveyed E. faecium-mediated protection in the 
following immune-deficient worm strains: pmk-1(km25) (p38 MAPK/Pmk-1 
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pathway)206,207, dbl-1(nk3) (TGF-β-like/Dbl-1 pathway)208,209, daf-16(mu86) and daf-
2(e1370); daf-16(mgDf47) (insulin-like receptor/Daf-2 pathway)210,211, and npr-1(ad609) 
(Npr-1-mediated pathogen avoidance)212. In pmk-1, dbl-1, and npr-1 mutants, survival of 
“uninfected”, OP50-fed worms was greatly decreased as compared to wild-type worms 
(Figure 4.25a, b, and e). This suggests that these immune pathways are involved in 
mitigating the pathogenicity of OP50 grown on BHI. Nevertheless, in all mutants, we 
observed prolonged survival of E. faecium-treated infected worms (Figure 4.25a-e), 
indicating that these pathways are each not exclusively required for E. faecium-mediated 
protection against a pulsed Salmonella infection. 
Figure 4.25. E. faecium activity in various C. elegans mutants. 
Survival curves assaying E. faecium-mediated protection in a. pmk-1(km25) b. dbl-1(nk3) 
c. daf-2(e1370);daf-16(mgDf47) d. daf-16(mu86) and e. npr-1(ad609). For c-e, each
condition was tested with 3 plates of 30 worms each, and data points represent mean ± 
standard deviation. For a and b, each condition was tested with one plate of 30 worms. 
Abbreviations: E. coli OP50 (OP); S. typhimurium (Stm); E. faecium (Efm). 
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C. elegans encodes one predicted homologue of Toll-like receptor, tol-1213. 
Mammalian Toll-like receptors recognize various microbial-associated molecular 
patterns, including bacterial cell-wall components, leading to immune activation27. In 
Drosophila, Toll plays a role in both development and immunity, and does not function 
as a pattern recognition receptor214. Instead, bacterial or fungal infection leads to the 
proteolytic cleavage of Spaetzle, which binds Toll to promote downstream immune 
signaling. In C. elegans, a deletion of part of the extracellular domain in tol-1(nr2013) 
mutants, results in an embryonic lethal or larval arrest phenotype, suggesting that tol-1 is 
required for proper development213. Deletion of the putative TIR signaling domain in tol-
1(nr2033) mutants, however, does not apparently affect development or viability. 
Interestingly, tol-1 is dispensable for C. elegans immunity against several pathogens 
including P. aeruginosa, S. aureus, and D. coniospora. However, tol-1 mutants are 
defective in pathogen avoidance to S. marsescens215. A recent study from the Ringstad 
laboratory at NYU has found that tol-1 is required for the differentiation of the CO2-
sensing BAG neurons216 necessary for pathogen avoidance to S. marsescens (N. Ringstad, 
personal communication). In adult animals, tol-1 expression has been reported in BAG 
neurons, 10 other neurons, and the head mesodermal cell; however, the extent of tol-1 
expression in other cells is unknown. We assessed SagA-mediated protection against 
Salmonella pathogenesis in tol-1(nr2033) and found that SagA was inactive in this 
mutant (Figure 4.26a). Similarly, we found that the peptidoglycan fragments MurNAc 
and MurNAc-L-ala were also inactive in tol-1(nr2033) (Figure 4.26b), suggesting that 
SagA activity is tol-1-dependent. It is unclear if TOL-1 is acting as a receptor for SagA or 
SagA-generated peptidoglycan fragments or if it has a more vague developmental role 
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that affects SagA activity, although we believe the latter is more likely. Nevertheless, the 
requirement of tol-1 suggests that a host process is necessary for SagA activity (Figure 
4.26c). 
Figure 4.26. Inhibition of Salmonella pathogenesis by SagA requires tol-1 
a. E. faecium culture supernatant (Efmsup) and purified SagA do not inhibit Salmonella
pathogenesis in tol-1(nr2033) worms. b. MurNAc and MurNAc-Ala do not inhibit 
Salmonella pathogenesis in tol-1(nr2033) worms. c. Model of SagA activity. E. faecium 
(green cocci) secretes SagA (blue pac-man) in the intestinal lumen. SagA hydrolyzes E. 
coli peptidoglycan (PG) into smaller fragments. SagA-generated PG fragments stimulate 
a host response that leads to the inhibition of Salmonella (red bacilli) pathogenesis. The 
dashed arrows indicate processes that may require tol-1. For a and b, data points represent 
mean ± standard deviation for 3 plates of 30 worms each. Abbreviations: E. coli OP50 
(OP); S. typhimurium (Stm). 
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Our hope in studying commensal-pathogen interactions in C. elegans was to more 
rapidly identify and characterize commensal factors relevant to mammalian infection. 
Having identified SagA as a protective factor in C. elegans, we sought to evaluate SagA 
activity against Salmonella pathogenesis in mice. Salmonella pathogenesis and invasion 
occurs in the mouse ileum, which is also a primary site of E. faecium colonization. Direct 
protein delivery to the small intestine, however, is difficult and requires the development 
of hydrogels to protect embedded protein from digestion217. Such methods are in 
development for insulin delivery, but they have not been used widely. In contrast, 
delivery of a SagA-expressing bacterial strain is a more tractable approach to directly 
target SagA to the small intestine. We decided to insert sagA-his6 into the chromosome of 
E. faecalis OG1RF218, a commensal human oral isolate that has been used extensively in 
mice. 
In mammals, E. faecalis is an intestinal bacteria occupying a similar niche to E. 
faecium. E. faecalis OG1RF encodes three proteins with features similar to SagA, 
namely: F2MNS9, F2MN84, and F2MNY6 (Figure 4.27). Protein expression, however, 
has not been verified for any of these genes. Both F2MNS9 and F2MN84 are putative 
secreted NlpC/p60-type hydrolases. F2MNS9 has 35% sequence identity to SagA, as well 
as a similar overall protein domain architecture and relative chromosome location. 
F2MN84 has only 13% sequence identity to SagA and entirely lacks an N-terminal 
domain, consisting instead of only an NlpC-p60-type hydrolase domain. F2MNY6 is also 
predicted to be secreted, and has 31% sequence identity to SagA. F2MNY6 has an N-
terminal domain most similar to SagA, but, interestingly, it lacks catalytic residues in its 
NlpC/p60-like domain. To determine whether any of these SagA-like proteins were 
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indeed secreted in vitro, we analyzed E. faecalis OG1RF culture supernatant by mass 
spectrometry (Figure 4.29a and b, Appendix 10). Interestingly, we detected only the non-
enzymatic protein F2MNY6 as abundantly secreted in culture (Figure 4.29b). This 
suggests that E. faecalis OG1RF does not secrete high amounts of any protein 
functionally similar to SagA. 
Figure 4.27. SagA-like proteins encoded by E. faecalis OG1RF. 
a. Predicted domain architecture of the top three proteins in the E. faecalis OG1RF
genome with significant alignment to SagA. By Needleman-Wunsch global alignment, 
F2MNS9 has 35.1% sequence identity and 50.6% sequence similarity to SagA; F2MNY6 
has 35.6% identity and 54.5% similarity, and F2MN84 has 14.5% identity and 24.2% 
similarity. Amino acid number is as indicated, and putative catalytic residues are 
indicated in red bold type. F2MNY6 lacks any putative catalytic residues in its NlpC/p60 
like domain, and F2MN84 lacks a predicted coiled-coil domain. As shown Figure 26a, 
both SagA and F2MNS9 are located after the mreCD operon in the chromosome. 
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Figure 4.28. Construction of E. faecalis-sagA. 
a. Schematic insertion of SagA-His6 into the E. faecalis OG1RF chromosome to generate
E. faecalis-sagA (top). CAT= chloramphenicol acyltransferase (chloramphenicol 
resistance gene). Also shown for comparison is a schematic of the SagA locus in E. 
faecium Com15 (bottom). b. Growth curves of E. faecalis OG1RF (Efl) and E. faecalis-
sagA (EflsagA). Cm+ and Cm- indicate ± 10 µg/ml chloramphenicol. c. Anti-His6 
Western blot (WB) of culture supernatants from the endpoint of the growth curve shown 
in b. SagA-His6 is secreted by E. faecalis-sagA grown in the presence or absence of 
chloramphenicol (lanes +Cm and -Cm) but not by wild type E. faecalis (wt).  
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Figure 4.29. Secretome profiling of E. faecium, E. faecalis, and E. faecalis-sagA. 
a. Stain-free imaging and anti-His6 Western blot (WB) of culture supernatants from E.
faecium Com15 (Efm), E. faecalis OG1RF (Efl), and E. faecalis-sagA (EflsagA). 
Remaining culture supernatant was trypsin digested in-solution for mass spectrometry 
analysis presented in b-e, and Appendices 9 and 10. b. Summary of proteins identified by 
mass spectrometry from E. faecalis OG1RF culture supernatant. Proteins shown were 
identified with at least 2 unique peptides. Proteins involved in cell-wall remodeling are 
highlighted in red. On the y-axis is peptide spectrum matches (PSMs); on the x-axis is 
arbitrary protein number. For the list of proteins identified, see Appendix 10. c. Summary 
of proteins identified by mass spectrometry from E. faecalis-sagA culture supernatant. 
Proteins shown were identified with at least 2 unique peptides. Proteins involved in cell-
wall remodeling are highlighted in red. For the list of proteins identified, see Appendix 
10. d. Summary of proteins identified by mass spectrometry from E. faecium Com15 
culture supernatant. Proteins shown were identified with at least 2 unique peptides. 
Proteins involved in cell-wall remodeling are highlighted in red. For the list of proteins 
identified, see Appendix 9. e. Venn diagram comparing the proteins identified by mass 
spectrometry after in-gel trypsin digestion (blue) (See Figure 4.10a. and b., and Appendix 
7) versus in-solution trypsin digestion (red). Proteins identified in both samples are
indicated in the overlap (grey). Proteins included in this graph were identified with at 
least 2 unique peptides, and at least 10 PSMs. 
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Using a homologous recombination strategy developed by Nallapareddy et al.219, 
we inserted sagA-his6 into the chromosome of E. faecalis, generating the strain E. 
faecalis-sagA (Figure 4.28a). In culture, SagA-His6 was expressed and secreted by E. 
faecalis-sagA (Figure 4.29a and Appendix 10). In culture, E. faecalis-sagA grew ~1.2 
times slower as compared to wild-type E faecalis (Figure 4.28b and c). By Coomassie 
blue staining and Western blot, we observed that E. faecalis-sagA secreted qualitatively 
less SagA-His6 as compared to E. faecium (data not shown). Reduced relative SagA 
secretion by E. faecalis-sagA was confirmed by mass spectrometry of E. faecalis-sagA 
culture supernatant (Figure 4.29c and Appendices 9 and 10). Interestingly, as compared 
to wild-type E. faecalis, E. faecalis-sagA secreted an abundance of additional cell wall 
remodeling enzymes, reminiscent of the secretion profile of E. faecium (Figure 4.29c and 
d). It may be that expression of SagA by E. faecalis necessitates the expression of 
compensatory peptidoglycan remodeling enzymes, which could explain the modest 
growth rate defect we observed in E. faecalis-sagA. 
To assess the role of the hydrolase domain, we also wanted to generate an active 
site mutant insertion strain of E. faecalis. However, the active site mutant was not 
robustly expressed by E. faecalis when either plasmid-encoded (Figure 4.30a) or 
chromosomally inserted (Figure 4.30b). We hypothesize that the active site mutant might 
have a dominant negative effect on E. faecalis cell wall remodeling and growth, thereby 
selecting for no expression. Consistent with this, in E. faecium we observed reduced 
expression of plasmid-encoded active site mutant compared to wild type SagA (Figure 
4.31a). E. faecium encodes an endogenous copy of SagA that could perhaps compete 
against the dominant negative effect of active site mutant expression, reducing its 
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deleterious effects. Interestingly, we found that SagA was almost entirely secreted by 
both E. faecium and E. faecalis-sagA (Figure 4.30b and 29a). In E. faecalis-sagA, we 
were unable to detect SagA by Western blot from cell lysates of unwashed stationary 
phase cells (Figure 4.30b), suggesting that SagA was not associated with the cell wall or 
envelope. We tracked SagA-His6 secretion by E. faecium over growth by Coomassie and 
Western blot and found that SagA was abundantly secreted at all growth phases, with 
hardly any associated with the cell lysate (Figure 4.31b and c). Other NlpC/p60-type 
peptidoglycan hydrolases, including PcsB220, are cell-wall associated, raising question as 
to the endogenous role of SagA in E. faecium. 
Figure 4.30. Expression of the SagA active site mutant is inhibited in E. faecalis. 
a. Stain-free imaging and anti-His6 Western blot (WB) of culture supernatants from E.
faecalis carrying plasmid-encoded SagA-His6 or active site mutant. Four clones are 
shown for E. faecalis encoding the active site mutant (AS), and two clones are shown for 
E. faecalis encoding SagA. b. Coomassie blue staining and anti-His6 WB of culture 
supernatants (Sup.) and cell lysates from E. faecalis expressing chromosomally-encoded 
SagA-His6 or active site mutant. SagA is fully secreted, while the active site mutant (AS) 
is neither expressed nor secreted. Wildtype E. faecalis (wt) is shown as a control.  
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Figure 4.31. Abundant SagA secretion by E. faecium. 
a. Coomassie blue staining and anti-His6 Western blot (WB) of culture supernatants
(Sup.) and cell lysates from E. faecium expressing plasmid-encoded SagA-His6 or active 
site mutant (AS). The Commassie blue gel picture is split for individual contrast 
adjustment of the supernatants and lysates. For WB images, both low (WB(lo)) and high 
(WB(hi)) exposures are shown. b. Time course of SagA expression and secretion. E. 
faecium expressing plasmid-encoded SagA-His6 was grown in culture and samples were 
taken at given hours throughout the growth curve. Stain-free imaging and anti-His6 WB 
of the culture supernatant and cell lysates are shown. c. Growth curve associated with b.  
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Before testing the activity of E. faecalis-sagA against S. typhimurium 
pathogenesis in mice, we first assessed the activity of this strain in C. elegans. We were 
unable to meaningfully evaluate the protection of E. faecalis-sagA in the pulsed 
treatment-infection assay as wild type E. faecalis treatment was able to inhibit 
Salmonella pathogenesis (Figure 4.32a). CFU analysis throughout the pulsed infection 
assay revealed a marked drop in Salmonella CFUs 1 day post infection in worms treated 
with either E. faecalis or E. faecium (Figure 4.32b). In addition, E. faecalis persistently 
colonized worms to higher numbers than either E. faecium or E. faecalis-sagA (Figure 
4.32c). The ability of E. faecalis to inhibit Salmonella pathogenesis in a pulsed infection 
assay may represent a more general protection strategy by Enterococcus that is reflected 
in the decrease in Salmonella CFUs observed at 1 day post-infection. 
In the continuous infection assay, however, E. faecalis treatment was unable to 
inhibit pathogenesis, while E. faecium treatment was protective (Figure 4.32d). In this 
assay, E. faecalis-sagA attenuated Salmonella pathogenesis similarly to E. faecium 
(Figure 4.32d). CFU analysis revealed robust, persistent Salmonella colonization across 
all infected conditions (Figure 4.32e). In contrast, Enterococcus numbers dwindled by 3 
days post treatment (Figure 4.32f) for all strains. Curiously, we observed a marked 
outgrowth of E. faecium in worms late in the assay (Figure 4.32f). A pulsed 2 hour liquid 
SagA treatment was insufficient to inhibit continuous Salmonella infection (Figure 
4.33a), suggesting that prolonged delivery of SagA by either E. faecium or E. faecalis-
sagA is required to mediate protection in this assay. 
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Figure 4.32. Analysis of E. faecalis-sagA treatment in pulsed and continuous 
infection assays. 
a. Survival curve from a pulsed treatment-infection assay showing that treatment with
wild type E. faecalis OG1RF inhibits Salmonella pathogenesis similarly to E. faecium. b. 
Salmonella CFUs measured in C. elegans throughout the pulsed treatment-infection 
assay. c. Enterococcus CFUs measured in C. elegans throughout the pulsed treatment-
infection assay. d. Survival curve from a continuous infection assay showing that 
treatment with E. faecalis-sagA inhibits Salmonella pathogenesis similarly to E. faecium, 
while wild type E. faecalis does not protect. e. Salmonella CFUs measured in C. elegans 
throughout the continuous-infection assay. f. Enterococcus CFUs measured in C. elegans 
throughout the continuous-infection assay. For a and d, data points represent mean ± 
standard deviation for 3 plates of 30 worms each. For b and c, the background shading 
indicates stages of the pulsed treatment-infection. Green indicates treatment, red indicates 
infection, and grey indicates feeding on E. coli OP50. Data points represent average 
CFUs from 5 worms from one experiment without error bars. The dotted line indicates 
detection limit. For e and f, the background shading indicates stages of the treatment-
continuous infection. Green indicates treatment and red indicates infection. Data points 
represent average CFUs from 5 worms ± standard deviation of two independent 
experiments. The dotted line indicates detection limit. Abbreviations: E. coli OP50 (OP); 
S. typhimurium (Stm); E. faecium (Efm); E. faecalis (Efl); E. faecalis-sagA (EflsagA). 
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Figure 4.32. Analysis of E. faecalis-sagA treatment in pulsed and continuous 
infection assays. 
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Figure 4.33. Characterization of SagA-mediated protection in various continuous 
infection assays. 
a. Survival curve showing that SagA protein treatment cannot inhibit Salmonella
pathogenesis in a continuous infection assay. b. Survival curve showing that E. faecium 
(Efm) and E. faecalis-sagA (EflsagA) do not inhibit Salmonella pathogenesis in tol-
1(nr2033) mutants in a continuous infection assay. c. Survival curve showing that 
EflsagA is less pathogenic than wild type E. faecalis (Efl) in a continuous E. faecalis 
infection assay. For a-c, data points represent mean ± standard deviation for 3 plates of 
30 worms each. Abbreviations: E. coli OP50 (OP); S. typhimurium (Stm); E. faecium 
(Efm); E. faecalis (Efl); E. faecalis-sagA (EflsagA). 
To determine if the SagA-dependent protection observed in the continuous 
infection assay relied on similar host factors as that observed in the pulsed infection 
assay, we assessed E. faecalis-sagA protection in tol-1(nr2033) mutant worms. Both E. 
faecium and E. faecalis-sagA were unable to inhibit continuous Salmonella pathogenesis 
in tol-1(nr2033) mutant worms (Figure 4.33b). This suggests that SagA-mediated 
protection in both the continuous and pulsed infection assays requires similar host 
factors, and is likely through a similar mechanism. 
Continuous feeding on E. faecalis, but not E. faecium, is pathogenic to C. 
elegans174. We found that worms continuously fed E. faecalis-sagA survived similarly 
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those fed E. faecium (Figure 4.33c), suggesting that SagA expression counteracts the 
intrinsic pathogenesis of E. faecalis OG1RF. 
Figure 4.34. E. faecalis-sagA inhibits Salmonella pathogenesis in mice. 
a. Enterococcus CFUs measured in mouse feces at indicated time-points during infection.
Data points represent average CFUs ± standard deviation from three independent 
experiments. The dotted line indicates detection limit. b. Salmonella CFUs measured in 
mouse feces at indicated time-points during infection. Data points represent average 
CFUs ± standard deviation from three independent experiments. The dotted line indicates 
detection limit. c. Kaplan-Meier survival curve of Salmonella infected germ-free B6 
mice. Pre-colonization with either E. faecalis-sagA (EflsagA) or E. faecium (Efm) 
prolongs survival. Significance was calculated by log-rank test and p-values were 
adjusted for multiple comparisons. For **, p < 0.01; for ns, p > 0.05. Data were pooled 
from 3 independent experiments. For each condition: PBS, n=2; Efl, n=8; Efm, n=5; and 
EflsagA, n=11.  
To evaluate the protective activity of E. faecalis-sagA in mice, germ-free 
C57BL/6 mice were gavaged with PBS or 108 CFUs of E. faecium, E. faecalis, or E. 
faecalis-sagA 4 to 5 days prior to infection with S. typhimurium. Enterococcus and 
Salmonella load were measured in the feces, and mouse survival was tracked. All 
Enterococcus strains were similarly recovered from the feces after gavage, indicating 
efficient colonization of the intestine (Figure 4.34a). In addition, S. typhimurium CFUs in 
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the feces were similar across all conditions throughout infection (Figure 4.34b). 
Consistent with our results in C. elegans, this suggests that E. faecium does not inhibit 
Salmonella colonization. Germ-free mice are highly susceptible to Salmonella, requiring 
only tens of bacteria to cause pathogenesis and rapid death. Accordingly, PBS gavage 
prior to infection resulted in a median survival of 5 days (Figure 4.34c). Compared to E. 
faecalis, E. faecium treatment shifted median survival from 6 to 9 days (Figure 4.34c). 
Mice gavaged with E. faecalis-sagA prior to infection survived similarly to E. faecium-
treated mice, and survived significantly longer than E. faecalis-treated mice (Figure 
4.34c). These results indicate that SagA contributes to E. faecium-mediated protection in 
mice, and that SagA expression is sufficient to convert E. faecalis into a protective strain. 
Figure 4.35. SagA expression and secretion by Lactobacillus plantarum. 
a. Stain-free imaging (SF) and anti-His6 Western blot (WB) of culture supernatants and
cell lysates of L. plantarum WCSF1 carrying plasmid-encoded SagA-His6 or empty 
vector. 2 clones each for SagA-His6 and empty vector are shown. Wild type L. plantarum 
WCSF1 (wt) is shown as a control. The black smear in the stain-free imaging of the 
supernatant lanes is due to growing bacteria in MRS broth. b. Growth curves of L. 
plantarum-sagA or L. plantarum-vector as compared to wild type L. plantarum. SagA 
expression causes a ~ 2 hour extension of lag phase. 
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Our eventual goal is to engineer a safe probiotic prophylaxis against Salmonella 
pathogenesis. E. faecalis is not an ideal probiotic candidate, since it has pathogenic 
potential189. Therefore, we decided to develop Lactobacillus plantarum WCFS1221 as a 
SagA-delivery strain. In general, Lactobacilli are safe commensal bacteria approved for 
use as probiotics in both humans and animals222. L. plantarum WCFS1 is a commensal 
human oral isolate that has been widely studied in mice as a probiotic. We constitutively 
expressed SagA-His6 on a low-copy number plasmid to generate L. plantarum-sagA. In 
culture, SagA-His6 was expressed and secreted by L.plantarum-sagA (Figure 4.35a). 
However, as compared to wild type L. plantarum, L.plantarum-sagA had a markedly 
protracted lag phase, and grew ~1.4 times slower during exponential phase (Figure 
4.35b). Similar to E. faecalis-sagA, we hypothesize that this reflects compensatory 
peptidoglycan remodeling in response to SagA expression. 
In preliminary mouse experiments, we have evaluated the protective activity of L. 
plantarum-sagA in a streptomycin-treatment Salmonella infection model as compared E. 
faecium or L. plantarum carrying an empty vector (L. plantarum-vector). Compared to 
germ-free rearing, streptomycin treatment prior to Salmonella infection results in a 
similar colitis phenotype, and is used extensively as a model for Salmonella 
pathogenesis223. We wanted to assess SagA activity in the streptomycin-colitis model, to 
determine if SagA could protect against Salmonella pathogenesis in mice with normally 
developed immune systems. In this assay, C57BL/6 mice were gavaged with 
streptomycin 24 hours before gavage with PBS or 108 CFUs of E. faecium, L. plantarum-
vector, or L. plantarum-sagA. After 3 hours, mice were infected with S. typhimurium. 
Promisingly, treatment with L. plantarum-sagA or E. faecium significantly prolonged 
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survival as compared to PBS or L. plantarum-vector treatment (data not shown, V. 
Pedicord). This suggests that SagA can inhibit Salmonella pathogenesis after a brief 
treatment period, and within the context of a healthy immune background. Given this, we 
are now engineering an L. plantarum chromosomal SagA-insertion strain for future 
mouse studies. 
SUMMARY. 
In this study, we used Caenorhabditis elegans as a simplified model system to 
investigate the mechanisms underlying E. faecium probiotic function. We identified and 
characterized secreted antigen A (SagA) from E. faecium as a peptidoglycan hydrolase 
that is sufficient to protect C. elegans and mice from Salmonella pathogenesis. Our 
results in C. elegans suggest that SagA does not inhibit pathogen growth, but instead 
remodels peptidoglycan fragments in vivo to activate host immune pathways required for 
resistance to pathogenesis. We hypothesize that SagA promotes a strengthening of 
intestinal barrier integrity to confine Salmonella to the intestinal lumen. These results 
suggest that commensal bacterial factors can remodel microbial-associated molecular 
patterns to modulate host resistance to pathogens. 
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MATERIALS and METHODS. 
Strains. 
C. elegans were maintained as described by (Stiernagle 1999)172. C. elegans strains npr-
1(ad609), daf-16(mu86), daf-2(e1370); daf-16(mgDf47), pmk-1(km25), dbl-1(nk3), and 
tol-1(nr2033) were all provided by the Caenorhabditis Genetics Center. 
E coli DH5α, E. coli BL21-RIL(DE3) (Agilent Technologies), and Salmonella enterica 
serovar typhimurium strain IR715 were grown in LB (BD Difco). Enterococcus faecium 
strains NCTC 7171 (ATCC 19434), Com15, Com12, and TX0016 (DO, ATCC BAA-
472), Enterococcus faecalis strain OG1RF (ATCC 47077), and Bacillus subtilis strain 
168 were grown in BHI (BD BBL). Lactobacillus plantarum WCFS1 (ATCC BAA-793) 
was grown in MRS (BD BBL). E. faecium strains Com15 and Com12 were a gift from 
Michael Gilmore. S. typhimurium strains ∆invA and ∆invA/∆spiB were a gift from 
Andreas Baumler85. S. typhimurium strain ∆spiB was a gift from Helene Andrews-
Polymenis224. 
When necessary, ampicillin was used at 100 µg/ml, gentamicin was used at 125 µg/ml, 
kanamycin was used at 50 µg/ml, and tetracycline was used at 15 µg/ml. 
Chloramphenicol was used at 25 µg/ml for E. coli, 10 µg/ml for Enterococcus, and 8 
µg/ml for L. plantarum. 
114	  
Cloning strategies: 
Table 4.1. Plasmids used in this study. SagA	  hydrolase	  domain	  prediction	  was	  determined	  using	  Phyre	  2	  software225.	  Coiled	  coil	  domain	  prediction	  were	  determined	  using	  COILS	  software226.	  Signal	  sequence	  prediction	  was	  determined	  using	  SignalP	  v4.1	  software227.	  
Name Backbone Description 
pET21a-SagA pET21a (Novagen) AmpR, SagA-His6
pET21a-AS pET21a Amp
R, AS-His6;  
C443A, H494A, H506A 
pET21a-∆Cterm pET21a Amp
R, ∆Cterm-His6; 
Δ390-529 
pET21a-SagA-SS pET21a Amp
R, SagA-SS-His6; 
Δ2-27 
pET21a-∆Linker pET21a Amp
R, ∆Linker-His6; 
∆225-377 
pET21a-∆Nterm+SS pET21a Amp
R, ∆Nterm+SS-His6; 
∆39-203 
pET21a-∆Nterm-SS pET21a Amp
R, ∆Nterm-SS-His6; 
∆2-26; ∆39-203 
pAM401-SagA pAM401 (ATCC 37429) Cam
R, psagA:SagA-His6 
pAM401-psagA:mcherry pAM401 CamR, psagA:mcherry 
pTEX5501ts-OG1RF-sagA pTEX5501ts  (Nallapareddy et al)219 Cam
R, GenR, *see below 
p67MC1 (Singer et al 
2010)228 Amp
R, mcherry 
pSMC21 (Bloemberg et al 
1997)229 Amp
R, KanR, GFP 
All cloning was done in E. coli DH5α. pET21a constructs were transformed into 
E. coli BL21-RIL (DE3) for expression. pAM401 constructs were transformed into i, E. 
faecium, and L. plantarum for expression. 
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pET21a-SagA: 
sagA was PCR amplified from the E. faecium Com15 genome using the following 
primers: 
FW: GGACATATGAAAAAGAGTTTAATATCAGCAGTAATGG 
RV: GGACTCGAGCATGCTGACAGCAAAGTCAGGTGCAAAC 
Restriction sites for Nde1 and Xho1 are underlined. The PCR product was gel purified 
and subcloned into pGEMTeasy (Promega) for sequencing. Then, an internal Nde1 site 
was mutated using the Quikchange multi-site directed mutagenesis kit (Stratagene) using 
the following primer:  
AAATATATCGGTACTCCtTATGTTTGGGGCGG 
The site mutated is indicated in lowercase, resulting in a synonymous mutation in the 
SagA protein sequence. sagA was then excised from pGEMTeasy with Nde1 and Xho1 
and was ligated into cut pET21a (Novagen).  
pET21a-AS: 
pET21a-SagA was mutagenized with the following primers to generate the indicated 
cysteine to alanine and histidine to alanine mutations in the SagA protein sequence: 
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C443A: CCAAGTGGATTTGACgcCTCAGGATTCACACG 
H494A: TCACCAGGCGGAACTTACgcCGTAGCGATTGC 
H506A: GGAGGACAATATATCgcTGCTCCTCAACCAGG 
The mutated sites are indicated in lowercase. 
pET21a-∆Cterm: 
pet21a-SagA was mutagenized with the following primers to insert BamH1 sites flanking 
the hydrolase domain: 
AACAGATCAAAGTGTgGATCCTGGGAACAGTACTGG 
TGCACCTGACTTTGCgGatccCATGCTCGAGCACCAC 
The BamH1 sites are underlined. The mutated sites are indicated in lowercase. The 
plasmid was then cut with BamH1 and re-ligated to form pET21a-∆Cterm, resulting in an 
in-frame excision of residues 390 through 529 in the SagA protein sequence. 
pET21a-SagA-SS: 
SagA-SS was PCR amplified from pET21a-SagA_BamH1 (see pAM401-SagA section 
below) using the following primers: 
FW: CATCACCATATGGACGATTTTGATTCTCAGATA 
RV: CATCACGGATCCTTTCGGGCTTTGTTA 
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The Nde1 and BamH1 sites are underlined. This PCR product was cut and ligated back 
into cut pET21a-SagA_BamH1, resulting in an in-frame excision of residues 2 through 
27 in the SagA protein sequence.  
pET21a-∆Linker: 
pet21a-SagA was mutagenized with the following primers to insert Kpn1 sites flanking 
the linker region: 
CGCCAAAAAGCAGAAGgTaccGCAGAACAAGCACGCG 
TCAACAACACCTGCGggTACcACACCATCAACAGATC 
The Kpn1 sites are underlined. The mutated sites are indicated in lowercase. The plasmid 
was then cut with Kpn1 and re-ligated to form pET21a-∆Linker, resulting in an in-frame 
excision of residues 225 through 377 in the SagA protein sequence. 
pET21a-∆Nterm+SS:  
pet21a-SagA was mutagenized with the following primers to insert Nhe1 sites flanking 
the N-terminal domain: 
TTCTCAGATACAACAgCtAGcTCAAAAGATTGCAGAC 
CGTACTGAAAACTTCgcTAGCTGCTGAACAAGCAAC 
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The Nhe1 sites are underlined. The mutated sites are indicated in lowercase. The plasmid 
was then cut with Nhe1 and re-ligated to form pET21a-∆Nterm+SS, resulting in an in-
frame excision of residues 39 through 203 in the SagA protein sequence. 
pET21a-∆Nterm-SS:  
pet21a-∆Nterm was cut with Nde1 and SacII, the ends were blunted with Klenow, and 
the gel-purified plasmid was re-ligated. This resulted in a one base-pair frame shift. The 
frame shift was corrected by mutagenizing the plasmid with the following primer, 
restoring the Nde1 restriction site: 
AAGGAGATATACAtATGGCGGACGATTTTG 
The Nde1 site is underlined. The mutated site is indicated in lowercase. This resulted in 
an in-frame excision of residues 2 through 26 in the ∆Nterm protein sequence, generating 
pET21a-∆Nterm-SS. 
pAM401-psagA:mcherry: 
The promoter region of sagA (psagA) was PCR amplified from the E. faecium Com15 
genome using following primers:  
FW: AAAGTCGACACGATGGTGGTCCAATTGAT 
RV: TTTCATATGTCATTCCTCCGACTGGCTTA 
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Restriction sites for Sal1 and Nde1 are underlined. The PCR product was gel purified and 
subcloned into pGEMTeasy for sequencing. psagA was excised with Sal1 and Nde1, and 
ligated into cut pAM401-padd9:mcherry (**see below) to replace paad9 with psagA. 
pAM401-SagA: 
pET21a-SagA was mutagenized to insert a BamH1 site after the 6X-His using the 
following primer to generate pET21a-SagA_BamH1: 
TAACAAAGCCCGAAAGGAtccTGAGTTGGCTGCTGC 
The BamH1 site is underlined. The mutated sites are indicated in lowercase. sagA-his6 
was then excised with Nde1 and BamH1, and ligated into cut pAM401-psagA:mcherry to 
replace mcherry with SagA-His6. pAM401-SagA was transformed into E. faecium 
Com15, E. faecalis OG1RF, and L. plantarum WCFS1 as described below.  
*Generating E. faecalis-sagA:
pTEX5501ts-OG1RF-sagA: 
pTEX5501ts was a gift from Barbara Murray. 986 bp of sequence “upstream” (on the 
minus strand) of the intended SagA insertion site was PCR amplified using the following 
primers: 
FW: AAACGGCCGAGTGGGGCGTGTTATTGAAG 
RV: TTTGTCGACGGGTAAGCTTCTCATCGTTTTG 
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The Eag1 and Sal1 sites are underlined. 1013 bp of sequence “downstream” (on the 
minus strand) of the intended SagA insertion site was PCR amplified using the following 
primers: 
FW: AAACTGCAGTGGAGCCTTGAAGAAAGTTG 
RV: TTTGGTACCATTGGCTGCTTTTGTTGCTT 
The Pst1 and Kpn1 sites are underlined. The upstream and downstream PCR products 
were subcloned into pGEMTeasy and sequenced, then were excised and ligated into cut 
pTEX5501ts sequentially. (Note: For the Eag1/Sal1 double digest of pTEX4401ts, Sal1 
was added first, then Eag1 because the restriction sites overlap in the vector, and Eag1 
can cut more efficiently at the end of a linear DNA fragment). psagA:sagA-his6 was 
excised from pAM401-SagA with Sal1 and BamH1 and inserted into the cut vector, 
generating pTEX5501ts-OG1RF-sagA. OG1RF-sagA-his6 was generated using the 
protocol described by (Nallapareddy et al)219. Briefly, OG1RF was transformed with 
pTEX5501ts-OG1RF-sagA and single recombinants were selected after plasmid curing at 
37 °C. Then colonies were passaged at 37 °C and screened for gentamicin sensitivity and 
chloramphenicol resistance until such a clone was identified. Chromosomal insertion was 
verified by PCR and sequencing. 
**pAM401-paad9:mcherry: 
paad9:mcherry was designed by us and synthesized by Genewiz into pUC57. It encodes 
the synthetic promoter to aad9230 flanked by Sal1 and Nde1 restriction sites, driving 
121	  
mcherry flanked by Nde1 and BamH1 restriction sites. paad9:mcherry was excised from 
pUC57 with Sal1 and BamH1 and ligated into cut pAM401, inserting into the TetR gene. 
Electroporation of Enterococcus and Lactobacillus:  
Protocol for preparation of electrocompetent cells and electroporation was adapted from 
(Dunny et al. 1991)231. Briefly, Enterococcus or Lactobacillus were grown for 18 hours 
in M9YE (M9 media, 0.1% casamino acids, 0.3% yeast extract) + 2% glycine. Cultures 
were diluted in half with M9YE + 3% glycine, and grown for an additional 3 hours. 
Cultures were chilled, pelleted, and washed 3 times in sucrose wash buffer (0.625 M 
sucrose, 1 mM MgCl2, pH 4 with HCl), reducing the original culture volume by 1/2, 
1/10, then 1/100 successively with each wash. Finally, cells were aliquoted, flash frozen 
in liquid nitrogen, and stored at -80 °C. Cells were electroporated in 2 mm cuvettes, 25 
µF, 400 ohm, 2.5 kV. Cells were allowed to recover for 2 hours at room temperature 
without shaking in Todd-Hewitt Broth (BD Bacto) for Enterococcus or MRS broth (BD 
Bacto) for Lactobacillus, then with shaking at 37 °C for another 2 hours before plating on 
selective media. 
Protein purification: 
For E. faecium Com15 protein expression, plasmid-carrying strains were grown in BHI 
with appropriate antibiotics overnight. For E. coli BL21-RIL (DE3), LB cultures were 
inoculated with overnight cultures with appropriate antibiotics, grown for 2 hours or until 
OD600 ~ 0.4, induced with 1 mM IPTG, then grown for an additional 2 hours. His6-tagged 
proteins were purified from culture supernatants using Ni-NTA agarose (Qiagen). Native 
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purifications were performed as recommended in the manufacturer’s protocol. Purified 
protein was dialyzed into PBS at 4 °C overnight using 5 kDa or 7 kDa MWCO Slide-a-
lyzers (Pierce Protein Biology). Protein concentration was estimated by BCA assay 
(Pierce Protein Biology) and protein was stored at -20 °C. 
Protein gel methods and Western blotting: 
Proteins were separated by SDS-PAGE on 4-20% Criterion Tris-HCl or Criterion TGX 
precast gels (Bio-Rad). Protein was visualized either by Coomassie blue (Bio-Rad) 
staining or stain-free imaging on a ChemiDoc MP system (Bio-Rad). Glycoproteins were 
visualized using the Pierce Glycoprotein staining kit (Thermo Scientific) as per the 
manufacturer’s protocol. For Western blotting, proteins were transferred to nitrocellulose 
membrane. HRP conjugated polyclonal anti-His6 (abcam ab1187) and monoclonal anti-
actin (abcam ab14128) were used for His6 and actin Western blots respectively. Western 
blots were visualized either by developing film or imaging on a ChemiDoc MP system. 
Bacterial growth curves: 
Growth of E. coli expressing SagA, AS, or SagA-SS: 
Cultures were grown as described for protein purification, except that OD600 was 
monitored at given time points using a Spectromax M2e spectrophotometer. 
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Growth of E. coli and S. typhimurium in the presence of SagA: 
LB media was inoculated with overnight cultures 1:100. Protein was added at 10 µg/ml 
and volumes were normalized across all conditions with PBS. OD600 was measured at 
given time points. 
Growth of OG1RF-sagA: 
BHI media was inoculated with overnight cultures 1:100. Chloramphenicol was added at 
10 µg/ml as indicated. OD600 was measured at given time points. 
Salmonella protein secretion assay: 
For each condition, 2 mL of LB was inoculated with overnight cultures 1:30. Protein was 
added to media at 10 µg/ml and volumes were normalized across all conditions with PBS. 
The ∆invA63 strain was a gift from the Baumler lab. Cultures were grown for 4 hours, 
shaking at 37 °C, the pelleted at 7000 g for 5 minutes. 1 ml of culture supernatant was 
precipitated with trichloro acetic acid (TCA) at a final concentration of 10% overnight at 
4 °C. Precipitated proteins were pelleted at 20,800 g for 30 minutes, rinsed 2 times in 
acetone, then air-dried. Proteins were then separated by SDS-PAGE and visualized by 
Coomassie blue staining. 
C. elegans infection assays: 
For each condition, 3 plates of 30 worms each (total 90 worms) were scored, unless 
otherwise noted. Mean percent survival and standard deviation of the triplicate plates for 
a representative experiment is shown. E. faecium refers to strain Com15 unless otherwise 
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noted in the figure legends. Worms were handled using a Leica M60 microscope and 
imaged using a Leica IC80 HD camera.  
Pulsed infection assay: 
Worms were synchronized as described in (Powell and Ausubel 2010).188 Synchronized 
young adult worms were washed in S buffer (129 ml 0.05 M K2HPO4, 871 ml 0.05 M 
KH2PO4, 5.85 g NaCl) and transferred to bacterial lawns grown on 2% agar BHI plates 
for colonization for 1 day. Then, worms were washed and transferred to lawns of OP50 
or IR715 grown on BHI plates for infection for another day. Finally, worms were washed 
and transferred to lawns of OP50 grown on NGM plates (Day 0). Worms were 
maintained on OP50-NGM plates and survival was scored as described in (Powell and 
Ausubel 2010)188.  
Liquid-treatment pulsed infection assay: 
Synchronized young adult worms were transferred to 96-well plate wells containing 32% 
BHI media, culture supernatant, or live cultures. For protein treatments, 10-20 µg/ml of 
protein in PBS was included in each well. For treatment with peptidoglycan digests, 100 
µl of each digest was added to each well. For treatment with defined peptidoglycan 
fragments, 50 µM of each fragment in a mixture of PBS and water was included in each 
well. MTP(mDAP), MTP(L-Lys), MTP-D-Asn, TriDAP, TriLys, and D-iGlu-mDAP 
were purchased from Invivogen. MDP, GlcNAc, and MurNAc were purchased from 
Sigma-Aldrich. MurNAc-L-Ala was synthesized by Yen-Chih Wang. After 2 hours, 
worms were washed and transferred to lawns of IR715 grown on BHI plates for 1 day. 
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Then, worms were washed and transferred to lawns of OP50 grown on NGM plates (Day 
0). Worms were maintained on OP50-NGM plates and survival was scored.  
Continuous infection assay: 
Synchronized young adult worms were washed and transferred to lawns of OP50 or 
IR715 grown on NGM plates (Day 0). Worms were maintained on OP50 or IR715 NGM 
plates and survival was scored. For liquid treatment prior to continuous infection, liquid 
treatments were performed as described above.  
OG1RF pathogenesis assay: 
This assay was performed as essentially as described by Garsin et al174. Briefly, 
synchronized young adult worms were transferred to Com15, OG1RF, or OG1RF-sagA 
bacterial lawns grown on BHI plates (Day 0). Worms were maintained on Com15, 
OG1RF, or OG1RF-sagA BHI plates, and survival was scored.  
Worm CFU measurements: 
Protocol for CFU measurements was adapted from Garsin et al174. Briefly, 5-20 worms 
were rinsed in drops of S buffer, and allowed to crawl free of bacteria on a sterile plate. 
These worms were then mechanically lysed in PBS using microtubes and pestles 
(Kimble-Chase). Serial dilutions of worm homogenate were plated on Salmonella-
Shigella agar (BD BBL) or Enterococcosel (BD BBL) agar plates, and plates were 
incubated at 37 °C overnight. 
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Treatment of culture supernatants: 
Proteinase K treatment: Culture supernatant or media was digested with 0.1 mg/ml of 
proteinase K in the presence of 1 mM CaCl2 for 2 hours at 37 °C. Then, 1 mM EGTA 
was added, and digestions were used in the liquid-treatment pulsed infection assay. 
Trichloro acetic acid precipitation: Culture supernatant or media was precipitated with 
TCA (final concentration of 10%) overnight at 4°C. Precipitated proteins were pelleted 
and rinsed 2 times in acetone, then air-dried and resuspended in BHI media before use in 
the liquid-treatment pulsed infection assay. 
10-kDa MWCO column filtration: E. faecium culture supernatant or media was filtered 
through 10-kDa MWCO columns (Vivaspin GE Healthcare), and the flow-thru was used 
in the liquid-treatment pulsed infection assay. 
5-kDa MWCO column filtration of E. coli culture supernatants: E. coli BL21-RIL(DE3) 
expressing SagA-His or AS-His were induced in BHI media instead of LB as described 
above. Portions of the culture supernatants were filtered through 5-kDa MWCO columns 
(Vivaspin GE Healthcare), and the unfiltered supernatants, column concentrate, and 
column flow-thru were used in the liquid-treatment pulsed infection assay.  
Peptidoglycan digests: 
100 µg of E. coli peptidoglycan (Invivogen) was digested with 20 µg lysozyme (Sigma) 
and 20 µg of SagA-His or AS-His overnight in a mixture of PBS and water at 37 °C. 
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Digests were then filtered through 5-kDa MWCO columns (Vivaspin GE Healthcare), 
and the flow-thru was used in the liquid-treatment pulsed infection assay 
Proteomics: 
In-gel digestion: 
1 ml of culture supernatant was precipitated with TCA as described above, resuspended 
in loading buffer and separated by SDS-PAGE. Proteins were processed for in-gel 
digestion with sequencing grade trypsin (Promega) as previously described232 except that 
dried samples were resuspended in 5% acetonitrile, 2% formic acid in water. 
In-solution digestion: 
1 ml of culture supernatant was precipitated with TCA as described above, and proteins 
were digested with 0.2 µg of trypsin in 50 mM ammonium bicarbonate buffer overnight 
at 37 °C. Samples were dried by speed-vac, then resuspended in 5% acetonitrile, 2% 
formic acid in water. LC-MS was performed on digested peptides and peptide spectra 
were analyzed against the E. faecium Com15 proteome using Mascot v2.3 and Proteome 
Discoverer software. 
8-aminonaphthalene 1,3,6 trisulfonic acid (ANTS) labeling assay: 
E. coli supernatants were prepared by inoculating cultures 1:50 with an overnight 
culture of E. coli BL21-RIL(DE3) expressing SagA-His6 or AS-His6. Cultures were 
grown for 2 hours, then induced with 1 mM IPTG, and grown for an additional 2 hours. 
Enterococcus supernatants were prepared by growing cultures overnight. Cultures were 
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pelleted, and supernatant was filtered through 10 kDa MWCO columns (Millipore 
Microcon). For peptidoglycan digests, 100 µg of E. coli peptidoglycan was digested with 
20 µg lysozyme and 20 µg of SagA-His or AS-His overnight in a mixture of PBS and 
water at 37 °C. Digests were filtered through 10 kDa MWCO columns. Culture 
supernatants, peptidoglycan digests, and defined peptidoglycan fragments were dried by 
speed-vac before ANTS labeling.  
ANTS labeling was performed essentially as described by Young205. ANTS 
reaction mix was added to each tube of dried material (1:1 mixture of 0.2M ANTS (in 
3:17 acetic acid:water): 1M NaCNBH3 (in DMSO)). Reactions were incubated overnight 
at 37 °C. 0.5-3.5 µl of the ANTS labeled mixtures were mixed 1:1 with 40% glycerol and 
samples were separated by native PAGE on a hand-cast 37-40% Tris-glycine acrylamide 
gel (19:1 polyacrylamide:bisacrylamide, with a 20% acrylamide stack). at 150 V for ~ 3 
hours or until the free ANTS front reached the bottom of the gel. Empty lanes adjacent to 
sample lanes were loaded with samples of ANTS labeled Ala-D-γ-Glu-Lys-D-Ala-D-Ala
(Sigma). Remaining lanes were loaded with 20% glycerol. 
Epifluorescence: 
For imaging of mcherry-Salmonella, worms were treated as described for the pulsed 
infection assays except worms were infected with S. typhimurium carrying the plasmid 
p67MC1. For imaging of E. faecium psagA:mcherry, worms were fed E. faecium 
carrying the plasmid pAM401-mcherry for 1 day on BHI plates. Worms were mounted as 
described by Shaham 2006233, except that worms were paralyzed in 1 mM tetramisole 
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(Sigma) instead of sodium azide. Worms were imaged on a Nikon Eclipse TS100 and 
pictures were taken using a Nikon Digital Sight DS-Fi1. 
Electron Microscopy: 
Animals were prepared for electron microscopy using standard methods234. Ultrathin 
serial sections (70 nm) were collected by using a Leica Ultracut UCT 
Ultramicrotome. Sections at two regions, 120 µm and 200 µm away from the head 
region, were examined for each condition. EM images were acquired using an FEI Tecnai 
G2 Spirit BioTwin transmission electron microscope operating at 80 kV with a Gatan 4K 
x 4K digital camera. 
Mouse Experiments: 
Mouse experiments were performed in accordance with NIH Animal Care guidelines, 
institutional guidelines, and animal protocols approved by the IACUC at The Rockefeller 
University. Germ-free C57BL/6 (B6) mice were bred and continuously housed in germ-
free isolators and exported at 7-8 weeks of age. Exported germ-free mice were 
maintained in autoclaved cages with autoclaved food and water throughout all 
experiments.  
Preparing bacterial cultures for gavage: 
S. typhimurium and Enterococcus strains were grown overnight in LB and BHI 
respectively. For Enterococcus strains, BHI cultures were inoculated with overnight 
cultures at 1:50, and incubated at 37 °C for 3-4 hours. Cultures were diluted in PBS to 
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achieve a concentration of 109 CFU/ml. For S. typhimurium, LB cultures were inoculated 
with overnight cultures at 1:30, and incubated at 37 °C for 3-4 hours. Cultures were 
diluted in PBS to achieve a concentration of 103 CFU/ml. These cultures were serially 
diluted and plated on selective agar to confirm concentration.  
Colonization-infection assay: 
Upon export, mice were gavaged with PBS or ~108 CFUs (in 100 µl) of OG1RF, 
OG1RF-sagA or Com15. Mice were rested for 4-5 days, then infected with ~102 CFU (in 
100 µl) of S. typhimurium per mouse by oral gavage. Infected mice were monitored daily 
for weight-loss, morbidity, and bacterial burden in the feces. Mice were euthanized upon 
overt signs of morbidity or loss of more than 20% of baseline body weight. 
Mouse fecal CFU measurements: 
Mouse feces were weighed and mechanically lysed in PBS using microtubes and pestles 
(Kimble-Chase). Serial dilutions of fecal homogenate were plated on Enterococcosel (BD 
BBL) and Salmonella-Shigella (BD BBL) agar plates, and plates were incubated at 37 °C 
overnight. 
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CHAPTER 5. Discussion and Outlook 
Metagenomic5,65 and metabolomic235 profiling has revealed an abundance and 
diversity of bacterial biomolecules and metabolites present in the intestine. As described 
in Chapter 1, relatively few of these bacterial products have been characterized in the 
context of microbiota-mediated pathogen resistance. In this thesis, we describe two 
projects that explore the effects of commensal-derived metabolites in the context of 
Salmonella pathogenesis. 
In Chapters 2 and 3, we use alkynyl-functionalized fatty acid chemical reporters to 
investigate how fatty acids modulate bacterial physiology and virulence. Genomic and 
proteomic profiling of intracellular Salmonella has revealed that this pathogen encodes an 
extensive metabolic capacity and exploits diverse host nutrients96,97. The specific 
contribution of fatty acids to Salmonella growth and virulence in vivo, however, is not 
clear. With our long-chain fatty acid reporter, alk-14, we show that Salmonella fully 
metabolizes exogenous long-chain fatty acids, and we track the covalent modification of 
metabolic enzymes labeled by alk-14 derived metabolites. We also show that alkynyl-
short chain fatty acid reporters can recapitulate the inhibition of Salmonella virulence 
observed with natural short-chain fatty acids. These reporters covalently modify an 
abundance of Salmonella proteins, which may yet reveal the mechanisms underlying 
fatty-acid mediated attenuation of virulence. In general, our studies suggest that alkynyl-
fatty acid reporters may be useful for tracking Salmonella metabolic flux and protein 
modifications in response to dietary or bacterial-derived fatty acids. Taken further, 
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alkynyl-fatty acid reporters could be used to follow the exchange of fatty acid derived 
metabolites between bacteria and host cells in more complex environments, such as the 
intestine. 
In Chapter 4, we identify a peptidoglycan hydrolase (SagA) secreted by 
Enterococcus faecium that confers protection against Salmonella pathogenesis in C. 
elegans and mice. We hypothesize that SagA remodels peptidoglycan in vivo to enhance 
host resistance to pathogenesis. The conservation of SagA-mediated protection in C. 
elegans and mice is suggestive of a conserved mechanism. In C. elegans, SagA-activity 
appears to require tol-1-dependent host processes. Electron microscopy of E. faecium-
treated worms revealed decreased degradation of the intestinal microvilli, despite robust 
Salmonella colonization, leading us to hypothesize that E. faecium may enhance 
epithelial barrier function. This is an attractive hypothesis since the secretion of 
antimicrobial peptides by intestinal epithelial cells constitutes a major arm of C. elegans 
immunity. Although little is known in C. elegans regarding epithelial barrier maintenance 
per se, in mammals, the secretion of mucins and antimicrobial peptides, most notably the 
C-type lectin Reg-IIIγ, by intestinal epithelial cells is required to segregate bacteria away 
from the intestinal border45. Preliminary experiments analyzing the inhibition of 
Salmonella pathogenesis by E. faecium in Rag2-deficient mice and Reg-IIIγ-deficient 
mice have indicated that E. faecium-mediated protection does not require adaptive 
immunity, but is dependent on Reg-IIIγ (data not shown, V. Pedicord). Although similar 
experiments using E. faecalis-sagA have yet to be performed, these data suggest that 
SagA-activity in mice leads to an enhancement in intestinal epithelial barrier function. If 
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true, the conserved action of SagA suggests a link between peptidoglycan recognition and 
innate immune enhancement of epithelial barrier function in both C. elegans and mice. 
Peptidoglycan recognition and modification is a widely conserved aspect of innate 
immunity in animals. In mammals, NOD1 and NOD2 are the best characterized 
peptidoglycan recognition receptors28. Activation of downstream NF-κB and MAPK 
pathways upon peptidoglycan recognition leads to the expression of inflammatory 
cytokines, reactive oxygen species, and antimicrobial peptides, including Reg-IIIγ236. 
Peptidoglycan recognition by TLR2 has also been reported237, although the specific 
peptidoglycan-derived ligand(s) recognized by TLR2 are unclear238. TLR2 activation 
leads to antimicrobial peptide production as well as an enhancement of tight junction 
integrity239. In the intestine, NOD1, NOD2, and TLR2 are involved in immune 
homeostasis and tolerance mechanisms, in part through the regulation of epithelial barrier 
function21.  
NOD1 and NOD2 respond to different peptidoglycan fragments; namely, NOD1 
recognizes MTP(mDAP), TriDAP, and iGlu-DAP, while NOD2 recognizes MDP240. To 
our knowledge, the response to smaller peptidoglycan fragments, such as MurNAc and 
MurNAc-L-Ala, has not been assessed. Although various peptidoglycan fragments can 
stimulate NOD1 and NOD2, the endogenous ligands recognized in vivo remain unknown. 
Direct binding of peptidoglycan fragments to NOD1 or NOD2 has been suggested, but is 
confounded by the fact that these are cytoplasmic proteins. Hydrophobic peptidoglycan 
fragments could potentially diffuse through the cell membrane. However, various 
mechanisms to actively transport peptidoglycan to the cytoplasm have been suggested, 
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including endocytosis241, peptide transporters242, and injection by bacterial secretion 
systems243.  
The ligand specificity of NOD1 and NOD2 calls to question the role of 
peptidoglycan remodeling enzymes in modulating NOD-dependent responses. Besides 
the abundance of bacterially-encoded peptidoglycan remodeling enzymes likely 
expressed in the intestine, mammals express 4 peptidoglycan recognition receptors 
(PGRPs) in the intestine, namely: PGLYRP-1, -2, -3, and -4199,244. PGLYRP-1, -3, and -4 
bind peptidoglycan and are bactericidal, possibly contributing to epithelial barrier 
function. In contrast, PGLYRP-2 has non-bactericidal peptidoglycan amidase activity, 
cleaving between MurNAc and L-Ala245,246. This activity could theoretically destroy 
NOD2 ligands, and decrease the uptake of NOD1 ligands (MTP --> tri-peptide). So far, 
the role of PGLYRP-2 in vivo is unclear, although in a Salmonella streptomycin-colitis 
model, PGLYRP-2-deficient mice exhibit enhanced caecal inflammation247. Drosophila 
encodes 20 PGRPs, of which 8 are known or predicted to have amidase activity. Several 
of the non-enzymatic PGRPS are involved in peptidoglycan recognition for immune 
activation, while those with amidase activity have been found to dampen excessive 
immune activation by cleaving and inactivating stimulatory peptidoglycan fragments. We 
hypothesize that SagA might function similarly to a PGRP, modulating the intestinal 
peptidoglycan pool to alter downstream host responses. A first step in addressing this 
hypothesis is to assess whether SagA-generated peptidoglycan fragments, or more 
specifically MurNAc and MurNAc-Lala, can activate NOD1, NOD2 or TLR2, given their 
well-characterized roles in epithelial barrier maintenance and innate immunity. 
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In C. elegans, no microbial-associated molecular patterns (MAMPs) or pattern 
recognition receptors (PRRs) have been characterized. In addition, C. elegans does not 
encode any obvious homologues to NOD-like receptors or PGRPs. Secreted intestinal 
lysozymes may be the only host-encoded peptidoglycan remodeling enzymes. C-type 
lectin domain (CTLD) containing proteins, which bind various monosaccharides and 
carbohydrates among other bacterial cell wall ligands30, could be involved in C. elegans 
pattern recognition159. In addition, C. elegans also encodes 8 LysM domain-containing 
(LMD) proteins248. LysM domains are glycan/peptidoglycan-binding domains249 that 
originated from bacteria, and are found in a variety of eukaryotes. However, whether 
LMD-containing proteins play a role in immunity is not known. Either CTLD- or LMD-
containing proteins could potentially bind to SagA or SagA-derived peptidoglycan 
fragments to enhance immunity. The differential activity we observe between MurNAc 
and GlcNAc in C. elegans could be, for example, due to differences in the sugar-binding 
specificity of these domains. Future investigation into peptidoglycan recognition in C. 
elegans, and how downstream immune responses enhance epithelial barrier function 
could inform the evolution of these processes. 
In the context of a diverse intestinal microbiome, we wonder: is the protective 
function of SagA actually unique? Peptidoglycan remodeling enzymes, including 
NlpC/p60 enzymes, are widespread amongst bacteria193,250. Nevertheless, the abundant 
secretion of SagA and other peptidoglycan remodeling enzymes by E. faecium may be an 
unusual property. It may be that our study has highlighted the activity of SagA through 
the use of simplified models, where a diverse microbiome is non-existent (as with C. 
elegans and germ-free mice) or severely compromised (as with streptomycin-treated 
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mice). It is possible, for example, that the protective activity of SagA is already partially 
reflected in the steady state resistance to Salmonella observed in wild-type mice. 
However, given that E. faecium is a minor member of the intestinal flora, one could 
imagine enhancing host resistance by increasing the abundance of SagA-producing 
bacteria. Future work assessing the roles of other secreted peptidoglycan remodeling 
enzymes could reveal an unappreciated tier of immune regulation in the intestine. 
In mammals, innate immune recognition of bacterial cell wall components is 
balanced between mechanisms of tolerance versus immune activation. As microbivores, 
C. elegans could be under pressure to evolve functionally similar mechanisms of immune 
homeostasis. Host- and bacterial-encoded peptidoglycan remodeling enzymes may work 
in concert to promote this balance. If E. faecium is truly an “ancient” member of the 
microbiome, perhaps it played a part in generating the symbiosis that exists between host 
and microbiota.
A
cc
es
si
on
U
ni
pr
ot
 ID
G
en
e 
N
am
e
D
es
cr
ip
tio
n
Li
po
P
M
W
 
(k
D
a)
D
M
SO
al
k-
14
D
M
SO
al
k-
14
D
M
SO
al
k-
14
al
k-
2
E
G
11
50
4
M
E
TQ
_E
C
O
LI
m
et
Q
P
er
ip
la
sm
ic
 m
et
hi
on
in
e 
bi
nd
in
g 
lip
op
ro
te
in
S
pI
I
29
0
51
4
0
25
0
0
0
E
G
14
22
2
B
A
M
D
_E
C
O
LI
ba
m
D
Li
po
pr
ot
ei
n 
re
qu
ire
d 
fo
r O
M
 
bi
og
en
es
is
S
pI
I
28
0
22
8
0
15
0
0
0
E
G
10
68
4
PA
L_
E
C
O
LI
pa
l
Li
po
pr
ot
ei
n 
as
so
ci
at
ed
 w
ith
 
pe
pt
id
og
ly
ca
n
S
pI
I
19
0
19
4
0
46
0
73
0
E
G
12
27
1
Y
IA
D
_E
C
O
LI
yi
aD
N
ov
el
 v
er
ifi
ed
 li
po
pr
ot
ei
n,
 
fu
nc
tio
n 
un
kn
ow
n
S
pI
I
22
0
14
7
0
13
0
0
0
E
G
10
65
8
B
A
M
C
_E
C
O
LI
ba
m
C
Li
po
pr
ot
ei
n 
re
qu
ire
d 
fo
r O
M
 
bi
og
en
es
is
S
pI
I
37
0
14
0
0
37
0
0
0
E
G
12
21
8
D
C
R
B
_E
C
O
LI
dc
rB
P
ro
ba
bl
e 
lip
op
ro
te
in
 re
qu
ire
d 
fo
r p
ha
ge
 C
1 
ad
so
rp
tio
n
S
pI
I
20
0
13
0
0
15
0
24
0
E
G
13
68
5
Y
B
JP
_E
C
O
LI
yb
jP
N
ov
el
 v
er
ifi
ed
 li
po
pr
ot
ei
n,
 
fu
nc
tio
n 
un
kn
ow
n
S
pI
I
19
0
11
3
0
0
0
64
0
E
G
13
75
5
Y
D
C
L_
E
C
O
LI
yd
cL
N
ov
el
 v
er
ifi
ed
 li
po
pr
ot
ei
n,
 
fu
nc
tio
n 
un
kn
ow
n
S
pI
I
24
0
11
3
0
0
0
0
0
E
G
14
20
8
B
A
M
B
_E
C
O
LI
ba
m
B
R
eq
ui
re
d 
fo
r O
M
 b
io
ge
ne
si
s,
 
in
 B
am
A
B
C
D
 c
om
pl
ex
S
pI
I
42
0
99
0
31
0
0
0
E
G
12
13
7
N
LP
E
_E
C
O
LI
nl
pE
Li
po
pr
ot
ei
n 
ac
tiv
at
in
g 
C
px
 in
 
re
sp
on
se
 to
 a
dh
es
io
n
S
pI
I
26
0
92
32
31
79
0
0
0
E
G
11
70
3
A
C
R
A
_E
C
O
LI
ac
rA
A
cr
A
B
-T
ol
C
 m
ul
tid
ru
g 
ef
flu
x 
pu
m
p
S
pI
I
42
0
85
2
47
0
0
0
E
G
13
40
9
S
LY
B
_E
C
O
LI
sl
yB
N
ov
el
 v
er
ifi
ed
 li
po
pr
ot
ei
n,
 
fu
nc
tio
n 
un
kn
ow
n
S
pI
I
16
0
71
0
23
0
42
0
E
G
12
18
2
YA
JG
_E
C
O
LI
ya
jG
P
ro
ba
bl
e 
lip
op
ro
te
in
, f
un
ct
io
n 
un
kn
ow
n
S
pI
I
21
0
69
0
10
0
19
0
A
PP
EN
D
IX
 1
. H
ig
h 
co
nf
id
en
ce
 p
ro
te
in
s 
id
en
tif
ie
d 
fro
m
 E
. c
ol
i l
ab
el
ed
 w
ith
 a
lk
-1
4.
 P
ro
te
in
s 
lis
te
d 
w
er
e 
id
en
tif
ie
d 
w
ith
 a
t l
ea
st
 2
 u
ni
qu
e 
pe
pt
id
es
 
an
d 
10
 fo
ld
 e
nr
ic
hm
en
t i
n 
at
 le
as
t o
ne
 s
am
pl
e 
ov
er
 th
e 
D
M
S
O
 c
on
tro
l. 
P
ro
te
in
s 
th
at
 w
er
e 
en
ric
he
d 
in
 th
e 
D
M
S
O
 c
on
tro
l o
f t
w
o 
of
 th
e 
th
re
e 
sa
m
pl
es
 w
er
e 
om
itt
ed
 fr
om
 th
is
 li
st
, a
nd
 in
cl
ud
ed
 in
 A
pp
en
di
x 
2.
  P
re
di
ct
ed
 li
po
pr
ot
ei
ns
 a
re
 h
ig
hl
ig
ht
ed
 in
 y
el
lo
w
. 
E
xp
t 1
: (
-)
 IP
TG
E
xp
t 2
: (
+)
 IP
TG
E
xp
t 3
137
E
G
12
78
1
Y
R
A
P
_E
C
O
LI
yr
aP
O
M
 li
po
pr
ot
ei
n,
 m
ut
an
t i
s 
S
D
S
-s
en
si
tiv
e
S
pI
I
20
0
68
0
5
0
16
0
E
G
10
36
0
E
FG
_E
C
O
LI
fu
sA
E
lo
ng
at
io
n 
Fa
ct
or
 E
F-
G
C
Y
T
78
4
64
0
47
17
2
27
E
G
13
43
1
LP
O
B
_E
C
O
LI
yc
fM
N
ov
el
 v
er
ifi
ed
 li
po
pr
ot
ei
n,
 
fu
nc
tio
n 
un
kn
ow
n
S
pI
I
23
0
49
0
0
0
0
0
E
G
11
38
4
A
H
P
C
_E
C
O
LI
ah
pC
A
lk
yl
 h
yd
ro
pe
ro
xi
de
 
re
du
ct
as
e,
 s
ub
un
it 
C
C
Y
T
21
14
48
0
0
0
10
2
0
E
G
11
29
1
LO
IP
_E
C
O
LI
yg
gG
H
ea
t s
ho
ck
 p
ro
te
in
 b
in
ds
 E
ra
S
pI
I
27
0
44
0
0
0
0
0
E
G
10
70
1
P
FL
B
_E
C
O
LI
pf
lB
P
yr
uv
at
e 
fo
rm
at
e 
ly
as
e 
I
C
Y
T
85
0
33
0
6
3
2
7
E
G
11
29
3
LO
LB
_E
C
O
LI
lo
lB
O
ut
er
 m
em
br
an
e 
lip
op
ro
te
in
 
re
qu
ire
d 
fo
r l
ip
op
ro
te
in
 
lo
ca
liz
at
io
n
S
pI
I
24
0
32
0
0
0
0
0
E
G
13
08
1
Y
G
D
I_
E
C
O
LI
yg
dI
N
ov
el
 v
er
ifi
ed
 li
po
pr
ot
ei
n,
 
fu
nc
tio
n 
un
kn
ow
n
S
pI
I
8
0
31
0
0
0
31
0
E
G
10
65
7
N
LP
A
_E
C
O
LI
nl
pA
Li
po
pr
ot
ei
n-
28
, i
nn
er
 
m
em
br
an
e 
pr
ot
ei
n,
 fu
nc
tio
n 
un
kn
ow
n
S
pI
I
29
0
31
0
0
0
0
0
E
G
10
85
5
LP
TE
_E
C
O
LI
lp
tE
LP
S
 a
ss
em
bl
y 
O
M
 c
om
pl
ex
 
Lp
tD
E
, l
ip
op
pr
ot
ei
n 
co
m
po
ne
nt
S
pI
I
21
3
28
0
0
0
22
0
E
G
10
02
5
O
D
P
2_
E
C
O
LI
ac
eF
P
yr
uv
at
e 
de
hy
dr
og
en
as
e,
 
di
hy
dr
ol
ip
oa
m
id
e 
ac
et
yl
tra
ns
fe
ra
se
 E
2
C
Y
T
66
0
27
4
6
0
0
0
E
G
11
50
2
R
C
S
F_
E
C
O
LI
rc
sF
Li
po
pr
ot
ei
n 
th
at
 s
ig
na
ls
 
in
cr
ea
se
d 
ca
ps
ul
e 
sy
nt
he
si
s
S
pI
I
14
0
25
0
0
0
0
0
E
G
14
27
6
M
LA
A
_E
C
O
LI
va
cJ
S
ur
fa
ce
-e
xp
os
ed
 li
po
pr
ot
ei
n
S
pI
I
28
0
23
0
0
0
0
0
E
G
10
95
4
S
O
D
F_
E
C
O
LI
so
dB
S
up
er
ox
id
e 
di
sm
ut
as
e,
 F
e
C
Y
T
21
16
21
0
0
0
18
0
E
G
12
52
4
R
ID
A
_E
C
O
LI
yj
gF
Fu
nc
tio
n 
un
kn
ow
n
C
Y
T
14
0
21
0
0
4
18
9
E
G
12
77
8
LP
O
A
_E
C
O
LI
yr
aM
P
ro
ba
bl
e 
lip
op
ro
te
in
, f
un
ct
io
n 
un
kn
ow
n
S
pI
I
73
0
19
0
0
2
0
0
E
G
11
16
4
Y
G
IB
_E
C
O
LI
yg
iB
P
ro
ba
bl
e 
lip
op
ro
te
in
, f
un
ct
io
n 
un
kn
ow
n
S
pI
I
23
0
17
0
14
0
0
0
E
G
12
27
3
Y
IA
F_
E
C
O
LI
yi
aF
P
ro
ba
bl
e 
lip
op
ro
te
in
, f
un
ct
io
n 
un
kn
ow
n
S
pI
I
26
0
17
0
3
0
0
0
138
E
G
13
08
5
M
LT
A
_E
C
O
LI
m
ltA
M
em
br
an
e-
bo
un
d 
ly
tic
 
tra
ns
gl
yc
os
yl
as
e 
A
, m
ur
ei
n 
hy
dr
ol
as
e
S
pI
I
40
0
17
0
0
0
0
0
E
G
10
93
2
S
D
H
B
_E
C
O
LI
sd
hB
S
uc
ci
na
te
 d
eh
yd
ro
ge
na
se
 
(S
Q
R
) i
ro
n-
su
lfu
r p
ro
te
in
C
Y
T
27
0
15
0
0
0
2
0
E
G
50
00
3
A
C
P
_E
C
O
LI
ac
pP
A
cy
l c
ar
rie
r p
ro
te
in
 A
C
P
C
Y
T
9
0
11
0
3
0
31
0
E
G
11
11
7
Y
C
E
B
_E
C
O
LI
yc
eB
N
ov
el
 v
er
ifi
ed
 li
po
pr
ot
ei
n,
 
fu
nc
tio
n 
un
kn
ow
n
S
pI
I
21
0
10
0
0
0
0
0
E
G
12
54
8
Y
JH
F_
E
C
O
LI
yj
hF
P
ut
at
iv
e 
G
nt
P 
fa
m
ily
 
tra
ns
po
rte
r, 
fu
nc
tio
n 
un
kn
ow
n
TM
H
47
0
10
0
0
0
0
0
E
G
11
89
0
S
LP
_E
C
O
LI
sl
p
O
ut
er
 m
em
br
an
e 
lip
op
ro
te
in
, 
st
at
io
na
ry
 p
ha
se
 in
du
ci
bl
e
S
pI
I
21
0
9
0
0
0
23
0
E
G
10
87
2
R
L1
1_
E
C
O
LI
rp
lK
50
S
 ri
bo
so
m
al
 s
ub
un
it 
pr
ot
ei
n 
L1
1
C
Y
T
15
0
6
0
0
0
10
0
E
G
10
86
8
R
L5
_E
C
O
LI
rp
lE
50
S
 ri
bo
so
m
al
 s
ub
un
it 
pr
ot
ei
n 
L5
C
Y
T
20
0
5
0
12
0
19
0
E
G
12
04
0
Y
E
JE
_E
C
O
LI
ye
jE
A
B
C
 tr
an
sp
or
te
r p
er
m
ea
se
 
pr
ot
ei
n 
fo
r m
ic
ro
ci
n 
C
 u
pt
ak
e
TM
H
38
0
0
0
10
0
0
0
E
G
10
04
4
O
S
M
E
_E
C
O
LI
os
m
E
O
sm
ot
ic
al
ly
 in
du
ci
bl
e 
lip
op
ro
te
in
, f
un
ct
io
n 
un
kn
ow
n
S
pI
I
12
0
0
0
0
0
16
1
0
E
G
10
54
4
LP
P
_E
C
O
LI
lp
p
M
ur
ei
n 
lip
op
ro
te
in
S
pI
I
8
0
0
0
0
0
28
0
E
G
12
67
2
TP
X
_E
C
O
LI
tp
x
Li
pi
d 
hy
dr
op
er
ox
id
e 
pe
ro
xi
da
se
C
Y
T
18
0
0
0
0
0
16
0
E
G
11
65
9
Y
E
D
D
_E
C
O
LI
ye
dD
N
ov
el
 v
er
ifi
ed
 li
po
pr
ot
ei
n,
 
fu
nc
tio
n 
un
kn
ow
n
S
pI
I
15
0
0
0
0
0
11
0
E
G
10
91
2
R
S
13
_E
C
O
LI
rp
sM
30
S
 ri
bo
so
m
al
 s
ub
un
it 
pr
ot
ei
n 
S
13
C
Y
T
13
0
0
0
0
0
10
0
139
A
cc
es
si
on
U
ni
pr
ot
 ID
G
en
e 
N
am
e
D
es
cr
ip
tio
n
Li
po
P
M
W
 
(k
D
a)
D
M
SO
al
k-
14
D
M
SO
al
k-
14
D
M
SO
al
k-
14
al
k-
2
E
G
10
67
1
O
M
P
F_
E
C
O
LI
om
pF
O
ut
er
 m
em
br
an
e 
po
rin
 F
S
pI
39
10
4
74
1
25
10
6
34
2
57
E
G
11
03
6
E
FT
U
1_
E
C
O
LI
tu
fA
E
F-
Tu
, E
lo
ng
at
io
n 
Fa
ct
or
-
Tr
an
sl
at
io
n,
 u
ns
ta
bl
e
C
Y
T
43
10
5
22
3
17
32
5
13
3
51
17
E
G
12
31
6
A
C
O
N
2_
E
C
O
LI
ac
nB
A
co
ni
ta
se
 B
C
Y
T
94
11
12
8
2
0
9
0
14
E
G
10
03
1
A
D
H
E
_E
C
O
LI
ad
hE
A
lc
oh
ol
 d
eh
yd
ro
ge
na
se
, 
la
rg
el
y 
an
ae
ro
bi
c
C
Y
T
96
8
11
8
14
0
27
22
57
E
G
10
70
3
P
G
K
_E
C
O
LI
pg
k
P
ho
sp
ho
gl
yc
er
at
e 
ki
na
se
C
Y
T
41
5
26
2
0
26
8
4
E
G
10
48
9
ID
H
_E
C
O
LI
ic
d
Is
oc
itr
at
e 
de
hy
dr
og
en
as
e,
 
N
A
D
P
+-
sp
ec
ifi
c
C
Y
T
46
26
20
0
7
11
4
2
E
G
10
42
3
G
Y
R
A
_E
C
O
LI
gy
rA
D
N
A 
gy
ra
se
, s
ub
un
it 
A
C
Y
T
97
0
11
21
0
0
0
2
E
G
11
01
5
TP
IS
_E
C
O
LI
tp
iA
Tr
io
se
ph
os
ph
at
e 
is
om
er
as
e
C
Y
T
27
0
10
0
0
8
0
6
E
G
10
90
3
R
S
4_
E
C
O
LI
rp
sD
30
S
 ri
bo
so
m
al
 s
ub
un
it 
pr
ot
ei
n 
S
4
C
Y
T
23
0
9
2
6
0
0
0
E
G
13
63
7
B
O
R
D
_E
C
O
LI
bo
rD
Li
po
pr
ot
ei
n 
in
 D
LP
12
 
pr
op
ha
ge
S
pI
I
10
0
9
0
3
0
0
0
E
G
10
98
2
S
U
C
D
_E
C
O
LI
su
cD
S
uc
ci
ny
l C
oA
 s
yn
th
as
e 
al
ph
a-
su
bu
ni
t
C
Y
T
30
0
9
0
2
4
2
16
E
G
10
97
9
O
D
O
1_
E
C
O
LI
su
cA
2-
ox
og
lu
ta
ra
te
 
de
hy
dr
og
en
as
e,
 E
1 
co
m
po
ne
nt
C
Y
T
10
5
0
9
0
0
0
2
3
E
G
11
32
5
A
C
O
N
1_
E
C
O
LI
ac
nA
A
co
ni
ta
se
 A
, s
ta
tio
na
ry
 p
ha
se
 
in
du
ce
d
C
Y
T
98
0
8
2
3
2
0
0
E
G
10
28
2
A
LF
_E
C
O
LI
fb
aA
Fr
uc
to
se
-b
is
ph
os
ph
at
e 
al
do
la
se
, c
la
ss
 II
C
Y
T
39
0
8
0
0
27
3
3
E
G
10
51
1
K
AT
G
_E
C
O
LI
ka
tG
C
at
al
as
e-
hy
dr
og
en
 
pe
ro
xi
da
se
 I
C
Y
T
80
0
8
0
0
0
0
0
A
PP
EN
D
IX
 2
. M
ed
iu
m
 c
on
fid
en
ce
 p
ro
te
in
s 
id
en
tif
ie
d 
fro
m
 E
. c
ol
i l
ab
el
ed
 w
ith
 a
lk
-1
4.
 P
ro
te
in
s 
lis
te
d 
w
er
e 
id
en
tif
ie
d 
w
ith
 a
t l
ea
st
 2
 u
ni
qu
e 
pe
pt
id
es
, a
nd
 5
 fo
ld
 e
nr
ic
hm
en
t i
n 
at
 le
as
t o
ne
 s
am
pl
e 
ov
er
 th
e 
D
M
S
O
 c
on
tro
l. 
  P
re
di
ct
ed
 li
po
pr
ot
ei
ns
 a
re
 h
ig
hl
ig
ht
ed
 in
 y
el
lo
w
. 
E
xp
t 1
: (
-)
 IP
TG
E
xp
t 2
: (
+)
 IP
TG
E
xp
t 3
140
E
G
12
11
1
N
LP
D
_E
C
O
LI
nl
pD
Li
po
pr
ot
ei
n,
 fu
nc
tio
n 
un
kn
ow
n
S
pI
I
40
0
7
0
0
0
0
0
E
G
10
09
8
AT
PA
_E
C
O
LI
at
pA
AT
P 
sy
nt
ha
se
 s
ub
un
it 
al
ph
a,
 
m
em
br
an
e-
bo
un
d,
 F
1 
se
ct
or
C
Y
T
55
0
7
0
0
0
0
0
E
G
10
66
9
O
M
PA
_E
C
O
LI
om
pA
O
ut
er
 m
em
br
an
e 
pr
ot
ei
n 
A
S
pI
37
0
6
0
0
0
0
0
E
G
11
10
0
Y
B
A
B
_E
C
O
LI
yb
aB
Fu
nc
tio
n 
un
kn
ow
n,
 in
 re
cR
 
op
er
on
C
Y
T
12
0
6
0
0
0
0
0
E
G
14
09
1
A
R
N
A
_E
C
O
LI
ar
nA
U
D
P
-g
lu
cu
ro
na
te
 
de
hy
dr
og
en
as
e 
an
d 
U
D
P
-
ar
a4
N
 fo
rm
yl
tra
ns
fe
ra
se
C
Y
T
74
0
5
0
6
0
0
0
E
G
11
39
0
U
S
PA
_E
C
O
LI
us
pA
G
lo
ba
l r
eg
ul
at
or
y 
ge
ne
 fo
r 
st
re
ss
 re
sp
on
se
C
Y
T
16
0
5
0
0
0
8
0
E
G
12
36
7
C
U
S
A
_E
C
O
LI
cu
sA
S
ilv
er
 a
nd
 c
op
pe
r e
ffl
ux
, 
m
em
br
an
e 
tra
ns
po
rte
r
TM
H
11
5
0
5
6
0
5
0
4
E
G
12
69
9
M
LT
B
_E
C
O
LI
m
ltB
M
em
br
an
e-
bo
un
d 
ly
tic
 
tra
ns
gl
yc
os
yl
as
e 
B
, m
ur
ei
n 
hy
dr
ol
as
e
S
pI
I
40
0
5
0
0
0
0
0
E
G
13
51
1
Y
E
AY
_E
C
O
LI
ye
aY
R
po
E
-r
eg
ul
at
ed
 li
po
pr
ot
ei
n,
 
fu
nc
tio
n 
un
kn
ow
n
S
pI
I
21
0
5
0
0
0
0
0
E
G
11
50
6
FT
S
H
_E
C
O
LI
fts
H
AT
P
-d
ep
en
de
nt
 m
em
br
an
e 
pr
ot
ea
se
, c
om
pl
ex
ed
 w
ith
 
H
flC
K
S
pI
71
0
5
0
0
0
0
0
E
G
13
13
4
U
U
P
_E
C
O
LI
uu
p
D
N
A
-b
in
di
ng
 A
TP
as
e 
in
vo
lv
ed
 
in
 re
pl
ic
at
io
n
C
Y
T
72
0
5
0
0
0
0
0
E
G
10
69
6
A
M
P
N
_E
C
O
LI
pe
pN
A
m
in
op
ep
tid
as
e 
N
C
Y
T
99
0
5
0
0
0
0
0
E
G
13
99
9
A
S
TC
_E
C
O
LI
as
tC
S
uc
ci
ny
lo
rn
ith
in
e 
tra
ns
am
in
as
e,
 m
ut
an
t c
an
no
t 
ca
ta
bo
liz
e 
ar
gi
ni
ne
, 
ov
er
pr
od
uc
tio
n 
co
m
pl
em
en
ts
 
ar
gD
 m
ut
an
ts
C
Y
T
44
0
5
0
0
0
0
0
E
G
10
88
6
R
L2
8_
E
C
O
LI
rp
m
B
50
S
 ri
bo
so
m
al
 s
ub
un
it 
pr
ot
ei
n 
L2
8
C
Y
T
9
0
5
0
0
0
0
0
E
G
10
30
3
FH
U
B
_E
C
O
LI
fh
uB
A
B
C
 tr
an
sp
or
te
r p
er
m
ea
se
, 
Fe
(3
+)
-fe
rr
ic
hr
om
e 
up
ta
ke
TM
H
70
0
4
0
8
0
0
0
141
E
G
12
47
4
B
LC
_E
C
O
LI
bl
c
O
ut
er
 m
em
br
an
e 
lip
op
ro
te
in
, 
ce
ll 
di
vi
si
on
 a
nd
 g
ro
w
th
 
fu
nc
tio
n
S
pI
I
20
0
4
0
0
0
5
0
E
G
12
60
6
FA
B
F_
E
C
O
LI
fa
bF
be
ta
-K
et
oa
cy
l-A
C
P 
sy
nt
ha
se
 
II
C
Y
T
43
0
3
0
7
0
0
0
E
G
10
86
9
R
L6
_E
C
O
LI
rp
lF
50
S
 ri
bo
so
m
al
 s
ub
un
it 
pr
ot
ei
n 
L6
C
Y
T
19
2
3
0
5
0
9
0
E
G
10
27
4
FA
B
B
_E
C
O
LI
fa
bB
be
ta
-K
et
oa
cy
l-A
C
P 
sy
nt
ha
se
 I
C
Y
T
43
0
3
0
5
0
0
0
E
G
10
35
6
FU
M
A
_E
C
O
LI
fu
m
A
Fu
m
ar
as
e 
A
, a
er
ob
ic
C
Y
T
60
0
3
0
0
0
6
0
E
G
12
09
4
S
G
R
R
_E
C
O
LI
sg
rR
Tr
an
sc
rip
tio
na
l a
ct
iv
at
or
 o
f 
sg
rS
 s
R
N
A
C
Y
T
64
0
2
0
5
0
0
0
E
G
13
90
5
Y
C
IT
_E
C
O
LI
yc
iT
G
lo
ba
l r
eg
ul
at
or
 o
f 
tra
ns
cr
ip
tio
n
C
Y
T
28
0
0
0
9
0
0
0
E
G
12
95
6
C
U
TC
_E
C
O
LI
cu
tC
C
op
pe
r s
en
si
tiv
ity
C
Y
T
27
3
0
0
7
0
0
0
E
G
14
16
1
M
U
R
R
_E
C
O
LI
m
ur
R
R
ep
re
ss
or
 fo
r m
ur
P
Q
, 
M
ur
N
A
c 
6-
P 
in
du
ci
bl
e
C
Y
T
31
2
0
0
6
0
0
2
E
G
10
93
6
S
E
C
A
_E
C
O
LI
se
cA
Tr
an
sl
oc
on
 A
TP
as
e
C
Y
T
10
2
3
0
0
6
0
0
0
E
G
13
22
6
FT
S
K
_E
C
O
LI
fts
K
D
N
A 
tra
ns
lo
ca
se
 a
t s
ep
ta
l 
rin
g 
so
rti
ng
 d
au
gh
te
r 
ch
ro
m
so
m
es
TM
H
14
7
0
0
0
5
0
5
2
E
G
13
68
9
Y
B
JT
_E
C
O
LI
yb
jT
Fu
nc
tio
n 
un
kn
ow
n
C
Y
T
54
0
0
0
5
4
2
5
E
G
11
98
5
W
B
B
K
_E
C
O
LI
w
bb
K
In
vo
lv
ed
 in
 li
po
po
ly
sa
cc
ha
rid
e 
bi
os
yn
th
es
is
C
Y
T
43
0
0
0
5
0
0
0
E
G
14
21
5
H
Y
FG
_E
C
O
LI
hy
fG
P
ut
at
iv
e 
hy
dr
og
en
as
e 
4 
co
m
po
ne
nt
 G
C
Y
T
63
16
0
11
4
0
8
0
E
G
10
93
8
S
E
C
D
_E
C
O
LI
se
cD
S
ec
D
Fy
aj
C
 in
ne
r m
em
br
an
e 
se
cr
et
io
n 
pr
ot
ei
n 
tri
m
er
ic
 
co
m
pl
ex
TM
H
67
0
0
0
0
2
11
7
E
G
13
25
3
Y
B
AY
_E
C
O
LI
yb
aY
N
ov
el
 v
er
ifi
ed
 li
po
pr
ot
ei
n,
 
fu
nc
tio
n 
un
kn
ow
n
S
pI
I
19
0
0
0
0
0
9
0
E
G
12
58
5
Y
JI
X
_E
C
O
LI
yj
iX
Fu
nc
tio
n 
un
kn
ow
n
C
Y
T
8
0
0
0
0
0
9
0
142
E
G
13
74
6
PA
A
X
_E
C
O
LI
pa
aX
P
he
ny
la
ce
tic
 a
ci
d 
de
gr
ad
at
io
n
C
Y
T
35
0
0
23
0
0
7
0
E
G
13
48
4
Y
D
JH
_E
C
O
LI
yd
jH
P
ut
at
iv
e 
su
ga
r k
in
as
e,
 
fu
nc
tio
n 
un
kn
ow
n
C
Y
T
34
0
0
0
0
0
6
3
E
G
10
34
9
FU
C
I_
E
C
O
LI
fu
cI
L-
Fu
co
se
 is
om
er
as
e
C
Y
T
65
0
0
0
0
0
6
0
E
G
10
93
7
S
E
C
B
_E
C
O
LI
se
cB
P
ro
te
in
 e
xp
or
t c
ha
pe
ro
ne
C
Y
T
17
0
0
0
0
0
6
0
143
A
cc
es
si
on
U
ni
pr
ot
 ID
G
en
e 
N
am
e
D
es
cr
ip
tio
n
Li
po
P
A
ce
ty
l-
at
io
n
M
W
 
(k
D
a)
D
M
SO
al
k-
2
al
k-
14
E
G
14
15
1
P
TF
X
1_
E
C
O
LI
fry
A
P
ut
at
iv
e 
fru
ct
os
e-
lik
e 
P
TS
 s
ys
te
m
 E
nz
ym
e 
I
C
Y
T
92
0
12
0
E
G
11
23
3
R
S
TB
_E
C
O
LI
rs
tB
P
ut
at
iv
e 
se
ns
or
 k
in
as
e
TM
H
49
0
8
0
E
G
11
81
5
TO
R
C
_E
C
O
LI
to
rC
c-
Ty
pe
 c
yt
oc
hr
om
e
TM
H
44
0
4
0
E
G
11
61
3
E
P
TA
_E
C
O
LI
ep
tA
Li
pi
d 
A 
ph
os
ph
oe
th
an
ol
am
in
e 
tra
ns
fe
ra
se
, a
ss
oc
ia
te
d 
w
ith
 p
ol
ym
yx
in
 re
si
st
an
ce
TM
H
62
0
4
0
E
G
11
60
8
C
LS
A
_E
C
O
LI
cl
s
C
ar
di
ol
ip
in
 s
yn
th
as
e
TM
H
55
0
4
0
E
G
12
05
1
Y
E
JO
_E
C
O
LI
ye
jO
P
se
ud
og
en
e 
re
co
ns
tru
ct
io
n,
 a
ut
ot
ra
ns
po
rte
r h
om
ol
og
S
pI
91
0
4
0
E
G
12
77
5
Y
R
A
J_
E
C
O
LI
yr
aJ
P
ut
at
iv
e 
ou
te
r m
em
br
an
e 
fim
br
ia
l s
ub
un
it 
ex
po
rt 
us
he
r 
pr
ot
ei
n
S
pI
94
0
4
0
E
G
13
21
7
Y
B
A
E
_E
C
O
LI
yb
aE
Fu
nc
tio
n 
un
kn
ow
n
C
Y
T
65
0
4
0
E
G
11
71
4
C
B
R
A
_E
C
O
LI
cb
rA
Fu
nc
tio
n 
un
kn
ow
n,
 c
re
B
C
 re
gu
lo
n
C
Y
T
40
0
4
0
E
G
10
35
3
FU
C
R
_E
C
O
LI
fu
cR
P
os
iti
ve
 re
gu
la
to
ry
 p
ro
te
in
 fo
r f
uc
 re
gu
lo
n
C
Y
T
27
0
4
0
E
G
11
66
7
AT
O
S
_E
C
O
LI
at
oS
Tr
an
sc
rip
tio
na
l h
is
tid
in
e 
pr
ot
ei
n 
ki
na
se
 re
gu
la
to
r o
f 
at
oD
A
E
B
TM
H
68
0
3
0
E
G
10
60
9
M
R
E
C
_E
C
O
LI
m
re
C
C
el
l d
iv
is
io
n 
an
d 
gr
ow
th
TM
H
40
0
3
0
E
G
10
16
7
C
S
TA
_E
C
O
LI
cs
tA
S
ta
rv
at
io
n-
in
du
ce
d 
pr
ot
ei
n 
in
vo
lv
ed
 in
 p
ep
tid
e 
ut
ili
za
tio
n 
du
rin
g 
ca
rb
on
 s
ta
rv
at
io
n
TM
H
75
0
3
0
E
G
12
07
7
N
IK
C
_E
C
O
LI
ni
kC
N
ic
ke
l t
ra
ns
po
rt 
sy
st
em
 p
er
m
ea
se
TM
H
30
0
3
0
E
G
13
86
3
P
G
A
C
_E
C
O
LI
pg
aC
R
eq
ui
re
d 
fo
r b
io
fil
m
 a
dh
es
in
 p
ol
ys
ac
ch
ar
id
e 
P
G
A 
sy
nt
he
si
s
TM
H
51
0
3
0
E
G
14
09
5
Y
FB
K
_E
C
O
LI
yf
bK
P
ro
ba
bl
e 
lip
op
ro
te
in
, f
un
ct
io
n 
un
kn
ow
n
S
pI
I
64
0
3
2
E
G
11
34
7
FL
IF
_E
C
O
LI
fli
F
Fl
ag
el
la
r b
as
al
 b
od
y 
M
-r
in
g 
pr
ot
ei
n
S
pI
61
0
3
0
E
xp
t. 
3
A
PP
EN
D
IX
 3
. P
ro
te
in
s 
id
en
tif
ie
d 
fro
m
 E
. c
ol
i l
ab
el
ed
 w
ith
 a
lk
-2
.  
P
ro
te
in
s 
lis
te
d 
w
er
e 
id
en
tif
ie
d 
w
ith
 a
t l
ea
st
 2
 u
ni
qu
e 
pe
pt
id
es
. T
he
 p
ep
tid
e-
sp
ec
tra
l c
ou
nt
s 
fro
m
 a
lk
-1
4 
la
be
lin
g 
in
 th
e 
sa
m
e 
ex
pe
rim
en
t a
re
 a
ls
o 
lis
te
d 
fo
r e
ac
h 
pr
ot
ei
n.
  P
ro
te
in
s 
pr
ev
io
us
ly
 id
en
tif
ie
d 
as
 a
ce
ty
la
te
d 
in
 
Zh
an
g 
et
 a
l. 
20
13
 a
re
 in
di
ca
te
d 
in
 b
la
ck
, i
n 
K
hu
n 
et
 a
l. 
20
14
 a
re
 in
di
ca
te
d 
in
 b
lu
e.
 N
o 
pr
ot
ei
ns
 w
er
e 
pr
ev
io
us
ly
 id
en
tif
ie
d 
fro
m
 Y
u 
et
 a
l. 
20
08
.  
P
re
di
ct
ed
 li
po
pr
ot
ei
ns
 a
re
 h
ig
hl
ig
ht
ed
 in
 y
el
lo
w
. 
144
E
G
12
85
9
O
P
G
D
_E
C
O
LI
op
gD
O
sm
or
eg
ul
at
ed
 p
er
ip
la
sm
ic
 g
lu
ca
n 
(O
P
G
) 
bi
os
yn
th
es
is
S
pI
63
0
3
4
E
G
14
08
2
Y
FA
T_
E
C
O
LI
yf
aT
Fu
nc
tio
n 
un
kn
ow
n
S
pI
24
0
3
0
E
G
13
21
3
Y
P
JA
_E
C
O
LI
yp
jA
O
ve
re
xp
re
ss
io
n 
in
cr
ea
se
s 
ad
he
si
on
, f
un
ct
io
n 
un
kn
ow
n
S
pI
15
7
0
3
0
E
G
10
31
1
FI
M
D
_E
C
O
LI
fim
D
O
ut
er
 m
em
br
an
e 
fim
br
ia
l s
ub
un
it 
ex
po
rt 
us
he
r p
ro
te
in
S
pI
96
0
3
0
E
G
13
99
5
A
S
TE
_E
C
O
LI
as
tE
P
ro
ba
bl
e 
su
cc
in
yl
gl
ut
am
at
e 
de
su
cc
in
yl
as
e,
 a
rg
in
in
e 
ca
ta
bo
lis
m
C
Y
T
36
0
3
0
E
G
12
41
8
G
AT
Z_
E
C
O
LI
ga
tZ
Ta
ga
to
se
 b
is
ph
os
ph
at
e 
al
do
la
se
 G
at
Y
Z 
su
bu
ni
t
C
Y
T
X
47
0
3
2
E
G
10
68
6
PA
R
C
_E
C
O
LI
pa
rC
To
po
is
om
er
as
e 
IV
, s
ub
un
it 
A
, A
TP
-d
ep
en
de
nt
, t
yp
e 
II
C
Y
T
84
0
3
0
E
G
10
66
0
R
IR
1_
E
C
O
LI
nr
dA
R
ib
on
uc
le
os
id
e 
di
ph
os
ph
at
e 
re
du
ct
as
e,
 s
ub
un
it 
al
ph
a
C
Y
T
X
X
86
0
3
0
E
G
13
50
6
D
M
LR
_E
C
O
LI
ye
aT
P
os
iti
ve
 tr
an
sc
rip
tio
na
l r
eg
ul
at
or
 fo
r y
ea
U
C
Y
T
35
0
3
0
E
G
10
43
5
H
FL
C
_E
C
O
LI
hf
lC
M
em
br
an
e 
bo
un
d 
pr
ot
ea
se
 c
om
pl
ex
, w
ith
 F
ts
H
 a
nd
 
H
flK
C
Y
T
38
0
3
0
E
G
13
60
0
P
R
P
R
_E
C
O
LI
pr
pR
Tr
an
sc
rip
tio
na
l r
eg
ul
at
or
 o
f p
rp
 o
pe
ro
n
C
Y
T
59
0
3
0
E
G
10
63
1
N
A
D
B
_E
C
O
LI
na
dB
Q
ui
no
lin
at
e 
sy
nt
ha
se
, B
 p
ro
te
in
C
Y
T
60
0
3
0
E
G
10
52
0
K
D
TA
_E
C
O
LI
w
aa
A
3-
de
ox
y-
D
-m
an
no
-o
ct
ul
os
on
at
e(
K
do
)-
lip
id
 A
 
tra
ns
fe
ra
se
C
Y
T
47
0
3
0
E
G
13
47
2
G
S
IA
_E
C
O
LI
gs
iA
G
lu
ta
th
io
ne
 tr
an
sp
or
te
r A
TP
-b
in
di
ng
 p
ro
te
in
C
Y
T
69
0
3
0
E
G
12
81
9
ZA
P
E
_E
C
O
LI
yh
cM
Fu
nc
tio
n 
un
kn
ow
n
C
Y
T
43
0
3
0
E
G
10
76
3
P
R
IA
_E
C
O
LI
pr
iA
P
rim
os
om
e 
fa
ct
or
 Y
, a
ls
o 
ca
lle
d 
pr
ot
ei
n 
n'
C
Y
T
82
0
3
0
E
G
11
55
8
C
A
IC
_E
C
O
LI
ca
iC
C
ro
to
no
be
ta
in
/c
ar
ni
tin
e-
C
oA
 li
ga
se
C
Y
T
59
0
3
0
E
G
13
69
5
M
A
C
B
_E
C
O
LI
m
ac
B
A
B
C
-ty
pe
 m
ac
ro
lid
e 
ef
flu
x 
tra
ns
po
rte
r, 
w
ith
 M
ac
A 
an
d 
To
lC
C
Y
T
71
0
3
0
E
G
12
59
9
Y
JJ
W
_E
C
O
LI
yj
jW
P
ut
at
iv
e 
Y
jjI
 a
ct
iv
as
e,
 fu
nc
tio
n 
un
kn
ow
n
C
Y
T
31
0
3
0
E
G
10
40
7
S
Y
E
_E
C
O
LI
gl
tX
G
lu
ta
m
at
e-
-tR
N
A 
lig
as
e
C
Y
T
X
54
0
3
0
E
G
11
48
1
TA
TD
_E
C
O
LI
ta
tD
M
g-
de
pe
nd
en
t c
yt
op
la
sm
ic
 D
N
as
e
C
Y
T
29
0
3
0
E
G
10
97
9
O
D
O
1_
E
C
O
LI
su
cA
2-
ox
og
lu
ta
ra
te
 d
eh
yd
ro
ge
na
se
, E
1 
co
m
po
ne
nt
C
Y
T
X
X
10
5
0
3
2
E
G
13
48
4
Y
D
JH
_E
C
O
LI
yd
jH
P
ut
at
iv
e 
su
ga
r k
in
as
e,
 fu
nc
tio
n 
un
kn
ow
n
C
Y
T
34
0
3
6
145
E
G
14
04
4
Y
E
D
V
_E
C
O
LI
ye
dV
P
ro
ba
bl
e 
hi
st
id
in
e 
pr
ot
ei
n 
ki
na
se
 s
en
so
r, 
fu
nc
tio
n 
un
kn
ow
n
TM
H
51
0
2
3
E
G
10
01
8
C
S
R
D
_E
C
O
LI
cs
rD
Ta
rg
et
s 
cs
rB
/C
 s
R
N
A
s 
fo
r d
eg
ra
da
tio
n 
by
 R
N
as
e 
E
TM
H
73
0
2
0
E
G
11
14
5
Y
FE
A
_E
C
O
LI
yf
eA
P
ut
at
iv
e 
c-
di
-G
M
P 
du
al
 a
ct
iv
ity
 e
nz
ym
e,
 fu
nc
tio
n 
un
kn
ow
n
TM
H
84
0
2
0
E
G
12
25
6
Y
H
JK
_E
C
O
LI
yh
jK
P
ut
at
iv
e 
c-
di
-G
M
P 
du
al
 a
ct
iv
ity
 e
nz
ym
e,
 fu
nc
tio
n 
un
kn
ow
n
TM
H
73
0
2
0
E
G
11
66
0
Y
E
D
E
_E
C
O
LI
ye
dE
Fu
nc
tio
n 
un
kn
ow
n
TM
H
44
0
2
0
E
G
10
01
2
C
Y
D
C
_E
C
O
LI
cy
dC
C
ys
te
in
e 
ex
po
rte
r C
yd
D
C
TM
H
63
0
2
0
E
G
14
07
5
Y
E
IU
_E
C
O
LI
lp
xT
Li
pi
d 
A 
1-
di
ph
os
ph
at
e 
sy
nt
ha
se
TM
H
27
0
2
0
E
G
13
98
7
Y
N
IB
_E
C
O
LI
yn
iB
Fu
nc
tio
n 
un
kn
ow
n
TM
H
20
0
2
2
E
G
10
34
4
FT
S
W
_E
C
O
LI
fts
W
S
ta
bi
liz
es
 F
ts
Z 
rin
g,
 m
em
br
an
e 
pr
ot
ei
n
TM
H
46
0
2
0
E
G
13
50
0
Y
E
A
N
_E
C
O
LI
ye
aN
P
ut
at
iv
e 
tra
ns
po
rte
r, 
fu
nc
tio
n 
un
kn
ow
n
TM
H
41
0
2
0
E
G
11
75
3
C
H
A
A
_E
C
O
LI
ch
aA
C
a2
+/
H
+ 
an
d 
K
+/
H
+ 
an
tip
or
te
r
TM
H
39
0
2
0
E
G
11
72
0
M
D
TL
_E
C
O
LI
m
dt
L
M
ul
tid
ru
g 
re
si
st
an
ce
 e
ffl
ux
 p
ro
te
in
TM
H
41
0
2
0
E
G
10
47
6
H
Y
C
C
_E
C
O
LI
hy
cC
Fo
rm
at
e 
hy
dr
og
en
ly
as
e 
co
m
pl
ex
 in
ne
r m
em
br
an
e 
pr
ot
ei
n
TM
H
64
0
2
0
E
G
12
56
3
G
N
TP
_E
C
O
LI
gn
tP
Fr
uc
tu
ro
na
te
 a
nd
 g
lu
co
na
te
 tr
an
sp
or
te
r
TM
H
47
0
2
0
E
G
12
62
5
D
P
P
B
_E
C
O
LI
dp
pB
D
ip
ep
tid
e/
he
m
e 
tra
ns
po
rt,
 p
er
m
ea
se
TM
H
37
0
2
0
E
G
13
24
8
Y
B
AT
_E
C
O
LI
yb
aT
M
ut
an
t i
nh
ib
its
 re
du
ct
io
n 
of
 s
el
en
at
e,
 fu
nc
tio
n 
un
kn
ow
n
TM
H
46
0
2
0
E
G
13
34
2
M
M
U
P
_E
C
O
LI
m
m
uP
S
-m
et
hy
lm
et
hi
on
in
e 
pe
rm
ea
se
, C
P
4-
6 
pu
ta
tiv
e 
pr
op
ha
ge
 re
m
na
n
TM
H
51
0
2
0
E
G
13
66
5
Y
B
H
I_
E
C
O
LI
yb
hI
P
ut
at
iv
e 
tra
ns
po
rte
r, 
fu
nc
tio
n 
un
kn
ow
n
TM
H
51
0
2
0
E
G
14
01
9
Y
E
B
Q
_E
C
O
LI
ye
bQ
P
ut
at
iv
e 
tra
ns
po
rte
r, 
fu
nc
tio
n 
un
kn
ow
n
TM
H
48
0
2
0
E
G
13
60
8
YA
IW
_E
C
O
LI
ya
iW
R
eq
ui
re
d 
fo
r s
w
ar
m
in
g 
ph
en
ot
yp
e,
 p
ro
ba
bl
e 
lip
op
ro
te
in
S
pI
I
40
0
2
2
E
G
12
25
8
G
U
N
_E
C
O
LI
bc
sZ
E
nd
o-
1,
4-
D
-g
lu
ca
na
se
S
pI
I
42
0
2
2
E
G
12
87
5
Y
B
H
C
_E
C
O
LI
yb
hC
A
cy
l-C
oA
 th
io
es
te
ra
se
, v
er
ifi
ed
 li
po
pr
ot
ei
n
S
pI
I
46
0
2
0
E
G
13
68
7
A
M
ID
_E
C
O
LI
am
iD
1,
6-
an
hy
dr
o-
N
-a
ce
ty
lm
ur
am
yl
-L
-a
la
ni
ne
 a
m
id
as
e,
 Z
n-
de
pe
nd
en
t
S
pI
I
31
0
2
0
146
E
G
14
00
7
Y
N
JE
_E
C
O
LI
yn
jE
R
ho
da
ne
se
-li
ke
 p
ro
te
in
, f
un
ct
io
n 
un
kn
ow
n
S
pI
48
0
2
0
E
G
20
17
3
P
TA
_E
C
O
LI
pt
a
P
ho
sp
ho
tra
ns
ac
et
yl
as
e.
 p
ro
du
ce
s 
ac
et
yl
 p
ho
sp
ha
te
S
pI
X
X
77
0
2
0
E
G
12
96
9
Y
C
IQ
_E
C
O
LI
yc
iQ
Fu
nc
tio
n 
un
kn
ow
n
S
pI
71
0
2
0
E
G
12
33
4
B
TU
F_
E
C
O
LI
bt
uF
B
12
 u
pt
ak
e,
 A
B
C
 tr
an
sp
or
te
r p
er
ip
la
sm
ic
 b
in
di
ng
 
pr
ot
ei
n
S
pI
29
0
2
0
E
G
13
49
6
Y
E
A
J_
E
C
O
LI
ye
aJ
P
ro
ba
bl
e 
di
gu
an
yl
at
e 
cy
cl
as
e,
 fu
nc
tio
n 
un
kn
ow
n
S
pI
57
0
2
0
E
G
13
63
5
LY
S
D
_E
C
O
LI
ar
rD
P
ha
ge
 la
m
bd
a 
ly
so
zy
m
e 
R
 p
ro
te
in
 h
om
ol
og
, D
LP
12
 
pr
op
ha
ge
S
pI
18
0
2
0
E
G
13
32
4
Y
B
IS
_E
C
O
LI
yb
iS
L,
D
-tr
an
sp
ep
tid
as
e 
lin
ki
ng
 L
pp
 to
 m
ur
ei
n,
 p
er
ip
la
sm
ic
S
pI
33
0
2
0
E
G
10
67
4
O
P
PA
_E
C
O
LI
op
pA
O
lig
op
ep
tid
e 
tra
ns
po
rt,
 p
er
ip
la
sm
ic
 o
lig
op
ep
tid
e 
bi
nd
in
g 
pr
ot
ei
n
S
pI
X
61
0
2
0
E
G
11
22
7
FD
N
G
_E
C
O
LI
fd
nG
Fo
rm
at
e 
de
hy
dr
og
en
as
e-
N
, s
el
en
op
ep
tid
e,
 a
na
er
ob
ic
S
pI
11
3
0
2
2
E
G
12
07
5
N
IK
A
_E
C
O
LI
ni
kA
N
ic
ke
l-b
in
di
ng
, h
em
e-
bi
nd
in
g 
pe
rip
la
sm
ic
 p
ro
te
in
S
pI
59
0
2
0
E
G
10
30
6
FH
U
E
_E
C
O
LI
fh
uE
O
ut
er
 m
em
br
an
e 
re
ce
pt
or
 fo
r f
er
ric
-r
ho
do
to
ru
lic
 a
ci
d
S
pI
81
0
2
0
E
G
13
80
9
LS
R
B
_E
C
O
LI
ls
rB
A
ut
oi
nd
uc
er
-2
 (A
I-2
) u
pt
ak
e
S
pI
X
X
37
0
2
0
E
G
12
67
6
B
A
M
A
_E
C
O
LI
ba
m
A
O
ut
er
 m
em
br
an
e 
pr
ot
ei
n 
as
se
m
bl
y 
fa
ct
or
, f
or
m
s 
po
re
s
S
pI
91
0
2
0
E
G
13
17
7
R
S
E
B
_E
C
O
LI
rs
eB
B
in
ds
 p
er
ip
la
sm
ic
 d
om
ai
n 
of
 a
nt
i-R
po
E
 s
ig
m
a 
fa
ct
or
 
R
se
A
S
pI
36
0
2
0
E
G
10
23
2
D
M
S
A
_E
C
O
LI
dm
sA
D
M
S
O
 re
du
ct
as
e 
su
bu
ni
t A
, a
na
er
ob
ic
, p
er
ip
la
sm
ic
S
pI
90
0
2
0
E
G
11
04
7
U
G
P
B
_E
C
O
LI
ug
pB
sn
-G
ly
ce
ro
l-3
-p
ho
sp
ha
te
 tr
an
sp
or
t s
ys
te
m
, 
pe
rip
la
sm
ic
 b
in
di
ng
 p
ro
te
in
S
pI
48
0
2
0
E
G
11
37
3
M
LT
F_
E
C
O
LI
m
ltF
M
em
br
an
e-
bo
un
d 
ly
tic
 tr
an
sg
ly
co
sy
la
se
 F
, m
ur
ei
n 
hy
dr
ol
as
e
S
pI
58
0
2
0
E
G
13
31
2
Y
B
G
P
_E
C
O
LI
yb
gP
P
ut
at
iv
e 
pe
rip
la
sm
ic
 p
ilu
s 
ch
ap
er
on
e,
 fu
nc
tio
n 
un
kn
ow
n
S
pI
27
0
2
0
E
G
10
73
8
PA
1_
E
C
O
LI
pl
dA
O
ut
er
-m
em
br
an
e 
ph
os
ph
ol
ip
as
e 
A
S
pI
33
0
2
0
E
G
10
15
5
C
IR
A
_E
C
O
LI
ci
rA
C
ol
ic
in
 I 
re
ce
pt
or
 p
ro
du
ct
io
n
S
pI
74
0
2
0
E
G
10
89
5
R
P
O
C
_E
C
O
LI
rp
oC
rp
oC
 R
N
A 
po
ly
m
er
as
e,
 b
et
a'
 s
ub
un
it
C
Y
T
X
X
15
5
0
2
0
E
G
11
06
3
U
V
R
C
_E
C
O
LI
uv
rC
E
xc
is
io
n 
nu
cl
ea
se
 s
ub
un
it 
C
C
Y
T
X
68
0
2
0
E
G
10
60
5
P
B
P
B
_E
C
O
LI
m
rc
B
M
ur
ei
n 
po
ly
m
er
as
e,
 P
B
P
1B
C
Y
T
94
0
2
0
147
E
G
10
16
1
M
A
N
C
_E
C
O
LI
cp
sB
C
ol
an
ic
 a
ci
d 
(C
P
S
) b
io
sy
nt
he
si
s
C
Y
T
53
0
2
0
E
G
12
58
3
Y
JI
V
_E
C
O
LI
yj
iV
P
se
ud
og
en
e 
re
co
ns
tru
ct
io
n,
 h
el
ic
as
e-
lik
e,
 C
-te
rm
in
al
 
fra
gm
en
t
C
Y
T
11
2
0
2
2
E
G
10
75
6
C
A
P
P
_E
C
O
LI
pp
c
P
ho
sp
ho
en
ol
py
ru
va
te
 c
ar
bo
xy
la
se
C
Y
T
X
99
0
2
0
E
G
10
84
8
R
H
S
C
_E
C
O
LI
rh
sC
Fu
nc
tio
n 
un
kn
ow
n,
 e
nc
od
ed
 w
ith
in
 R
hs
C
 re
pe
at
C
Y
T
15
8
0
2
0
E
G
13
49
3
Y
E
A
G
_E
C
O
LI
ye
aG
P
ro
te
in
 k
in
as
e,
 fu
nc
tio
n 
un
kn
ow
n
C
Y
T
X
74
0
2
4
E
G
13
07
9
B
G
LA
_E
C
O
LI
bg
lA
 P
ho
sp
ho
-b
et
a-
gl
uc
os
id
as
e 
A
C
Y
T
X
55
0
2
0
E
G
10
79
5
P
U
R
9_
E
C
O
LI
pu
rH
P
ho
sp
ho
rib
os
yl
am
in
oi
m
id
az
ol
ec
ar
bo
xa
m
id
e 
fo
rm
yl
tra
ns
fe
ra
se
C
Y
T
X
57
0
2
0
E
G
10
03
4
S
YA
_E
C
O
LI
al
aS
A
la
ni
ne
--
tR
N
A 
lig
as
e
C
Y
T
X
X
96
0
2
0
E
G
10
86
6
R
L3
_E
C
O
LI
rp
lC
50
S
 ri
bo
so
m
al
 s
ub
un
it 
pr
ot
ei
n 
L3
C
Y
T
X
22
0
2
0
E
G
14
01
1
Y
N
JI
_E
C
O
LI
yn
jI
Fu
nc
tio
n 
un
kn
ow
n
C
Y
T
X
40
0
2
0
E
G
10
04
2
A
M
P
E
_E
C
O
LI
am
pE
A
m
pi
ci
lli
n 
re
si
st
an
ce
C
Y
T
32
0
2
0
E
G
10
21
3
D
D
LA
_E
C
O
LI
dd
lA
 D
-a
la
ni
ne
:D
-a
la
ni
ne
 li
ga
se
 A
, A
D
P
-fo
rm
in
g
C
Y
T
X
39
0
2
0
E
G
10
69
0
P
C
N
B
_E
C
O
LI
pc
nB
P
ol
y(
A
) p
ol
ym
er
as
e
C
Y
T
X
54
0
2
0
E
G
10
79
7
P
U
R
4_
E
C
O
LI
pu
rL
P
ho
sp
ho
rib
os
yl
fo
rm
yl
gl
yc
in
am
id
e 
sy
nt
ha
se
C
Y
T
X
14
1
0
2
2
E
G
10
00
4
C
O
A
B
C
_E
C
O
LI
df
p
C
oe
nz
ym
e 
A 
bi
os
yn
th
es
is
, b
ifu
nc
tio
na
l e
nz
ym
e
C
Y
T
43
0
2
4
E
G
11
92
9
ZU
R
_E
C
O
LI
zu
r
R
ep
re
ss
or
 fo
r z
nu
A
B
C
, t
he
 z
in
c 
hi
gh
-a
ffi
ni
ty
 tr
an
sp
or
t 
ge
ne
s
C
Y
T
19
0
2
0
E
G
10
56
2
M
A
LT
_E
C
O
LI
m
al
T
AT
P
-d
ep
en
de
nt
 tr
an
sc
rip
tio
na
l a
ct
iv
at
or
 fo
r t
he
 m
al
 
re
gu
lo
n
C
Y
T
10
3
0
2
0
E
G
11
87
0
Y
IIM
_E
C
O
LI
yi
iM
6-
N
-h
yd
ro
xy
la
m
in
op
ur
in
e 
re
si
st
an
ce
, f
un
ct
io
n 
un
kn
ow
n
C
Y
T
X
25
0
2
0
E
G
10
06
1
A
R
C
A
_E
C
O
LI
ar
cA
R
es
po
ns
e 
re
gu
la
to
r, 
re
pr
es
se
s 
ae
ro
bi
c 
ge
ne
s 
an
ae
ro
bi
ca
lly
C
Y
T
X
27
0
2
0
E
G
11
98
3
W
B
B
I_
E
C
O
LI
w
bb
I
d-
G
al
f:a
lp
ha
-d
-G
lc
 b
et
a-
1,
6-
ga
la
ct
of
ur
an
os
yl
tra
ns
fe
ra
se
C
Y
T
X
38
0
2
0
E
G
14
21
9
H
Y
FR
_E
C
O
LI
hy
fR
Fo
rm
at
e-
se
ns
in
g 
re
gu
la
to
r f
or
 h
yf
 o
pe
ro
n
C
Y
T
75
0
2
0
E
G
10
84
1
FL
ID
_E
C
O
LI
fli
D
H
oo
k-
as
so
ci
at
ed
 p
ro
te
in
 2
, a
xi
al
 fa
m
ily
C
Y
T
48
0
2
2
E
G
12
53
1
Y
JG
L_
E
C
O
LI
yj
gL
 F
un
ct
io
n 
un
kn
ow
n
C
Y
T
70
0
2
3
148
E
G
11
76
8
S
E
LU
_E
C
O
LI
se
lU
tR
N
A 
2-
se
le
no
ur
id
in
e 
sy
nt
ha
se
, s
el
en
op
ho
sp
ha
te
-
de
pe
nd
en
t
C
Y
T
41
0
2
0
E
G
10
92
3
R
U
VA
_E
C
O
LI
ru
vA
H
ol
lid
ay
 ju
nc
tio
n 
re
co
gn
iti
on
 fa
ct
or
, r
ec
ru
its
 R
uv
B
C
Y
T
22
0
2
0
E
G
11
74
6
PA
N
C
_E
C
O
LI
pa
nC
P
an
to
th
en
at
e 
sy
nt
ha
se
, d
im
er
ic
C
Y
T
X
X
32
0
2
0
E
G
12
07
9
N
IK
E
_E
C
O
LI
ni
kE
N
ic
ke
l t
ra
ns
po
rt 
AT
P
-b
in
di
ng
 p
ro
te
in
C
Y
T
30
0
2
2
E
G
20
08
0
M
A
S
Z_
E
C
O
LI
gl
cB
M
al
at
e 
sy
nt
ha
se
 G
C
Y
T
X
X
80
0
2
3
E
G
10
19
2
C
Y
S
K
_E
C
O
LI
cy
sK
C
ys
te
in
e 
sy
nt
ha
se
 A
, O
-a
ce
ty
ls
er
in
e 
su
lfh
yd
ry
la
se
 A
C
Y
T
X
X
34
0
2
0
E
G
10
19
6
S
Y
C
_E
C
O
LI
cy
sS
C
ys
te
in
e-
-tR
N
A 
lig
as
e
C
Y
T
X
52
0
2
0
E
G
10
08
0
A
R
O
H
_E
C
O
LI
ar
oH
3-
de
ox
y-
D
-a
ra
bi
no
-h
ep
tu
lo
so
na
te
-7
-p
ho
sp
ha
te
 
(D
A
H
P
) s
yn
th
as
e
C
Y
T
39
0
2
0
E
G
10
43
1
H
E
M
H
_E
C
O
LI
he
m
H
Fe
rr
oc
he
la
ta
se
C
Y
T
36
0
2
0
E
G
11
02
5
TR
P
B
_E
C
O
LI
trp
B
Tr
yp
to
ph
an
 s
yn
th
as
e,
 b
et
a 
su
bu
ni
t
C
Y
T
43
0
2
0
E
G
10
55
0
A
K
3_
E
C
O
LI
ly
sC
A
sp
ar
to
ki
na
se
 II
I
C
Y
T
49
0
2
0
E
G
14
22
8
Y
Q
IG
_E
C
O
LI
yq
iG
P
se
ud
og
en
e 
re
co
ns
tru
ct
io
n,
 F
im
D
 fa
m
ily
, i
nt
er
ru
pt
ed
 
by
 IS
2I
C
Y
T
92
0
2
0
E
G
11
60
9
E
V
G
A
_E
C
O
LI
ev
gA
R
es
po
ns
e 
re
gu
la
to
r f
or
 a
ci
d 
an
d 
dr
ug
 re
si
st
an
ce
, 
co
gn
at
e 
to
 E
vg
S
C
Y
T
23
0
2
0
E
G
10
37
2
D
H
E
4_
E
C
O
LI
gd
hA
G
lu
ta
m
at
e 
de
hy
dr
og
en
as
e
C
Y
T
X
49
0
2
0
E
G
10
45
8
T1
M
K
_E
C
O
LI
hs
dM
D
N
A 
m
et
hy
ltr
an
sf
er
as
e 
M
, h
os
t m
od
ifi
ca
tio
n 
of
 fo
re
ig
n 
D
N
A
C
Y
T
59
0
2
0
E
G
10
22
1
D
E
O
C
_E
C
O
LI
de
oC
2-
de
ox
y-
D
-r
ib
os
e 
5-
ph
os
ph
at
e 
al
do
la
se
 (D
E
R
A
)
C
Y
T
X
28
0
2
0
E
G
13
26
2
Y
B
B
O
_E
C
O
LI
yb
bO
Fu
nc
tio
n 
un
kn
ow
n
C
Y
T
29
0
2
0
E
G
11
42
7
TK
T1
_E
C
O
LI
tk
tA
Tr
an
sk
et
ol
as
e 
A
C
Y
T
X
X
72
0
2
0
E
G
10
55
2
S
Y
K
1_
E
C
O
LI
ly
sS
Ly
si
ne
--
tR
N
A 
lig
as
e,
 c
on
st
itu
tiv
e
C
Y
T
X
X
58
0
2
0
E
G
12
10
5
Y
E
IE
_E
C
O
LI
ye
iE
P
ro
ba
bl
e 
po
si
tiv
e 
re
gu
la
to
r o
f l
ys
P 
tra
ns
cr
ip
tio
n
C
Y
T
33
0
2
0
E
G
14
33
9
Y
IF
N
_E
C
O
LI
yi
fN
P
se
ud
og
en
e 
re
co
ns
tru
ct
io
n
C
Y
T
17
0
2
0
E
G
13
15
0
YA
FM
_E
C
O
LI
ya
fM
Fu
nc
tio
n 
un
kn
ow
n
C
Y
T
20
0
2
0
E
G
10
26
5
LP
X
C
_E
C
O
LI
lp
xC
Li
pi
d 
A 
sy
nt
he
si
s,
 U
D
P
-3
-O
-(
R
-3
-h
yd
ro
xy
m
yr
is
to
yl
)-
N
-
ac
et
yl
gl
uc
os
am
in
e 
de
ac
et
yl
as
e
C
Y
T
34
0
2
0
E
G
12
52
2
G
A
R
D
_E
C
O
LI
ga
rD
D
-g
al
ac
ta
ra
te
 d
eh
yd
ra
ta
se
C
Y
T
56
0
2
0
E
G
13
40
5
Y
E
C
M
_E
C
O
LI
ye
cM
Fu
nc
tio
n 
un
kn
ow
n,
 lo
w
 a
bu
nd
an
ce
 p
ro
te
in
C
Y
T
21
0
2
0
149
E
G
11
91
3
Y
IJ
O
_E
C
O
LI
yi
jO
A
ra
C
 fa
m
ily
 tr
an
sc
rip
tio
na
l a
ct
iv
at
or
, f
un
ct
io
n 
un
kn
ow
n
C
Y
T
32
0
2
0
E
G
14
22
6
Y
P
JD
_E
C
O
LI
yp
jD
Fu
nc
tio
n 
un
kn
ow
n
C
Y
T
29
0
2
0
E
G
50
00
9
D
C
E
A
_E
C
O
LI
ga
dA
G
lu
ta
m
at
e 
de
ca
rb
ox
yl
as
e 
A
C
Y
T
X
X
53
0
2
0
E
G
20
05
0
D
G
O
D
_E
C
O
LI
dg
oD
G
al
ac
to
na
te
 d
eh
yd
ra
ta
se
C
Y
T
43
0
2
0
E
G
11
66
3
S
LY
D
_E
C
O
LI
sl
yD
FK
B
P
-ty
pe
 p
ep
tid
yl
-p
ro
ly
l c
is
-tr
an
s 
is
om
er
as
e
C
Y
T
21
0
2
0
E
G
13
00
5
Y
G
H
U
_E
C
O
LI
yg
hU
Fu
nc
tio
n 
un
kn
ow
n,
 g
lu
ta
th
io
ne
 S
-tr
an
sf
er
as
e 
ho
m
ol
og
C
Y
T
X
32
0
2
0
E
G
10
01
3
M
E
P
M
_E
C
O
LI
ye
bA
P
ut
at
iv
e 
m
et
al
lo
pr
ot
ea
se
, f
un
ct
io
n 
un
kn
ow
n
C
Y
T
49
0
2
0
E
G
10
81
8
R
B
S
K
_E
C
O
LI
rb
sK
R
ib
ok
in
as
e
C
Y
T
32
0
2
0
E
G
11
83
9
Y
IH
M
_E
C
O
LI
yi
hM
Fu
nc
tio
n 
un
kn
ow
n
C
Y
T
37
0
2
0
E
G
11
92
2
Y
JB
D
_E
C
O
LI
pa
gB
S
al
m
on
el
la
 o
rth
ol
og
 re
gu
la
te
d 
by
 P
ho
P
C
Y
T
11
0
2
0
E
G
12
88
6
G
S
P
G
_E
C
O
LI
gs
pG
P
se
ud
op
ili
n 
in
 H
-N
S
-s
ile
nc
ed
 g
sp
 d
iv
er
go
n,
 ty
pe
 II
 
se
cr
et
on
C
Y
T
16
0
2
0
E
G
13
99
7
A
S
TD
_E
C
O
LI
as
tD
S
uc
ci
ny
lg
lu
ta
m
ic
 s
em
ia
ld
eh
yd
e 
de
hy
dr
og
en
as
e,
 N
A
D
-
de
pe
nd
en
t
C
Y
T
53
0
2
0
E
G
13
99
8
A
S
TA
_E
C
O
LI
as
tA
P
ro
ba
bl
e 
ar
gi
ni
ne
 s
uc
ci
ny
ltr
an
sf
er
as
e,
 a
rg
in
in
e 
ca
ta
bo
lis
m
C
Y
T
X
38
0
2
0
E
G
10
42
3
G
Y
R
A
_E
C
O
LI
gy
rA
D
N
A 
gy
ra
se
, s
ub
un
it 
A
C
Y
T
X
97
0
2
0
E
G
13
22
6
FT
S
K
_E
C
O
LI
fts
K
D
N
A 
tra
ns
lo
ca
se
 a
t s
ep
ta
l r
in
g 
so
rti
ng
 d
au
gh
te
r 
ch
ro
m
so
m
es
TM
H
14
7
0
2
5
E
G
14
16
1
M
U
R
R
_E
C
O
LI
m
ur
R
R
ep
re
ss
or
 fo
r m
ur
P
Q
, M
ur
N
A
c 
6-
P 
in
du
ci
bl
e
C
Y
T
31
0
2
0
150
U
ni
pr
ot
 
A
cc
es
si
on
G
en
e 
N
am
e
Li
po
P
A
ce
ty
l-
at
io
n
D
es
cr
ip
tio
n
M
W
 
(k
D
a)
al
k-
14
D
M
SO
al
k-
14
D
M
SO
al
k-
14
D
M
SO
D
0Z
IM
1_
S
A
LT
1
tu
f_
1
C
Y
T
E
lo
ng
at
io
n 
fa
ct
or
 T
u
43
33
4
17
43
1
55
11
02
55
D
0Z
TJ
5_
S
A
LT
1
om
pA
S
pI
O
ut
er
 m
em
br
an
e 
pr
ot
ei
n 
A
38
32
5
6
26
6
22
35
7
D
0Z
Q
G
7_
S
A
LT
1
pa
l
S
pI
I
P
ep
tid
og
ly
ca
n-
as
so
ci
at
ed
 o
ut
er
 
m
em
br
an
e 
lip
op
ro
te
in
19
22
4
2
16
2
5
56
0
D
0Z
W
Q
1_
S
A
LT
1
lp
p
S
pI
I
M
ur
ei
n 
lip
op
ro
te
in
8
16
2
11
69
7
55
0
D
0Z
W
45
_S
A
LT
1
os
m
E
S
pI
I
D
N
A
-b
in
di
ng
 tr
an
sc
rip
tio
na
l a
ct
iv
at
or
 
O
sm
E
12
12
8
0
11
1
0
15
0
D
0Z
M
Z4
_S
A
LT
1
ts
x
S
pI
N
uc
le
os
id
e 
ch
an
ne
l
37
11
9
0
12
1
5
0
0
D
0Z
N
V
0_
S
A
LT
1
ud
p
C
Y
T
U
rid
in
e 
ph
os
ph
or
yl
as
e
27
11
8
0
14
8
14
36
0
D
0Z
P
K
7_
S
A
LT
1
om
pC
S
pI
O
ut
er
 m
em
br
an
e 
po
rin
 p
ro
te
in
 C
41
11
1
6
14
8
25
87
2
45
D
0Z
N
53
_S
A
LT
1
yb
aY
S
pI
I
P
ut
at
iv
e 
un
ch
ar
ac
te
riz
ed
 p
ro
te
in
 y
ba
Y
19
10
7
0
90
0
9
0
D
0Z
IM
2_
S
A
LT
1
fu
sA
C
Y
T
X
E
lo
ng
at
io
n 
fa
ct
or
 G
78
89
0
13
4
8
83
0
D
0Z
IK
3_
S
A
LT
1
rp
lE
C
Y
T
50
S
 ri
bo
so
m
al
 p
ro
te
in
 L
5
20
80
0
10
4
2
21
5
0
D
0Z
IC
9_
S
A
LT
1
m
dh
S
pI
X
M
al
at
e 
de
hy
dr
og
en
as
e
32
73
0
97
6
16
8
9
D
0Z
IK
9_
S
A
LT
1
rp
sC
C
Y
T
X
30
S
 ri
bo
so
m
al
 p
ro
te
in
 S
3
26
73
0
62
3
5
5
D
0Z
W
X
1_
S
A
LT
1
sl
yB
S
pI
I
P
ut
at
iv
e 
ou
te
r m
em
br
an
e 
lip
op
ro
te
in
16
70
0
46
6
11
9
0
D
0Z
Q
V
4_
S
A
LT
1
rp
oB
C
Y
T
D
N
A
-d
ire
ct
ed
 R
N
A 
po
ly
m
er
as
e 
su
bu
ni
t 
be
ta
15
1
68
0
87
0
10
2
D
0Z
X
Q
1_
S
A
LT
1
om
pD
S
pI
X
P
ut
at
iv
e 
ou
te
r m
em
br
an
e 
po
rin
40
67
2
77
11
44
4
12
D
0Z
L0
0_
S
A
LT
1
m
et
Q
S
pI
I
D
L-
m
et
hi
on
in
e 
tra
ns
po
rte
r s
ub
st
ra
te
-
bi
nd
in
g 
su
bu
ni
t
29
67
0
69
0
14
0
D
0Z
JZ
6_
S
A
LT
1
ac
nB
C
Y
T
B
ifu
nc
tio
na
l a
co
ni
ta
te
 h
yd
ra
ta
se
 2
94
60
0
10
6
3
35
0
D
0Z
Q
F3
_S
A
LT
1
su
cC
C
Y
T
X
S
uc
ci
ny
l-C
oA
 li
ga
se
 [A
D
P
-fo
rm
in
g]
 
su
bu
ni
t b
et
a
41
59
7
79
7
12
4
10
E
xp
t. 
1
E
xp
t. 
2
E
xp
t. 
3 
A
PP
EN
D
IX
 4
. P
ro
te
in
s 
id
en
tif
ie
d 
fro
m
 S
al
m
on
el
la
 ty
ph
im
ur
iu
m
 a
fte
r a
lk
-1
4 
la
be
lin
g 
in
 L
B
 m
ed
ia
. O
nl
y 
pr
ot
ei
ns
 th
at
 w
er
e 
id
en
tif
ie
d 
w
ith
 2
 u
ni
qu
e 
pe
pt
id
es
, a
nd
 1
0 
fo
ld
 e
nr
ic
hm
en
t i
n 
at
 le
as
t o
ne
 a
lk
-1
4 
sa
m
pl
e 
as
 c
om
pa
re
d 
to
 th
e 
D
M
S
O
 c
on
tro
l a
re
 s
ho
w
n.
 P
ro
te
in
s 
pr
ev
io
us
ly
 id
en
tif
ie
d 
as
 
ac
et
yl
at
ed
 in
 W
an
g 
et
 a
l 2
01
0 
ar
e 
in
di
ca
te
d.
 P
re
di
ct
ed
 li
po
pr
ot
ei
ns
 a
re
 h
ig
hl
ig
ht
ed
 in
 y
el
lo
w
. 
151
D
0Z
R
F0
_S
A
LT
1
dp
s
C
Y
T
D
N
A 
st
ar
va
tio
n/
st
at
io
na
ry
 p
ha
se
 
pr
ot
ec
tio
n 
pr
ot
ei
n
19
59
0
63
8
6
0
D
0Z
R
81
_S
A
LT
1
gp
m
A
C
Y
T
2,
3-
bi
sp
ho
sp
ho
gl
yc
er
at
e-
de
pe
nd
en
t 
ph
os
ph
og
ly
ce
ra
te
-d
ep
en
de
nt
 
ph
os
ph
og
ly
ce
ra
te
 m
ut
as
e
28
56
2
53
0
0
0
D
0Z
J7
1_
S
A
LT
1
C
Y
T
P
ut
at
iv
e 
gl
ut
am
ic
 d
eh
yr
og
en
as
e-
lik
e 
pr
ot
ei
n
48
56
0
44
0
38
0
D
0Z
JM
1_
S
A
LT
1
S
pI
I
P
ut
at
iv
e 
un
ch
ar
ac
te
riz
ed
 p
ro
te
in
20
54
0
49
0
0
0
D
0Z
IX
6_
S
A
LT
1
ac
nA
C
Y
T
A
co
ni
ta
te
 h
yd
ra
ta
se
98
53
0
79
2
17
0
D
0Z
W
18
_S
A
LT
1
ga
pA
C
Y
T
X
G
ly
ce
ra
ld
eh
yd
e-
3-
ph
os
ph
at
e 
de
hy
dr
og
en
as
e
36
51
0
45
5
23
1
10
D
0Z
R
F5
_S
A
LT
1
om
pX
S
pI
O
ut
er
 m
em
br
an
e 
pr
ot
ei
n 
X
18
50
0
58
5
10
0
D
0Z
V
T3
_S
A
LT
1
yg
dI
S
pI
I
P
ut
at
iv
e 
lip
op
ro
te
in
8
47
0
33
0
18
0
D
0Z
N
75
_S
A
LT
1
ht
pG
C
Y
T
C
ha
pe
ro
ne
 p
ro
te
in
 h
tp
G
72
46
0
56
0
3
0
D
0Z
JZ
0_
S
A
LT
1
ac
eE
C
Y
T
P
yr
uv
at
e 
de
hy
dr
og
en
as
e 
E
1 
co
m
po
ne
nt
10
0
45
0
61
2
18
0
D
0Z
IJ
3_
S
A
LT
1
rp
sM
C
Y
T
30
S
 ri
bo
so
m
al
 p
ro
te
in
 S
13
13
45
0
41
0
54
3
D
0Z
J1
7_
S
A
LT
1
ad
hE
C
Y
T
B
ifu
nc
tio
na
l a
ce
ta
ld
eh
yd
e-
C
oA
/a
lc
oh
ol
 
de
hy
dr
og
en
as
e
96
42
0
59
0
30
0
D
0Z
N
63
_S
A
LT
1
ac
rA
S
pI
I
A
cr
id
in
e 
ef
flu
x 
pu
m
p
42
42
0
39
0
6
0
D
0Z
TR
4_
S
A
LT
1
cl
pB
C
Y
T
P
ro
te
in
 d
is
ag
gr
eg
at
io
n 
ch
ap
er
on
e
95
41
0
72
0
22
0
D
0Z
K
E
5_
S
A
LT
1
us
pA
C
Y
T
U
ni
ve
rs
al
 s
tre
ss
 p
ro
te
in
 A
16
41
2
12
0
59
0
D
0Z
Q
V
5_
S
A
LT
1
rp
oC
C
Y
T
D
N
A
-d
ire
ct
ed
 R
N
A 
po
ly
m
er
as
e 
su
bu
ni
t 
be
ta
15
5
39
2
54
0
5
0
D
0Z
K
X
1_
S
A
LT
1
rp
sB
C
Y
T
30
S
 ri
bo
so
m
al
 p
ro
te
in
 S
2
27
39
0
48
3
94
4
D
0Z
N
K
2_
S
A
LT
1
cd
d
C
Y
T
C
yt
id
in
e 
de
am
in
as
e
32
38
0
51
2
0
0
D
0Z
W
H
3_
S
A
LT
1
pg
k
C
Y
T
X
P
ho
sp
ho
gl
yc
er
at
e 
ki
na
se
41
37
3
56
4
22
6
2
D
0Z
W
H
2_
S
A
LT
1
fb
aA
C
Y
T
Fr
uc
to
se
-b
is
ph
os
ph
at
e 
al
do
la
se
39
37
3
51
3
43
0
D
0Z
W
35
_S
A
LT
1
ar
gD
_1
C
Y
T
B
ifu
nc
tio
na
l s
uc
ci
ny
lo
rn
ith
in
e 
tra
ns
am
in
as
e
44
37
0
48
0
30
0
D
0Z
R
Q
2_
S
A
LT
1
nl
pB
S
pI
I
Li
po
pr
ot
ei
n
37
36
0
23
0
0
0
D
0Z
IQ
6_
S
A
LT
1
ta
lB
C
Y
T
Tr
an
sa
ld
ol
as
e 
B
35
34
0
35
7
56
5
152
D
0Z
X
61
_S
A
LT
1
yg
hA
C
Y
T
O
xi
do
re
du
ct
as
e
31
33
0
25
2
12
6
10
D
0Z
Q
F1
_S
A
LT
1
kg
d
C
Y
T
A
lp
ha
-k
et
og
lu
ta
ra
te
 d
ec
ar
bo
xy
la
se
10
5
32
0
55
2
15
0
D
0Z
U
E
5_
S
A
LT
1
de
oC
C
Y
T
D
eo
xy
rib
os
e-
ph
os
ph
at
e 
al
do
la
se
28
32
0
36
0
0
0
D
0Z
S
C
1_
S
A
LT
1
yb
jP
S
pI
I
P
ut
at
iv
e 
lip
op
ro
te
in
19
32
0
22
0
6
0
D
0Z
Q
Q
1_
S
A
LT
1
fa
dL
S
pI
Lo
ng
-c
ha
in
 fa
tty
 a
ci
d 
ou
te
r m
em
br
an
e 
tra
ns
po
rt
48
30
0
44
2
0
0
D
0Z
I1
3_
S
A
LT
1
S
pI
I
P
ut
at
iv
e 
ou
te
r m
em
br
an
e 
lip
op
ro
te
in
24
30
0
42
0
0
0
D
0Z
IJ
0_
S
A
LT
1
rp
oA
C
Y
T
D
N
A
-d
ire
ct
ed
 R
N
A 
po
ly
m
er
as
e 
su
bu
ni
t 
al
ph
a
37
29
2
38
3
50
0
D
0Z
Q
F0
_S
A
LT
1
sd
hB
C
Y
T
X
S
uc
ci
na
te
 d
eh
yd
ro
ge
na
se
 ir
on
-s
ul
fu
r 
su
bu
ni
t
27
29
0
36
0
67
0
D
0Z
X
W
2_
S
A
LT
1
yr
aP
S
pI
I
P
ut
at
iv
e 
un
ch
ar
ac
te
riz
ed
 p
ro
te
in
 y
ra
P
20
29
0
28
0
0
0
D
0Z
Q
E
5_
S
A
LT
1
gl
tA
C
Y
T
X
C
itr
at
e 
sy
nt
ha
se
48
27
0
99
3
88
21
D
0Z
L9
1_
S
A
LT
1
ye
dD
S
pI
I
P
ut
at
iv
e 
un
ch
ar
ac
te
riz
ed
 p
ro
te
in
 y
ed
D
15
26
0
31
0
0
0
D
0Z
IK
8_
S
A
LT
1
rp
lP
C
Y
T
X
50
S
 ri
bo
so
m
al
 p
ro
te
in
 L
16
15
26
0
30
0
2
0
D
0Z
IJ
1_
S
A
LT
1
rp
sD
C
Y
T
30
S
 ri
bo
so
m
al
 p
ro
te
in
 S
4
23
26
0
29
0
67
0
D
0Z
Q
F4
_S
A
LT
1
su
cD
C
Y
T
S
uc
ci
ny
l-C
oA
 li
ga
se
 [A
D
P
-fo
rm
in
g]
 
su
bu
ni
t a
lp
ha
30
26
0
26
4
61
0
D
0Z
W
75
_S
A
LT
1
rp
lT
C
Y
T
50
S
 ri
bo
so
m
al
 p
ro
te
in
 L
20
13
26
0
26
0
0
0
D
0Z
N
F4
_S
A
LT
1
fb
aB
C
Y
T
Fr
uc
to
se
-b
is
ph
os
ph
at
e 
al
do
la
se
38
26
0
23
2
40
0
D
0Z
W
92
_S
A
LT
1
pp
s
C
Y
T
P
ho
sp
ho
en
ol
py
ru
va
te
 s
yn
th
as
e
87
25
0
42
0
12
0
D
0Z
IZ
8_
S
A
LT
1
yc
iE
C
Y
T
P
ut
at
iv
e 
cy
to
pl
as
m
ic
 p
ro
te
in
19
23
2
24
0
61
9
19
7
D
0Z
JZ
1_
S
A
LT
1
ac
eF
C
Y
T
X
D
ih
yd
ro
lip
oa
m
id
e 
ac
et
yl
tra
ns
fe
ra
se
66
22
0
45
0
20
0
D
0Z
Q
E
9_
S
A
LT
1
sd
hA
C
Y
T
S
uc
ci
na
te
 d
eh
yd
ro
ge
na
se
 fl
av
op
ro
te
in
 
su
bu
ni
t
64
22
0
26
3
33
0
D
0Z
M
T9
_S
A
LT
1
at
pF
C
Y
T
AT
P 
sy
nt
ha
se
 s
ub
un
it 
b
17
22
0
24
0
21
28
D
0Z
R
N
4_
S
A
LT
1
ta
lA
C
Y
T
X
Tr
an
sa
ld
ol
as
e 
A
36
22
0
21
0
86
9
D
0Z
U
E
8_
S
A
LT
1
de
oD
C
Y
T
P
ur
in
e 
nu
cl
eo
si
de
 p
ho
sp
ho
ry
la
se
 d
eo
D
-
ty
pe
26
22
0
21
2
21
0
D
0Z
S
H
5_
S
A
LT
1
pf
lB
C
Y
T
P
yr
uv
at
e 
fo
rm
at
e 
ly
as
e 
I
85
21
0
42
0
21
41
D
0Z
P
Y
0_
S
A
LT
1
ls
rF
C
Y
T
U
nc
ha
ra
ct
er
iz
ed
 a
ld
ol
as
e 
ls
rF
32
21
0
33
0
31
0
153
D
0Z
W
53
_S
A
LT
1
ka
tE
C
Y
T
C
at
al
as
e
84
20
0
51
0
7
0
D
0Z
IJ
8_
S
A
LT
1
rp
sE
C
Y
T
30
S
 ri
bo
so
m
al
 p
ro
te
in
 S
5
18
20
0
26
0
2
0
D
0Z
X
P
4_
S
A
LT
1
ad
hP
C
Y
T
A
lc
oh
ol
 d
eh
yd
ro
ge
na
se
36
20
0
18
0
61
0
D
0Z
H
Y
7_
S
A
LT
1
tra
T
S
pI
I
X
C
on
ju
ga
tiv
e 
tra
ns
fe
r: 
su
rfa
ce
 e
xc
lu
si
on
26
20
0
18
0
36
16
D
0Z
J5
4_
S
A
LT
1
pr
sA
C
Y
T
R
ib
os
e-
ph
os
ph
at
e 
py
ro
ph
os
ph
ok
in
as
e
34
20
0
18
0
14
0
D
0Z
N
29
_S
A
LT
1
ya
jG
S
pI
I
P
ut
at
iv
e 
un
ch
ar
ac
te
riz
ed
 p
ro
te
in
 y
aj
G
21
20
0
14
0
0
0
D
0Z
PA
7_
S
A
LT
1
ah
pC
C
Y
T
A
lk
yl
 h
yd
ro
pe
ro
xi
de
 re
du
ct
as
e 
su
bu
ni
t C
21
20
0
13
0
41
0
D
0Z
X
Z2
_S
A
LT
1
hf
lB
S
pI
AT
P
-d
ep
en
de
nt
 m
et
al
lo
pr
ot
ea
se
71
19
0
12
0
0
0
D
0Z
S
K
4_
S
A
LT
1
as
pC
C
Y
T
A
ro
m
at
ic
 a
m
in
o 
ac
id
 a
m
in
ot
ra
ns
fe
ra
se
44
18
0
29
0
13
0
D
0Z
W
F1
_S
A
LT
1
gc
vP
C
Y
T
G
ly
ci
ne
 d
eh
yd
ro
ge
na
se
 [d
ec
ar
bo
xy
la
tin
g]
10
4
18
0
22
0
11
0
D
0Z
Q
V
2_
S
A
LT
1
rp
lJ
C
Y
T
50
S
 ri
bo
so
m
al
 p
ro
te
in
 L
10
18
18
0
19
0
96
0
D
0Z
K
07
_S
A
LT
1
m
in
D
C
Y
T
C
el
l d
iv
is
io
n 
in
hi
bi
to
r M
in
D
30
18
0
19
0
13
0
D
0Z
Q
V
0_
S
A
LT
1
rp
lK
C
Y
T
X
50
S
 ri
bo
so
m
al
 p
ro
te
in
 L
11
15
17
0
31
0
10
3
0
D
0Z
W
I1
_S
A
LT
1
tk
tA
C
Y
T
Tr
an
sk
et
ol
as
e
72
17
0
23
2
3
0
D
0Z
M
Y
7_
S
A
LT
1
ya
jC
TM
H
P
re
pr
ot
ei
n 
tra
ns
lo
ca
se
 s
ub
un
it 
Ya
jC
12
17
0
17
0
0
0
D
0Z
TR
7_
S
A
LT
1
yf
iO
S
pI
I
O
ut
er
 m
em
br
an
e 
pr
ot
ei
n 
as
se
m
bl
y 
co
m
pl
ex
 s
ub
un
it
28
17
0
16
0
0
0
D
0Z
IL
2_
S
A
LT
1
rp
lB
C
Y
T
X
50
S
 ri
bo
so
m
al
 p
ro
te
in
 L
2
30
17
0
14
0
5
0
D
0Z
R
97
_S
A
LT
1
yb
hC
S
pI
I
P
ut
at
iv
e 
pe
ct
in
es
te
ra
se
46
17
0
9
0
0
0
D
0Z
N
W
5_
S
A
LT
1
fa
dB
C
Y
T
M
ul
tif
un
ct
io
na
l f
at
ty
 a
ci
d 
ox
id
at
io
n 
co
m
pl
ex
 s
ub
un
it
85
16
0
29
0
0
0
D
0Z
IK
0_
S
A
LT
1
rp
lF
C
Y
T
50
S
 ri
bo
so
m
al
 p
ro
te
in
 L
6
19
16
2
15
0
13
8
6
D
0Z
M
T6
_S
A
LT
1
at
pG
C
Y
T
AT
P 
sy
nt
ha
se
 g
am
m
a 
ch
ai
n
32
16
0
14
0
5
0
D
0Z
IZ
7_
S
A
LT
1
yc
iF
C
Y
T
P
ut
at
iv
e 
cy
to
pl
as
m
ic
 p
ro
te
in
19
16
0
10
0
40
0
8
D
0Z
W
V
7_
S
A
LT
1
so
dB
C
Y
T
X
S
up
er
ox
id
e 
di
sm
ut
as
e
21
16
0
10
0
19
0
D
0Z
V
P
5_
S
A
LT
1
en
o
C
Y
T
X
E
no
la
se
46
15
5
59
6
24
1
5
D
0Z
W
F3
_S
A
LT
1
gc
vT
C
Y
T
A
m
in
om
et
hy
ltr
an
sf
er
as
e
40
15
0
15
0
12
0
D
0Z
Y
43
_S
A
LT
1
ss
pA
C
Y
T
S
tri
ng
en
t s
ta
rv
at
io
n 
pr
ot
ei
n 
A
24
15
0
10
0
24
0
154
D
0Z
IL
5_
S
A
LT
1
rp
lC
C
Y
T
X
50
S
 ri
bo
so
m
al
 p
ro
te
in
 L
3
22
15
0
8
0
38
0
D
0Z
N
37
_S
A
LT
1
lo
n
C
Y
T
AT
P
-d
ep
en
de
nt
 p
ro
te
as
e
87
14
0
26
2
8
8
D
0Z
R
Z7
_S
A
LT
1
ac
s
C
Y
T
X
A
ce
ty
l-C
oA
 s
yn
th
et
as
e
72
14
0
24
0
39
4
D
0Z
Q
T7
_S
A
LT
1
cy
sK
C
Y
T
C
ys
te
in
e 
sy
nt
ha
se
35
14
0
21
0
88
0
D
0Z
IK
5_
S
A
LT
1
rp
lN
C
Y
T
X
50
S
 ri
bo
so
m
al
 p
ro
te
in
 L
14
14
14
0
17
2
22
0
D
0Z
II9
_S
A
LT
1
rp
lQ
C
Y
T
50
S
 ri
bo
so
m
al
 p
ro
te
in
 L
17
14
14
0
16
0
61
0
D
0Z
Q
59
_S
A
LT
1
lp
tE
S
pI
I
LP
S
-a
ss
em
bl
y 
lip
op
ro
te
in
 R
pl
B
21
14
0
16
0
0
0
D
0Z
K
R
3_
S
A
LT
1
yi
bF
C
Y
T
G
lu
ta
th
io
ne
 S
-tr
an
sf
er
as
e
23
14
0
15
0
35
0
D
0Z
U
P
2_
S
A
LT
1
fa
bG
C
Y
T
3-
ke
to
ac
yl
-(
A
cy
l-c
ar
rie
r-
pr
ot
ei
n)
 re
du
ct
as
e
26
14
0
13
2
44
0
D
0Z
R
U
1_
S
A
LT
1
yf
gL
S
pI
I
O
ut
er
 m
em
br
an
e 
pr
ot
ei
n 
as
se
m
bl
y 
co
m
pl
ex
 s
ub
un
it
42
14
0
13
0
3
0
D
0Z
K
Z9
_S
A
LT
1
rc
sF
S
pI
I
O
ut
er
 m
em
br
an
e 
lip
op
ro
te
in
14
14
0
13
0
0
0
D
0Z
I6
5_
S
A
LT
1
yn
aF
C
Y
T
P
ut
at
iv
e 
un
iv
er
sa
l s
tre
ss
 p
ro
te
in
16
14
0
11
0
62
0
D
0Z
M
Y
2_
S
A
LT
1
C
Y
T
P
ut
at
iv
e 
th
io
l-a
lk
yl
 h
yd
ro
pe
ro
xi
de
 
re
du
ct
as
e
22
13
2
30
2
10
9
0
D
0Z
W
11
_S
A
LT
1
ye
aG
C
Y
T
P
ut
at
iv
e 
se
rin
e 
pr
ot
ei
n 
ki
na
se
74
13
0
25
0
24
0
D
0Z
U
V
1_
S
A
LT
1
al
aS
C
Y
T
A
la
ny
l-t
R
N
A 
sy
nt
he
ta
se
96
13
0
19
0
0
0
D
0Z
K
25
_S
A
LT
1
m
an
X
C
Y
T
M
an
no
se
-s
pe
ci
fic
 e
nz
ym
e 
IIA
B
35
13
0
15
0
0
0
D
0Z
K
W
6_
S
A
LT
1
ya
eH
C
Y
T
X
U
P
F0
32
5 
pr
ot
ei
n 
ya
eH
15
13
0
9
0
22
6
0
D
0Z
Y
47
_S
A
LT
1
rp
lM
C
Y
T
50
S
 ri
bo
so
m
al
 p
ro
te
in
 L
13
16
13
0
9
2
0
0
D
0Z
JD
2_
S
A
LT
1
om
pR
C
Y
T
O
sm
ol
ar
ity
 re
sp
on
se
 re
gu
la
to
r
27
13
0
8
0
28
0
D
0Z
U
E
7_
S
A
LT
1
de
oB
C
Y
T
P
ho
sp
ho
pe
nt
om
ut
as
e
44
12
0
25
0
17
0
D
0Z
P
31
_S
A
LT
1
pp
iB
C
Y
T
P
ep
tid
yl
-p
ro
ly
l c
is
-tr
an
s 
is
om
er
as
e
18
12
0
10
0
26
0
D
0Z
IB
8_
S
A
LT
1
fa
bI
C
Y
T
E
no
yl
-(
A
cy
l c
ar
rie
r p
ro
te
in
) r
ed
uc
ta
se
28
12
0
9
0
6
0
D
0Z
W
77
_S
A
LT
1
ph
eS
C
Y
T
P
he
ny
la
la
ny
l-t
R
N
A 
sy
nt
he
ta
se
 s
ub
un
it 
al
ph
a
37
12
0
7
0
0
0
D
0Z
S
62
_S
A
LT
1
gr
oL
C
Y
T
60
 k
D
a 
ch
ap
er
on
in
57
11
24
15
7
62
64
2
11
D
0Z
IP
4_
S
A
LT
1
cr
p
C
Y
T
cA
M
P
-r
eg
ul
at
or
y 
pr
ot
ei
n
24
11
0
24
0
64
0
D
0Z
R
U
8_
S
A
LT
1
nd
k
C
Y
T
N
uc
le
os
id
e 
di
ph
os
ph
at
e 
ki
na
se
16
11
0
21
0
76
0
155
D
0Z
K
E
8_
S
A
LT
1
pr
lC
C
Y
T
O
lig
op
ep
tid
as
e 
A
77
11
0
18
0
4
0
D
0Z
VA
9_
S
A
LT
1
C
Y
T
P
ut
at
iv
e 
un
ch
ar
ac
te
riz
ed
 p
ro
te
in
40
11
0
15
0
0
0
D
0Z
J5
0_
S
A
LT
1
lo
lB
S
pI
I
O
ut
er
 m
em
br
an
e 
lip
op
ro
te
in
 L
ol
B
24
11
0
13
0
0
6
D
0Z
IL
4_
S
A
LT
1
rp
lD
C
Y
T
X
50
S
 ri
bo
so
m
al
 p
ro
te
in
 L
4
22
11
0
13
0
0
0
D
0Z
T1
0_
S
A
LT
1
hf
lC
C
Y
T
Ft
sH
 p
ro
te
as
e 
re
gu
la
to
r H
flC
38
11
0
9
0
0
0
D
0Z
R
N
2_
S
A
LT
1
m
ae
B
C
Y
T
M
al
ic
 e
nz
ym
e
82
10
0
22
0
17
0
D
0Z
TI
0_
S
A
LT
1
pe
pN
C
Y
T
A
m
in
op
ep
tid
as
e 
N
10
4
10
0
16
0
0
0
D
0Z
LX
7_
S
A
LT
1
gm
hA
C
Y
T
P
ho
sp
ho
he
pt
os
e 
is
om
er
as
e
21
10
0
15
0
7
0
D
0Z
LJ
2_
S
A
LT
1
kb
l
C
Y
T
2-
am
in
o-
3-
ke
to
bu
ty
ra
te
 c
oe
nz
ym
e 
A 
lig
as
e
43
10
0
15
0
7
0
D
0Z
Q
H
3_
S
A
LT
1
nu
oG
C
Y
T
N
A
D
H
-q
ui
no
ne
 o
xi
do
re
du
ct
as
e
10
0
10
0
12
0
3
0
D
0Z
T4
2_
S
A
LT
1
rp
sR
C
Y
T
30
S
 ri
bo
so
m
al
 p
ro
te
in
 S
18
9
10
0
10
0
35
0
D
0Z
U
V
5_
S
A
LT
1
re
cA
C
Y
T
P
ro
te
in
 re
cA
38
10
0
7
0
5
0
D
0Z
N
27
_S
A
LT
1
cy
oA
TM
H
C
yt
oc
hr
om
e 
o 
ub
iq
ui
no
l o
xi
da
se
 s
ub
un
it 
II
35
10
0
6
0
5
0
D
0Z
V
H
8_
S
A
LT
1
pa
gC
S
pI
Vi
ru
le
nc
e 
m
em
br
an
e 
pr
ot
ei
n 
PA
G
C
20
10
0
6
0
0
0
D
0Z
TQ
2_
S
A
LT
1
w
ra
B
C
Y
T
Tr
pR
 b
in
di
ng
 p
ro
te
in
 W
rb
A
21
9
0
23
0
0
0
D
0Z
K
L9
_S
A
LT
1
yi
aF
S
pI
I
P
ut
at
iv
e 
ou
te
r m
em
br
an
e 
lip
op
ro
te
in
26
9
0
15
0
8
0
D
0Z
W
X
7_
S
A
LT
1
gs
t
C
Y
T
G
lu
ta
th
io
ni
ne
 S
-tr
an
sf
er
as
e
22
9
0
14
0
23
0
D
0Z
I7
6_
S
A
LT
1
yd
aA
C
Y
T
U
ni
ve
rs
al
 s
tre
ss
 p
ro
te
in
 U
sp
E
36
9
0
11
0
3
0
D
0Z
X
70
_S
A
LT
1
dk
gA
C
Y
T
2,
5-
di
ke
to
-D
-g
lu
co
na
te
 re
du
ct
as
e 
A
31
9
0
11
0
2
0
D
0Z
S
K
6_
S
A
LT
1
om
pF
S
pI
O
ut
er
 m
em
br
an
e 
pr
ot
ei
n 
F
40
9
0
10
0
28
0
D
0Z
T6
7_
S
A
LT
1
fb
p
C
Y
T
X
Fr
uc
to
se
-1
,6
-b
is
ph
os
ph
at
as
e 
cl
as
s 
1
37
9
0
10
0
12
0
D
0Z
U
91
_S
A
LT
1
C
Y
T
P
ut
at
iv
e 
N
A
D
-d
ep
en
de
nt
 a
ld
eh
yd
e 
de
hy
dr
og
en
as
e
50
8
0
69
5
15
8
5
D
0Z
U
E
6_
S
A
LT
1
de
oA
C
Y
T
X
Th
ym
id
in
e 
ph
os
ph
or
yl
as
e
51
8
0
29
0
0
0
D
0Z
X
X
7_
S
A
LT
1
pn
p
C
Y
T
P
ol
yr
ib
on
uc
le
ot
id
e 
nu
cl
eo
tid
yl
tra
ns
fe
ra
se
77
8
0
17
0
2
0
D
0Z
JW
7_
S
A
LT
1
fts
Z
C
Y
T
C
el
l d
iv
is
io
n 
pr
ot
ei
n 
fts
Z
40
8
0
14
0
0
0
D
0Z
TS
8_
S
A
LT
1
rp
lS
C
Y
T
50
S
 ri
bo
so
m
al
 p
ro
te
in
 L
19
13
8
0
14
0
0
0
156
D
0Z
R
60
_S
A
LT
1
qo
r
C
Y
T
Q
ui
no
ne
 o
xi
do
re
du
ct
as
e,
 N
A
D
P
H
-
de
pe
nd
en
t
35
8
0
13
0
2
0
D
0Z
P
Y
3_
S
A
LT
1
tp
iA
C
Y
T
X
Tr
io
se
ph
os
ph
at
e 
is
om
er
as
e
27
8
0
12
0
88
0
D
0Z
K
M
7_
S
A
LT
1
gl
yS
C
Y
T
G
ly
cy
l-t
R
N
A 
sy
nt
he
ta
se
 b
et
a 
su
bu
ni
t
76
8
0
12
0
10
0
D
0Z
U
K
9_
S
A
LT
1
gr
xB
C
Y
T
G
lu
ta
re
do
xi
n 
2
24
8
0
10
0
6
0
D
0Z
K
L6
_S
A
LT
1
yi
aD
S
pI
I
P
ut
at
iv
e 
ou
te
r m
em
br
an
e 
lip
op
ro
te
in
22
8
0
10
0
0
0
D
0Z
Q
V
3_
S
A
LT
1
rp
lL
C
Y
T
50
S
 ri
bo
so
m
al
 p
ro
te
in
 L
7/
L1
2
12
8
0
10
0
0
0
D
0Z
IR
2_
S
A
LT
1
dn
aK
C
Y
T
C
ha
pe
ro
ne
 p
ro
te
in
 d
na
K
69
8
0
7
3
66
0
D
0Z
TB
4_
S
A
LT
1
yj
gF
C
Y
T
P
ut
at
iv
e 
tra
ns
la
tio
n 
in
iti
at
io
n 
in
hi
bi
to
r y
jg
F
14
8
3
7
4
38
0
D
0Z
V
97
_S
A
LT
1
ic
dA
C
Y
T
Is
oc
itr
at
e 
de
hy
dr
og
en
as
e 
[N
A
D
P
]
46
7
0
88
2
84
2
D
0Z
T0
9_
S
A
LT
1
hf
lK
C
Y
T
Ft
sH
 p
ro
te
as
e 
re
gu
la
to
r H
flK
46
7
0
21
0
0
0
D
0Z
L4
7_
S
A
LT
1
ch
eA
C
Y
T
C
he
m
ot
ax
is
 p
ro
te
in
 C
he
A
73
7
0
15
0
4
0
D
0Z
K
X
2_
S
A
LT
1
ts
f
C
Y
T
E
lo
ng
at
io
n 
fa
ct
or
 T
s
30
7
0
12
3
14
0
D
0Z
W
36
_S
A
LT
1
as
tA
C
Y
T
A
rg
in
in
e 
su
cc
in
yl
tra
ns
fe
ra
se
38
7
0
6
0
14
0
D
0Z
Q
N
6_
S
A
LT
1
fa
bB
C
Y
T
3-
ox
oa
cy
l-(
A
cy
l c
ar
rie
r p
ro
te
in
) s
yn
th
as
e 
I
42
6
0
23
0
19
0
D
0Z
K
R
8_
S
A
LT
1
ya
dF
C
Y
T
C
ar
bo
ni
c 
an
hy
dr
as
e
25
6
0
13
0
7
0
D
0Z
S
90
_S
A
LT
1
da
cC
S
pI
D
-a
la
ny
l-D
-a
la
ni
ne
 c
ar
bo
xy
pe
pt
id
as
e 
fra
ct
io
n 
C
44
6
0
12
0
5
6
D
0Z
X
C
6_
S
A
LT
1
rp
oD
C
Y
T
X
R
N
A 
po
ly
m
er
as
e 
si
gm
a 
fa
ct
or
76
6
0
12
0
0
0
D
0Z
R
N
5_
S
A
LT
1
tk
tB
C
Y
T
Tr
an
sk
et
ol
as
e
73
6
0
11
0
7
0
D
0Z
S
I1
_S
A
LT
1
se
rC
C
Y
T
P
ho
sp
ho
se
rin
e 
am
in
ot
ra
ns
fe
ra
se
40
6
0
10
0
4
0
D
0Z
Q
92
_S
A
LT
1
na
gB
C
Y
T
G
lu
co
sa
m
in
e-
6-
ph
os
ph
at
e 
de
am
in
as
e
30
6
0
6
0
12
0
D
0Z
X
S
7_
S
A
LT
1
yn
cB
C
Y
T
P
ut
at
iv
e 
N
A
D
P
-d
ep
en
de
nt
 
ox
id
or
ed
uc
ta
se
39
6
0
6
0
12
0
D
0Z
Q
J2
_S
A
LT
1
pt
a
C
Y
T
P
ho
sp
ha
te
 a
ce
ty
ltr
an
sf
er
as
e
77
5
0
15
0
9
0
D
0Z
N
W
4_
S
A
LT
1
fa
dA
C
Y
T
3-
ke
to
ac
yl
-C
oA
 th
io
la
se
41
5
0
12
0
10
0
D
0Z
K
Y
0_
S
A
LT
1
ba
m
A
S
pI
O
ut
er
 m
em
br
an
e 
pr
ot
ei
n 
as
se
m
bl
y 
fa
ct
or
 
Ya
eT
90
5
0
11
0
0
0
157
D
0Z
LJ
3_
S
A
LT
1
rfa
D
C
Y
T
A
D
P
-L
-g
ly
ce
ro
-D
-m
an
no
he
pt
os
e-
6-
ep
im
er
as
e
35
5
0
11
0
0
0
D
0Z
Y
46
_S
A
LT
1
rp
sI
C
Y
T
30
S
 ri
bo
so
m
al
 p
ro
te
in
 S
9
15
5
0
10
0
0
0
D
0Z
U
S
6_
S
A
LT
1
yg
aM
C
Y
T
P
ut
at
iv
e 
un
ch
ar
ac
te
riz
ed
 p
ro
te
in
 y
ga
M
12
5
0
8
0
72
0
D
0Z
V
78
_S
A
LT
1
ar
cA
C
Y
T
Tw
o-
co
m
po
ne
nt
 re
sp
on
se
 re
gu
la
to
r
27
5
0
8
0
10
0
D
0Z
I9
5_
S
A
LT
1
tp
x
C
Y
T
Th
io
l p
er
ox
id
as
e
18
5
2
5
0
80
0
D
0Z
IK
1_
S
A
LT
1
rp
sH
C
Y
T
30
S
 ri
bo
so
m
al
 p
ro
te
in
 S
8
14
5
0
5
0
51
0
D
0Z
S
I6
_S
A
LT
1
rp
sA
C
Y
T
30
S
 ri
bo
so
m
al
 p
ro
te
in
 S
1
61
5
0
5
2
18
0
D
0Z
X
C
4_
S
A
LT
1
rp
sU
C
Y
T
30
S
 ri
bo
so
m
al
 p
ro
te
in
 S
21
9
5
0
2
0
13
0
D
0Z
Q
F2
_S
A
LT
1
su
cB
C
Y
T
D
ih
yd
ro
lip
oa
m
id
e 
ac
et
yl
tra
ns
fe
ra
se
44
4
0
43
0
4
0
D
0Z
J2
0_
S
A
LT
1
hn
s
C
Y
T
X
G
lo
ba
l D
N
A
-b
in
di
ng
 tr
an
sc
rip
tio
na
l d
ua
l 
re
gu
la
to
r
16
4
0
12
2
18
0
0
D
0Z
IM
3_
S
A
LT
1
rp
sG
C
Y
T
30
S
 ri
bo
so
m
al
 p
ro
te
in
 S
7
18
4
0
10
0
0
0
D
0Z
R
Q
1_
S
A
LT
1
pu
rC
C
Y
T
P
ho
sp
ho
rib
os
yl
am
in
oi
m
id
az
ol
e-
su
cc
in
oc
ar
bo
xa
m
id
e 
sy
nt
ha
se
27
4
0
9
0
21
0
D
0Z
W
V
9_
S
A
LT
1
yd
hD
C
Y
T
P
ut
at
iv
e 
un
ch
ar
ac
te
riz
ed
 p
ro
te
in
 y
dh
D
13
4
0
6
0
39
0
D
0Z
IK
2_
S
A
LT
1
rp
sN
C
Y
T
30
S
 ri
bo
so
m
al
 s
ub
un
it 
pr
ot
ei
n 
S
14
11
4
0
6
0
26
0
D
0Z
U
B
5_
S
A
LT
1
C
Y
T
P
ut
at
iv
e 
gl
uc
os
am
in
e-
fru
ct
os
e-
6-
ph
os
ph
at
e 
am
in
ot
ra
ns
fe
ra
se
39
4
0
5
0
10
0
D
0Z
Q
H
7_
S
A
LT
1
nu
oB
C
Y
T
N
A
D
H
 d
eh
yd
ro
ge
na
se
 s
ub
un
it 
B
25
4
0
0
0
10
0
D
0Z
M
T5
_S
A
LT
1
at
pD
C
Y
T
AT
P 
sy
nt
ha
se
 s
ub
un
it 
be
ta
50
3
0
13
4
4
13
2
0
D
0Z
S
P
0_
S
A
LT
1
gl
yA
C
Y
T
S
er
in
e 
hy
dr
ox
ym
et
hy
ltr
an
sf
er
as
e
45
3
0
23
0
56
0
D
0Z
J2
2_
S
A
LT
1
ga
lU
C
Y
T
U
TP
--
gl
uc
os
e-
1-
ph
os
ph
at
e 
ur
id
yl
yl
tra
ns
fe
ra
se
 s
ub
un
it
33
3
0
6
0
13
0
D
0Z
W
43
_S
A
LT
1
na
dE
C
Y
T
N
H
(3
)-
de
pe
nd
en
t N
A
D
(+
) s
yn
th
et
as
e
30
3
0
5
0
19
0
D
0Z
W
73
_S
A
LT
1
in
fC
C
Y
T
X
Tr
an
sl
at
io
n 
in
iti
at
io
n 
fa
ct
or
 IF
-3
21
3
0
4
0
68
0
D
0Z
N
77
_S
A
LT
1
ad
k
C
Y
T
A
de
ny
la
te
 k
in
as
e
23
3
0
3
0
21
0
D
0Z
N
J0
_S
A
LT
1
yo
hF
C
Y
T
A
ce
to
in
 d
eh
yd
ro
ge
na
se
27
3
0
2
0
14
0
D
0Z
U
U
5_
S
A
LT
1
lu
xS
C
Y
T
X
S
-r
ib
os
yl
ho
m
oc
ys
te
in
e 
ly
as
e
19
3
0
0
0
33
0
D
0Z
K
B
9_
S
A
LT
1
as
pS
C
Y
T
A
sp
ar
ty
l-t
R
N
A 
sy
nt
he
ta
se
66
2
0
15
0
0
0
158
D
0Z
R
Q
5_
S
A
LT
1
bc
p
C
Y
T
Th
io
re
do
xi
n-
de
pe
nd
en
t t
hi
ol
 p
er
ox
id
as
e
18
2
0
2
0
30
0
D
0Z
M
R
9_
S
A
LT
1
yi
eF
C
Y
T
P
ut
at
iv
e 
ox
id
or
ed
uc
ta
se
20
2
0
0
0
12
0
D
0Z
Q
H
5_
S
A
LT
1
nu
oE
C
Y
T
N
A
D
H
 d
eh
yd
ro
ge
na
se
 s
ub
un
it 
E
19
2
0
0
0
10
0
D
0Z
M
T7
_S
A
LT
1
at
pA
C
Y
T
AT
P 
sy
nt
ha
se
 s
ub
un
it 
al
ph
a
55
0
0
71
4
52
0
D
0Z
K
Q
9_
S
A
LT
1
al
dB
C
Y
T
A
ld
eh
yd
e 
de
hy
dr
og
en
as
e 
B
56
0
0
56
3
54
5
D
0Z
M
I7
_S
A
LT
1
gn
d
C
Y
T
6-
ph
os
ph
og
lu
co
na
te
 d
eh
yd
ro
ge
na
se
51
0
0
40
0
29
0
D
0Z
JZ
2_
S
A
LT
1
lp
dA
C
Y
T
D
ih
yd
ro
lip
oy
l d
eh
yd
ro
ge
na
se
51
0
0
33
2
46
0
D
0Z
R
32
_S
A
LT
1
pg
i
C
Y
T
X
G
lu
co
se
-6
-p
ho
sp
ha
te
 is
om
er
as
e
61
0
0
32
0
0
0
D
0Z
S
57
_S
A
LT
1
as
pA
C
Y
T
A
sp
ar
ta
te
 a
m
m
on
ia
-ly
as
e
52
0
0
26
2
70
24
D
0Z
Q
Y
9_
S
A
LT
1
ac
eA
C
Y
T
X
Is
oc
itr
at
e 
ly
as
e
48
0
0
26
0
56
0
D
0Z
M
J6
_S
A
LT
1
rfb
H
C
Y
T
C
D
P
-6
-d
eo
xy
-D
-x
yl
o-
4-
he
xu
lo
se
-3
-
de
hy
dr
as
e
48
0
0
26
0
17
0
D
0Z
Q
B
1_
S
A
LT
1
pg
m
C
Y
T
P
ho
sp
ho
gl
uc
om
ut
as
e
58
0
0
25
0
10
2
D
0Z
P
Y
9_
S
A
LT
1
gl
pK
C
Y
T
G
ly
ce
ro
l k
in
as
e
56
0
0
25
0
0
0
D
0Z
Q
H
6_
S
A
LT
1
nu
oC
C
Y
T
B
ifu
nc
tio
na
l N
A
D
H
:u
bi
qu
in
on
e 
ox
id
or
ed
uc
ta
se
 s
ub
un
it
69
0
0
24
0
0
0
D
0Z
V
61
_S
A
LT
1
yj
jK
C
Y
T
P
ut
at
iv
e 
A
B
C
 tr
an
sp
or
te
r A
TP
-b
in
di
ng
 
pr
ot
ei
n
62
0
0
22
0
9
0
D
0Z
Q
U
2_
S
A
LT
1
pt
sI
C
Y
T
P
ho
sp
ho
en
ol
py
ru
va
te
-p
ro
te
in
 
ph
os
ph
ot
ra
ns
fe
ra
se
63
0
0
22
0
8
0
D
0Z
S
K
8_
S
A
LT
1
as
nS
C
Y
T
A
sp
ar
ag
in
yl
-tR
N
A 
sy
nt
he
ta
se
53
0
0
21
0
6
0
D
0Z
J1
4_
S
A
LT
1
op
pA
S
pI
O
lig
op
ep
tid
e 
tra
ns
po
rt 
pr
ot
ei
n
61
0
0
21
0
0
0
D
0Z
W
D
6_
S
A
LT
1
ly
sS
C
Y
T
Ly
sy
l-t
R
N
A 
sy
nt
he
ta
se
58
0
0
21
0
0
0
D
0Z
Q
Y
8_
S
A
LT
1
ac
eB
C
Y
T
X
M
al
at
e 
sy
nt
ha
se
60
0
0
20
0
14
3
D
0Z
N
P
6_
S
A
LT
1
rh
o
C
Y
T
Tr
an
sc
rip
tio
n 
te
rm
in
at
io
n 
fa
ct
or
 R
ho
47
0
0
20
0
6
5
D
0Z
W
Z8
_S
A
LT
1
fu
m
C
C
Y
T
X
Fu
m
ar
at
e 
hy
dr
at
as
e
50
0
0
19
0
13
0
D
0Z
LY
2_
S
A
LT
1
pe
pD
C
Y
T
A
m
in
oa
cy
l-h
is
tid
in
e 
di
pe
pt
id
as
e
52
0
0
17
0
6
3
D
0Z
U
14
_S
A
LT
1
ga
bD
C
Y
T
S
uc
ci
na
te
-s
em
ia
ld
eh
yd
e 
de
hy
dr
og
en
as
e 
I
52
0
0
16
0
19
0
D
0Z
W
37
_S
A
LT
1
as
tD
C
Y
T
N
-s
uc
ci
ny
lg
lu
ta
m
at
e 
5-
se
m
ia
ld
eh
yd
e 
de
hy
dr
og
en
as
e
53
0
0
16
0
0
0
159
D
0Z
K
Z7
_S
A
LT
1
pr
oS
C
Y
T
X
P
ro
ly
l-t
R
N
A 
sy
nt
he
ta
se
64
0
0
15
0
48
37
D
0Z
J7
3_
S
A
LT
1
tre
A
S
pI
Tr
eh
al
as
e
64
0
0
15
0
0
0
D
0Z
W
Z4
_S
A
LT
1
yd
gA
S
pI
P
ut
at
iv
e 
pe
rip
la
sm
ic
 p
ro
te
in
54
0
0
15
0
0
0
D
0Z
J8
0_
S
A
LT
1
da
dA
S
pI
D
-a
m
in
o 
ac
id
 d
eh
yd
ro
ge
na
se
 s
m
al
l 
su
bu
ni
t
48
0
0
13
13
13
0
D
0Z
L4
5_
S
A
LT
1
ch
eM
C
Y
T
M
et
hy
l a
cc
ep
tin
g 
ch
em
ot
ax
is
 p
ro
te
in
 II
68
0
2
13
0
0
0
D
0Z
T1
3_
S
A
LT
1
pu
rA
C
Y
T
A
de
ny
lo
su
cc
in
at
e 
sy
nt
he
ta
se
47
0
0
12
0
11
0
D
0Z
K
A
0_
S
A
LT
1
zw
f
C
Y
T
G
lu
co
se
-6
-p
ho
sp
ha
te
 1
-d
eh
yd
ro
ge
na
se
56
0
0
11
0
0
0
D
0Z
W
G
5_
S
A
LT
1
rp
iA
C
Y
T
R
ib
os
e-
5-
ph
os
ph
at
e 
is
om
er
as
e 
A
23
0
0
10
0
47
0
D
0Z
W
Q
2_
S
A
LT
1
py
kF
C
Y
T
X
P
yr
uv
at
e 
ki
na
se
51
0
0
8
0
22
0
D
0Z
IF
4_
S
A
LT
1
ac
cC
C
Y
T
A
ce
ty
l-C
oA
 c
ar
bo
xy
la
se
 b
io
tin
 
ca
rb
ox
yl
as
e 
su
bu
ni
t
49
0
0
6
0
34
0
D
0Z
IJ
2_
S
A
LT
1
rp
sK
C
Y
T
30
S
 ri
bo
so
m
al
 p
ro
te
in
 S
11
14
0
0
6
0
10
0
D
0Z
K
97
_S
A
LT
1
ed
a
C
Y
T
K
et
o-
hy
dr
ox
yg
lu
ta
ra
te
-a
ld
ol
as
e/
ke
to
-
de
ox
y-
ph
os
ph
og
lu
co
na
te
 a
ld
ol
as
e
22
0
0
4
0
21
0
D
0Z
X
N
9_
S
A
LT
1
os
m
C
C
Y
T
P
ut
at
iv
e 
en
ve
lo
pe
 p
ro
te
in
15
0
0
3
0
38
0
D
0Z
K
X
4_
S
A
LT
1
frr
C
Y
T
X
R
ib
os
om
e-
re
cy
cl
in
g 
fa
ct
or
21
0
0
3
0
16
0
D
0Z
K
08
_S
A
LT
1
m
in
E
C
Y
T
C
el
l d
iv
is
io
n 
to
po
lo
gi
ca
l s
pe
ci
fic
ity
 fa
ct
or
10
0
0
2
0
21
0
D
0Z
R
R
3_
S
A
LT
1
up
p
C
Y
T
X
U
ra
ci
l p
ho
sp
ho
rib
os
yl
tra
ns
fe
ra
se
23
0
0
0
0
42
0
D
0Z
JA
6_
S
A
LT
1
yh
fL
S
pI
I
P
ut
at
iv
e 
ou
te
r m
em
br
an
e 
lip
op
ro
te
in
6
0
0
0
0
38
0
D
0Z
IZ
9_
S
A
LT
1
C
Y
T
P
ut
at
iv
e 
ca
ta
la
se
32
0
0
0
0
30
0
D
0Z
LK
0_
S
A
LT
1
rfa
J
C
Y
T
Li
po
po
ly
sa
cc
ha
rid
e 
1,
2-
gl
uc
os
yl
tra
ns
fe
ra
se
39
0
0
0
0
28
0
D
0Z
R
R
0_
S
A
LT
1
yf
gD
C
Y
T
P
ut
at
iv
e 
ar
se
na
te
 re
du
ct
as
e
13
0
0
0
0
20
0
D
0Z
N
73
_S
A
LT
1
yb
aB
C
Y
T
U
P
F0
13
3 
pr
ot
ei
n 
yb
aB
12
0
0
0
0
20
0
D
0Z
S
69
_S
A
LT
1
ef
p
C
Y
T
E
lo
ng
at
io
n 
fa
ct
or
 P
21
0
0
0
0
19
0
D
0Z
TK
4_
S
A
LT
1
C
Y
T
P
ut
at
iv
e 
cy
to
pl
as
m
ic
 p
ro
te
in
15
0
0
0
0
17
0
D
0Z
S
77
_S
A
LT
1
frd
B
C
Y
T
Fu
m
ar
at
e 
re
du
ct
as
e
27
0
0
0
0
14
0
D
0Z
W
Y
4_
S
A
LT
1
rs
xC
C
Y
T
E
le
ct
ro
n 
tra
ns
po
rt 
co
m
pl
ex
 p
ro
te
in
 rn
fC
79
0
0
0
0
13
0
D
0Z
K
93
_S
A
LT
1
ye
bE
C
Y
T
P
ut
at
iv
e 
in
ne
r m
em
br
an
e 
pr
ot
ei
n
24
0
0
0
0
13
0
160
D
0Z
Y
25
_S
A
LT
1
yh
bL
C
Y
T
S
ig
m
a 
cr
os
s-
re
ac
tin
g 
pr
ot
ei
n 
27
A
23
0
0
0
0
12
0
D
0Z
X
H
9_
S
A
LT
1
yd
fG
C
Y
T
N
A
D
P
-d
ep
en
de
nt
 L
-s
er
in
e/
L-
al
lo
-
th
re
on
in
e 
de
hy
dy
dr
og
en
as
e
27
0
0
0
0
11
0
D
0Z
IN
6_
S
A
LT
1
yh
eS
C
Y
T
P
ut
at
iv
e 
AT
P
as
e 
co
m
po
ne
nt
 o
f A
B
C
 
tra
ns
po
rte
r
72
0
0
0
0
11
0
D
0Z
T5
4_
S
A
LT
1
cy
sQ
C
Y
T
3'
(2
'),
5'
-b
is
ph
os
ph
at
e 
nu
cl
eo
tid
as
e 
cy
sQ
27
0
0
0
0
10
0
D
0Z
X
W
4_
S
A
LT
1
yh
bO
C
Y
T
P
ut
at
iv
e 
in
tra
ce
llu
la
r p
ro
te
in
as
e
19
0
0
0
0
10
0
161
U
ni
pr
ot
 
A
cc
es
si
on
G
en
e 
N
am
e
D
es
cr
ip
tio
n
Li
po
P
M
W
 
(k
D
a)
al
k-
14
D
M
SO
al
k-
14
D
M
SO
al
k-
14
D
M
SO
D
0Z
TJ
5_
S
A
LT
1
om
pA
O
ut
er
 m
em
br
an
e 
pr
ot
ei
n 
A
S
pI
38
22
9
20
85
0
12
8
43
D
0Z
L0
0_
S
A
LT
1
m
et
Q
D
L-
m
et
hi
on
in
e 
tra
ns
po
rte
r s
ub
st
ra
te
-b
in
di
ng
 
su
bu
ni
t
S
pI
I
29
20
2
0
6
0
39
9
0
D
0Z
W
45
_S
A
LT
1
os
m
E
D
N
A
-b
in
di
ng
 tr
an
sc
rip
tio
na
l a
ct
iv
at
or
 O
sm
E
S
pI
I
12
18
8
0
14
0
69
0
D
0Z
Q
G
7_
S
A
LT
1
pa
l
P
ep
tid
og
ly
ca
n-
as
so
ci
at
ed
 o
ut
er
 m
em
br
an
e 
lip
op
ro
te
in
S
pI
I
19
15
1
2
70
0
26
6
55
D
0Z
W
Q
1_
S
A
LT
1
lp
p
M
ur
ei
n 
lip
op
ro
te
in
S
pI
I
8
13
7
15
44
0
0
15
D
0Z
S
62
_S
A
LT
1
gr
oL
60
  c
ha
pe
ro
ni
n
C
Y
T
57
10
8
31
21
8
5
67
5
40
4
D
0Z
N
53
_S
A
LT
1
yb
aY
P
ut
at
iv
e 
un
ch
ar
ac
te
riz
ed
 p
ro
te
in
 y
ba
Y
S
pI
I
19
60
0
27
0
23
8
0
D
0Z
V
T3
_S
A
LT
1
yg
dI
P
ut
at
iv
e 
lip
op
ro
te
in
S
pI
I
8
59
0
0
0
0
0
D
0Z
R
F5
_S
A
LT
1
om
pX
O
ut
er
 m
em
br
an
e 
pr
ot
ei
n 
X
S
pI
18
58
4
36
0
28
29
D
0Z
L9
1_
S
A
LT
1
ye
dD
P
ut
at
iv
e 
un
ch
ar
ac
te
riz
ed
 p
ro
te
in
 y
ed
D
S
pI
I
15
53
0
0
0
0
0
D
0Z
I1
3_
S
A
LT
1
P
ut
at
iv
e 
ou
te
r m
em
br
an
e 
lip
op
ro
te
in
S
pI
I
24
48
0
0
0
37
0
D
0Z
W
X
1_
S
A
LT
1
sl
yB
P
ut
at
iv
e 
ou
te
r m
em
br
an
e 
lip
op
ro
te
in
S
pI
I
16
47
0
22
0
0
9
D
0Z
JM
1_
S
A
LT
1
P
ut
at
iv
e 
in
ne
r m
em
br
an
e 
lip
op
ro
te
in
S
pI
I
20
46
0
4
0
53
0
D
0Z
P
K
7_
S
A
LT
1
om
pC
O
ut
er
 m
em
br
an
e 
po
rin
 p
ro
te
in
 C
S
pI
41
45
2
40
6
59
75
4
55
9
D
0Z
IM
2_
S
A
LT
1
fu
sA
E
lo
ng
at
io
n 
fa
ct
or
 G
C
Y
T
78
45
0
54
0
24
5
10
5
D
0Z
W
18
_S
A
LT
1
ga
pA
G
ly
ce
ra
ld
eh
yd
e-
3-
ph
os
ph
at
e 
de
hy
dr
og
en
as
e
C
Y
T
36
44
4
12
4
2
31
6
13
8
D
0Z
S
C
1_
S
A
LT
1
yb
jP
P
ut
at
iv
e 
lip
op
ro
te
in
S
pI
I
19
44
0
4
0
39
0
D
0Z
TZ
6_
S
A
LT
1
iro
N
O
ut
er
 m
em
br
an
e 
re
ce
pt
or
 F
ep
A
S
pI
79
42
3
0
0
0
0
D
0Z
R
Q
2_
S
A
LT
1
nl
pB
Li
po
pr
ot
ei
n
S
pI
I
37
41
0
25
0
11
6
0
D
0Z
U
Z6
_S
A
LT
1
si
tA
P
ut
at
iv
e 
pe
rip
la
sm
ic
 b
in
di
ng
 p
ro
te
in
S
pI
34
41
4
0
0
0
0
E
xp
t. 
1
E
xp
t. 
2
E
xp
t. 
3
A
PP
EN
D
IX
 5
. P
ro
te
in
s 
id
en
tif
ie
d 
fro
m
 S
al
m
on
el
la
 ty
ph
im
ur
iu
m
 a
fte
r a
lk
-1
4 
la
be
lin
g 
in
 M
gM
+ 
m
ed
ia
. O
nl
y 
pr
ot
ei
ns
 th
at
 w
er
e 
id
en
tif
ie
d 
w
ith
 2
 
un
iq
ue
 p
ep
tid
es
, a
nd
 1
0 
fo
ld
 e
nr
ic
hm
en
t i
n 
at
 le
as
t o
ne
 a
lk
-1
4 
sa
m
pl
e 
as
 c
om
pa
re
d 
to
 th
e 
D
M
S
O
 c
on
tro
l a
re
 s
ho
w
n.
 P
re
di
ct
ed
 li
po
pr
ot
ei
ns
 a
re
 
hi
gh
lig
ht
ed
 in
 y
el
lo
w
.
162
D
0Z
R
81
_S
A
LT
1
gp
m
A
2,
3-
bi
sp
ho
sp
ho
gl
yc
er
at
e-
de
pe
nd
en
t 
ph
os
ph
og
ly
ce
ra
te
-d
ep
en
de
nt
 p
ho
sp
ho
gl
yc
er
at
e 
m
ut
as
e
C
Y
T
28
38
0
2
0
0
0
D
0Z
IC
9_
S
A
LT
1
m
dh
M
al
at
e 
de
hy
dr
og
en
as
e
S
pI
32
33
6
43
4
19
3
13
8
D
0Z
N
U
5_
S
A
LT
1
m
et
E
5-
m
et
hy
lte
tra
hy
dr
op
te
ro
yl
tri
gl
ut
am
at
e-
-
ho
m
oc
ys
te
in
e 
m
et
hy
ltr
an
sf
er
as
e
C
Y
T
85
33
0
0
0
0
0
D
0Z
JZ
0_
S
A
LT
1
ac
eE
P
yr
uv
at
e 
de
hy
dr
og
en
as
e 
E
1 
co
m
po
ne
nt
C
Y
T
10
0
30
0
76
2
31
6
16
4
D
0Z
H
Y
7_
S
A
LT
1
tra
T
C
on
ju
ga
tiv
e 
tra
ns
fe
r: 
su
rfa
ce
 e
xc
lu
si
on
S
pI
I
26
28
0
60
0
26
2
0
D
0Z
TR
7_
S
A
LT
1
yf
iO
O
ut
er
 m
em
br
an
e 
pr
ot
ei
n 
as
se
m
bl
y 
co
m
pl
ex
 
su
bu
ni
t
S
pI
I
28
28
0
2
0
21
0
D
0Z
N
63
_S
A
LT
1
ac
rA
A
cr
id
in
e 
ef
flu
x 
pu
m
p
S
pI
I
42
27
0
36
0
23
3
0
D
0Z
Q
V
4_
S
A
LT
1
rp
oB
D
N
A
-d
ire
ct
ed
 R
N
A 
po
ly
m
er
as
e 
su
bu
ni
t b
et
a
C
Y
T
15
1
27
2
4
0
10
2
50
D
0Z
IK
9_
S
A
LT
1
rp
sC
30
S
 ri
bo
so
m
al
 p
ro
te
in
 S
3
C
Y
T
26
26
0
0
0
10
0
D
0Z
IJ
3_
S
A
LT
1
rp
sM
30
S
 ri
bo
so
m
al
 p
ro
te
in
 S
13
C
Y
T
13
26
0
0
0
0
0
D
0Z
M
T5
_S
A
LT
1
at
pD
AT
P 
sy
nt
ha
se
 s
ub
un
it 
be
ta
C
Y
T
50
25
0
39
0
23
2
30
D
0Z
X
W
2_
S
A
LT
1
yr
aP
P
ut
at
iv
e 
un
ch
ar
ac
te
riz
ed
 p
ro
te
in
 y
ra
P
S
pI
I
20
25
0
9
0
39
0
D
0Z
N
75
_S
A
LT
1
ht
pG
C
ha
pe
ro
ne
 p
ro
te
in
 h
tp
G
C
Y
T
72
25
0
0
0
7
0
D
0Z
X
Q
1_
S
A
LT
1
om
pD
P
ut
at
iv
e 
ou
te
r m
em
br
an
e 
po
rin
S
pI
40
24
2
43
2
65
1
43
0
D
0Z
Q
V
5_
S
A
LT
1
rp
oC
D
N
A
-d
ire
ct
ed
 R
N
A 
po
ly
m
er
as
e 
su
bu
ni
t b
et
a
C
Y
T
15
5
24
0
8
2
20
6
33
D
0Z
JZ
1_
S
A
LT
1
ac
eF
D
ih
yd
ro
lip
oa
m
id
e 
ac
et
yl
tra
ns
fe
ra
se
C
Y
T
66
20
0
55
0
90
32
D
0Z
M
I7
_S
A
LT
1
gn
d
6-
ph
os
ph
og
lu
co
na
te
 d
eh
yd
ro
ge
na
se
C
Y
T
51
20
0
13
0
66
43
D
0Z
J1
7_
S
A
LT
1
ad
hE
B
ifu
nc
tio
na
l a
ce
ta
ld
eh
yd
e-
C
oA
/a
lc
oh
ol
 
de
hy
dr
og
en
as
e
C
Y
T
96
19
0
84
0
28
3
96
D
0Z
Q
E
5_
S
A
LT
1
gl
tA
C
itr
at
e 
sy
nt
ha
se
C
Y
T
48
19
0
21
0
88
47
D
0Z
K
X
1_
S
A
LT
1
rp
sB
30
S
 ri
bo
so
m
al
 p
ro
te
in
 S
2
C
Y
T
27
19
0
11
0
52
19
D
0Z
W
H
3_
S
A
LT
1
pg
k
P
ho
sp
ho
gl
yc
er
at
e 
ki
na
se
C
Y
T
41
18
0
31
0
15
8
64
D
0Z
JN
6_
S
A
LT
1
ca
rB
C
ar
ba
m
oy
l p
ho
sp
ha
te
 s
yn
th
as
e 
la
rg
e 
su
bu
ni
t
C
Y
T
11
8
18
0
7
3
35
16
D
0Z
TR
4_
S
A
LT
1
cl
pB
P
ro
te
in
 d
is
ag
gr
eg
at
io
n 
ch
ap
er
on
e
C
Y
T
95
17
0
35
0
15
2
50
D
0Z
S
H
5_
S
A
LT
1
pf
lB
P
yr
uv
at
e 
fo
rm
at
e 
ly
as
e 
I
C
Y
T
85
16
0
49
0
19
7
15
5
163
D
0Z
R
U
1_
S
A
LT
1
yf
gL
O
ut
er
 m
em
br
an
e 
pr
ot
ei
n 
as
se
m
bl
y 
co
m
pl
ex
 
su
bu
ni
t
S
pI
I
42
16
0
21
0
44
0
D
0Z
V
97
_S
A
LT
1
ic
dA
Is
oc
itr
at
e 
de
hy
dr
og
en
as
e 
[N
A
D
P
]
C
Y
T
46
16
2
17
0
15
0
48
D
0Z
IJ
1_
S
A
LT
1
rp
sD
30
S
 ri
bo
so
m
al
 p
ro
te
in
 S
4
C
Y
T
23
16
0
6
0
17
5
D
0Z
Q
V
0_
S
A
LT
1
rp
lK
50
S
 ri
bo
so
m
al
 p
ro
te
in
 L
11
C
Y
T
15
15
0
8
0
0
0
D
0Z
R
97
_S
A
LT
1
yb
hC
P
ut
at
iv
e 
pe
ct
in
es
te
ra
se
S
pI
I
46
15
0
6
0
11
0
D
0Z
N
29
_S
A
LT
1
ya
jG
P
ut
at
iv
e 
un
ch
ar
ac
te
riz
ed
 p
ro
te
in
 y
aj
G
S
pI
I
21
15
0
0
0
16
0
D
0Z
Q
T7
_S
A
LT
1
cy
sK
C
ys
te
in
e 
sy
nt
ha
se
C
Y
T
35
14
0
49
0
71
39
D
0Z
M
T7
_S
A
LT
1
at
pA
AT
P 
sy
nt
ha
se
 s
ub
un
it 
al
ph
a
C
Y
T
55
14
0
31
0
18
1
91
D
0Z
IK
3_
S
A
LT
1
rp
lE
50
S
 ri
bo
so
m
al
 p
ro
te
in
 L
5
C
Y
T
20
14
0
13
0
52
22
D
0Z
K
Z9
_S
A
LT
1
rc
sF
O
ut
er
 m
em
br
an
e 
lip
op
ro
te
in
S
pI
I
14
14
0
3
0
8
0
D
0Z
R
32
_S
A
LT
1
pg
i
G
lu
co
se
-6
-p
ho
sp
ha
te
 is
om
er
as
e
C
Y
T
61
14
0
0
0
4
4
D
0Z
IR
2_
S
A
LT
1
dn
aK
C
ha
pe
ro
ne
 p
ro
te
in
 d
na
K
C
Y
T
69
13
2
70
0
23
0
81
D
0Z
K
E
5_
S
A
LT
1
us
pA
U
ni
ve
rs
al
 s
tre
ss
 p
ro
te
in
 A
C
Y
T
16
13
0
7
0
0
5
D
0Z
S
K
6_
S
A
LT
1
om
pF
O
ut
er
 m
em
br
an
e 
pr
ot
ei
n 
F
S
pI
40
13
0
0
0
3
9
D
0Z
S
P
0_
S
A
LT
1
gl
yA
S
er
in
e 
hy
dr
ox
ym
et
hy
ltr
an
sf
er
as
e
C
Y
T
45
12
0
30
6
91
43
D
0Z
J8
0_
S
A
LT
1
da
dA
D
-a
m
in
o 
ac
id
 d
eh
yd
ro
ge
na
se
 s
m
al
l s
ub
un
it
S
pI
48
12
0
11
14
0
80
D
0Z
Q
F3
_S
A
LT
1
su
cC
S
uc
ci
ny
l-C
oA
 li
ga
se
 [A
D
P
-fo
rm
in
g]
 s
ub
un
it 
be
ta
C
Y
T
41
12
0
3
0
15
6
11
6
D
0Z
W
I3
_S
A
LT
1
yg
gG
P
ut
at
iv
e 
Zn
-d
ep
en
de
nt
 p
ro
te
as
e
S
pI
I
27
12
0
0
0
0
0
D
0Z
JG
1_
S
A
LT
1
gl
pD
G
ly
ce
ro
l-3
-p
ho
sp
ha
te
 d
eh
yd
ro
ge
na
se
C
Y
T
57
11
0
19
0
60
15
D
0Z
S
K
4_
S
A
LT
1
as
pC
A
ro
m
at
ic
 a
m
in
o 
ac
id
 a
m
in
ot
ra
ns
fe
ra
se
C
Y
T
44
11
0
10
0
40
30
D
0Z
Q
F4
_S
A
LT
1
su
cD
S
uc
ci
ny
l-C
oA
 li
ga
se
 [A
D
P
-fo
rm
in
g]
 s
ub
un
it 
al
ph
a
C
Y
T
30
11
0
7
0
45
6
D
0Z
X
V
9_
S
A
LT
1
yr
aM
P
ut
at
iv
e 
tra
ns
gl
yc
os
yl
as
e
S
pI
I
73
11
0
3
0
13
0
D
0Z
K
L9
_S
A
LT
1
yi
aF
P
ut
at
iv
e 
ou
te
r m
em
br
an
e 
lip
op
ro
te
in
S
pI
I
26
11
0
0
0
28
0
D
0Z
V
I8
_S
A
LT
1
P
ut
at
iv
e 
ou
te
r m
em
br
an
e 
lip
op
ro
te
in
S
pI
I
11
11
0
0
0
0
0
D
0Z
M
Y
7_
S
A
LT
1
ya
jC
P
re
pr
ot
ei
n 
tra
ns
lo
ca
se
 s
ub
un
it 
Ya
jC
TM
H
12
11
0
0
0
0
0
D
0Z
S
I6
_S
A
LT
1
rp
sA
30
S
 ri
bo
so
m
al
 p
ro
te
in
 S
1
C
Y
T
61
10
0
35
0
12
5
11
164
D
0Z
IF
3_
S
A
LT
1
ac
cB
A
ce
ty
l-C
oA
 c
ar
bo
xy
la
se
 b
io
tin
 c
ar
bo
xy
l c
ar
rie
r
C
Y
T
17
10
6
22
0
58
81
D
0Z
P
Y
9_
S
A
LT
1
gl
pK
G
ly
ce
ro
l k
in
as
e
C
Y
T
56
10
0
16
0
11
3
56
D
0Z
W
H
2_
S
A
LT
1
fb
a
Fr
uc
to
se
-b
is
ph
os
ph
at
e 
al
do
la
se
C
Y
T
39
10
2
16
0
82
43
D
0Z
IL
5_
S
A
LT
1
rp
lC
50
S
 ri
bo
so
m
al
 p
ro
te
in
 L
3
C
Y
T
22
10
0
16
0
35
24
D
0Z
W
92
_S
A
LT
1
pp
s
P
ho
sp
ho
en
ol
py
ru
va
te
 s
yn
th
as
e
C
Y
T
87
10
0
11
0
20
7
D
0Z
Q
V
1_
S
A
LT
1
rp
lA
50
S
 ri
bo
so
m
al
 p
ro
te
in
 L
1
C
Y
T
25
10
0
2
0
15
0
D
0Z
R
N
4_
S
A
LT
1
ta
lA
Tr
an
sa
ld
ol
as
e 
A
C
Y
T
36
10
0
0
0
17
15
D
0Z
X
99
_S
A
LT
1
yg
iB
P
ut
at
iv
e 
un
ch
ar
ac
te
riz
ed
 p
ro
te
in
 y
gi
B
S
pI
23
9
0
13
0
22
0
D
0Z
W
D
6_
S
A
LT
1
ly
sS
Ly
sy
l-t
R
N
A 
sy
nt
he
ta
se
C
Y
T
58
7
0
3
0
8
0
D
0Z
U
Q
5_
S
A
LT
1
yc
fM
P
ut
at
iv
e 
ou
te
r m
em
br
an
e 
lip
op
ro
te
in
S
pI
I
23
7
0
0
0
20
0
D
0Z
X
P
4_
S
A
LT
1
ad
hP
A
lc
oh
ol
 d
eh
yd
ro
ge
na
se
C
Y
T
36
6
0
28
0
58
14
D
0Z
R
Q
1_
S
A
LT
1
pu
rC
P
ho
sp
ho
rib
os
yl
am
in
oi
m
id
az
ol
e-
su
cc
in
oc
ar
bo
xa
m
id
e 
sy
nt
ha
se
C
Y
T
27
6
2
16
0
20
15
D
0Z
JZ
2_
S
A
LT
1
lp
dA
D
ih
yd
ro
lip
oy
l d
eh
yd
ro
ge
na
se
C
Y
T
51
6
0
14
0
13
4
55
D
0Z
P
Y
3_
S
A
LT
1
tp
iA
Tr
io
se
ph
os
ph
at
e 
is
om
er
as
e
C
Y
T
27
6
0
12
0
19
29
D
0Z
M
Y
2_
S
A
LT
1
P
ut
at
iv
e 
th
io
l-a
lk
yl
 h
yd
ro
pe
ro
xi
de
 re
du
ct
as
e
C
Y
T
22
6
0
11
0
79
35
D
0Z
U
V
1_
S
A
LT
1
al
aS
A
la
ny
l-t
R
N
A 
sy
nt
he
ta
se
C
Y
T
96
6
0
3
0
20
0
D
0Z
Q
59
_S
A
LT
1
lp
tE
LP
S
-a
ss
em
bl
y 
lip
op
ro
te
in
 R
pl
B
S
pI
I
21
6
0
0
0
14
0
D
0Z
J2
0_
S
A
LT
1
hn
s
G
lo
ba
l D
N
A
-b
in
di
ng
 tr
an
sc
rip
tio
na
l d
ua
l 
re
gu
la
to
r
C
Y
T
16
5
0
18
0
0
6
D
0Z
W
11
_S
A
LT
1
ye
aG
P
ut
at
iv
e 
se
rin
e 
pr
ot
ei
n 
ki
na
se
C
Y
T
74
5
0
16
0
12
8
D
0Z
Q
J2
_S
A
LT
1
pt
a
P
ho
sp
ha
te
 a
ce
ty
ltr
an
sf
er
as
e
C
Y
T
77
5
0
11
0
35
10
D
0Z
U
Z7
_S
A
LT
1
si
tB
P
ut
at
iv
e 
AT
P
-b
in
di
ng
 p
ro
te
in
C
Y
T
30
4
0
18
0
0
0
D
0Z
X
X
7_
S
A
LT
1
pn
p
P
ol
yr
ib
on
uc
le
ot
id
e 
nu
cl
eo
tid
yl
tra
ns
fe
ra
se
C
Y
T
77
4
0
3
0
10
0
D
0Z
PA
7_
S
A
LT
1
ah
pC
A
lk
yl
 h
yd
ro
pe
ro
xi
de
 re
du
ct
as
e 
su
bu
ni
t C
C
Y
T
21
3
0
13
0
18
9
D
0Z
IB
8_
S
A
LT
1
fa
bI
E
no
yl
-(
A
cy
l c
ar
rie
r p
ro
te
in
) r
ed
uc
ta
se
C
Y
T
28
3
0
5
0
9
0
D
0Z
JZ
6_
S
A
LT
1
ac
nB
B
ifu
nc
tio
na
l a
co
ni
ta
te
 h
yd
ra
ta
se
 2
C
Y
T
94
3
0
0
0
73
4
D
0Z
S
G
4_
S
A
LT
1
se
rS
S
er
yl
-tR
N
A 
sy
nt
he
ta
se
C
Y
T
49
3
0
0
0
15
0
D
0Z
JN
5_
S
A
LT
1
ca
rA
C
ar
ba
m
oy
l-p
ho
sp
ha
te
 s
yn
th
as
e 
sm
al
l c
ha
in
C
Y
T
42
3
0
0
0
9
0
165
D
0Z
V
78
_S
A
LT
1
ar
cA
Tw
o-
co
m
po
ne
nt
 re
sp
on
se
 re
gu
la
to
r
C
Y
T
27
3
0
0
0
6
0
D
0Z
Q
N
6_
S
A
LT
1
fa
bB
3-
ox
oa
cy
l-(
A
cy
l c
ar
rie
r p
ro
te
in
) s
yn
th
as
e 
I
C
Y
T
42
2
0
12
0
44
15
D
0Z
T1
3_
S
A
LT
1
pu
rA
A
de
ny
lo
su
cc
in
at
e 
sy
nt
he
ta
se
C
Y
T
47
2
0
5
0
13
0
D
0Z
K
14
_S
A
LT
1
sl
p
P
ut
at
iv
e 
ou
te
r m
em
br
an
e 
pr
ot
ei
n
S
pI
I
21
2
0
4
0
6
0
D
0Z
J5
4_
S
A
LT
1
pr
sA
R
ib
os
e-
ph
os
ph
at
e 
py
ro
ph
os
ph
ok
in
as
e
C
Y
T
34
2
0
0
0
14
0
D
0Z
TQ
2_
S
A
LT
1
Fl
av
op
ro
te
in
 w
rb
A
C
Y
T
21
2
0
0
0
10
0
D
0Z
U
E
7_
S
A
LT
1
de
oB
P
ho
sp
ho
pe
nt
om
ut
as
e
C
Y
T
44
2
0
0
0
10
0
D
0Z
N
Z0
_S
A
LT
1
gl
nA
G
lu
ta
m
in
e 
sy
nt
he
ta
se
C
Y
T
52
0
0
34
3
69
25
D
0Z
W
35
_S
A
LT
1
ar
gD
A
ce
ty
lo
rn
ith
in
e/
su
cc
in
yl
di
am
in
op
im
el
at
e 
am
in
ot
ra
ns
fe
ra
se
C
Y
T
44
0
0
15
0
28
8
D
0Z
W
C
6_
S
A
LT
1
P
ut
at
iv
e 
pe
rip
la
sm
ic
 p
ro
te
in
S
pI
23
0
0
13
0
0
0
D
0Z
I5
3_
S
A
LT
1
hr
pA
AT
P
-d
ep
en
de
nt
 R
N
A 
he
lic
as
e 
H
rp
A
C
Y
T
14
6
0
5
12
0
0
0
D
0Z
JD
2_
S
A
LT
1
om
pR
O
sm
ol
ar
ity
 re
sp
on
se
 re
gu
la
to
r
C
Y
T
27
0
0
10
0
6
0
D
0Z
N
P
6_
S
A
LT
1
rh
o
Tr
an
sc
rip
tio
n 
te
rm
in
at
io
n 
fa
ct
or
 R
ho
C
Y
T
47
0
0
8
0
13
0
D
0Z
M
W
7_
S
A
LT
1
ilv
E
B
ra
nc
he
d-
ch
ai
n 
am
in
o 
ac
id
 a
m
in
ot
ra
ns
fe
ra
se
C
Y
T
34
0
0
7
0
6
0
D
0Z
X
Y
2_
S
A
LT
1
in
fB
Tr
an
sl
at
io
n 
in
iti
at
io
n 
fa
ct
or
 IF
-2
C
Y
T
97
0
0
5
0
25
0
D
0Z
U
P
3_
S
A
LT
1
ac
pP
A
cy
l c
ar
rie
r p
ro
te
in
C
Y
T
9
0
0
4
0
17
0
D
0Z
Q
30
_S
A
LT
1
pp
c
P
ho
sp
ho
en
ol
py
ru
va
te
 c
ar
bo
xy
la
se
C
Y
T
99
0
0
4
0
14
0
D
0Z
U
P
4_
S
A
LT
1
fa
bF
3-
ox
oa
cy
l-(
A
cy
l c
ar
rie
r p
ro
te
in
) s
yn
th
as
e 
II
S
pI
43
0
0
4
0
14
0
D
0Z
U
P
2_
S
A
LT
1
fa
bG
3-
ke
to
ac
yl
-(
A
cy
l-c
ar
rie
r-
pr
ot
ei
n)
 re
du
ct
as
e
C
Y
T
26
0
0
2
0
9
0
D
0Z
Q
H
3_
S
A
LT
1
nu
oG
N
A
D
H
-q
ui
no
ne
 o
xi
do
re
du
ct
as
e
C
Y
T
10
0
0
0
0
0
50
0
D
0Z
U
L5
_S
A
LT
1
m
ur
J
Vi
ru
le
nc
e 
fa
ct
or
 m
vi
N
TM
H
57
0
0
0
0
38
0
D
0Z
TL
7_
S
A
LT
1
so
pB
S
ec
re
te
d 
ef
fe
ct
or
 p
ro
te
in
C
Y
T
62
0
0
0
0
37
0
D
0Z
V
19
_S
A
LT
1
si
pA
S
ec
re
te
d 
ef
fe
ct
or
 p
ro
te
in
C
Y
T
74
0
0
0
0
36
0
D
0Z
K
V
8_
S
A
LT
1
cl
cA
H
(+
)/C
l(-
) e
xc
ha
ng
e 
tra
ns
po
rte
r c
lc
A
C
Y
T
50
0
0
0
0
26
0
D
0Z
K
25
_S
A
LT
1
m
an
X
M
an
no
se
-s
pe
ci
fic
 e
nz
ym
e 
IIA
B
C
Y
T
35
0
0
0
0
21
0
D
0Z
J4
3_
S
A
LT
1
kd
sA
2-
de
hy
dr
o-
3-
de
ox
yp
ho
sp
ho
oc
to
na
te
 a
ld
ol
as
e
C
Y
T
31
0
0
0
0
21
0
D
0Z
V
22
_S
A
LT
1
si
pB
Tr
an
sl
oc
at
io
n 
m
ac
hi
ne
ry
 c
om
po
ne
nt
C
Y
T
62
0
0
0
0
16
0
D
0Z
M
Z4
_S
A
LT
1
ts
x
N
uc
le
os
id
e 
ch
an
ne
l
S
pI
37
0
0
0
0
16
0
166
D
0Z
R
F0
_S
A
LT
1
dp
s
D
N
A 
st
ar
va
tio
n/
st
at
io
na
ry
 p
ha
se
 p
ro
te
ct
io
n 
pr
o
C
Y
T
19
0
0
0
0
12
0
D
0Z
N
27
_S
A
LT
1
cy
oA
C
yt
oc
hr
om
e 
o 
ub
iq
ui
no
l o
xi
da
se
 s
ub
un
it 
II
TM
H
35
0
0
0
0
9
0
D
0Z
S
I9
_S
A
LT
1
m
sb
A
Li
pi
d 
A 
ex
po
rt 
AT
P
-b
in
di
ng
/p
er
m
ea
se
 p
ro
te
in
TM
H
64
0
0
0
0
6
0
D
0Z
K
23
_S
A
LT
1
yo
aE
P
ut
at
iv
e 
in
ne
r m
em
br
an
e 
pr
ot
ei
n
TM
H
56
0
0
0
0
0
0
167
U
ni
pr
ot
 
A
cc
es
si
on
G
en
e 
N
am
e
D
es
cr
ip
tio
n
Li
po
P
M
W
 
(k
D
a)
al
k-
14
D
M
SO
al
k-
14
D
M
SO
al
k-
14
D
M
SO
D
0Z
L0
0_
S
A
LT
1
m
et
Q
D
L-
m
et
hi
on
in
e 
tra
ns
po
rte
r s
ub
st
ra
te
-b
in
di
ng
 
su
bu
ni
t
S
pI
I
29
21
9
0
58
0
25
1
0
D
0Z
TJ
5_
S
A
LT
1
om
pA
O
ut
er
 m
em
br
an
e 
pr
ot
ei
n 
A
S
pI
38
20
3
17
64
0
10
2
14
D
0Z
W
Q
1_
S
A
LT
1
lp
p
M
ur
ei
n 
lip
op
ro
te
in
S
pI
I
8
18
2
15
35
11
58
11
D
0Z
W
45
_S
A
LT
1
os
m
E
D
N
A
-b
in
di
ng
 tr
an
sc
rip
tio
na
l a
ct
iv
at
or
 O
sm
E
S
pI
I
12
15
0
0
45
0
17
3
0
D
0Z
Q
G
7_
S
A
LT
1
pa
l
P
ep
tid
og
ly
ca
n-
as
so
ci
at
ed
 o
ut
er
 m
em
br
an
e 
lip
op
ro
te
in
S
pI
I
19
14
8
2
12
1
0
26
4
11
D
0Z
N
53
_S
A
LT
1
yb
aY
P
ut
at
iv
e 
un
ch
ar
ac
te
riz
ed
 p
ro
te
in
 y
ba
Y
S
pI
I
19
12
8
0
15
0
0
27
0
0
D
0Z
P
K
7_
S
A
LT
1
om
pC
O
ut
er
 m
em
br
an
e 
po
rin
 p
ro
te
in
 C
S
pI
41
11
1
5
12
34
62
89
3
42
0
D
0Z
R
F5
_S
A
LT
1
om
pX
O
ut
er
 m
em
br
an
e 
pr
ot
ei
n 
X
S
pI
18
10
5
13
76
7
71
42
D
0Z
S
62
_S
A
LT
1
gr
oL
60
 k
D
a 
ch
ap
er
on
in
C
Y
T
57
95
28
16
4
5
74
3
22
6
D
0Z
W
X
1_
S
A
LT
1
sl
yB
P
ut
at
iv
e 
ou
te
r m
em
br
an
e 
lip
op
ro
te
in
S
pI
I
16
83
0
76
0
45
7
0
D
0Z
V
T3
_S
A
LT
1
yg
dI
P
ut
at
iv
e 
lip
op
ro
te
in
S
pI
I
8
78
0
0
0
52
0
D
0Z
V
P
5_
S
A
LT
1
en
o
E
no
la
se
C
Y
T
46
63
14
43
3
34
0
90
D
0Z
JM
1_
S
A
LT
1
P
ut
at
iv
e 
in
ne
r m
em
br
an
e 
lip
op
ro
te
in
S
pI
I
20
56
0
37
0
76
0
D
0Z
I1
3_
S
A
LT
1
P
ut
at
iv
e 
ou
te
r m
em
br
an
e 
lip
op
ro
te
in
S
pI
I
24
51
0
11
0
20
0
D
0Z
IM
2_
S
A
LT
1
fu
sA
E
lo
ng
at
io
n 
fa
ct
or
 G
C
Y
T
78
39
0
10
8
6
16
6
33
D
0Z
S
C
1_
S
A
LT
1
yb
jP
P
ut
at
iv
e 
lip
op
ro
te
in
S
pI
I
19
39
0
8
0
32
0
D
0Z
N
63
_S
A
LT
1
ac
rA
A
cr
id
in
e 
ef
flu
x 
pu
m
p
S
pI
I
42
37
0
69
0
26
5
0
D
0Z
H
Y
7_
S
A
LT
1
tra
T
C
on
ju
ga
tiv
e 
tra
ns
fe
r: 
su
rfa
ce
 e
xc
lu
si
on
S
pI
I
26
34
0
60
0
17
6
0
D
0Z
R
Q
2_
S
A
LT
1
nl
pB
Li
po
pr
ot
ei
n
S
pI
I
37
33
0
39
0
53
0
D
0Z
X
W
2_
S
A
LT
1
yr
aP
P
ut
at
iv
e 
un
ch
ar
ac
te
riz
ed
 p
ro
te
in
 y
ra
P
S
pI
I
20
29
0
25
0
52
0
D
0Z
W
18
_S
A
LT
1
ga
pA
G
ly
ce
ra
ld
eh
yd
e-
3-
ph
os
ph
at
e 
de
hy
dr
og
en
as
e
C
Y
T
36
28
0
13
6
19
25
2
11
4
E
xp
t. 
1
E
xp
t. 
2
E
xp
t. 
3
A
PP
EN
D
IX
 6
. P
ro
te
in
s 
id
en
tif
ie
d 
fro
m
 S
al
m
on
el
la
 ty
ph
im
ur
iu
m
 a
fte
r a
lk
-1
4 
la
be
lin
g 
in
 M
gM
 m
ed
ia
. O
nl
y 
pr
ot
ei
ns
 th
at
 w
er
e 
id
en
tif
ie
d 
w
ith
 2
 
un
iq
ue
 p
ep
tid
es
, a
nd
 1
0 
fo
ld
 e
nr
ic
hm
en
t i
n 
at
 le
as
t o
ne
 a
lk
-1
4 
sa
m
pl
e 
as
 c
om
pa
re
d 
to
 th
e 
D
M
S
O
 c
on
tro
l a
re
 s
ho
w
n.
 P
re
di
ct
ed
 li
po
pr
ot
ei
ns
 a
re
 
hi
gh
lig
ht
ed
 in
 y
el
lo
w
.
168
D
0Z
L9
1_
S
A
LT
1
ye
dD
P
ut
at
iv
e 
un
ch
ar
ac
te
riz
ed
 p
ro
te
in
 y
ed
D
S
pI
I
15
28
0
0
0
0
0
D
0Z
TR
7_
S
A
LT
1
yf
iO
O
ut
er
 m
em
br
an
e 
pr
ot
ei
n 
as
se
m
bl
y 
co
m
pl
ex
 
su
bu
ni
t
S
pI
I
28
26
0
3
0
6
0
D
0Z
S
H
5_
S
A
LT
1
pf
lB
P
yr
uv
at
e 
fo
rm
at
e 
ly
as
e 
I
C
Y
T
85
24
0
13
2
33
11
9
35
D
0Z
JZ
0_
S
A
LT
1
ac
eE
P
yr
uv
at
e 
de
hy
dr
og
en
as
e 
E
1 
co
m
po
ne
nt
C
Y
T
10
0
24
0
62
0
19
9
30
D
0Z
J1
7_
S
A
LT
1
ad
hE
B
ifu
nc
tio
na
l a
ce
ta
ld
eh
yd
e-
C
oA
/a
lc
oh
ol
 
de
hy
dr
og
en
as
e
C
Y
T
96
21
0
15
5
0
26
2
33
D
0Z
JG
1_
S
A
LT
1
gl
pD
G
ly
ce
ro
l-3
-p
ho
sp
ha
te
 d
eh
yd
ro
ge
na
se
C
Y
T
57
21
0
34
0
64
0
D
0Z
K
L9
_S
A
LT
1
yi
aF
P
ut
at
iv
e 
ou
te
r m
em
br
an
e 
lip
op
ro
te
in
S
pI
I
26
19
0
5
0
14
0
D
0Z
K
L6
_S
A
LT
1
yi
aD
P
ut
at
iv
e 
ou
te
r m
em
br
an
e 
lip
op
ro
te
in
S
pI
I
22
18
0
10
0
0
0
D
0Z
Q
V
4_
S
A
LT
1
rp
oB
D
N
A
-d
ire
ct
ed
 R
N
A 
po
ly
m
er
as
e 
su
bu
ni
t b
et
a
C
Y
T
15
1
17
2
15
0
58
3
D
0Z
N
V
0_
S
A
LT
1
ud
p
U
rid
in
e 
ph
os
ph
or
yl
as
e
C
Y
T
27
17
0
0
0
7
0
D
0Z
Q
T7
_S
A
LT
1
cy
sK
C
ys
te
in
e 
sy
nt
ha
se
C
Y
T
35
16
10
39
0
67
30
D
0Z
Q
V
5_
S
A
LT
1
rp
oC
D
N
A
-d
ire
ct
ed
 R
N
A 
po
ly
m
er
as
e 
su
bu
ni
t b
et
a
C
Y
T
15
5
16
0
26
0
10
1
3
D
0Z
W
H
3_
S
A
LT
1
pg
k
P
ho
sp
ho
gl
yc
er
at
e 
ki
na
se
C
Y
T
41
16
0
21
0
17
5
30
D
0Z
J5
0_
S
A
LT
1
lo
lB
O
ut
er
 m
em
br
an
e 
lip
op
ro
te
in
 L
ol
B
S
pI
I
24
16
0
19
0
0
0
D
0Z
R
81
_S
A
LT
1
gp
m
A
2,
3-
bi
sp
ho
sp
ho
gl
yc
er
at
e-
de
pe
nd
en
t 
ph
os
ph
og
ly
ce
ra
te
-d
ep
en
de
nt
 p
ho
sp
ho
gl
yc
er
at
e 
m
ut
as
e
C
Y
T
28
16
0
0
0
7
0
D
0Z
N
75
_S
A
LT
1
ht
pG
C
ha
pe
ro
ne
 p
ro
te
in
 h
tp
G
C
Y
T
72
16
0
0
0
0
0
D
0Z
Q
59
_S
A
LT
1
lp
tE
LP
S
-a
ss
em
bl
y 
lip
op
ro
te
in
 R
pl
B
S
pI
I
21
15
0
10
0
10
0
D
0Z
IC
9_
S
A
LT
1
m
dh
M
al
at
e 
de
hy
dr
og
en
as
e
S
pI
32
14
5
24
0
19
2
11
0
D
0Z
M
I7
_S
A
LT
1
gn
d
6-
ph
os
ph
og
lu
co
na
te
 d
eh
yd
ro
ge
na
se
C
Y
T
51
14
0
9
0
57
12
D
0Z
M
Y
2_
S
A
LT
1
P
ut
at
iv
e 
th
io
l-a
lk
yl
 h
yd
ro
pe
ro
xi
de
 re
du
ct
as
e
C
Y
T
22
13
2
71
3
65
32
D
0Z
W
H
2_
S
A
LT
1
fb
a
Fr
uc
to
se
-b
is
ph
os
ph
at
e 
al
do
la
se
C
Y
T
39
13
2
17
0
78
46
D
0Z
R
32
_S
A
LT
1
pg
i
G
lu
co
se
-6
-p
ho
sp
ha
te
 is
om
er
as
e
C
Y
T
61
13
5
9
0
0
0
D
0Z
R
U
1_
S
A
LT
1
yf
gL
O
ut
er
 m
em
br
an
e 
pr
ot
ei
n 
as
se
m
bl
y 
co
m
pl
ex
 
su
bu
ni
t
S
pI
I
42
12
0
28
0
34
0
D
0Z
M
T5
_S
A
LT
1
at
pD
AT
P 
sy
nt
ha
se
 s
ub
un
it 
be
ta
C
Y
T
50
12
0
9
0
24
7
10
D
0Z
U
Q
5_
S
A
LT
1
yc
fM
P
ut
at
iv
e 
ou
te
r m
em
br
an
e 
lip
op
ro
te
in
S
pI
I
23
12
0
6
0
8
0
169
D
0Z
K
Z9
_S
A
LT
1
rc
sF
O
ut
er
 m
em
br
an
e 
lip
op
ro
te
in
S
pI
I
14
12
0
6
0
8
0
D
0Z
V
90
_S
A
LT
1
ph
oP
D
N
A
-b
in
di
ng
 tr
an
sc
rip
tio
na
l r
eg
ul
at
or
 P
ho
P
C
Y
T
26
12
0
0
0
4
0
D
0Z
N
Y
5_
S
A
LT
1
he
m
N
C
op
ro
po
rp
hy
rin
og
en
 II
I o
xi
da
se
C
Y
T
53
12
0
0
0
0
0
D
0Z
U
Z6
_S
A
LT
1
si
tA
P
ut
at
iv
e 
pe
rip
la
sm
ic
 b
in
di
ng
 p
ro
te
in
S
pI
34
12
0
0
0
0
0
D
0Z
IR
2_
S
A
LT
1
dn
aK
C
ha
pe
ro
ne
 p
ro
te
in
 d
na
K
C
Y
T
69
11
0
30
0
11
6
2
D
0Z
N
29
_S
A
LT
1
ya
jG
P
ut
at
iv
e 
un
ch
ar
ac
te
riz
ed
 p
ro
te
in
 y
aj
G
S
pI
I
21
11
0
5
0
18
0
D
0Z
X
Q
1_
S
A
LT
1
om
pD
P
ut
at
iv
e 
ou
te
r m
em
br
an
e 
po
rin
S
pI
40
10
0
11
9
0
66
2
27
7
D
0Z
JZ
1_
S
A
LT
1
ac
eF
D
ih
yd
ro
lip
oa
m
id
e 
ac
et
yl
tra
ns
fe
ra
se
C
Y
T
66
10
0
39
0
52
5
D
0Z
M
T7
_S
A
LT
1
at
pA
AT
P 
sy
nt
ha
se
 s
ub
un
it 
al
ph
a
C
Y
T
55
10
0
33
0
23
0
25
D
0Z
JN
6_
S
A
LT
1
ca
rB
C
ar
ba
m
oy
l p
ho
sp
ha
te
 s
yn
th
as
e 
la
rg
e 
su
bu
ni
t
C
Y
T
11
8
10
0
13
5
17
0
D
0Z
S
49
_S
A
LT
1
ph
oN
N
on
-s
pe
ci
fic
 a
ci
d 
ph
os
ph
at
as
e
S
pI
28
10
0
0
0
0
0
D
0Z
X
P
4_
S
A
LT
1
ad
hP
A
lc
oh
ol
 d
eh
yd
ro
ge
na
se
C
Y
T
36
9
0
15
0
66
27
D
0Z
U
91
_S
A
LT
1
P
ut
at
iv
e 
N
A
D
-d
ep
en
de
nt
 a
ld
eh
yd
e 
de
hy
dr
og
en
as
e
C
Y
T
50
8
0
21
0
66
11
D
0Z
M
Z4
_S
A
LT
1
ts
x
N
uc
le
os
id
e 
ch
an
ne
l
S
pI
37
8
0
0
0
15
0
D
0Z
P
Y
3_
S
A
LT
1
tp
iA
Tr
io
se
ph
os
ph
at
e 
is
om
er
as
e
C
Y
T
27
7
0
20
0
17
20
D
0Z
PA
7_
S
A
LT
1
ah
pC
A
lk
yl
 h
yd
ro
pe
ro
xi
de
 re
du
ct
as
e 
su
bu
ni
t C
C
Y
T
21
7
0
17
0
14
5
D
0Z
JZ
2_
S
A
LT
1
lp
dA
D
ih
yd
ro
lip
oy
l d
eh
yd
ro
ge
na
se
C
Y
T
51
7
2
15
0
15
7
13
D
0Z
K
14
_S
A
LT
1
sl
p
P
ut
at
iv
e 
ou
te
r m
em
br
an
e 
pr
ot
ei
n
S
pI
I
21
7
0
10
0
21
0
D
0Z
Q
F4
_S
A
LT
1
su
cD
S
uc
ci
ny
l-C
oA
 li
ga
se
 [A
D
P
-fo
rm
in
g]
 s
ub
un
it 
al
ph
a
C
Y
T
30
7
0
2
0
23
0
D
0Z
LQ
5_
S
A
LT
1
m
gt
B
M
g2
+ 
tra
ns
po
rte
r
C
Y
T
10
0
6
0
12
6
8
12
2
6
D
0Z
TR
4_
S
A
LT
1
cl
pB
P
ro
te
in
 d
is
ag
gr
eg
at
io
n 
ch
ap
er
on
e
C
Y
T
95
6
0
22
0
81
5
D
0Z
X
99
_S
A
LT
1
yg
iB
P
ut
at
iv
e 
un
ch
ar
ac
te
riz
ed
 p
ro
te
in
 y
gi
B
S
pI
23
6
0
11
0
13
2
D
0Z
P
Y
9_
S
A
LT
1
gl
pK
G
ly
ce
ro
l k
in
as
e
C
Y
T
56
6
0
9
0
91
6
D
0Z
TQ
2_
S
A
LT
1
w
rb
A
Fl
av
op
ro
te
in
 w
rb
A
C
Y
T
21
6
0
6
0
8
0
D
0Z
S
Q
2_
S
A
LT
1
pu
rG
P
ho
sp
ho
rib
os
yl
fo
rm
yl
gl
yc
in
am
id
in
e 
sy
nt
ha
se
C
Y
T
14
1
6
0
4
0
6
0
D
0Z
R
97
_S
A
LT
1
yb
hC
P
ut
at
iv
e 
pe
ct
in
es
te
ra
se
S
pI
I
46
5
0
11
0
20
0
D
0Z
Q
Q
2_
S
A
LT
1
va
cJ
Li
po
pr
ot
ei
n
S
pI
I
28
5
0
11
0
3
0
170
D
0Z
S
P
0_
S
A
LT
1
gl
yA
S
er
in
e 
hy
dr
ox
ym
et
hy
ltr
an
sf
er
as
e
C
Y
T
45
5
0
8
0
74
4
D
0Z
W
53
_S
A
LT
1
ka
tE
C
at
al
as
e
C
Y
T
84
5
0
7
0
0
0
D
0Z
S
I6
_S
A
LT
1
rp
sA
30
S
 ri
bo
so
m
al
 p
ro
te
in
 S
1
C
Y
T
61
4
0
25
0
11
4
0
D
0Z
W
I1
_S
A
LT
1
tk
tA
Tr
an
sk
et
ol
as
e
C
Y
T
72
4
0
12
0
33
2
D
0Z
R
Q
1_
S
A
LT
1
pu
rC
P
ho
sp
ho
rib
os
yl
am
in
oi
m
id
az
ol
e-
su
cc
in
oc
ar
bo
xa
m
id
e 
sy
nt
ha
se
C
Y
T
27
4
2
10
0
14
2
D
0Z
Q
E
5_
S
A
LT
1
gl
tA
C
itr
at
e 
sy
nt
ha
se
C
Y
T
48
4
0
8
0
88
8
D
0Z
U
E
8_
S
A
LT
1
de
oD
P
ur
in
e 
nu
cl
eo
si
de
 p
ho
sp
ho
ry
la
se
 d
eo
D
-ty
pe
C
Y
T
26
4
0
2
0
10
0
D
0Z
JZ
6_
S
A
LT
1
ac
nB
B
ifu
nc
tio
na
l a
co
ni
ta
te
 h
yd
ra
ta
se
 2
C
Y
T
94
4
0
0
0
14
0
D
0Z
V
97
_S
A
LT
1
ic
dA
Is
oc
itr
at
e 
de
hy
dr
og
en
as
e 
[N
A
D
P
]
C
Y
T
46
3
0
5
0
15
9
8
D
0Z
U
E
7_
S
A
LT
1
de
oB
P
ho
sp
ho
pe
nt
om
ut
as
e
C
Y
T
44
3
0
2
0
11
0
D
0Z
M
J6
_S
A
LT
1
rfb
H
C
D
P
-6
-d
eo
xy
-D
-x
yl
o-
4-
he
xu
lo
se
-3
-d
eh
yd
ra
se
C
Y
T
48
3
0
0
0
43
3
D
0Z
U
P
3_
S
A
LT
1
ac
pP
A
cy
l c
ar
rie
r p
ro
te
in
C
Y
T
9
3
0
0
0
20
0
D
0Z
Q
60
_S
A
LT
1
le
uS
P
ut
at
iv
e 
un
ch
ar
ac
te
riz
ed
 p
ro
te
in
TM
H
10
6
2
0
6
0
17
0
D
0Z
X
Y
2_
S
A
LT
1
in
fB
Tr
an
sl
at
io
n 
in
iti
at
io
n 
fa
ct
or
 IF
-2
C
Y
T
97
2
0
5
0
10
0
D
0Z
S
K
8_
S
A
LT
1
as
nS
A
sp
ar
ag
in
yl
-tR
N
A 
sy
nt
he
ta
se
C
Y
T
53
2
0
4
0
18
0
D
0Z
S
K
4_
S
A
LT
1
as
pC
A
ro
m
at
ic
 a
m
in
o 
ac
id
 a
m
in
ot
ra
ns
fe
ra
se
C
Y
T
44
2
0
0
0
47
2
D
0Z
K
M
7_
S
A
LT
1
gl
yS
G
ly
cy
l-t
R
N
A 
sy
nt
he
ta
se
 b
et
a 
su
bu
ni
t
C
Y
T
76
2
0
0
0
16
0
D
0Z
U
V
1_
S
A
LT
1
al
aS
A
la
ny
l-t
R
N
A 
sy
nt
he
ta
se
C
Y
T
96
2
0
0
0
11
0
D
0Z
W
Q
2_
S
A
LT
1
py
kF
P
yr
uv
at
e 
ki
na
se
C
Y
T
51
0
0
41
0
61
0
D
0Z
P
B
8_
S
A
LT
1
rn
a
R
N
as
e 
I
S
pI
30
0
0
22
0
0
0
D
0Z
IL
5_
S
A
LT
1
rp
lC
50
S
 ri
bo
so
m
al
 p
ro
te
in
 L
3
C
Y
T
22
0
0
18
0
26
15
D
0Z
Q
N
6_
S
A
LT
1
fa
bB
3-
ox
oa
cy
l-(
A
cy
l c
ar
rie
r p
ro
te
in
) s
yn
th
as
e 
I
C
Y
T
42
0
0
14
0
62
3
D
0Z
N
Z0
_S
A
LT
1
gl
nA
G
lu
ta
m
in
e 
sy
nt
he
ta
se
C
Y
T
52
0
0
14
0
29
3
D
0Z
J2
0_
S
A
LT
1
hn
s
G
lo
ba
l D
N
A
-b
in
di
ng
 tr
an
sc
rip
tio
na
l d
ua
l r
eg
ul
at
or
C
Y
T
16
0
0
12
0
10
3
D
0Z
N
27
_S
A
LT
1
cy
oA
C
yt
oc
hr
om
e 
o 
ub
iq
ui
no
l o
xi
da
se
 s
ub
un
it 
II
TM
H
35
0
0
12
0
5
0
D
0Z
X
M
2_
S
A
LT
1
P
ut
at
iv
e 
S
-a
de
no
sy
lm
et
hi
on
in
e:
tR
N
A
-
rib
os
yl
tra
ns
fe
ra
se
C
Y
T
40
0
0
12
0
0
0
171
D
0Z
V
61
_S
A
LT
1
yj
jK
P
ut
at
iv
e 
A
B
C
 tr
an
sp
or
te
r A
TP
-b
in
di
ng
 p
ro
te
in
C
Y
T
62
0
0
11
0
5
0
D
0Z
Q
50
_S
A
LT
1
rlp
A
R
ar
e 
lip
op
ro
te
in
 A
S
pI
I
39
0
0
6
0
6
0
D
0Z
T1
3_
S
A
LT
1
pu
rA
A
de
ny
lo
su
cc
in
at
e 
sy
nt
he
ta
se
C
Y
T
47
0
0
5
0
9
0
D
0Z
N
P
6_
S
A
LT
1
rh
o
Tr
an
sc
rip
tio
n 
te
rm
in
at
io
n 
fa
ct
or
 R
ho
C
Y
T
47
0
0
5
0
7
0
D
0Z
Q
U
2_
S
A
LT
1
pt
sI
P
ho
sp
ho
en
ol
py
ru
va
te
-p
ro
te
in
 
ph
os
ph
ot
ra
ns
fe
ra
se
C
Y
T
63
0
0
4
0
6
0
D
0Z
LG
6_
S
A
LT
1
m
tlD
M
an
ni
to
l-1
-p
ho
sp
ha
te
 5
-d
eh
yd
ro
ge
na
se
C
Y
T
41
0
0
3
0
7
0
D
0Z
Q
H
3_
S
A
LT
1
nu
oG
N
A
D
H
-q
ui
no
ne
 o
xi
do
re
du
ct
as
e
C
Y
T
10
0
0
0
2
0
40
0
D
0Z
Q
F7
_S
A
LT
1
cy
dA
C
yt
oc
hr
om
e 
d 
te
rm
in
al
 o
xi
da
se
 p
ol
yp
ep
tid
e 
su
bu
ni
t
TM
H
58
0
0
0
0
90
0
D
0Z
J7
1_
S
A
LT
1
P
ut
at
iv
e 
ho
m
ol
og
 o
f g
lu
ta
m
ic
 d
eh
yd
ro
ge
na
se
C
Y
T
48
0
0
0
0
61
5
D
0Z
IZ
4_
S
A
LT
1
trp
B
Tr
yp
to
ph
an
 s
yn
th
as
e 
be
ta
 c
ha
in
C
Y
T
43
0
0
0
0
55
0
D
0Z
Q
E
9_
S
A
LT
1
sd
hA
S
uc
ci
na
te
 d
eh
yd
ro
ge
na
se
 fl
av
op
ro
te
in
 s
ub
un
it
C
Y
T
64
0
0
0
0
40
0
D
0Z
K
25
_S
A
LT
1
m
an
X
M
an
no
se
-s
pe
ci
fic
 e
nz
ym
e 
IIA
B
C
Y
T
35
0
0
0
0
23
0
D
0Z
Q
F2
_S
A
LT
1
su
cB
D
ih
yd
ro
lip
oa
m
id
e 
ac
et
yl
tra
ns
fe
ra
se
C
Y
T
44
0
0
0
0
21
0
D
0Z
U
P
4_
S
A
LT
1
fa
bF
3-
ox
oa
cy
l-(
A
cy
l c
ar
rie
r p
ro
te
in
) s
yn
th
as
e 
II
S
pI
43
0
0
0
0
19
0
D
0Z
R
44
_S
A
LT
1
la
m
B
M
al
to
po
rin
S
pI
51
0
0
0
0
19
0
D
0Z
V
I4
_S
A
LT
1
P
ut
at
iv
e 
m
ol
ec
ul
ar
 c
ha
pe
ro
ne
C
Y
T
18
0
0
0
0
18
0
D
0Z
IJ
1_
S
A
LT
1
rp
sD
30
S
 ri
bo
so
m
al
 p
ro
te
in
 S
4
C
Y
T
23
0
0
0
0
18
0
D
0Z
W
J6
_S
A
LT
1
m
et
K
S
-a
de
no
sy
lm
et
hi
on
in
e 
sy
nt
ha
se
C
Y
T
42
0
0
0
0
17
0
D
0Z
M
E
1_
S
A
LT
1
pd
uC
G
ly
ce
ro
l d
eh
yd
ra
ta
se
 la
rg
e 
su
bu
ni
t
C
Y
T
60
0
0
0
0
16
0
D
0Z
Q
J1
_S
A
LT
1
ac
kA
A
ce
ta
te
 k
in
as
e
C
Y
T
43
0
0
0
0
16
0
D
0Z
N
77
_S
A
LT
1
ad
k
A
de
ny
la
te
 k
in
as
e
C
Y
T
23
0
0
0
0
16
0
D
0Z
M
E
0_
S
A
LT
1
pd
uB
P
ro
pa
ne
di
ol
 u
til
iz
at
io
n 
pr
ot
ei
n 
pd
uB
C
Y
T
24
0
0
0
0
14
0
D
0Z
V
13
_S
A
LT
1
hi
lA
Tr
an
sc
rip
tio
na
l r
eg
ul
at
or
 h
ilA
C
Y
T
63
0
0
0
0
14
0
D
0Z
IF
4_
S
A
LT
1
ac
cC
A
ce
ty
l-C
oA
 c
ar
bo
xy
la
se
 b
io
tin
 c
ar
bo
xy
la
se
 
su
bu
ni
t
C
Y
T
49
0
0
0
0
14
0
D
0Z
W
Z8
_S
A
LT
1
fu
m
C
Fu
m
ar
at
e 
hy
dr
at
as
e
C
Y
T
50
0
0
0
0
13
0
D
0Z
Q
H
6_
S
A
LT
1
nu
oC
B
ifu
nc
tio
na
l N
A
D
H
:u
bi
qu
in
on
e 
ox
id
or
ed
uc
ta
se
 
su
bu
ni
t
C
Y
T
69
0
0
0
0
12
0
172
D
0Z
LJ
2_
S
A
LT
1
kb
l
2-
am
in
o-
3-
ke
to
bu
ty
ra
te
 c
oe
nz
ym
e 
A 
lig
as
e
C
Y
T
43
0
0
0
0
12
0
D
0Z
M
37
_S
A
LT
1
pr
pR
P
ro
pi
on
at
e 
ca
ta
bo
lis
m
 o
pe
ro
n 
re
gu
la
to
ry
 p
ro
te
in
C
Y
T
60
0
0
0
0
11
0
D
0Z
M
E
3_
S
A
LT
1
pd
uE
P
ro
pa
ne
di
ol
 u
til
iz
at
io
n 
de
hy
dr
at
as
e,
 s
m
al
l 
su
bu
ni
t
C
Y
T
19
0
0
0
0
10
0
D
0Z
K
A
4_
S
A
LT
1
py
kA
P
yr
uv
at
e 
ki
na
se
C
Y
T
51
0
0
0
0
10
0
D
0Z
Q
J2
_S
A
LT
1
pt
a
P
ho
sp
ha
te
 a
ce
ty
ltr
an
sf
er
as
e
C
Y
T
77
0
0
0
0
9
0
D
0Z
M
W
7_
S
A
LT
1
ilv
E
B
ra
nc
he
d-
ch
ai
n 
am
in
o 
ac
id
 a
m
in
ot
ra
ns
fe
ra
se
C
Y
T
34
0
0
0
0
9
0
D
0Z
S
I9
_S
A
LT
1
m
sb
A
Li
pi
d 
A 
ex
po
rt 
AT
P
-b
in
di
ng
/p
er
m
ea
se
 p
ro
te
in
TM
H
64
0
0
0
0
8
0
D
0Z
TE
2_
S
A
LT
1
G
ifs
y-
2 
pr
op
ha
ge
 p
ro
te
in
C
Y
T
23
0
0
0
0
0
0
D
0Z
V
L2
_S
A
LT
1
P
ut
at
iv
e 
3-
po
ly
pr
en
yl
-4
-h
yd
ro
xy
be
nz
oa
te
 
de
ca
rb
ox
yl
as
e
C
Y
T
52
0
0
0
0
0
0
P
U
TA
_S
A
LT
Y
pu
tA
B
ifu
nc
tio
na
l p
ro
te
in
 p
ut
A
C
Y
T
14
4
0
0
0
0
49
0
173
U
ni
pr
ot
 A
cc
es
si
on
G
en
e 
na
m
e
D
es
cr
ip
tio
n
# 
 U
ni
qu
e 
Pe
pt
id
es
# 
PS
M
s
C
9A
S
F4
, C
9A
S
F5
sa
gA
S
ec
re
te
d 
lip
as
e
33
44
7
C
9A
S
94
M
an
no
sy
l-g
ly
co
pr
ot
ei
n 
en
do
-b
et
a-
N
-a
ce
ty
lg
lu
co
sa
m
id
as
e 
16
10
3
C
9A
K
Y
4
P
ep
tid
og
ly
ca
n-
bi
nd
in
g 
pr
ot
ei
n 
Ly
sM
 
8
93
C
9A
Q
S
4
E
xt
ra
ce
llu
la
r s
ol
ut
e-
bi
nd
in
g 
pr
ot
ei
n 
18
92
C
9A
Q
L4
B
as
ic
 m
em
br
an
e 
lip
op
ro
te
in
 
24
85
C
9A
S
J4
N
-a
ce
ty
lm
ur
am
oy
l-L
-a
la
ni
ne
 a
m
id
as
e 
23
78
C
9A
TH
2
B
et
a-
1,
4-
N
-a
ce
ty
lm
ur
am
oy
lh
yd
ro
la
se
 
16
76
C
9A
K
Y
1
P
er
ip
la
sm
ic
 s
ol
ut
e 
bi
nd
in
g 
pr
ot
ei
n 
21
68
C
9A
Q
T6
P
er
ip
la
sm
ic
 b
in
di
ng
 p
ro
te
in
 
16
63
C
9A
N
P
2
N
-a
ce
ty
lm
ur
am
oy
l-L
-a
la
ni
ne
 a
m
id
as
e 
10
57
C
9A
P
B
3
P
ut
at
iv
e 
un
ch
ar
ac
te
riz
ed
 p
ro
te
in
 
16
56
C
9A
LQ
1
en
o
E
no
la
se
23
55
C
9A
P
J5
P
en
ic
ill
in
-b
in
di
ng
 p
ro
te
in
 
23
48
C
9A
M
B
1
S
ul
fa
ta
se
20
45
C
9A
LP
8
G
ly
ce
ra
ld
eh
yd
e-
3-
ph
os
ph
at
e 
de
hy
dr
og
en
as
e 
10
43
C
9A
Q
M
8
tu
f
E
lo
ng
at
io
n 
fa
ct
or
 T
u 
2 
13
41
C
9A
LW
6
G
ly
co
sy
l t
ra
ns
fe
ra
se
 
20
41
C
9A
R
Z3
E
xt
ra
ce
llu
la
r s
ol
ut
e-
bi
nd
in
g 
pr
ot
ei
n 
12
41
C
9A
M
G
6
ar
cA
 
A
rg
in
in
e 
de
im
in
as
e 
17
39
C
9A
M
L5
A
m
in
o 
ac
id
 A
B
C
 tr
an
sp
or
te
r 
8
36
A
PP
EN
D
IX
 7
.  
P
ro
te
in
s 
id
en
tif
ie
d 
fro
m
 E
. f
ae
ci
um
 C
om
15
 c
ul
tu
re
 s
up
er
na
ta
nt
 b
y 
m
as
s 
sp
ec
tro
m
et
ry
. P
ro
te
in
s 
lis
te
d 
ha
ve
 a
t l
ea
st
 2
 u
ni
qu
e 
pe
pt
id
es
 id
en
tif
ie
d.
 P
ro
te
in
s 
in
vo
lv
ed
 in
 p
ep
tid
og
ly
ca
n 
re
m
od
el
in
g 
ar
e 
hi
gh
lig
ht
ed
 in
 y
el
lo
w
. P
S
M
 =
 p
ep
tid
e 
sp
ec
tru
m
 m
at
ch
.
174
C
9A
S
F9
E
rfK
/Y
bi
S
/Y
cf
S
/Y
nh
G
 fa
m
ily
 p
ro
te
in
 
16
34
C
9A
S
22
FM
N
-b
in
di
ng
 p
ro
te
in
 
10
34
C
9A
P
I8
P
yr
uv
at
e 
ki
na
se
 
19
33
C
9A
LP
9
pg
k 
P
ho
sp
ho
gl
yc
er
at
e 
ki
na
se
 
13
31
C
9A
M
K
8
dn
aK
 
C
ha
pe
ro
ne
 p
ro
te
in
 D
na
K
 
23
31
C
9A
M
B
7
pg
i
G
lu
co
se
-6
-p
ho
sp
ha
te
 is
om
er
as
e
15
29
C
9A
LB
5
S
ul
fa
ta
se
 
16
29
C
9A
M
H
5
ts
f 
E
lo
ng
at
io
n 
fa
ct
or
 T
s 
11
27
C
9A
Q
B
2
Fr
uc
to
se
-b
is
ph
os
ph
at
e 
al
do
la
se
 c
la
ss
-II
 
10
25
C
9A
R
P
7
G
ly
ci
ne
 b
et
ai
ne
/L
-p
ro
lin
e 
A
B
C
 tr
an
sp
or
te
r 
9
25
C
9A
P
18
D
-a
la
ny
l-D
-a
la
ni
ne
 c
ar
bo
xy
pe
pt
id
as
e 
10
23
C
9A
P
P
4
Tr
an
sc
rip
tio
na
l r
eg
ul
at
or
 
10
23
C
9A
N
A
8
E
xt
ra
ce
llu
la
r s
ol
ut
e-
bi
nd
in
g 
pr
ot
ei
n 
17
23
C
9A
L0
1
E
xt
ra
ce
llu
la
r s
ol
ut
e-
bi
nd
in
g 
pr
ot
ei
n 
12
21
C
9A
N
Q
7
P
ep
tid
yl
-p
ro
ly
l c
is
-tr
an
s 
is
om
er
as
e 
7
20
C
9A
R
Q
9
 g
ro
E
L 
60
 k
D
a 
ch
ap
er
on
in
 
15
19
C
9A
N
B
6
E
xt
ra
ce
llu
la
r s
ol
ut
e-
bi
nd
in
g 
pr
ot
ei
n 
9
19
C
9A
TA
9
AT
P
-d
ep
en
de
nt
 C
lp
 p
ro
te
as
e 
14
18
C
9A
M
E
5
Iro
n 
co
m
po
un
d 
A
B
C
 tr
an
sp
or
te
r 
11
18
C
9A
Q
M
7
fu
sA
 
E
lo
ng
at
io
n 
fa
ct
or
 G
 
10
16
C
9A
S
40
A
B
C
 tr
an
sp
or
te
r s
ub
st
ra
te
 b
in
di
ng
 p
ro
te
in
 
10
16
C
9A
N
N
9
N
A
D
H
 o
xi
da
se
 
10
15
C
9A
M
N
8
tig
Tr
ig
ge
r f
ac
to
r
11
14
C
9A
P
M
7
P
ho
sp
ho
en
ol
py
ru
va
te
-p
ro
te
in
 p
ho
sp
ho
tra
ns
fe
ra
se
11
12
C
9A
M
G
7
O
rn
ith
in
e 
ca
rb
am
oy
ltr
an
sf
er
as
e 
7
12
175
C
9A
P
95
R
ib
os
om
al
 p
ro
te
in
 S
1 
10
12
C
9A
R
E
8
pr
sA
 
P
pi
C
-ty
pe
 p
ep
tid
yl
-p
ro
ly
l c
is
-tr
an
s 
is
om
er
as
e 
8
12
C
9A
LQ
0
tp
iA
 
Tr
io
se
ph
os
ph
at
e 
is
om
er
as
e 
6
12
C
9A
S
G
0
ld
h
L-
la
ct
at
e 
de
hy
dr
og
en
as
e 
2 
8
11
C
9A
P
R
1
P
re
di
ct
ed
 p
ro
te
in
 
5
11
C
9A
Q
P
2
rp
lE
50
S
 ri
bo
so
m
al
 p
ro
te
in
 L
5 
4
10
C
9A
N
Q
4
G
ly
ce
ra
ld
eh
yd
e-
3-
ph
os
ph
at
e 
de
hy
dr
og
en
as
e 
7
10
C
9A
PA
2
P
ep
tid
as
e 
M
20
A 
8
10
C
9A
N
B
3
P
ut
at
iv
e 
un
ch
ar
ac
te
riz
ed
 p
ro
te
in
 
5
10
C
9A
R
88
P
ep
tid
as
e 
S
1 
6
10
C
9A
P
C
1
tu
f
E
lo
ng
at
io
n 
fa
ct
or
 T
u 
1
7
9
C
9A
P
I4
6-
ph
os
ph
og
lu
co
na
te
 d
eh
yd
ro
ge
na
se
, d
ec
ar
bo
xy
la
tin
g
8
9
C
9A
Q
B
4
G
lu
ta
m
in
e 
sy
nt
he
ta
se
8
9
C
9A
N
26
H
ea
t s
ho
ck
 p
ro
te
in
3
9
C
9A
R
H
9
A
cy
ltr
an
sf
er
as
e
6
8
C
9A
L5
4
N
LP
A 
lip
op
ro
te
in
4
8
C
9A
P
P
1
C
hi
tin
-b
in
di
ng
 p
ro
te
in
6
8
C
9A
LX
9
P
ho
sp
ho
gl
uc
om
ut
as
e/
ph
os
ph
om
an
no
m
ut
as
e
7
7
C
9A
R
81
P
ep
tid
as
e 
M
20
A
5
7
C
9A
S
X
8
P
ut
at
iv
e 
un
ch
ar
ac
te
riz
ed
 p
ro
te
in
4
7
C
9A
TI
6
E
xt
ra
ce
llu
la
r s
ol
ut
e-
bi
nd
in
g 
pr
ot
ei
n
5
7
C
9A
R
T9
S
ul
fa
ta
se
6
7
C
9A
Q
P
7
rp
sE
30
S
 ri
bo
so
m
al
 p
ro
te
in
 S
5
4
6
176
C
9A
Q
K
7
gu
aA
G
M
P 
sy
nt
ha
se
 [g
lu
ta
m
in
e-
hy
dr
ol
yz
in
g]
5
6
C
9A
S
47
Fe
rr
iti
n
4
6
C
9A
N
E
7
P
ut
at
iv
e 
un
ch
ar
ac
te
riz
ed
 p
ro
te
in
2
6
C
9A
TD
5
In
tra
ce
llu
la
r p
ro
te
as
e
4
6
C
9A
Q
P
5
rp
lF
50
S
 ri
bo
so
m
al
 p
ro
te
in
 L
6
5
6
C
9A
Q
I8
O
lig
op
ep
tid
e 
bi
nd
in
g 
pr
ot
ei
n
5
6
C
9A
R
L2
rp
lK
50
S
 ri
bo
so
m
al
 p
ro
te
in
 L
11
4
5
C
9A
S
H
2
ly
sS
 
Ly
si
ne
--
tR
N
A 
lig
as
e
4
5
C
9A
M
H
7
frr
 
R
ib
os
om
e-
re
cy
cl
in
g 
fa
ct
or
5
5
C
9A
M
C
8
P
re
di
ct
ed
 p
ro
te
in
5
5
C
9A
Q
Q
1
ad
k
A
de
ny
la
te
 k
in
as
e
5
5
C
9A
R
L5
rp
lL
50
S
 ri
bo
so
m
al
 p
ro
te
in
 L
7/
L1
2
4
5
C
9A
K
W
7
N
A
D
(F
A
D
)-
de
pe
nd
en
t d
eh
yd
ro
ge
na
se
5
5
C
9A
M
30
P
ut
at
iv
e 
un
ch
ar
ac
te
riz
ed
 p
ro
te
in
4
5
C
9A
LT
5
S
ig
m
a 
54
 m
od
ul
at
io
n 
pr
ot
ei
n/
rib
os
om
al
 p
ro
te
in
 S
30
E
A
4
5
C
9A
N
78
P
ut
at
iv
e 
un
ch
ar
ac
te
riz
ed
 p
ro
te
in
5
5
C
9A
L8
5
pr
sA
P
pi
C
-ty
pe
 p
ep
tid
yl
-p
ro
ly
l c
is
-tr
an
s 
is
om
er
as
e
4
5
C
9A
N
90
C
el
l e
nv
el
op
e 
tra
ns
cr
ip
tio
na
l a
tte
nu
at
or
4
5
C
9A
S
N
4
P
ut
at
iv
e 
un
ch
ar
ac
te
riz
ed
 p
ro
te
in
3
5
C
9A
Q
M
6
rp
sG
30
S
 ri
bo
so
m
al
 p
ro
te
in
 S
7
2
4
C
9A
P
Q
3
S
up
er
ox
id
e 
di
sm
ut
as
e
3
4
C
9A
P
93
D
N
A 
bi
nd
in
g 
pr
ot
ei
n 
H
U
4
4
C
9A
Q
P
4
rp
sH
 
30
S
 ri
bo
so
m
al
 p
ro
te
in
 S
8
3
4
C
9A
S
49
rp
sI
30
S
 ri
bo
so
m
al
 p
ro
te
in
 S
9
2
4
C
9A
P
I9
pf
kA
6-
ph
os
ph
of
ru
ct
ok
in
as
e
3
4
177
C
9A
S
N
2
P
yr
id
ox
al
-d
ep
en
de
nt
 d
ec
ar
bo
xy
la
se
3
4
C
9A
Q
Q
7
rp
lQ
50
S
 ri
bo
so
m
al
 p
ro
te
in
 L
17
4
4
C
9A
N
Y
2
Tr
an
sk
et
ol
as
e
4
4
C
9A
R
X
0
S
ig
na
l p
ep
tid
as
e 
I
3
4
C
9A
Q
P
1
rp
lX
 
50
S
 ri
bo
so
m
al
 p
ro
te
in
 L
24
4
4
C
9A
Q
B
3
py
rG
 
C
TP
 s
yn
th
as
e
4
4
C
9A
LR
9
at
pD
AT
P 
sy
nt
ha
se
 F
1
4
4
C
9A
Q
M
2
gp
m
A
2,
3-
bi
sp
ho
sp
ho
gl
yc
er
at
e-
de
pe
nd
en
t p
ho
sp
ho
gl
yc
er
at
e 
m
ut
as
e 
2
2
4
C
9A
R
X
9
up
p
U
ra
ci
l p
ho
sp
ho
rib
os
yl
tra
ns
fe
ra
se
3
4
C
9A
P
R
6
P
ut
at
iv
e 
un
ch
ar
ac
te
riz
ed
 p
ro
te
in
4
4
C
9A
TB
9
C
up
in
 d
om
ai
n-
co
nt
ai
ni
ng
 p
ro
te
in
2
4
C
9A
S
G
5
S
ep
tu
m
 fo
rm
at
io
n 
in
iti
at
or
3
4
C
9A
K
X
7
P
ut
at
iv
e 
un
ch
ar
ac
te
riz
ed
 p
ro
te
in
2
4
C
9A
N
Y
1
D
ih
yd
ro
lip
oa
m
id
e 
S
-s
uc
ci
ny
ltr
an
sf
er
as
e
3
3
C
9A
LN
5
G
ly
ox
al
as
e/
bl
eo
m
yc
in
 re
si
st
an
ce
 p
ro
te
in
/d
io
xy
ge
na
se
3
3
C
9A
N
P
3
Tr
an
sk
et
ol
as
e
2
3
C
9A
R
Q
8
 g
ro
E
S
10
 k
D
a 
ch
ap
er
on
in
3
3
C
9A
Q
F3
gu
aB
In
os
in
e-
5'
-m
on
op
ho
sp
ha
te
 d
eh
yd
ro
ge
na
se
2
3
C
9A
R
L3
rp
lA
 
50
S
 ri
bo
so
m
al
 p
ro
te
in
 L
1
3
3
C
9A
Q
N
1
rp
lD
 
50
S
 ri
bo
so
m
al
 p
ro
te
in
 L
4
2
3
C
9A
LV
5
U
TP
-g
lu
co
se
-1
-p
ho
sp
ha
te
 u
rid
yl
yl
tra
ns
fe
ra
se
2
3
C
9A
R
L4
rp
lJ
50
S
 ri
bo
so
m
al
 p
ro
te
in
 L
10
3
3
C
9A
M
D
1
P
ut
at
iv
e 
un
ch
ar
ac
te
riz
ed
 p
ro
te
in
2
3
178
C
9A
P
R
5
gr
eA
Tr
an
sc
rip
tio
n 
el
on
ga
tio
n 
fa
ct
or
 g
re
A
2
3
C
9A
S
03
m
et
G
 
M
et
hi
on
yl
-tR
N
A 
sy
nt
he
ta
se
2
3
C
9A
P
54
pp
aC
P
ro
ba
bl
e 
m
an
ga
ne
se
-d
ep
en
de
nt
 in
or
ga
ni
c 
py
ro
ph
os
ph
at
as
e
2
3
C
9A
R
H
5
A
ld
o/
ke
to
 re
du
ct
as
e
2
3
C
9A
R
84
G
lu
ta
m
yl
 a
m
in
op
ep
tid
as
e
3
3
C
9A
LL
0
P
ut
at
iv
e 
un
ch
ar
ac
te
riz
ed
 p
ro
te
in
3
3
C
9A
Q
N
6
rp
sC
30
S
 ri
bo
so
m
al
 p
ro
te
in
 S
3
3
3
C
9A
LV
7
P
ut
at
iv
e 
un
ch
ar
ac
te
riz
ed
 p
ro
te
in
3
3
C
9A
N
I8
H
D
 d
om
ai
n-
co
nt
ai
ni
ng
 p
ro
te
in
3
3
C
9A
N
38
pr
sA
Fo
ld
as
e 
pr
ot
ei
n 
pr
sA
 2
2
3
C
9A
P
35
P
ut
at
iv
e 
un
ch
ar
ac
te
riz
ed
 p
ro
te
in
3
3
C
9A
Q
M
9
rp
sJ
R
ib
os
om
al
 p
ro
te
in
 S
10
2
2
C
9A
M
H
4
rp
sB
30
S
 ri
bo
so
m
al
 p
ro
te
in
 S
2
2
2
C
9A
M
N
9
cl
pX
AT
P
-d
ep
en
de
nt
 C
lp
 p
ro
te
as
e 
AT
P
-b
in
di
ng
 s
ub
un
it 
C
lp
X
2
2
C
9A
S
A
9
gl
tX
 
G
lu
ta
m
at
e-
-tR
N
A 
lig
as
e
2
2
C
9A
Q
Z1
pn
p
P
ol
yr
ib
on
uc
le
ot
id
e 
nu
cl
eo
tid
yl
tra
ns
fe
ra
se
2
2
C
9A
Q
P
6
rp
lR
50
S
 ri
bo
so
m
al
 p
ro
te
in
 L
18
2
2
C
9A
L2
2
M
13
 fa
m
ily
 p
ep
tid
as
e
2
2
C
9A
R
B
8
P
re
di
ct
ed
 p
ro
te
in
2
2
C
9A
R
X
7
gl
yA
P
yr
id
ox
al
-p
ho
sp
ha
te
-d
ep
en
de
nt
 s
er
in
e 
hy
dr
ox
ym
et
hy
ltr
an
sf
er
as
e
2
2
C
9A
Q
30
fts
Z
C
el
l d
iv
is
io
n 
pr
ot
ei
n 
fts
Z
2
2
C
9A
P
56
Fo
rm
at
e 
ac
et
yl
tra
ns
fe
ra
se
2
2
C
9A
P
C
4
2,
5-
di
de
hy
dr
og
lu
co
na
te
 re
du
ct
as
e
2
2
C
9A
P
L6
3-
ox
oa
cy
l-[
ac
yl
-c
ar
rie
r-
pr
ot
ei
n]
 s
yn
th
as
e 
2
2
2
C
9A
Q
A
9
rp
m
E
2
50
S
 ri
bo
so
m
al
 p
ro
te
in
 L
31
 ty
pe
 B
2
2
179
C
9A
M
29
D
-a
la
ny
l-D
-a
la
ni
ne
 c
ar
bo
xy
pe
pt
id
as
e
2
2
C
9A
S
N
3
ty
rS
Ty
ro
si
ne
--
tR
N
A 
lig
as
e
2
2
C
9A
N
P
1
C
ys
te
in
e 
sy
nt
ha
se
2
2
C
9A
Q
59
rp
m
A 
50
S
 ri
bo
so
m
al
 p
ro
te
in
 L
27
2
2
C
9A
Q
N
5
rp
lV
50
S
 ri
bo
so
m
al
 p
ro
te
in
 L
22
2
2
C
9A
Q
61
rp
lU
50
S
 ri
bo
so
m
al
 p
ro
te
in
 L
21
2
2
C
9A
P
L9
ac
pP
A
cy
l c
ar
rie
r p
ro
te
in
 1
2
2
C
9A
M
M
5
P
ut
at
iv
e 
un
ch
ar
ac
te
riz
ed
 p
ro
te
in
2
2
C
9A
R
S
4
na
dE
N
H
(3
)-
de
pe
nd
en
t N
A
D
(+
) s
yn
th
et
as
e
2
2
C
9A
LC
7
P
ut
at
iv
e 
un
ch
ar
ac
te
riz
ed
 p
ro
te
in
2
2
C
9A
P
38
A
B
C
 tr
an
sp
or
te
r
2
2
C
9A
S
J8
P
ut
at
iv
e 
un
ch
ar
ac
te
riz
ed
 p
ro
te
in
2
2
C
9A
LI
4
P
ut
at
iv
e 
un
ch
ar
ac
te
riz
ed
 p
ro
te
in
2
2
C
9A
N
28
P
re
di
ct
ed
 p
ro
te
in
2
2
C
9A
LC
4
Li
po
pr
ot
ei
n 
Ya
eC
2
2
C
9A
S
P
9
C
el
l w
al
l s
ur
fa
ce
 a
dh
es
io
n 
pr
ot
ei
n
2
2
C
9A
P
R
0
P
ut
at
iv
e 
un
ch
ar
ac
te
riz
ed
 p
ro
te
in
2
2
180
U
ni
pr
ot
 
A
cc
es
si
on
G
en
e 
N
am
e
D
es
cr
ip
tio
n
M
W
 (k
D
a)
U
ni
qu
e 
Pe
pt
id
es
# 
PS
M
s 
To
p 
B
an
d
# 
PS
M
s 
B
ot
to
m
 b
an
d
C
9A
S
F4
,C
9A
S
F5
sa
gA
S
ec
re
te
d 
lip
as
e
53
.6
17
10
4
13
C
9A
LL
0
P
ut
at
iv
e 
un
ch
ar
ac
te
riz
ed
 p
ro
te
in
84
.5
11
19
C
9A
P
J5
P
en
ic
ill
in
-b
in
di
ng
 p
ro
te
in
78
.3
10
18
C
9A
Q
M
7
fu
sA
E
lo
ng
at
io
n 
fa
ct
or
 G
76
.7
9
17
C
9A
S
J4
N
-a
ce
ty
lm
ur
am
oy
l-L
-a
la
ni
ne
 a
m
id
as
e
77
.3
8
12
C
9A
Q
Z1
pn
p
P
ol
yr
ib
on
uc
le
ot
id
e 
nu
cl
eo
tid
yl
tra
ns
fe
ra
se
76
.9
3
4
C
9A
N
P
3
Tr
an
sk
et
ol
as
e
72
.4
2
3
C
9A
N
Y
1
D
ih
yd
ro
lip
oa
m
id
e 
S
-s
uc
ci
ny
ltr
an
sf
er
as
e
57
.9
2
2
C
9A
N
A
8
E
xt
ra
ce
llu
la
r s
ol
ut
e-
bi
nd
in
g 
pr
ot
ei
n
45
.7
12
25
C
9A
S
94
M
an
no
sy
l-g
ly
co
pr
ot
ei
n 
en
do
-b
et
a-
N
-a
ce
ty
lg
lu
co
sa
m
id
as
e
46
.6
9
20
C
9A
LQ
1
en
o
E
no
la
se
46
.5
10
18
C
9A
P
P
4
Tr
an
sc
rip
tio
na
l r
eg
ul
at
or
42
.5
9
13
C
9A
Q
B
4
G
lu
ta
m
in
e 
sy
nt
he
ta
se
50
.6
7
11
C
9A
Q
M
8
tu
f
E
lo
ng
at
io
n 
fa
ct
or
 T
u 
2
43
.2
6
11
C
9A
TH
2
B
et
a-
1,
4-
N
-a
ce
ty
lm
ur
am
oy
lh
yd
ro
la
se
71
.0
4
9
C
9A
M
B
7
pg
i
G
lu
co
se
-6
-p
ho
sp
ha
te
 is
om
er
as
e
49
.7
6
9
C
9A
P
I4
6-
ph
os
ph
og
lu
co
na
te
 d
eh
yd
ro
ge
na
se
, d
ec
ar
bo
xy
la
tin
g
52
.7
4
7
C
9A
LB
5
S
ul
fa
ta
se
79
.1
3
6
C
9A
P
95
R
ib
os
om
al
 p
ro
te
in
 S
1
45
.7
3
5
C
9A
M
G
6
ar
cA
A
rg
in
in
e 
de
im
in
as
e
46
.1
4
5
C
9A
R
T9
S
ul
fa
ta
se
70
.9
3
5
C
9A
LR
9
at
pD
AT
P 
sy
nt
ha
se
 F
1
51
.0
2
4
C
9A
M
B
1
S
ul
fa
ta
se
80
.4
3
4
C
9A
N
E
7
P
ut
at
iv
e 
un
ch
ar
ac
te
riz
ed
 p
ro
te
in
36
.7
2
3
C
9A
Q
L4
B
as
ic
 m
em
br
an
e 
lip
op
ro
te
in
37
.8
2
2
A
PP
EN
D
IX
 8
. P
ro
te
in
s 
id
en
tif
ie
d 
by
 m
as
s 
sp
ec
tro
m
et
ry
 fr
om
 th
e 
to
p 
an
d 
bo
tto
m
 b
an
ds
 a
s 
in
di
ca
te
d 
in
 F
ig
ur
e 
4.
12
a.
181
U
ni
pr
ot
 A
cc
es
si
on
G
en
e 
N
am
e
D
es
cr
ip
tio
n
# 
U
ni
qu
e 
Pe
pt
id
es
# 
PS
M
s
C
9A
LQ
1
en
o
E
no
la
se
20
57
C
9A
S
F4
/C
9A
S
F5
sa
gA
S
ec
re
te
d 
lip
as
e
21
54
C
9A
K
Y
1
P
er
ip
la
sm
ic
 s
ol
ut
e 
bi
nd
in
g 
pr
ot
ei
n
19
43
C
9A
Q
S
4
E
xt
ra
ce
llu
la
r s
ol
ut
e-
bi
nd
in
g 
pr
ot
ei
n
20
41
C
9A
M
B
1
S
ul
fa
ta
se
14
39
C
9A
Q
T6
P
er
ip
la
sm
ic
 b
in
di
ng
 p
ro
te
in
12
37
C
9A
R
Q
9
gr
oE
L
60
 k
D
a 
ch
ap
er
on
in
17
36
C
9A
P
J5
P
en
ic
ill
in
-b
in
di
ng
 p
ro
te
in
16
31
C
9A
P
I8
P
yr
uv
at
e 
ki
na
se
15
31
C
9A
Q
M
7
fu
sA
E
lo
ng
at
io
n 
fa
ct
or
 G
11
30
C
9A
TH
2
B
et
a-
1,
4-
N
-a
ce
ty
lm
ur
am
oy
lh
yd
ro
la
se
13
29
C
9A
Q
M
8
tu
f
E
lo
ng
at
io
n 
fa
ct
or
 T
u
13
27
C
9A
TA
9
AT
P
-d
ep
en
de
nt
 C
lp
 p
ro
te
as
e
15
26
C
9A
S
94
M
an
no
sy
l-g
ly
co
pr
ot
ei
n 
en
do
-b
et
a-
N
-a
ce
ty
lg
lu
co
sa
m
id
as
e
11
26
C
9A
M
K
8
dn
aK
C
ha
pe
ro
ne
 p
ro
te
in
18
25
C
9A
M
B
7
pg
i
G
lu
co
se
-6
-p
ho
sp
ha
te
 is
om
er
as
e
11
25
C
9A
LP
9
pg
k
P
ho
sp
ho
gl
yc
er
at
e 
ki
na
se
11
24
C
9A
LP
8
G
ly
ce
ra
ld
eh
yd
e-
3-
ph
os
ph
at
e 
de
hy
dr
og
en
as
e
11
23
C
9A
M
G
7
O
rn
ith
in
e 
ca
rb
am
oy
ltr
an
sf
er
as
e
10
22
C
9A
M
H
5
ts
f
E
lo
ng
at
io
n 
fa
ct
or
 T
s
12
19
C
9A
P
B
3
P
ut
at
iv
e 
un
ch
ar
ac
te
riz
ed
 p
ro
te
in
9
18
C
9A
Q
B
2
Fr
uc
to
se
-b
is
ph
os
ph
at
e 
al
do
la
se
 c
la
ss
-II
8
18
C
9A
M
N
8
tig
Tr
ig
ge
r f
ac
to
r
10
17
C
9A
P
W
8
P
ut
at
iv
e 
un
ch
ar
ac
te
riz
ed
 p
ro
te
in
9
17
A
PP
EN
D
IX
 9
. P
ro
te
in
s 
in
 E
. f
ae
ci
um
 C
om
15
 c
ul
tu
re
 s
up
er
na
ta
nt
 id
en
tif
ie
d 
by
 m
as
s 
sp
ec
tro
m
et
ry
, a
fte
r i
n 
so
lu
tio
n 
di
ge
st
io
n.
 
P
ro
te
in
s 
lis
te
d 
ha
ve
 a
t l
ea
st
 2
 u
ni
qu
e 
pe
pt
id
es
. P
S
M
 =
 p
ep
tid
e 
sp
ec
tru
m
 m
at
ch
. P
ro
te
in
s 
in
vo
lv
ed
 in
 c
el
l w
al
l r
em
od
el
in
g 
ar
e 
hi
gh
lig
ht
ed
 in
 y
el
lo
w
. 
182
C
9A
S
N
3
ty
rS
Ty
ro
si
ne
--
tR
N
A 
lig
as
e
7
17
C
9A
P
18
D
-a
la
ny
l-D
-a
la
ni
ne
 c
ar
bo
xy
pe
pt
id
as
e
7
16
C
9A
S
J4
N
-a
ce
ty
lm
ur
am
oy
l-L
-a
la
ni
ne
 a
m
id
as
e
9
15
C
9A
M
L5
A
m
in
o 
ac
id
 A
B
C
 tr
an
sp
or
te
r
6
15
C
9A
LB
5
S
ul
fa
ta
se
8
14
C
9A
S
F9
E
rfK
/Y
bi
S
/Y
cf
S
/Y
nh
G
 fa
m
ily
 p
ro
te
in
7
14
C
9A
K
Y
4
P
ep
tid
og
ly
ca
n-
bi
nd
in
g 
pr
ot
ei
n 
Ly
sM
6
14
C
9A
N
A
8
E
xt
ra
ce
llu
la
r s
ol
ut
e-
bi
nd
in
g 
pr
ot
ei
n
8
13
C
9A
R
E
8
pr
sA
Fo
ld
as
e 
pr
ot
ei
n 
P
rs
A
6
13
C
9A
P
M
7
P
ho
sp
ho
en
ol
py
ru
va
te
-p
ro
te
in
 p
ho
sp
ho
tra
ns
fe
ra
se
9
12
C
9A
Q
N
3
rp
lB
50
S
 ri
bo
so
m
al
 p
ro
te
in
 L
2
5
12
C
9A
S
40
A
B
C
 tr
an
sp
or
te
r s
ub
st
ra
te
 b
in
di
ng
 p
ro
te
in
7
11
C
9A
N
B
6
E
xt
ra
ce
llu
la
r s
ol
ut
e-
bi
nd
in
g 
pr
ot
ei
n
6
11
C
9A
L0
1
E
xt
ra
ce
llu
la
r s
ol
ut
e-
bi
nd
in
g 
pr
ot
ei
n
5
11
C
9A
R
P
7
G
ly
ci
ne
 b
et
ai
ne
/L
-p
ro
lin
e 
A
B
C
 tr
an
sp
or
te
r
4
11
C
9A
Q
Z1
pn
p
P
ol
yr
ib
on
uc
le
ot
id
e 
nu
cl
eo
tid
yl
tra
ns
fe
ra
se
4
11
C
9A
Q
B
4
G
lu
ta
m
in
e 
sy
nt
he
ta
se
6
10
C
9A
P
W
3
P
ut
at
iv
e 
un
ch
ar
ac
te
riz
ed
 p
ro
te
in
5
10
C
9A
P
C
1
tu
f
E
lo
ng
at
io
n 
fa
ct
or
 T
u
5
10
C
9A
P
P
1
C
hi
tin
-b
in
di
ng
 p
ro
te
in
4
10
C
9A
N
Y
2
Tr
an
sk
et
ol
as
e
4
10
C
9A
TC
6
U
nc
ha
ra
ct
er
iz
ed
 p
ro
te
in
3
10
C
9A
N
P
2
N
-a
ce
ty
lm
ur
am
oy
l-L
-a
la
ni
ne
 a
m
id
as
e
5
9
C
9A
R
Y
2
C
el
l w
al
l s
ur
fa
ce
 a
dh
es
io
n 
pr
ot
ei
n
6
8
C
9A
TC
3
U
nc
ha
ra
ct
er
iz
ed
 p
ro
te
in
6
8
C
9A
LV
5
U
TP
-g
lu
co
se
-1
-p
ho
sp
ha
te
 u
rid
yl
yl
tra
ns
fe
ra
se
4
8
C
9A
Q
24
ile
S
Is
ol
eu
ci
ne
--
tR
N
A 
lig
as
e
3
8
183
C
9A
LL
0
P
ut
at
iv
e 
un
ch
ar
ac
te
riz
ed
 p
ro
te
in
6
7
C
9A
S
G
0
ld
h
L-
la
ct
at
e 
de
hy
dr
og
en
as
e
5
7
C
9A
M
G
6
ar
cA
A
rg
in
in
e 
de
im
in
as
e
5
7
C
9A
Q
K
7
gu
aA
G
M
P 
sy
nt
ha
se
 [g
lu
ta
m
in
e-
hy
dr
ol
yz
in
g]
5
7
C
9A
R
S
4
na
dE
N
H
(3
)-
de
pe
nd
en
t N
A
D
(+
) s
yn
th
et
as
e
5
7
C
9A
P
R
1
P
re
di
ct
ed
 p
ro
te
in
4
7
C
9A
R
L2
rp
lK
50
S
 ri
bo
so
m
al
 p
ro
te
in
 L
11
4
7
C
9A
S
47
Fe
rr
iti
n
4
7
C
9A
LR
9
at
pD
AT
P 
sy
nt
ha
se
 s
ub
un
it 
be
ta
4
7
C
9A
P
W
2
P
re
di
ct
ed
 p
ro
te
in
3
7
C
9A
P
L9
ac
pP
A
cy
l c
ar
rie
r p
ro
te
in
3
7
C
9A
TD
5
In
tra
ce
llu
la
r p
ro
te
as
e
3
7
C
9A
S
03
m
et
G
M
et
hi
on
in
e-
-tR
N
A 
lig
as
e
2
7
C
9A
N
N
9
N
A
D
H
 o
xi
da
se
2
7
C
9A
L8
5
pr
sA
Fo
ld
as
e 
pr
ot
ei
n 
P
rs
A
6
6
C
9A
Q
L4
B
as
ic
 m
em
br
an
e 
lip
op
ro
te
in
5
6
C
9A
S
42
rp
oC
D
N
A
-d
ire
ct
ed
 R
N
A 
po
ly
m
er
as
e 
su
bu
ni
t b
et
a'
5
6
C
9A
S
49
rp
sI
30
S
 ri
bo
so
m
al
 p
ro
te
in
 S
9
4
6
C
9A
PA
2
P
ep
tid
as
e 
M
20
A
4
6
C
9A
N
Y
3
P
yr
uv
at
e 
de
hy
dr
og
en
as
e
3
6
C
9A
Q
P
6
rp
lR
50
S
 ri
bo
so
m
al
 p
ro
te
in
 L
18
3
6
C
9A
K
W
7
N
A
D
(F
A
D
)-
de
pe
nd
en
t d
eh
yd
ro
ge
na
se
3
6
C
9A
R
84
G
lu
ta
m
yl
 a
m
in
op
ep
tid
as
e
3
6
C
9A
LQ
0
tp
iA
Tr
io
se
ph
os
ph
at
e 
is
om
er
as
e
3
6
C
9A
LX
9
P
ho
sp
ho
gl
uc
om
ut
as
e/
ph
os
ph
om
an
no
m
ut
as
e
3
6
C
9A
TF
4
C
itr
at
e 
ly
as
e 
al
ph
a 
su
bu
ni
t
3
6
C
9A
Q
P
9
rp
lO
50
S
 ri
bo
so
m
al
 p
ro
te
in
 L
15
2
6
C
9A
N
96
A
lk
yl
 h
yd
ro
pe
ro
xi
de
 re
du
ct
as
e
2
6
184
C
9A
P
R
5
gr
eA
Tr
an
sc
rip
tio
n 
el
on
ga
tio
n 
fa
ct
or
 G
re
A
2
6
C
9A
LV
9
C
at
ab
ol
ite
 c
on
tro
l p
ro
te
in
 A
4
5
C
9A
S
A
9
gl
tX
G
lu
ta
m
at
e-
-tR
N
A 
lig
as
e
4
5
C
9A
N
Q
4
G
ly
ce
ra
ld
eh
yd
e-
3-
ph
os
ph
at
e 
de
hy
dr
og
en
as
e
3
5
C
9A
P
I9
pf
kA
6-
ph
os
ph
of
ru
ct
ok
in
as
e
3
5
C
9A
S
H
2
ly
sS
Ly
si
ne
--
tR
N
A 
lig
as
e
3
5
C
9A
Q
07
P
re
di
ct
ed
 p
ro
te
in
3
5
C
9A
N
Y
1
D
ih
yd
ro
lip
oa
m
id
e 
S
-s
uc
ci
ny
ltr
an
sf
er
as
e
2
5
C
9A
S
N
4
P
ut
at
iv
e 
un
ch
ar
ac
te
riz
ed
 p
ro
te
in
2
5
C
9A
R
P
9
D
eg
V
 fa
m
ily
 p
ro
te
in
2
5
C
9A
R
L5
rp
lL
50
S
 ri
bo
so
m
al
 p
ro
te
in
 L
7/
L1
2
4
4
C
9A
R
Q
8
gr
oE
S
10
 k
D
a 
ch
ap
er
on
in
4
4
C
9A
S
41
rp
oB
D
N
A
-d
ire
ct
ed
 R
N
A 
po
ly
m
er
as
e 
su
bu
ni
t b
et
a
4
4
C
9A
Q
F3
gu
aB
In
os
in
e-
5'
-m
on
op
ho
sp
ha
te
 d
eh
yd
ro
ge
na
se
4
4
C
9A
T0
2
U
nc
ha
ra
ct
er
iz
ed
 p
ro
te
in
3
4
C
9A
P
93
D
N
A 
bi
nd
in
g 
pr
ot
ei
n 
H
U
3
4
C
9A
M
H
4
rp
sB
30
S
 ri
bo
so
m
al
 p
ro
te
in
 S
2
3
4
C
9A
N
Q
7
P
ep
tid
yl
-p
ro
ly
l c
is
-tr
an
s 
is
om
er
as
e
3
4
C
9A
R
T9
S
ul
fa
ta
se
3
4
C
9A
Q
23
zw
f
G
lu
co
se
-6
-p
ho
sp
ha
te
 1
-d
eh
yd
ro
ge
na
se
3
4
C
9A
Q
M
2
gp
m
A
2,
3-
bi
sp
ho
sp
ho
gl
yc
er
at
e-
de
pe
nd
en
t p
ho
sp
ho
gl
yc
er
at
e 
m
ut
as
e
2
4
C
9A
L7
8
C
el
l w
al
l s
ur
fa
ce
 a
nc
ho
r f
am
ily
 p
ro
te
in
2
4
C
9A
Q
N
6
rp
sC
30
S
 ri
bo
so
m
al
 p
ro
te
in
 S
3
2
4
C
9A
P
L6
3-
ox
oa
cy
l-[
ac
yl
-c
ar
rie
r-
pr
ot
ei
n]
 s
yn
th
as
e 
2
2
4
C
9A
P
Q
3
S
up
er
ox
id
e 
di
sm
ut
as
e
2
4
C
9A
Q
P
1
rp
lX
50
S
 ri
bo
so
m
al
 p
ro
te
in
 L
24
2
4
C
9A
R
81
P
ep
tid
as
e 
M
20
A
2
4
185
C
9A
R
88
P
ep
tid
as
e 
S
1
2
4
C
9A
M
29
D
-a
la
ny
l-D
-a
la
ni
ne
 c
ar
bo
xy
pe
pt
id
as
e
2
4
C
9A
P
08
xp
t
X
an
th
in
e 
ph
os
ph
or
ib
os
yl
tra
ns
fe
ra
se
2
4
C
9A
K
X
7
P
ut
at
iv
e 
un
ch
ar
ac
te
riz
ed
 p
ro
te
in
3
3
C
9A
P
I4
6-
ph
os
ph
og
lu
co
na
te
 d
eh
yd
ro
ge
na
se
, d
ec
ar
bo
xy
la
tin
g
3
3
C
9A
LU
9
P
ut
at
iv
e 
un
ch
ar
ac
te
riz
ed
 p
ro
te
in
3
3
C
9A
P
54
pp
aC
P
ro
ba
bl
e 
m
an
ga
ne
se
-d
ep
en
de
nt
 in
or
ga
ni
c 
py
ro
ph
os
ph
at
as
e
3
3
C
9A
Q
R
6
D
ak
 p
ho
sp
ha
ta
se
3
3
C
9A
P
V
0
N
-a
ce
ty
lm
ur
am
oy
l-L
-a
la
ni
ne
 a
m
id
as
e
2
3
C
9A
R
H
9
A
cy
ltr
an
sf
er
as
e
2
3
C
9A
N
Y
0
D
ih
yd
ro
lip
oy
l d
eh
yd
ro
ge
na
se
2
3
C
9A
N
P
3
Tr
an
sk
et
ol
as
e
2
3
C
9A
S
48
rp
lM
50
S
 ri
bo
so
m
al
 p
ro
te
in
 L
13
2
3
C
9A
P
V
4
P
ut
at
iv
e 
un
ch
ar
ac
te
riz
ed
 p
ro
te
in
2
3
C
9A
P
95
R
ib
os
om
al
 p
ro
te
in
 S
1
2
3
C
9A
M
30
P
ut
at
iv
e 
un
ch
ar
ac
te
riz
ed
 p
ro
te
in
2
3
C
9A
Q
25
D
iv
IV
A 
pr
ot
ei
n
2
3
C
9A
N
X
7
G
TP
-b
in
di
ng
 p
ro
te
in
 T
yp
A
2
3
C
9A
P
W
1
P
re
di
ct
ed
 p
ro
te
in
2
3
C
9A
S
27
C
el
l s
ur
fa
ce
 p
ro
te
in
 (F
ra
gm
en
t)
2
3
C
9A
Q
61
rp
lU
50
S
 ri
bo
so
m
al
 p
ro
te
in
 L
21
2
2
C
9A
Q
Z7
rp
lY
50
S
 ri
bo
so
m
al
 p
ro
te
in
 L
25
2
2
C
9A
Q
Q
1
ad
k
A
de
ny
la
te
 k
in
as
e
2
2
C
9A
LR
7
at
pA
AT
P 
sy
nt
ha
se
 s
ub
un
it 
al
ph
a
2
2
C
9A
LT
5
S
ig
m
a 
54
 m
od
ul
at
io
n 
pr
ot
ei
n/
rib
os
om
al
 p
ro
te
in
 S
30
E
A
2
2
C
9A
Q
N
4
rp
sS
30
S
 ri
bo
so
m
al
 p
ro
te
in
 S
19
2
2
C
9A
R
J0
P
ep
tid
as
e 
M
3B
2
2
C
9A
M
Q
2
ga
tB
A
sp
ar
ty
l/g
lu
ta
m
yl
-tR
N
A
(A
sn
/G
ln
) a
m
id
ot
ra
ns
fe
ra
se
 s
ub
un
it 
B
2
2
186
U
ni
pr
ot
 
A
cc
es
si
on
G
en
e 
N
am
e
D
es
cr
ip
tio
n
# 
U
ni
qu
e 
pe
pt
id
es
# 
PS
M
s
# 
U
ni
qu
e 
Pe
pt
id
es
# 
PS
M
s
F2
M
N
Y
6
S
ec
re
te
d 
an
tig
en
5
48
4
36
F2
M
P
G
2
pg
k
P
ho
sp
ho
gl
yc
er
at
e 
ki
na
se
10
24
10
13
F2
M
P
G
0
en
o
E
no
la
se
9
22
8
15
F2
M
R
31
U
nc
ha
ra
ct
er
iz
ed
 p
ro
te
in
8
16
14
47
F2
M
Q
S
5
pt
sI
P
ho
sp
ho
en
ol
py
ru
va
te
-p
ro
te
in
 p
ho
sp
ho
tra
ns
fe
ra
se
7
16
7
15
F2
M
P
K
1
P
ep
tid
e 
A
B
C
 s
up
er
fa
m
ily
 A
B
C
 tr
an
sp
or
te
r, 
bi
nd
in
g 
pr
ot
ei
n
7
15
12
23
F2
M
N
H
6
ge
lE
G
el
at
in
as
e
7
15
9
22
F2
M
Q
41
np
r
N
A
D
H
 p
er
ox
id
as
e
4
15
4
4
F2
M
N
Q
3
ht
rA
S
er
in
e 
pr
ot
ea
se
 H
trA
4
13
3
4
F2
M
Q
L1
rp
oC
D
N
A
-d
ire
ct
ed
 R
N
A 
po
ly
m
er
as
e 
su
bu
ni
t b
et
a'
7
12
5
7
F2
M
M
76
A
B
C
 s
up
er
fa
m
ily
 A
B
C
 tr
an
sp
or
te
r, 
bi
nd
in
g 
pr
ot
ei
n
6
11
10
23
F2
M
N
H
5
sp
rE
S
pr
E
 p
ro
te
in
4
11
5
20
F2
M
Q
69
ac
kA
A
ce
ta
te
 k
in
as
e
5
11
5
14
F2
M
R
21
dn
aK
C
ha
pe
ro
ne
 p
ro
te
in
 D
na
K
9
11
8
11
F2
M
TS
3
gr
oE
L
60
 k
D
a 
ch
ap
er
on
in
7
11
7
10
F2
M
M
D
6
pe
pQ
X
aa
-P
ro
 d
ip
ep
tid
as
e
4
11
4
9
F2
M
S
U
5
pg
i
G
lu
co
se
-6
-p
ho
sp
ha
te
 is
om
er
as
e
4
11
4
9
F2
M
T6
6
op
pA
O
lig
op
ep
tid
e 
A
B
C
 s
up
er
fa
m
ily
 A
B
C
 tr
an
sp
or
te
r, 
bi
nd
in
g 
pr
ot
ei
n
7
11
6
8
F2
M
R
X
7
pd
hA
P
yr
uv
at
e 
de
hy
dr
og
en
as
e 
co
m
pl
ex
 E
1 
co
m
po
ne
nt
 a
lp
ha
 s
ub
un
it
3
11
2
5
F2
M
M
98
tu
f
E
lo
ng
at
io
n 
fa
ct
or
 T
u
7
10
5
6
E.
 fa
ec
al
is
E.
 fa
ec
al
is
-s
ag
A
A
PP
EN
D
IX
 1
0.
  P
ro
te
in
s 
in
 E
. f
ae
ca
lis
 O
G
1R
F 
an
d 
E
. f
ae
ca
lis
-s
ag
A 
cu
ltu
re
 s
up
er
na
ta
nt
s 
id
en
tif
ie
d 
by
 m
as
s 
sp
ec
tro
m
et
ry
, a
fte
r i
n 
so
lu
tio
n 
di
ge
st
io
n.
 P
ro
te
in
s 
lis
te
d 
ha
ve
 a
t l
ea
st
 2
 u
ni
qu
e 
pe
pt
id
es
. P
S
M
 =
 p
ep
tid
e 
sp
ec
tru
m
 m
at
ch
. P
ro
te
in
s 
in
vo
lv
ed
 in
 c
el
l w
al
l r
em
od
el
in
g 
ar
e 
hi
gh
lig
ht
ed
 in
 y
el
lo
w
. F
2M
N
Y
6 
an
d 
S
ag
A
-H
is
6 
ar
e 
hi
gh
lig
ht
ed
 in
 o
ra
ng
e.
187
F2
M
P
U
3
Tr
an
sc
rip
tio
na
l r
eg
ul
at
or
3
9
6
10
F2
M
Q
A
4
A
B
C
 s
up
er
fa
m
ily
 A
B
C
 tr
an
sp
or
te
r, 
bi
nd
in
g 
pr
ot
ei
n
2
9
4
10
F2
M
S
T4
trx
A
Th
io
re
do
xi
n
2
9
2
10
F2
M
Q
C
6
gl
nA
G
lu
ta
m
in
e 
sy
nt
he
ta
se
5
9
4
7
F2
M
N
33
ld
h
L-
la
ct
at
e 
de
hy
dr
og
en
as
e
4
9
3
6
F2
M
R
74
A
B
C
 s
up
er
fa
m
ily
 A
B
C
 tr
an
sp
or
te
r, 
bi
nd
in
g 
pr
ot
ei
n
3
8
9
15
F2
M
R
Q
5
ly
zl
6
C
el
l w
al
l l
ys
is
 p
ro
te
in
5
8
5
8
F2
M
P
V
9
ty
rS
Ty
ro
si
ne
--
tR
N
A 
lig
as
e
5
8
2
7
F2
M
Q
H
3
ub
iD
2
U
bi
D
 fa
m
ily
 d
ec
ar
bo
xy
la
se
6
8
4
6
F2
M
Q
K
7
dp
s
D
N
A 
st
ar
va
tio
n/
st
at
io
na
ry
 p
ha
se
 p
ro
te
ct
io
n 
pr
ot
ei
n 
D
ps
5
8
4
4
F2
M
M
L0
gn
d
6-
ph
os
ph
og
lu
co
na
te
 d
eh
yd
ro
ge
na
se
, d
ec
ar
bo
xy
la
tin
g
6
8
2
3
F2
M
S
U
4
gd
hA
G
lu
ta
m
at
e 
de
hy
dr
og
en
as
e
4
7
6
10
F2
M
Q
H
5
W
xL
 d
om
ai
n 
su
rfa
ce
 p
ro
te
in
3
7
3
6
F2
M
Q
03
fb
aB
Fr
uc
to
se
-b
is
ph
os
ph
at
e 
al
do
la
se
3
7
3
5
F2
M
R
X
1
S
ug
ar
 A
B
C
 s
up
er
fa
m
ily
 A
B
C
 tr
an
sp
or
te
r, 
su
ga
r-
bi
nd
in
g 
pr
ot
ei
n
5
7
3
5
F2
M
M
C
3
ad
k
A
de
ny
la
te
 k
in
as
e
3
7
2
4
F2
M
Q
X
6
S
ul
fa
ta
se
 d
om
ai
n 
pr
ot
ei
n
5
6
8
15
F2
M
R
L8
gl
nP
A
m
in
o 
ac
id
 A
B
C
 s
up
er
fa
m
ily
 A
B
C
 tr
an
sp
or
te
r, 
bi
nd
in
g/
pe
rm
ea
se
 
pr
ot
ei
n
3
6
4
8
F2
M
R
Y
0
lp
d
D
ih
yd
ro
lip
oy
l d
eh
yd
ro
ge
na
se
4
6
3
7
F2
M
N
60
fa
bF
3-
ox
oa
cy
l-[
ac
yl
-c
ar
rie
r-
pr
ot
ei
n]
 s
yn
th
as
e 
2
3
6
3
5
F2
M
M
K
6
pf
kA
6-
ph
os
ph
of
ru
ct
ok
in
as
e
4
6
3
4
F2
M
Q
T2
fru
K
2
Ta
ga
to
se
-6
-p
ho
sp
ha
te
 k
in
as
e
2
6
2
4
F2
M
TK
3
nd
h
N
A
D
H
 d
eh
yd
ro
ge
na
se
3
6
2
4
F2
M
M
R
7
cc
pA
C
at
ab
ol
ite
 c
on
tro
l p
ro
te
in
 A
4
6
3
3
F2
M
TG
7
hu
p
D
N
A
-b
in
di
ng
 p
ro
te
in
 H
U
3
6
2
2
F2
M
M
84
de
oB
P
ho
sp
ho
pe
nt
om
ut
as
e
3
5
4
6
F2
M
R
Y
7
H
yd
ro
xy
m
et
hy
lg
lu
ta
ry
l-C
oA
 s
yn
th
as
e
2
5
2
5
F2
M
TV
6
pf
lB
Fo
rm
at
e 
ac
et
yl
tra
ns
fe
ra
se
4
5
3
4
188
F2
M
M
91
ad
h3
P
ut
at
iv
e 
al
co
ho
l d
eh
yd
ro
ge
na
se
 (N
A
D
P
(+
))
2
4
3
7
F2
M
TA
8
pt
a
P
ho
sp
ha
te
 a
ce
ty
ltr
an
sf
er
as
e
3
4
3
4
F2
M
R
X
8
pd
hB
P
yr
uv
at
e 
de
hy
dr
og
en
as
e 
co
m
pl
ex
 E
1 
co
m
po
ne
nt
 b
et
a 
su
bu
ni
t
3
4
2
2
F2
M
S
34
frr
R
ib
os
om
e-
re
cy
cl
in
g 
fa
ct
or
4
4
2
2
F2
M
S
37
rp
sB
30
S
 ri
bo
so
m
al
 p
ro
te
in
 S
2
3
4
2
2
F2
M
TE
1
U
nc
ha
ra
ct
er
iz
ed
 p
ro
te
in
2
3
4
10
F2
M
R
B
6
P
he
ro
m
on
e 
cA
D
1 
lip
op
ro
te
in
2
3
3
3
F2
M
T5
9
aa
d
A
ld
eh
yd
e-
al
co
ho
l d
eh
yd
ro
ge
na
se
2
2
10
18
F2
M
R
B
5
Th
ia
m
in
e 
bi
os
yn
th
es
is
 li
po
pr
ot
ei
n
2
2
3
5
F2
M
TQ
5
at
pA
2
AT
P 
sy
nt
ha
se
 s
ub
un
it 
al
ph
a
2
2
2
3
F2
M
U
99
ah
pC
P
er
ox
ire
do
xi
n
2
2
2
3
F2
M
M
92
gp
m
A
2,
3-
bi
sp
ho
sp
ho
gl
yc
er
at
e-
de
pe
nd
en
t p
ho
sp
ho
gl
yc
er
at
e 
m
ut
as
e
2
2
2
2
F2
M
N
I5
W
xL
 d
om
ai
n 
su
rfa
ce
 p
ro
te
in
0
0
5
69
F2
M
N
H
1
P
ho
sp
ha
tid
yl
gl
yc
er
ol
--
m
em
br
an
e-
ol
ig
os
ac
ch
ar
id
e 
gl
yc
er
op
ho
sp
ho
tra
ns
fe
ra
se
0
0
9
28
F2
M
M
F2
pb
pC
P
en
ic
ill
in
-b
in
di
ng
 p
ro
te
in
 C
0
0
9
19
F2
M
N
V
6
C
hi
tin
-b
in
di
ng
 p
ro
te
in
/c
ar
bo
hy
dr
at
e-
bi
nd
in
g 
pr
ot
ei
n
0
0
6
17
F2
M
U
F4
pe
nA
P
en
ic
ill
in
-b
in
di
ng
 p
ro
te
in
 2
B
0
0
11
15
F2
M
R
A
7
C
el
l-e
nv
el
op
e 
as
so
ci
at
ed
 a
ci
d 
ph
os
ph
at
as
e
0
0
5
8
F2
M
TN
5
pm
i
M
an
no
se
-6
-p
ho
sp
ha
te
 is
om
er
as
e
0
0
4
8
F2
M
S
L7
op
uC
C
G
ly
ci
ne
/b
et
ai
ne
/c
ar
ni
tin
e/
ch
ol
in
e 
A
B
C
 s
up
er
fa
m
ily
 A
B
C
 
tra
ns
po
rte
r, 
bi
nd
in
g 
pr
ot
ei
n
0
0
3
7
F2
M
U
67
Tr
an
sc
rip
tio
na
l r
eg
ul
at
or
0
0
6
6
F2
M
S
22
pr
oS
P
ro
lin
e-
-tR
N
A 
lig
as
e
0
0
2
5
F2
M
M
R
4
pb
p1
B
P
en
ic
ill
in
-b
in
di
ng
 p
ro
te
in
 1
B
0
0
3
4
F2
M
M
V
9
A
B
C
 s
up
er
fa
m
ily
 A
B
C
 tr
an
sp
or
te
r, 
su
bs
tra
te
-b
in
di
ng
 p
ro
te
in
0
0
3
4
xx
xx
xx
S
ag
A
-H
is
6
0
0
3
4
F2
M
TQ
3
at
pD
2
AT
P 
sy
nt
ha
se
 s
ub
un
it 
be
ta
0
0
2
4
F2
M
M
X
1
pa
bC
A
m
in
od
eo
xy
ch
or
is
m
at
e 
ly
as
e
0
0
3
3
189
F2
M
N
F9
U
nc
ha
ra
ct
er
iz
ed
 p
ro
te
in
0
0
3
3
F2
M
Q
M
9
pe
pV
D
ip
ep
tid
as
e 
P
ep
V
0
0
3
3
F2
M
TH
6
U
nc
ha
ra
ct
er
iz
ed
 p
ro
te
in
0
0
3
3
F2
M
P
85
dk
gB
2,
5-
di
ke
to
-D
-g
lu
co
na
te
 re
du
ct
as
e
0
0
2
3
F2
M
Q
25
U
nc
ha
ra
ct
er
iz
ed
 p
ro
te
in
0
0
2
3
F2
M
R
N
8
A
cy
ltr
an
sf
er
as
e
0
0
2
3
F2
M
TE
4
ga
p
G
ly
ce
ra
ld
eh
yd
e-
3-
ph
os
ph
at
e 
de
hy
dr
og
en
as
e
0
0
2
3
F2
M
U
19
S
41
A 
fa
m
ily
 c
ar
bo
xy
-te
rm
in
al
 p
ep
tid
as
e
0
0
2
3
F2
M
M
97
fu
sA
E
lo
ng
at
io
n 
fa
ct
or
 G
0
0
2
2
F2
M
N
V
5
ch
iC
C
hi
tin
as
e 
C
1
0
0
2
2
F2
M
P
G
1
tp
iA
Tr
io
se
ph
os
ph
at
e 
is
om
er
as
e
0
0
2
2
F2
M
S
G
8
ar
cA
A
rg
in
in
e 
de
im
in
as
e
0
0
2
2
F2
M
T4
1
gl
yA
S
er
in
e 
hy
dr
ox
ym
et
hy
ltr
an
sf
er
as
e
0
0
2
2
F2
M
P
W
0
D
ec
ar
bo
xy
la
se
10
28
0
0
F2
M
R
04
U
nc
ha
ra
ct
er
iz
ed
 p
ro
te
in
9
17
0
0
F2
M
M
N
0
ps
tS
P
ho
sp
ha
te
 A
B
C
 s
up
er
fa
m
ily
 A
B
C
 tr
an
sp
or
te
r, 
bi
nd
in
g 
pr
ot
ei
n
6
13
0
0
F2
M
T4
7
Fu
m
ar
at
e 
re
du
ct
as
e
6
9
0
0
F2
M
M
K
7
py
k
P
yr
uv
at
e 
ki
na
se
5
7
0
0
F2
M
Q
L2
rp
oB
D
N
A
-d
ire
ct
ed
 R
N
A 
po
ly
m
er
as
e 
su
bu
ni
t b
et
a
4
7
0
0
F2
M
TJ
8
tk
t
Tr
an
sk
et
ol
as
e
3
7
0
0
F2
M
M
A
5
rp
lB
50
S
 ri
bo
so
m
al
 p
ro
te
in
 L
2
3
6
0
0
F2
M
P
87
gl
oA
5
La
ct
oy
lg
lu
ta
th
io
ne
 ly
as
e
3
6
0
0
F2
M
Q
H
1
ub
iD
U
bi
D
 fa
m
ily
 d
ec
ar
bo
xy
la
se
2
6
0
0
F2
M
U
24
co
aC
P
ho
sp
ho
pa
nt
ot
he
no
yl
cy
st
ei
ne
 d
ec
ar
bo
xy
la
se
2
6
0
0
F2
M
R
I2
rp
lI
50
S
 ri
bo
so
m
al
 p
ro
te
in
 L
9
4
5
0
0
F2
M
R
M
7
cl
pP
AT
P
-d
ep
en
de
nt
 C
lp
 p
ro
te
as
e 
pr
ot
eo
ly
tic
 s
ub
un
it
4
5
0
0
F2
M
R
Q
6
le
uS
Le
uc
in
e-
-tR
N
A 
lig
as
e
3
5
0
0
F2
M
M
X
0
gr
eA
Tr
an
sc
rip
tio
n 
el
on
ga
tio
n 
fa
ct
or
 G
re
A
2
5
0
0
190
F2
M
N
Z2
pc
p
P
yr
ro
lid
on
e-
ca
rb
ox
yl
at
e 
pe
pt
id
as
e
2
5
0
0
F2
M
U
79
rp
lK
50
S
 ri
bo
so
m
al
 p
ro
te
in
 L
11
2
5
0
0
F2
M
M
N
1
as
pC
2
A
m
in
ot
ra
ns
fe
ra
se
3
4
0
0
F2
M
Q
K
0
C
ho
lin
e 
bi
nd
in
g 
pr
ot
ei
n
3
4
0
0
F2
M
Q
K
6
rp
lM
50
S
 ri
bo
so
m
al
 p
ro
te
in
 L
13
2
4
0
0
F2
M
Q
V
8
G
fo
/Id
h/
M
oc
A 
fa
m
ily
 o
xi
do
re
du
ct
as
e
2
4
0
0
F2
M
T7
3
in
fC
Tr
an
sl
at
io
n 
in
iti
at
io
n 
fa
ct
or
 IF
-3
2
4
0
0
F2
M
M
A
3
rp
lD
50
S
 ri
bo
so
m
al
 p
ro
te
in
 L
4
3
3
0
0
F2
M
Q
Q
0
pr
sA
Fo
ld
as
e 
pr
ot
ei
n 
P
rs
A
3
3
0
0
F2
M
R
57
pe
pS
A
m
in
op
ep
tid
as
e 
P
ep
S
2
3
0
0
F2
M
S
C
3
pu
rR
P
ur
in
e 
op
er
on
 re
pr
es
so
r
2
3
0
0
F2
M
M
66
gu
aA
G
M
P 
sy
nt
ha
se
 [g
lu
ta
m
in
e-
hy
dr
ol
yz
in
g]
2
2
0
0
F2
M
M
95
rp
sL
30
S
 ri
bo
so
m
al
 p
ro
te
in
 S
12
2
2
0
0
F2
M
M
A
1
rp
sJ
30
S
 ri
bo
so
m
al
 p
ro
te
in
 S
10
2
2
0
0
F2
M
M
A
2
rp
lC
50
S
 ri
bo
so
m
al
 p
ro
te
in
 L
3
2
2
0
0
F2
M
M
A
6
rp
sS
30
S
 ri
bo
so
m
al
 p
ro
te
in
 S
19
2
2
0
0
F2
M
M
A
8
rp
sC
30
S
 ri
bo
so
m
al
 p
ro
te
in
 S
3
2
2
0
0
F2
M
M
B
9
rp
sE
30
S
 ri
bo
so
m
al
 p
ro
te
in
 S
5
2
2
0
0
F2
M
M
D
3
rp
m
A
50
S
 ri
bo
so
m
al
 p
ro
te
in
 L
27
2
2
0
0
F2
M
N
V
0
pe
pC
A
m
in
op
ep
tid
as
e 
C
2
2
0
0
F2
M
PA
1
rp
lS
50
S
 ri
bo
so
m
al
 p
ro
te
in
 L
19
2
2
0
0
F2
M
Q
T1
fru
A
P
TS
 fa
m
ily
 fr
uc
to
se
 p
or
te
r, 
IIA
B
C
 c
om
po
ne
nt
2
2
0
0
F2
M
R
X
9
ac
eF
P
yr
uv
at
e 
de
hy
dr
og
en
as
e 
co
m
pl
ex
 E
2,
 d
ih
yd
ro
lip
oa
m
id
e 
ac
et
yl
tra
ns
fe
ra
se
2
2
0
0
F2
M
TV
4
pp
aC
P
ro
ba
bl
e 
m
an
ga
ne
se
-d
ep
en
de
nt
 in
or
ga
ni
c 
py
ro
ph
os
ph
at
as
e
2
2
0
0
F2
M
U
40
pe
pF
O
lig
oe
nd
op
ep
tid
as
e 
F
2
2
0
0
F2
M
U
A
4
ce
lM
M
42
 fa
m
ily
 g
lu
ta
m
yl
 a
m
in
op
ep
tid
as
e
2
2
0
0
191
192	  
REFERENCES. 
1 Chung, H. et al. Gut immune maturation depends on colonization with a host-
specific microbiota. Cell 149, 1578-1593, doi:10.1016/j.cell.2012.04.037 (2012). 
2 Caballero, S. & Pamer, E. G. Microbiota-Mediated Inflammation and 
Antimicrobial Defense in the Intestine. Annu Rev Immunol, doi:10.1146/annurev-
immunol-032713-120238 (2015). 
3 Kamada, N., Chen, G. Y., Inohara, N. & Nunez, G. Control of pathogens and 
pathobionts by the gut microbiota. Nat Immunol 14, 685-690, doi:10.1038/ni.2608 
(2013). 
4 Kamada, N., Seo, S. U., Chen, G. Y. & Nunez, G. Role of the gut microbiota in 
immunity and inflammatory disease. Nat Rev Immunol 13, 321-335, 
doi:10.1038/nri3430 (2013). 
5 Human Microbiome Project, C. Structure, function and diversity of the healthy 
human microbiome. Nature 486, 207-214, doi:10.1038/nature11234 (2012). 
6 Shreiner, A., Huffnagle, G. B. & Noverr, M. C. The "Microflora Hypothesis" of 
allergic disease. Adv Exp Med Biol 635, 113-134, doi:10.1007/978-0-387-09550-
9_10 (2008). 
7 Wen, L. et al. Innate immunity and intestinal microbiota in the development of 
Type 1 diabetes. Nature 455, 1109-1113, doi:10.1038/nature07336 (2008). 
8 Turnbaugh, P. J. et al. An obesity-associated gut microbiome with increased 
capacity for energy harvest. Nature 444, 1027-1031, doi:10.1038/nature05414 
(2006). 
193	  
9 Nell, S., Suerbaum, S. & Josenhans, C. The impact of the microbiota on the 
pathogenesis of IBD: lessons from mouse infection models. Nat Rev Microbiol 8, 
564-577, doi:10.1038/nrmicro2403 (2010). 
10 Sekirov, I. et al. Antibiotic-induced perturbations of the intestinal microbiota alter 
host susceptibility to enteric infection. Infect Immun 76, 4726-4736, 
doi:10.1128/IAI.00319-08 (2008). 
11 Endt, K. et al. The microbiota mediates pathogen clearance from the gut lumen 
after non-typhoidal Salmonella diarrhea. PLoS Pathog 6, e1001097, 
doi:10.1371/journal.ppat.1001097 (2010). 
12 Buffie, C. G. & Pamer, E. G. Microbiota-mediated colonization resistance against 
intestinal pathogens. Nat Rev Immunol 13, 790-801, doi:10.1038/nri3535 (2013). 
13 Chu, H. & Mazmanian, S. K. Innate immune recognition of the microbiota 
promotes host-microbial symbiosis. Nat Immunol 14, 668-675, 
doi:10.1038/ni.2635 (2013). 
14 Gantois, I. et al. Butyrate specifically down-regulates salmonella pathogenicity 
island 1 gene expression. Appl Environ Microbiol 72, 946-949, 
doi:10.1128/AEM.72.1.946-949.2006 (2006). 
15 Hung, C. C. et al. The intestinal fatty acid propionate inhibits Salmonella invasion 
through the post-translational control of HilD. Mol Microbiol 87, 1045-1060, 
doi:10.1111/mmi.12149 (2013). 
16 Lawhon, S. D., Maurer, R., Suyemoto, M. & Altier, C. Intestinal short-chain fatty 
acids alter Salmonella typhimurium invasion gene expression and virulence 
through BarA/SirA. Mol Microbiol 46, 1451-1464 (2002). 
  194	  
17 Pacheco, A. R. et al. Fucose sensing regulates bacterial intestinal colonization. 
Nature 492, 113-117, doi:10.1038/nature11623 (2012). 
18 Buffie, C. G. et al. Precision microbiome reconstitution restores bile acid 
mediated resistance to Clostridium difficile. Nature 517, 205-208, 
doi:10.1038/nature13828 (2015). 
19 Lebeer, S., Vanderleyden, J. & De Keersmaecker, S. C. Genes and molecules of 
lactobacilli supporting probiotic action. Microbiol Mol Biol Rev 72, 728-764, 
Table of Contents, doi:10.1128/MMBR.00017-08 (2008). 
20 Kleerebezem, M. et al. The extracellular biology of the lactobacilli. FEMS 
Microbiol Rev 34, 199-230, doi:10.1111/j.1574-6976.2010.00208.x (2010). 
21 Peterson, L. W. & Artis, D. Intestinal epithelial cells: regulators of barrier 
function and immune homeostasis. Nat Rev Immunol 14, 141-153, 
doi:10.1038/nri3608 (2014). 
22 Johansson, M. E. et al. The inner of the two Muc2 mucin-dependent mucus layers 
in colon is devoid of bacteria. Proc Natl Acad Sci U S A 105, 15064-15069, 
doi:10.1073/pnas.0803124105 (2008). 
23 Ivanov, II et al. Induction of intestinal Th17 cells by segmented filamentous 
bacteria. Cell 139, 485-498, doi:10.1016/j.cell.2009.09.033 (2009). 
24 Mazmanian, S. K., Round, J. L. & Kasper, D. L. A microbial symbiosis factor 
prevents intestinal inflammatory disease. Nature 453, 620-625, 
doi:10.1038/nature07008 (2008). 
  195	  
25 Round, J. L. & Mazmanian, S. K. Inducible Foxp3+ regulatory T-cell 
development by a commensal bacterium of the intestinal microbiota. Proc Natl 
Acad Sci U S A 107, 12204-12209, doi:10.1073/pnas.0909122107 (2010). 
26 Mazmanian, S. K., Liu, C. H., Tzianabos, A. O. & Kasper, D. L. An 
immunomodulatory molecule of symbiotic bacteria directs maturation of the host 
immune system. Cell 122, 107-118, doi:10.1016/j.cell.2005.05.007 (2005). 
27 Akira, S. & Takeda, K. Toll-like receptor signalling. Nat Rev Immunol 4, 499-
511, doi:10.1038/nri1391 (2004). 
28 Philpott, D. J., Sorbara, M. T., Robertson, S. J., Croitoru, K. & Girardin, S. E. 
NOD proteins: regulators of inflammation in health and disease. Nat Rev Immunol 
14, 9-23, doi:10.1038/nri3565 (2014). 
29 de Zoete, M. R. & Flavell, R. A. Interactions between Nod-Like Receptors and 
Intestinal Bacteria. Front Immunol 4, 462, doi:10.3389/fimmu.2013.00462 
(2013). 
30 Dambuza, I. M. & Brown, G. D. C-type lectins in immunity: recent 
developments. Curr Opin Immunol 32C, 21-27, doi:10.1016/j.coi.2014.12.002 
(2015). 
31 Rakoff-Nahoum, S., Paglino, J., Eslami-Varzaneh, F., Edberg, S. & Medzhitov, 
R. Recognition of commensal microflora by toll-like receptors is required for 
intestinal homeostasis. Cell 118, 229-241, doi:10.1016/j.cell.2004.07.002 (2004). 
32 Lebeer, S., Vanderleyden, J. & De Keersmaecker, S. C. Host interactions of 
probiotic bacterial surface molecules: comparison with commensals and 
pathogens. Nat Rev Microbiol 8, 171-184, doi:10.1038/nrmicro2297 (2010). 
  196	  
33 Mohamadzadeh, M. et al. Regulation of induced colonic inflammation by 
Lactobacillus acidophilus deficient in lipoteichoic acid. Proc Natl Acad Sci U S A 
108 Suppl 1, 4623-4630, doi:10.1073/pnas.1005066107 (2011). 
34 Grangette, C. et al. Enhanced antiinflammatory capacity of a Lactobacillus 
plantarum mutant synthesizing modified teichoic acids. Proc Natl Acad Sci U S A 
102, 10321-10326, doi:10.1073/pnas.0504084102 (2005). 
35 Macho Fernandez, E. et al. Anti-inflammatory capacity of selected lactobacilli in 
experimental colitis is driven by NOD2-mediated recognition of a specific 
peptidoglycan-derived muropeptide. Gut 60, 1050-1059, 
doi:10.1136/gut.2010.232918 (2011). 
36 Kinnebrew, M. A. et al. Interleukin 23 production by intestinal 
CD103(+)CD11b(+) dendritic cells in response to bacterial flagellin enhances 
mucosal innate immune defense. Immunity 36, 276-287, 
doi:10.1016/j.immuni.2011.12.011 (2012). 
37 Kinnebrew, M. A. et al. Bacterial flagellin stimulates Toll-like receptor 5-
dependent defense against vancomycin-resistant Enterococcus infection. J Infect 
Dis 201, 534-543, doi:10.1086/650203 (2010). 
38 Konstantinov, S. R. et al. S layer protein A of Lactobacillus acidophilus NCFM 
regulates immature dendritic cell and T cell functions. Proc Natl Acad Sci U S A 
105, 19474-19479, doi:10.1073/pnas.0810305105 (2008). 
39 Petersson, J. et al. Importance and regulation of the colonic mucus barrier in a 
mouse model of colitis. Am J Physiol Gastrointest Liver Physiol 300, G327-333, 
doi:10.1152/ajpgi.00422.2010 (2011). 
  197	  
40 Mack, D. R., Ahrne, S., Hyde, L., Wei, S. & Hollingsworth, M. A. Extracellular 
MUC3 mucin secretion follows adherence of Lactobacillus strains to intestinal 
epithelial cells in vitro. Gut 52, 827-833 (2003). 
41 Macpherson, A. J. & Uhr, T. Induction of protective IgA by intestinal dendritic 
cells carrying commensal bacteria. Science 303, 1662-1665, 
doi:10.1126/science.1091334 (2004). 
42 Bevins, C. L. & Salzman, N. H. Paneth cells, antimicrobial peptides and 
maintenance of intestinal homeostasis. Nat Rev Microbiol 9, 356-368, 
doi:10.1038/nrmicro2546 (2011). 
43 Cash, H. L., Whitham, C. V., Behrendt, C. L. & Hooper, L. V. Symbiotic bacteria 
direct expression of an intestinal bactericidal lectin. Science 313, 1126-1130, 
doi:10.1126/science.1127119 (2006). 
44 Vaishnava, S., Behrendt, C. L., Ismail, A. S., Eckmann, L. & Hooper, L. V. 
Paneth cells directly sense gut commensals and maintain homeostasis at the 
intestinal host-microbial interface. Proc Natl Acad Sci U S A 105, 20858-20863, 
doi:10.1073/pnas.0808723105 (2008). 
45 Vaishnava, S. et al. The antibacterial lectin RegIIIgamma promotes the spatial 
segregation of microbiota and host in the intestine. Science 334, 255-258, 
doi:10.1126/science.1209791 (2011). 
46 Schlee, M. et al. Induction of human beta-defensin 2 by the probiotic Escherichia 
coli Nissle 1917 is mediated through flagellin. Infect Immun 75, 2399-2407, 
doi:10.1128/IAI.01563-06 (2007). 
  198	  
47 Wehkamp, J. et al. NF-kappaB- and AP-1-mediated induction of human beta 
defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917: a novel 
effect of a probiotic bacterium. Infect Immun 72, 5750-5758, 
doi:10.1128/IAI.72.10.5750-5758.2004 (2004). 
48 Kobayashi, K. S. et al. Nod2-dependent regulation of innate and adaptive 
immunity in the intestinal tract. Science 307, 731-734, 
doi:10.1126/science.1104911 (2005). 
49 Anderson, R. C. et al. Lactobacillus plantarum MB452 enhances the function of 
the intestinal barrier by increasing the expression levels of genes involved in tight 
junction formation. BMC Microbiol 10, 316, doi:10.1186/1471-2180-10-316 
(2010). 
50 Karczewski, J. et al. Regulation of human epithelial tight junction proteins by 
Lactobacillus plantarum in vivo and protective effects on the epithelial barrier. 
Am J Physiol Gastrointest Liver Physiol 298, G851-859, 
doi:10.1152/ajpgi.00327.2009 (2010). 
51 Qin, H., Zhang, Z., Hang, X. & Jiang, Y. L. plantarum prevents enteroinvasive 
Escherichia coli-induced tight junction proteins changes in intestinal epithelial 
cells. BMC Microbiol 9, 63, doi:10.1186/1471-2180-9-63 (2009). 
52 Bansal, T., Alaniz, R. C., Wood, T. K. & Jayaraman, A. The bacterial signal 
indole increases epithelial-cell tight-junction resistance and attenuates indicators 
of inflammation. Proc Natl Acad Sci U S A 107, 228-233, 
doi:10.1073/pnas.0906112107 (2010). 
  199	  
53 Shimada, Y. et al. Commensal bacteria-dependent indole production enhances 
epithelial barrier function in the colon. PLoS One 8, e80604, 
doi:10.1371/journal.pone.0080604 (2013). 
54 Yan, F. et al. Soluble proteins produced by probiotic bacteria regulate intestinal 
epithelial cell survival and growth. Gastroenterology 132, 562-575, 
doi:10.1053/j.gastro.2006.11.022 (2007). 
55 Yan, F. & Polk, D. B. Characterization of a probiotic-derived soluble protein 
which reveals a mechanism of preventive and treatment effects of probiotics on 
intestinal inflammatory diseases. Gut Microbes 3, 25-28, doi:10.4161/gmic.19245 
(2012). 
56 Fukuda, S. et al. Bifidobacteria can protect from enteropathogenic infection 
through production of acetate. Nature 469, 543-547, doi:10.1038/nature09646 
(2011). 
57 Fukuda, S., Toh, H., Taylor, T. D., Ohno, H. & Hattori, M. Acetate-producing 
bifidobacteria protect the host from enteropathogenic infection via carbohydrate 
transporters. Gut Microbes 3, 449-454, doi:10.4161/gmic.21214 (2012). 
58 Atarashi, K. et al. ATP drives lamina propria T(H)17 cell differentiation. Nature 
455, 808-812, doi:10.1038/nature07240 (2008). 
59 O'Mahony, C. et al. Commensal-induced regulatory T cells mediate protection 
against pathogen-stimulated NF-kappaB activation. PLoS Pathog 4, e1000112, 
doi:10.1371/journal.ppat.1000112 (2008). 
  200	  
60 Kamada, N. et al. Regulated virulence controls the ability of a pathogen to 
compete with the gut microbiota. Science 336, 1325-1329, 
doi:10.1126/science.1222195 (2012). 
61 Maltby, R., Leatham-Jensen, M. P., Gibson, T., Cohen, P. S. & Conway, T. 
Nutritional basis for colonization resistance by human commensal Escherichia 
coli strains HS and Nissle 1917 against E. coli O157:H7 in the mouse intestine. 
PLoS One 8, e53957, doi:10.1371/journal.pone.0053957 (2013). 
62 Fischbach, M. A., Lin, H., Liu, D. R. & Walsh, C. T. How pathogenic bacteria 
evade mammalian sabotage in the battle for iron. Nat Chem Biol 2, 132-138, 
doi:10.1038/nchembio771 (2006). 
63 Raffatellu, M. et al. Lipocalin-2 resistance confers an advantage to Salmonella 
enterica serotype Typhimurium for growth and survival in the inflamed intestine. 
Cell Host Microbe 5, 476-486, doi:10.1016/j.chom.2009.03.011 (2009). 
64 Deriu, E. et al. Probiotic bacteria reduce salmonella typhimurium intestinal 
colonization by competing for iron. Cell Host Microbe 14, 26-37, 
doi:10.1016/j.chom.2013.06.007 (2013). 
65 Donia, M. S. et al. A systematic analysis of biosynthetic gene clusters in the 
human microbiome reveals a common family of antibiotics. Cell 158, 1402-1414, 
doi:10.1016/j.cell.2014.08.032 (2014). 
66 Cotter, P. D., Hill, C. & Ross, R. P. Bacteriocins: developing innate immunity for 
food. Nat Rev Microbiol 3, 777-788, doi:10.1038/nrmicro1273 (2005). 
67 Bron, P. A., Grangette, C., Mercenier, A., de Vos, W. M. & Kleerebezem, M. 
Identification of Lactobacillus plantarum genes that are induced in the 
  201	  
gastrointestinal tract of mice. J Bacteriol 186, 5721-5729, 
doi:10.1128/JB.186.17.5721-5729.2004 (2004). 
68 Corr, S. C. et al. Bacteriocin production as a mechanism for the antiinfective 
activity of Lactobacillus salivarius UCC118. Proc Natl Acad Sci U S A 104, 7617-
7621, doi:10.1073/pnas.0700440104 (2007). 
69 Rea, M. C. et al. Effect of broad- and narrow-spectrum antimicrobials on 
Clostridium difficile and microbial diversity in a model of the distal colon. Proc 
Natl Acad Sci U S A 108 Suppl 1, 4639-4644, doi:10.1073/pnas.1001224107 
(2011). 
70 Rea, M. C. et al. Thuricin CD, a posttranslationally modified bacteriocin with a 
narrow spectrum of activity against Clostridium difficile. Proc Natl Acad Sci U S 
A 107, 9352-9357, doi:10.1073/pnas.0913554107 (2010). 
71 Marteyn, B. et al. Modulation of Shigella virulence in response to available 
oxygen in vivo. Nature 465, 355-358, doi:10.1038/nature08970 (2010). 
72 Kankainen, M. et al. Comparative genomic analysis of Lactobacillus rhamnosus 
GG reveals pili containing a human-mucus binding protein. Proc Natl Acad Sci U 
S A 106, 17193-17198, doi:DOI 10.1073/pnas.0908876106 (2009). 
73 Asahara, T. et al. Probiotic bifidobacteria protect mice from lethal infection with 
Shiga toxin-producing Escherichia coli O157:H7. Infect Immun 72, 2240-2247 
(2004). 
74 de Sablet, T. et al. Human microbiota-secreted factors inhibit shiga toxin 
synthesis by enterohemorrhagic Escherichia coli O157:H7. Infect Immun 77, 783-
790, doi:10.1128/IAI.01048-08 (2009). 
  202	  
75 Ferreyra, J. A. et al. Gut microbiota-produced succinate promotes C. difficile 
infection after antibiotic treatment or motility disturbance. Cell Host Microbe 16, 
770-777, doi:10.1016/j.chom.2014.11.003 (2014). 
76 Curtis, M. M. et al. The gut commensal bacteroides thetaiotaomicron exacerbates 
enteric infection through modification of the metabolic landscape. Cell Host 
Microbe 16, 759-769, doi:10.1016/j.chom.2014.11.005 (2014). 
77 Soares, J. A. & Ahmer, B. M. Detection of acyl-homoserine lactones by 
Escherichia and Salmonella. Curr Opin Microbiol 14, 188-193, 
doi:10.1016/j.mib.2011.01.006 (2011). 
78 Swearingen, M. C., Sabag-Daigle, A. & Ahmer, B. M. Are there acyl-homoserine 
lactones within mammalian intestines? J Bacteriol 195, 173-179, 
doi:10.1128/JB.01341-12 (2013). 
79 Hughes, D. T. et al. Chemical sensing in mammalian host-bacterial commensal 
associations. Proc Natl Acad Sci U S A 107, 9831-9836, 
doi:10.1073/pnas.1002551107 (2010). 
80 Dyszel, J. L. et al. Salmonella enterica serovar Typhimurium can detect acyl 
homoserine lactone production by Yersinia enterocolitica in mice. J Bacteriol 
192, 29-37, doi:10.1128/JB.01139-09 (2010). 
81 Smith, J. N. et al. SdiA, an N-acylhomoserine lactone receptor, becomes active 
during the transit of Salmonella enterica through the gastrointestinal tract of 
turtles. PLoS One 3, e2826, doi:10.1371/journal.pone.0002826 (2008). 
  203	  
82 Thompson, J. A., Oliveira, R. A., Djukovic, A., Ubeda, C. & Xavier, K. B. 
Manipulation of the Quorum Sensing Signal AI-2 Affects the Antibiotic-Treated 
Gut Microbiota. Cell Rep, doi:10.1016/j.celrep.2015.02.049 (2015). 
83 Fabich, A. J. et al. Comparison of carbon nutrition for pathogenic and commensal 
Escherichia coli strains in the mouse intestine. Infect Immun 76, 1143-1152, 
doi:10.1128/IAI.01386-07 (2008). 
84 Lupp, C. et al. Host-mediated inflammation disrupts the intestinal microbiota and 
promotes the overgrowth of Enterobacteriaceae. Cell Host Microbe 2, 204 (2007). 
85 Winter, S. E. et al. Gut inflammation provides a respiratory electron acceptor for 
Salmonella. Nature 467, 426-429, doi:10.1038/nature09415 (2010). 
86 Thiennimitr, P. et al. Intestinal inflammation allows Salmonella to use 
ethanolamine to compete with the microbiota. Proc Natl Acad Sci U S A 108, 
17480-17485, doi:10.1073/pnas.1107857108 (2011). 
87 Bertin, Y. et al. Enterohaemorrhagic Escherichia coli gains a competitive 
advantage by using ethanolamine as a nitrogen source in the bovine intestinal 
content. Environ Microbiol 13, 365-377, doi:10.1111/j.1462-2920.2010.02334.x 
(2011). 
88 Garsin, D. A. Ethanolamine utilization in bacterial pathogens: roles and 
regulation. Nat Rev Microbiol 8, 290-295, doi:10.1038/nrmicro2334 (2010). 
89 Winter, S. E. et al. Host-derived nitrate boosts growth of E. coli in the inflamed 
gut. Science 339, 708-711, doi:10.1126/science.1232467 (2013). 
  204	  
90 Nedialkova, L. P. et al. Inflammation fuels colicin Ib-dependent competition of 
Salmonella serovar Typhimurium and E. coli in enterobacterial blooms. PLoS 
Pathog 10, e1003844, doi:10.1371/journal.ppat.1003844 (2014). 
91 MacIntyre, D. L., Miyata, S. T., Kitaoka, M. & Pukatzki, S. The Vibrio cholerae 
type VI secretion system displays antimicrobial properties. Proc Natl Acad Sci U 
S A 107, 19520-19524, doi:10.1073/pnas.1012931107 (2010). 
92 Fu, Y., Waldor, M. K. & Mekalanos, J. J. Tn-Seq analysis of Vibrio cholerae 
intestinal colonization reveals a role for T6SS-mediated antibacterial activity in 
the host. Cell Host Microbe 14, 652-663, doi:10.1016/j.chom.2013.11.001 (2013). 
93 Cummings, J. H., Pomare, E. W., Branch, W. J., Naylor, C. P. & Macfarlane, G. 
T. Short chain fatty acids in human large intestine, portal, hepatic and venous 
blood. Gut 28, 1221-1227 (1987). 
94 Verger, R. et al. Regulation of lumen fat digestion: enzymic aspects. Proc Nutr 
Soc 55, 5-18 (1996). 
95 Eisenreich, W., Dandekar, T., Heesemann, J. & Goebel, W. Carbon metabolism 
of intracellular bacterial pathogens and possible links to virulence. Nat Rev 
Microbiol 8, 401-412, doi:10.1038/nrmicro2351 (2010). 
96 Steeb, B. et al. Parallel exploitation of diverse host nutrients enhances Salmonella 
virulence. PLoS Pathog 9, e1003301, doi:10.1371/journal.ppat.1003301 (2013). 
97 Becker, D. et al. Robust Salmonella metabolism limits possibilities for new 
antimicrobials. Nature 440, 303-307, doi:10.1038/nature04616 (2006). 
98 Haraga, A., Ohlson, M. B. & Miller, S. I. Salmonellae interplay with host cells. 
Nat Rev Microbiol 6, 53-66, doi:10.1038/nrmicro1788 (2008). 
  205	  
99 Fass, E. & Groisman, E. A. Control of Salmonella pathogenicity island-2 gene 
expression. Curr Opin Microbiol 12, 199-204, doi:10.1016/j.mib.2009.01.004 
(2009). 
100 Buddelmeijer, N. The molecular mechanism of bacterial lipoprotein modification-
How, when and why? FEMS Microbiol Rev 39, 246-261, 
doi:10.1093/femsre/fuu006 (2015). 
101 Nakayama, H., Kurokawa, K. & Lee, B. L. Lipoproteins in bacteria: structures 
and biosynthetic pathways. FEBS J 279, 4247-4268, doi:10.1111/febs.12041 
(2012). 
102 Kovacs-Simon, A., Titball, R. W. & Michell, S. L. Lipoproteins of bacterial 
pathogens. Infect Immun 79, 548-561, doi:10.1128/IAI.00682-10 (2011). 
103 Stanley, P., Koronakis, V. & Hughes, C. Acylation of Escherichia coli hemolysin: 
a unique protein lipidation mechanism underlying toxin function. Microbiol Mol 
Biol Rev 62, 309-333 (1998). 
104 Jones, J. D. & O'Connor, C. D. Protein acetylation in prokaryotes. Proteomics 11, 
3012-3022, doi:10.1002/pmic.201000812 (2011). 
105 Hu, L. I., Lima, B. P. & Wolfe, A. J. Bacterial protein acetylation: the dawning of 
a new age. Mol Microbiol 77, 15-21, doi:10.1111/j.1365-2958.2010.07204.x 
(2010). 
106 Grammel, M. & Hang, H. C. Chemical reporters for biological discovery. Nat 
Chem Biol 9, 475-484, doi:10.1038/nchembio.1296 (2013). 
  206	  
107 Hirano, Y., Hossain, M. M., Takeda, K., Tokuda, H. & Miki, K. Structural studies 
of the Cpx pathway activator NlpE on the outer membrane of Escherichia coli. 
Structure 15, 963-976, doi:10.1016/j.str.2007.06.014 (2007). 
108 Yang, Y. Y., Grammel, M., Raghavan, A. S., Charron, G. & Hang, H. C. 
Comparative analysis of cleavable azobenzene-based affinity tags for 
bioorthogonal chemical proteomics. Chem Biol 17, 1212-1222, 
doi:10.1016/j.chembiol.2010.09.012 (2010). 
109 Yang, Y. Y. & Hang, H. C. Chemical approaches for the detection and synthesis 
of acetylated proteins. Chembiochem 12, 314-322, doi:10.1002/cbic.201000558 
(2011). 
110 Juncker, A. S. et al. Prediction of lipoprotein signal peptides in Gram-negative 
bacteria. Protein Sci 12, 1652-1662, doi:10.1110/ps.0303703 (2003). 
111 Christopherson, M. R., Schmitz, G. E. & Downs, D. M. YjgF is required for 
isoleucine biosynthesis when Salmonella enterica is grown on pyruvate medium. 
J Bacteriol 190, 3057-3062, doi:10.1128/JB.01700-07 (2008). 
112 Yount, J. S., Charron, G. & Hang, H. C. Bioorthogonal proteomics of 15-
hexadecynyloxyacetic acid chemical reporter reveals preferential targeting of fatty 
acid modified proteins and biosynthetic enzymes. Bioorg Med Chem 20, 650-654, 
doi:10.1016/j.bmc.2011.03.062 (2012). 
113 Ray, T. K. & Cronan, J. E. Acylation of Sn-Glycerol 3-Phosphate in Escherichia-
Coli - Study of Reaction with Native Palmitoyl-Acyl Carrier Protein. Journal of 
Biological Chemistry 250, 8422-8427 (1975). 
  207	  
114 Volz, K. A test case for structure-based functional assignment: the 1.2 A crystal 
structure of the yjgF gene product from Escherichia coli. Protein Sci 8, 2428-
2437, doi:10.1110/ps.8.11.2428 (1999). 
115 Burman, J. D., Stevenson, C. E., Sawers, R. G. & Lawson, D. M. The crystal 
structure of Escherichia coli TdcF, a member of the highly conserved 
YjgF/YER057c/UK114 family. BMC Struct Biol 7, 30, doi:10.1186/1472-6807-7-
30 (2007). 
116 Knapik, A. A. et al. Structure of Escherichia coli RutC, a member of the YjgF 
family and putative aminoacrylate peracid reductase of the rut operon. Acta 
Crystallogr Sect F Struct Biol Cryst Commun 68, 1294-1299, 
doi:10.1107/S1744309112041796 (2012). 
117 Parsons, L. et al. Solution structure and functional ligand screening of HI0719, a 
highly conserved protein from bacteria to humans in the YjgF/YER057c/UK114 
family. Biochemistry 42, 80-89, doi:10.1021/bi020541w (2003). 
118 Lambrecht, J. A., Flynn, J. M. & Downs, D. M. Conserved YjgF protein family 
deaminates reactive enamine/imine intermediates of pyridoxal 5'-phosphate 
(PLP)-dependent enzyme reactions. J Biol Chem 287, 3454-3461, 
doi:10.1074/jbc.M111.304477 (2012). 
119 Lambrecht, J. A., Schmitz, G. E. & Downs, D. M. RidA proteins prevent 
metabolic damage inflicted by PLP-dependent dehydratases in all domains of life. 
MBio 4, e00033-00013, doi:10.1128/mBio.00033-13 (2013). 
  208	  
120 Charron, G. et al. Robust fluorescent detection of protein fatty-acylation with 
chemical reporters. J Am Chem Soc 131, 4967-4975, doi:10.1021/ja810122f 
(2009). 
121 LaRock, D. L., Chaudhary, A. & Miller, S. I. Salmonellae interactions with host 
processes. Nat Rev Microbiol 13, 191-205, doi:10.1038/nrmicro3420 (2015). 
122 Watson, K. G. & Holden, D. W. Dynamics of growth and dissemination of 
Salmonella in vivo. Cell Microbiol 12, 1389-1397, doi:10.1111/j.1462-
5822.2010.01511.x (2010). 
123 Jepson, M. A., Collares-Buzato, C. B., Clark, M. A., Hirst, B. H. & Simmons, N. 
L. Rapid disruption of epithelial barrier function by Salmonella typhimurium is 
associated with structural modification of intercellular junctions. Infect Immun 63, 
356-359 (1995). 
124 Ellermeier, J. R. & Slauch, J. M. Adaptation to the host environment: regulation 
of the SPI1 type III secretion system in Salmonella enterica serovar 
Typhimurium. Curr Opin Microbiol 10, 24-29, doi:10.1016/j.mib.2006.12.002 
(2007). 
125 Kato, A., Groisman, E. A. & Howard Hughes Medical, I. The PhoQ/PhoP 
regulatory network of Salmonella enterica. Adv Exp Med Biol 631, 7-21 (2008). 
126 Dalebroux, Z. D. & Miller, S. I. Salmonellae PhoPQ regulation of the outer 
membrane to resist innate immunity. Curr Opin Microbiol 17, 106-113, 
doi:10.1016/j.mib.2013.12.005 (2014). 
  209	  
127 Bijlsma, J. J. E. & Groisman, E. A. The PhoP/PhoQ system controls the 
intramacrophage type three secretion system of Salmonella enterica. Mol 
Microbiol 57, 85-96, doi:DOI 10.1111/j.1365-2958.2005.04668.x (2005). 
128 Bajaj, V., Lucas, R. L., Hwang, C. & Lee, C. A. Co-ordinate regulation of 
Salmonella typhimurium invasion genes by environmental and regulatory factors 
is mediated by control of hilA expression. Mol Microbiol 22, 703-714 (1996). 
129 Behlau, I. & Miller, S. I. A PhoP-repressed gene promotes Salmonella 
typhimurium invasion of epithelial cells. J Bacteriol 175, 4475-4484 (1993). 
130 Perez, J. C. et al. Evolution of a bacterial regulon controlling virulence and 
Mg(2+) homeostasis. PLoS Genet 5, e1000428, 
doi:10.1371/journal.pgen.1000428 (2009). 
131 Viarengo, G. et al. Unsaturated long chain free fatty acids are input signals of the 
Salmonella enterica PhoP/PhoQ regulatory system. J Biol Chem 288, 22346-
22358, doi:10.1074/jbc.M113.472829 (2013). 
132 Yu, B. J., Kim, J. A., Moon, J. H., Ryu, S. E. & Pan, J. G. The diversity of lysine-
acetylated proteins in Escherichia coli. J Microbiol Biotechnol 18, 1529-1536 
(2008). 
133 Zhang, J. et al. Lysine acetylation is a highly abundant and evolutionarily 
conserved modification in Escherichia coli. Mol Cell Proteomics 8, 215-225, 
doi:10.1074/mcp.M800187-MCP200 (2009). 
134 Wang, Q. et al. Acetylation of metabolic enzymes coordinates carbon source 
utilization and metabolic flux. Science 327, 1004-1007, 
doi:10.1126/science.1179687 (2010). 
  210	  
135 Kuhn, M. L. et al. Structural, kinetic and proteomic characterization of acetyl 
phosphate-dependent bacterial protein acetylation. PLoS One 9, e94816, 
doi:10.1371/journal.pone.0094816 (2014). 
136 Thao, S., Chen, C. S., Zhu, H. & Escalante-Semerena, J. C. Nepsilon-lysine 
acetylation of a bacterial transcription factor inhibits Its DNA-binding activity. 
PLoS One 5, e15123, doi:10.1371/journal.pone.0015123 (2010). 
137 Garrity, J., Gardner, J. G., Hawse, W., Wolberger, C. & Escalante-Semerena, J. C. 
N-lysine propionylation controls the activity of propionyl-CoA synthetase. J Biol 
Chem 282, 30239-30245, doi:10.1074/jbc.M704409200 (2007). 
138 Peng, C. et al. The first identification of lysine malonylation substrates and its 
regulatory enzyme. Mol Cell Proteomics 10, M111 012658, 
doi:10.1074/mcp.M111.012658 (2011). 
139 Colak, G. et al. Identification of lysine succinylation substrates and the 
succinylation regulatory enzyme CobB in Escherichia coli. Mol Cell Proteomics 
12, 3509-3520, doi:10.1074/mcp.M113.031567 (2013). 
140 Weinert, B. T. et al. Lysine succinylation is a frequently occurring modification in 
prokaryotes and eukaryotes and extensively overlaps with acetylation. Cell Rep 4, 
842-851, doi:10.1016/j.celrep.2013.07.024 (2013). 
141 Zhang, Z. et al. Identification of lysine succinylation as a new post-translational 
modification. Nat Chem Biol 7, 58-63, doi:10.1038/nchembio.495 (2011). 
142 Weinert, B. T. et al. Acetyl-phosphate is a critical determinant of lysine 
acetylation in E. coli. Mol Cell 51, 265-272, doi:10.1016/j.molcel.2013.06.003 
(2013). 
  211	  
143 AbouElfetouh, A. et al. The E. coli sirtuin CobB shows no preference for 
enzymatic and nonenzymatic lysine acetylation substrate sites. Microbiologyopen 
4, 66-83, doi:10.1002/mbo3.223 (2015). 
144 Beuzon, C. R., Banks, G., Deiwick, J., Hensel, M. & Holden, D. W. pH-
dependent secretion of SseB, a product of the SPI-2 type III secretion system of 
Salmonella typhimurium. Mol Microbiol 33, 806-816 (1999). 
145 Lee, E. J., Pontes, M. H. & Groisman, E. A. A bacterial virulence protein 
promotes pathogenicity by inhibiting the bacterium's own F1Fo ATP synthase. 
Cell 154, 146-156, doi:10.1016/j.cell.2013.06.004 (2013). 
146 Soncini, F. C., Garcia Vescovi, E., Solomon, F. & Groisman, E. A. Molecular 
basis of the magnesium deprivation response in Salmonella typhimurium: 
identification of PhoP-regulated genes. J Bacteriol 178, 5092-5099 (1996). 
147 Zwir, I., Latifi, T., Perez, J. C., Huang, H. & Groisman, E. A. The promoter 
architectural landscape of the Salmonella PhoP regulon. Mol Microbiol 84, 463-
485, doi:10.1111/j.1365-2958.2012.08036.x (2012). 
148 Yount, J. S. et al. Visible fluorescence detection of type III protein secretion from 
bacterial pathogens. J Am Chem Soc 132, 8244-8245, doi:10.1021/ja102257v 
(2010). 
149 Groisman, E. A., Kayser, J. & Soncini, F. C. Regulation of polymyxin resistance 
and adaptation to low-Mg2+ environments. J Bacteriol 179, 7040-7045 (1997). 
150 Stecher, B., Maier, L. & Hardt, W. D. 'Blooming' in the gut: how dysbiosis might 
contribute to pathogen evolution. Nat Rev Microbiol 11, 277-284, 
doi:10.1038/nrmicro2989 (2013). 
  212	  
151 Keeney, K. M., Yurist-Doutsch, S., Arrieta, M. C. & Finlay, B. B. Effects of 
antibiotics on human microbiota and subsequent disease. Annu Rev Microbiol 68, 
217-235, doi:10.1146/annurev-micro-091313-103456 (2014). 
152 Mattila, E. et al. Fecal transplantation, through colonoscopy, is effective therapy 
for recurrent Clostridium difficile infection. Gastroenterology 142, 490-496, 
doi:10.1053/j.gastro.2011.11.037 (2012). 
153 van Nood, E. et al. Duodenal infusion of donor feces for recurrent Clostridium 
difficile. N Engl J Med 368, 407-415, doi:10.1056/NEJMoa1205037 (2013). 
154 Irazoqui, J. E., Urbach, J. M. & Ausubel, F. M. Evolution of host innate defence: 
insights from Caenorhabditis elegans and primitive invertebrates. Nat Rev 
Immunol 10, 47-58, doi:10.1038/nri2689 (2010). 
155 Pukkila-Worley, R. & Ausubel, F. M. Immune defense mechanisms in the 
Caenorhabditis elegans intestinal epithelium. Curr Opin Immunol 24, 3-9, 
doi:10.1016/j.coi.2011.10.004 (2012). 
156 Irazoqui, J. E. et al. Distinct pathogenesis and host responses during infection of 
C. elegans by P. aeruginosa and S. aureus. PLoS Pathog 6, e1000982, 
doi:10.1371/journal.ppat.1000982 (2010). 
157 Pukkila-Worley, R., Ausubel, F. M. & Mylonakis, E. Candida albicans infection 
of Caenorhabditis elegans induces antifungal immune defenses. PLoS Pathog 7, 
e1002074, doi:10.1371/journal.ppat.1002074 (2011). 
158 Schulenburg, H. & Ewbank, J. J. The genetics of pathogen avoidance in 
Caenorhabditis elegans. Mol Microbiol 66, 563-570, doi:10.1111/j.1365-
2958.2007.05946.x (2007). 
  213	  
159 Schulenburg, H., Hoeppner, M. P., Weiner, J., 3rd & Bornberg-Bauer, E. 
Specificity of the innate immune system and diversity of C-type lectin domain 
(CTLD) proteins in the nematode Caenorhabditis elegans. Immunobiology 213, 
237-250, doi:10.1016/j.imbio.2007.12.004 (2008). 
160 Aballay, A., Yorgey, P. & Ausubel, F. M. Salmonella typhimurium proliferates 
and establishes a persistent infection in the intestine of Caenorhabditis elegans. 
Curr Biol 10, 1539-1542 (2000). 
161 Labrousse, A., Chauvet, S., Couillault, C., Kurz, C. L. & Ewbank, J. J. 
Caenorhabditis elegans is a model host for Salmonella typhimurium. Curr Biol 
10, 1543-1545 (2000). 
162 Stecher, B. et al. Salmonella enterica serovar typhimurium exploits inflammation 
to compete with the intestinal microbiota. PLoS Biol 5, 2177-2189, 
doi:10.1371/journal.pbio.0050244 (2007). 
163 Tenor, J. L., McCormick, B. A., Ausubel, F. M. & Aballay, A. Caenorhabditis 
elegans-based screen identifies Salmonella virulence factors required for 
conserved host-pathogen interactions. Curr Biol 14, 1018-1024, 
doi:10.1016/j.cub.2004.05.050 (2004). 
164 Jia, K. et al. Autophagy genes protect against Salmonella typhimurium infection 
and mediate insulin signaling-regulated pathogen resistance. Proc Natl Acad Sci 
U S A 106, 14564-14569, doi:10.1073/pnas.0813319106 (2009). 
165 McGhee, J. D. The C. elegans intestine. WormBook, 1-36, 
doi:10.1895/wormbook.1.133.1 (2007). 
  214	  
166 Labouesse, M. Epithelial junctions and attachments. WormBook, 1-21, 
doi:10.1895/wormbook.1.56.1 (2006). 
167 Borgonie, G., Claeys, M., Vanfleteren, J., Dewaele, D. & Coomans, A. Presence 
of Peritrophic-Like Membranes in the Intestine of 3 Bacteriophagous Nematodes 
(Nematoda, Rhabditida). Fund Appl Nematol 18, 227-233 (1995). 
168 Borgonie, G. et al. Internal lectin binding patterns in the nematodes 
Caenorhabditis elegans, Panagrolaimus superbus and Acrobeloides maximus. 
Fund Appl Nematol 20, 173-186 (1997). 
169 Schimpf, J., Sames, K. & Zwilling, R. Proteoglycan distribution pattern during 
aging in the nematode Caenorhabditis elegans: An ultrastructural histochemical 
study. Histochem J 31, 285-292, doi:Doi 10.1023/A:1003761817109 (1999). 
170 Kramer, J. M. Basement membranes. WormBook, 1-15, 
doi:10.1895/wormbook.1.16.1 (2005). 
171 Chauhan, V. M., Orsi, G., Brown, A., Pritchard, D. I. & Aylott, J. W. Mapping 
the Pharyngeal and Intestinal pH of Caenorhabditis elegans and Real-Time 
Luminal pH Oscillations Using Extended Dynamic Range pH-Sensitive 
Nanosensors. Acs Nano 7, 5577-5587, doi:DOI 10.1021/nn401856u (2013). 
172 Stiernagle, T. Maintenance of C. elegans. WormBook, 1-11, 
doi:10.1895/wormbook.1.101.1 (2006). 
173 Felix, M. A. & Duveau, F. Population dynamics and habitat sharing of natural 
populations of Caenorhabditis elegans and C. briggsae. BMC Biol 10, 59, 
doi:10.1186/1741-7007-10-59 (2012). 
  215	  
174 Garsin, D. A. et al. A simple model host for identifying Gram-positive virulence 
factors. Proc Natl Acad Sci U S A 98, 10892-10897, doi:10.1073/pnas.191378698 
(2001). 
175 Lebreton, F., Willems, R. J. L. & Gilmore, M. S. in Enterococci: From 
Commensals to Leading Causes of Drug Resistant Infection   (eds M. S. Gilmore, 
D. B. Clewell, Y. Ike, & N. Shankar)  (2014). 
176 Gilmore, M. S., Lebreton, F. & van Schaik, W. Genomic transition of enterococci 
from gut commensals to leading causes of multidrug-resistant hospital infection in 
the antibiotic era. Curr Opin Microbiol 16, 10-16, doi:10.1016/j.mib.2013.01.006 
(2013). 
177 Staley, C., Dunny, G. M. & Sadowsky, M. J. Environmental and animal-
associated enterococci. Adv Appl Microbiol 87, 147-186, doi:10.1016/B978-0-12-
800261-2.00004-9 (2014). 
178 Tetlock, A., Yost, C. K., Stavrinides, J. & Manzon, R. G. Changes in the Gut 
Microbiome of the Sea Lamprey during Metamorphosis. Appl Environ Microbiol 
78, 7638-7644, doi:Doi 10.1128/Aem.01640-12 (2012). 
179 Charrier, M., Combet-Blanc, Y. & Ollivier, B. Bacterial flora in the gut of Helix 
aspersa (Gastropoda Pulmonata): evidence for a permanent population with a 
dominant homolactic intestinal bacterium, Enterococcus casseliflavus. Can J 
Microbiol 44, 20-27, doi:DOI 10.1139/cjm-44-1-20 (1998). 
180 Hayashi, H., Takahashi, R., Nishi, T., Sakamoto, M. & Benno, Y. Molecular 
analysis of jejunal, ileal, caecal and recto-sigmoidal human colonic microbiota 
using 16S rRNA gene libraries and terminal restriction fragment length 
  216	  
polymorphism. J Med Microbiol 54, 1093-1101, doi:10.1099/jmm.0.45935-0 
(2005). 
181 Tannock, G. W. & Cook, G. The Enterococci: Pathogenesis, Molecular Biology, 
and Antibiotic Resistance.  101-132 (ASM Press, 2002). 
182 Maia, O. B., Duarte, R., Silva, A. M., Cara, D. C. & Nicoli, J. R. Evaluation of 
the components of a commercial probiotic in gnotobiotic mice experimentally 
challenged with Salmonella enterica subsp. enterica ser. Typhimurium. Vet 
Microbiol 79, 183-189 (2001). 
183 Franz, C. M., van Belkum, M. J., Holzapfel, W. H., Abriouel, H. & Galvez, A. 
Diversity of enterococcal bacteriocins and their grouping in a new classification 
scheme. FEMS Microbiol Rev 31, 293-310, doi:10.1111/j.1574-
6976.2007.00064.x (2007). 
184 Cao, G. T. et al. Effects of a probiotic, Enterococcus faecium, on growth 
performance, intestinal morphology, immune response, and cecal microflora in 
broiler chickens challenged with Escherichia coli K88. Poult Sci 92, 2949-2955, 
doi:10.3382/ps.2013-03366 (2013). 
185 Jin, L. Z., Marquardt, R. R. & Zhao, X. A strain of Enterococcus faecium (18C23) 
inhibits adhesion of enterotoxigenic Escherichia coli K88 to porcine small 
intestine mucus. Appl Environ Microbiol 66, 4200-4204 (2000). 
186 Top, J., Willems, R. & Bonten, M. Emergence of CC17 Enterococcus faecium: 
from commensal to hospital-adapted pathogen. FEMS Immunol Med Microbiol 
52, 297-308, doi:10.1111/j.1574-695X.2008.00383.x (2008). 
  217	  
187 Arias, C. A. & Murray, B. E. The rise of the Enterococcus: beyond vancomycin 
resistance. Nat Rev Microbiol 10, 266-278, doi:10.1038/nrmicro2761 (2012). 
188 Powell, J. R. & Ausubel, F. M. Models of Caenorhabditis elegans infection by 
bacterial and fungal pathogens. Methods Mol Biol 415, 403-427, doi:10.1007/978-
1-59745-570-1_24 (2008). 
189 Lebreton, F. et al. Emergence of epidemic multidrug-resistant Enterococcus 
faecium from animal and commensal strains. MBio 4, doi:10.1128/mBio.00534-
13 (2013). 
190 Palmer, K. L. et al. Comparative genomics of enterococci: variation in 
Enterococcus faecalis, clade structure in E. faecium, and defining characteristics 
of E. gallinarum and E. casseliflavus. MBio 3, e00318-00311, 
doi:10.1128/mBio.00318-11 (2012). 
191 Knodler, L. A. et al. Cloning vectors and fluorescent proteins can significantly 
inhibit Salmonella enterica virulence in both epithelial cells and macrophages: 
Implications for bacterial pathogenesis studies. Infect Immun 73, 7027-7031, 
doi:Doi 10.1128/Iai.73.10.7027-7031.2005 (2005). 
192 Teng, F., Kawalec, M., Weinstock, G. M., Hryniewicz, W. & Murray, B. E. An 
Enterococcus faecium secreted antigen, SagA, exhibits broad-spectrum binding to 
extracellular matrix proteins and appears essential for E. faecium growth. Infect 
Immun 71, 5033-5041 (2003). 
193 Anantharaman, V. & Aravind, L. Evolutionary history, structural features and 
biochemical diversity of the NlpC/P60 superfamily of enzymes. Genome Biol 4, 
R11 (2003). 
  218	  
194 Bartual, S. G. et al. Structural basis of PcsB-mediated cell separation in 
Streptococcus pneumoniae. Nat Commun 5, 3842, doi:10.1038/ncomms4842 
(2014). 
195 Tuteja, R. Type I signal peptidase: an overview. Arch Biochem Biophys 441, 107-
111, doi:10.1016/j.abb.2005.07.013 (2005). 
196 Rolain, T. et al. O-glycosylation as a novel control mechanism of peptidoglycan 
hydrolase activity. J Biol Chem 288, 22233-22247, doi:10.1074/jbc.M113.470716 
(2013). 
197 Alegado, R. A. & Tan, M. W. Resistance to antimicrobial peptides contributes to 
persistence of Salmonella typhimurium in the C. elegans intestine. Cell Microbiol 
10, 1259-1273, doi:10.1111/j.1462-5822.2008.01124.x (2008). 
198 Sahu, S. N. et al. Identification of virulence properties in Salmonella 
Typhimurium DT104 using Caenorhabditis elegans. PLoS One 8, e76673, 
doi:10.1371/journal.pone.0076673 (2013). 
199 Royet, J. & Dziarski, R. Peptidoglycan recognition proteins: pleiotropic sensors 
and effectors of antimicrobial defences. Nat Rev Microbiol 5, 264-277, 
doi:10.1038/nrmicro1620 (2007). 
200 Dworkin, J. The medium is the message: interspecies and interkingdom signaling 
by peptidoglycan and related bacterial glycans. Annu Rev Microbiol 68, 137-154, 
doi:10.1146/annurev-micro-091213-112844 (2014). 
201 Johnson, J. W., Fisher, J. F. & Mobashery, S. Bacterial cell-wall recycling. Ann N 
Y Acad Sci 1277, 54-75, doi:10.1111/j.1749-6632.2012.06813.x (2013). 
  219	  
202 Goodell, E. W. & Schwarz, U. Release of cell wall peptides into culture medium 
by exponentially growing Escherichia coli. J Bacteriol 162, 391-397 (1985). 
203 Mauck, J., Chan, L. & Glaser, L. Turnover of the cell wall of Gram-positive 
bacteria. J Biol Chem 246, 1820-1827 (1971). 
204 Li, S. Y., Holtje, J. V. & Young, K. D. Comparison of high-performance liquid 
chromatography and fluorophore-assisted carbohydrate electrophoresis methods 
for analyzing peptidoglycan composition of Escherichia coli. Anal Biochem 326, 
1-12, doi:10.1016/j.ab.2003.11.007 (2004). 
205 Young, K. D. A simple gel electrophoretic method for analyzing the muropeptide 
composition of bacterial peptidoglycan. J Bacteriol 178, 3962-3966 (1996). 
206 Kim, D. H. et al. A conserved p38 MAP kinase pathway in Caenorhabditis 
elegans innate immunity. Science 297, 623-626, doi:10.1126/science.1073759 
(2002). 
207 Troemel, E. R. et al. p38 MAPK regulates expression of immune response genes 
and contributes to longevity in C. elegans. PLoS Genet 2, e183, 
doi:10.1371/journal.pgen.0020183 (2006). 
208 Mallo, G. V. et al. Inducible antibacterial defense system in C. elegans. Curr Biol 
12, 1209-1214 (2002). 
209 Zugasti, O. & Ewbank, J. J. Neuroimmune regulation of antimicrobial peptide 
expression by a noncanonical TGF-beta signaling pathway in Caenorhabditis 
elegans epidermis. Nat Immunol 10, 249-256, doi:10.1038/ni.1700 (2009). 
210 Garsin, D. A. et al. Long-lived C. elegans daf-2 mutants are resistant to bacterial 
pathogens. Science 300, 1921, doi:10.1126/science.1080147 (2003). 
  220	  
211 Evans, E. A., Chen, W. C. & Tan, M. W. The DAF-2 insulin-like signaling 
pathway independently regulates aging and immunity in C. elegans. Aging Cell 7, 
879-893, doi:10.1111/j.1474-9726.2008.00435.x (2008). 
212 Reddy, K. C., Andersen, E. C., Kruglyak, L. & Kim, D. H. A polymorphism in 
npr-1 is a behavioral determinant of pathogen susceptibility in C. elegans. Science 
323, 382-384, doi:10.1126/science.1166527 (2009). 
213 Pujol, N. et al. A reverse genetic analysis of components of the Toll signaling 
pathway in Caenorhabditis elegans. Curr Biol 11, 809-821 (2001). 
214 Valanne, S., Wang, J. H. & Ramet, M. The Drosophila Toll signaling pathway. J 
Immunol 186, 649-656, doi:10.4049/jimmunol.1002302 (2011). 
215 Pradel, E. et al. Detection and avoidance of a natural product from the pathogenic 
bacterium Serratia marcescens by Caenorhabditis elegans. Proc Natl Acad Sci U S 
A 104, 2295-2300, doi:10.1073/pnas.0610281104 (2007). 
216 Smith, E. S., Martinez-Velazquez, L. & Ringstad, N. A chemoreceptor that 
detects molecular carbon dioxide. J Biol Chem 288, 37071-37081, 
doi:10.1074/jbc.M113.517367 (2013). 
217 Bhattarai, N., Gunn, J. & Zhang, M. Chitosan-based hydrogels for controlled, 
localized drug delivery. Adv Drug Deliv Rev 62, 83-99, 
doi:10.1016/j.addr.2009.07.019 (2010). 
218 Bourgogne, A. et al. Large scale variation in Enterococcus faecalis illustrated by 
the genome analysis of strain OG1RF. Genome Biol 9, R110, doi:10.1186/gb-
2008-9-7-r110 (2008). 
  221	  
219 Nallapareddy, S. R., Singh, K. V. & Murray, B. E. Construction of improved 
temperature-sensitive and mobilizable vectors and their use for constructing 
mutations in the adhesin-encoding acm gene of poorly transformable clinical 
Enterococcus faecium strains. Appl Environ Microbiol 72, 334-345, 
doi:10.1128/AEM.72.1.334-345.2006 (2006). 
220 Barendt, S. M. et al. Influences of capsule on cell shape and chain formation of 
wild-type and pcsB mutants of serotype 2 Streptococcus pneumoniae. J Bacteriol 
191, 3024-3040, doi:10.1128/JB.01505-08 (2009). 
221 Kleerebezem, M. et al. Complete genome sequence of Lactobacillus plantarum 
WCFS1. Proc Natl Acad Sci U S A 100, 1990-1995, 
doi:10.1073/pnas.0337704100 (2003). 
222 Bron, P. A., van Baarlen, P. & Kleerebezem, M. Emerging molecular insights into 
the interaction between probiotics and the host intestinal mucosa. Nat Rev 
Microbiol 10, 66-78, doi:10.1038/nrmicro2690 (2012). 
223 Kaiser, P., Diard, M., Stecher, B. & Hardt, W. D. The streptomycin mouse model 
for Salmonella diarrhea: functional analysis of the microbiota, the pathogen's 
virulence factors, and the host's mucosal immune response. Immunol Rev 245, 56-
83, doi:10.1111/j.1600-065X.2011.01070.x (2012). 
224 Santiviago, C. A. et al. Analysis of pools of targeted Salmonella deletion mutants 
identifies novel genes affecting fitness during competitive infection in mice. PLoS 
Pathog 5, e1000477, doi:10.1371/journal.ppat.1000477 (2009). 
  222	  
225 Kelley, L. A. & Sternberg, M. J. Protein structure prediction on the Web: a case 
study using the Phyre server. Nat Protoc 4, 363-371, doi:10.1038/nprot.2009.2 
(2009). 
226 Lupas, A., Van Dyke, M. & Stock, J. Predicting coiled coils from protein 
sequences. Science 252, 1162-1164, doi:10.1126/science.252.5009.1162 (1991). 
227 Petersen, T. N., Brunak, S., von Heijne, G. & Nielsen, H. SignalP 4.0: 
discriminating signal peptides from transmembrane regions. Nat Methods 8, 785-
786, doi:10.1038/nmeth.1701 (2011). 
228 Singer, J. T. et al. Broad-host-range plasmids for red fluorescent protein labeling 
of gram-negative bacteria for use in the zebrafish model system. Appl Environ 
Microbiol 76, 3467-3474, doi:10.1128/AEM.01679-09 (2010). 
229 Bloemberg, G. V., O'Toole, G. A., Lugtenberg, B. J. & Kolter, R. Green 
fluorescent protein as a marker for Pseudomonas spp. Appl Environ Microbiol 63, 
4543-4551 (1997). 
230 Podbielski, A., Spellerberg, B., Woischnik, M., Pohl, B. & Lutticken, R. Novel 
series of plasmid vectors for gene inactivation and expression analysis in group A 
streptococci (GAS). Gene 177, 137-147 (1996). 
231 Dunny, G. M., Lee, L. N. & LeBlanc, D. J. Improved electroporation and cloning 
vector system for gram-positive bacteria. Appl Environ Microbiol 57, 1194-1201 
(1991). 
232 Rangan, K. J., Yang, Y. Y., Charron, G. & Hang, H. C. Rapid visualization and 
large-scale profiling of bacterial lipoproteins with chemical reporters. J Am Chem 
Soc 132, 10628-10629, doi:10.1021/ja101387b (2010). 
  223	  
233 Shaham (ed.), S. Methods in cell biology. WormBook, 1551-8507, 
doi:10.1895/wormbook.1.49.1 (2006). 
234 Lundquist, E. A., Reddien, P. W., Hartwieg, E., Horvitz, H. R. & Bargmann, C. I. 
Three C. elegans Rac proteins and several alternative Rac regulators control axon 
guidance, cell migration and apoptotic cell phagocytosis. Development 128, 4475-
4488 (2001). 
235 Matsumoto, M. et al. Impact of intestinal microbiota on intestinal luminal 
metabolome. Sci Rep 2, 233, doi:10.1038/srep00233 (2012). 
236 Natividad, J. M. et al. Commensal and probiotic bacteria influence intestinal 
barrier function and susceptibility to colitis in Nod1-/-; Nod2-/- mice. Inflamm 
Bowel Dis 18, 1434-1446, doi:10.1002/ibd.22848 (2012). 
237 Asong, J., Wolfert, M. A., Maiti, K. K., Miller, D. & Boons, G. J. Binding and 
Cellular Activation Studies Reveal That Toll-like Receptor 2 Can Differentially 
Recognize Peptidoglycan from Gram-positive and Gram-negative Bacteria. J Biol 
Chem 284, 8643-8653, doi:10.1074/jbc.M806633200 (2009). 
238 Travassos, L. H. et al. Toll-like receptor 2-dependent bacterial sensing does not 
occur via peptidoglycan recognition. EMBO Rep 5, 1000-1006, 
doi:10.1038/sj.embor.7400248 (2004). 
239 Cario, E., Gerken, G. & Podolsky, D. K. Toll-like receptor 2 enhances ZO-1-
associated intestinal epithelial barrier integrity via protein kinase C. 
Gastroenterology 127, 224-238 (2004). 
  224	  
240 Girardin, S. E. et al. Peptidoglycan molecular requirements allowing detection by 
Nod1 and Nod2. J Biol Chem 278, 41702-41708, doi:10.1074/jbc.M307198200 
(2003). 
241 Lee, J. et al. pH-dependent internalization of muramyl peptides from early 
endosomes enables Nod1 and Nod2 signaling. J Biol Chem 284, 23818-23829, 
doi:10.1074/jbc.M109.033670 (2009). 
242 Vavricka, S. R. et al. hPepT1 transports muramyl dipeptide, activating NF-
kappaB and stimulating IL-8 secretion in human colonic Caco2/bbe cells. 
Gastroenterology 127, 1401-1409 (2004). 
243 Viala, J. et al. Nod1 responds to peptidoglycan delivered by the Helicobacter 
pylori cag pathogenicity island. Nat Immunol 5, 1166-1174, doi:10.1038/ni1131 
(2004). 
244 Dziarski, R. & Gupta, D. The peptidoglycan recognition proteins (PGRPs). 
Genome Biol 7, 232, doi:10.1186/gb-2006-7-8-232 (2006). 
245 Wang, Z. M. et al. Human peptidoglycan recognition protein-L is an N-
acetylmuramoyl-L-alanine amidase. J Biol Chem 278, 49044-49052, 
doi:10.1074/jbc.M307758200 (2003). 
246 Gelius, E., Persson, C., Karlsson, J. & Steiner, H. A mammalian peptidoglycan 
recognition protein with N-acetylmuramoyl-L-alanine amidase activity. Biochem 
Biophys Res Commun 306, 988-994 (2003). 
247 Lee, J., Geddes, K., Streutker, C., Philpott, D. J. & Girardin, S. E. Role of mouse 
peptidoglycan recognition protein PGLYRP2 in the innate immune response to 
  225	  
Salmonella enterica serovar Typhimurium infection in vivo. Infect Immun 80, 
2645-2654, doi:10.1128/IAI.00168-12 (2012). 
248 Buist, G., Steen, A., Kok, J. & Kuipers, O. P. LysM, a widely distributed protein 
motif for binding to (peptido)glycans. Mol Microbiol 68, 838-847, 
doi:10.1111/j.1365-2958.2008.06211.x (2008). 
249 Mesnage, S. et al. Molecular basis for bacterial peptidoglycan recognition by 
LysM domains. Nat Commun 5, 4269, doi:10.1038/ncomms5269 (2014). 
250 Vollmer, W., Joris, B., Charlier, P. & Foster, S. Bacterial peptidoglycan (murein) 
hydrolases. FEMS Microbiol Rev 32, 259-286, doi:10.1111/j.1574-
6976.2007.00099.x (2008). 
 
